{"nersets":[[{"setid":"PMC2883751","drugname":"saquinavir","startOffset":403,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"might have a higher clearance of the HIV protease inhibitor ","suffix":", administered by mouth, compared with subjects lacking func","exact":"saquinavir"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":597,"endOffset":606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"y than subjects lacking functional CYP3A5 alleles. Enhanced ","suffix":" hydroxylation and cyclosporin metabolism occur in an in vit","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":458,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"zole, fluconazole, and voriconazole were determined against ","suffix":" hydroxylation catalyzed by liver microsomal P450 3A enzymes","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":220,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" in Table 1. Inhibition by triazoles of 1′-hydroxylation of ","suffix":" varied by a factor of 10 between the Ki values of fluconazo","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":340,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ssed in bacterial membranes. Recombinant P450 3A5 catalyzed ","suffix":" 1′-hydroxylation more efficiently than did P450 3A4 (Table ","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":446,"endOffset":455,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"an did P450 3A4 (Table 3). Ki values of these triazoles for ","suffix":" hydroxylation catalyzed by recombinant P450 3A4 were lower ","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":1167,"endOffset":1176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"P450 3A5 than P450 3A4 in a Michaels-Menten kinetic manner. ","suffix":" can adopt an orientation suitable for 1′-hydroxylation over","exact":"Midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":1392,"endOffset":1401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"dapts closely to the P450 3A5 heme (Figure 1D) and enhances ","suffix":" 1′-hydroxylation or cyclosporin A clearance of P450 3A5 [14","exact":"midazolam"},{"setid":"PMC2883751","drugname":"cyclosporin","startOffset":625,"endOffset":636,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"tional CYP3A5 alleles. Enhanced midazolam hydroxylation and ","suffix":" metabolism occur in an in vitro P450 3A5 system and in live","exact":"cyclosporin"},{"setid":"PMC2883751","drugname":"cyclosporin","startOffset":572,"endOffset":583,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"P450 3A enzymes [14]. Inhibitory effects of voriconazole on ","suffix":" oxidation were also determined [14]. To predict the potenti","exact":"cyclosporin"},{"setid":"PMC2883751","drugname":"cyclosporin","startOffset":319,"endOffset":330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"50 3A4 than by P450 3A5 [16]. Using voriconazole to inhibit ","suffix":" oxidation, it was found that voriconazole was a weak inhibi","exact":"cyclosporin"},{"setid":"PMC2883751","drugname":"cyclosporin a","startOffset":1422,"endOffset":1435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"heme (Figure 1D) and enhances midazolam 1′-hydroxylation or ","suffix":" clearance of P450 3A5 [14] via an unexpected phenomenon, wh","exact":"cyclosporin A"},{"setid":"PMC2883751","drugname":"thalidomide","startOffset":748,"endOffset":759,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" in liver microsomes expressing P450 3A5 in the presence of ","suffix":". However, inhibition constants (Ki) of three triazole anti-","exact":"thalidomide"},{"setid":"PMC2883751","drugname":"thalidomide","startOffset":1319,"endOffset":1330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ure 1C) as well as the P450 3A4 heme. It is noteworthy that ","suffix":" adapts closely to the P450 3A5 heme (Figure 1D) and enhance","exact":"thalidomide"},{"setid":"PMC2883751","drugname":"thalidomide","startOffset":1640,"endOffset":1651,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" from that of voriconazole. In our preliminary experiments, ","suffix":" was hydroxylated in a sigmoidal velocity curve vs. substrat","exact":"thalidomide"},{"setid":"PMC2883751","drugname":"thalidomide","startOffset":1901,"endOffset":1912,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"3]. Why the mechanism is different between voriconazole and ","suffix":" is not known but it might be due to substrate molecular siz","exact":"thalidomide"},{"setid":"PMC2883751","drugname":"itraconazole","startOffset":833,"endOffset":845,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ibition constants (Ki) of three triazole anti-fungal drugs (","suffix":", fluconazole, and voriconazole) for liver microsomal P450 3","exact":"itraconazole"},{"setid":"PMC2883751","drugname":"itraconazole","startOffset":153,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ally important for serious, invasive fungal infections [9]. ","suffix":" is a fat-soluble synthetic triazole antifungal drug and is ","exact":"Itraconazole"},{"setid":"PMC2883751","drugname":"itraconazole","startOffset":390,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"e used as enzyme sources [14]. Inhibition constants (Ki) of ","suffix":", fluconazole, and voriconazole were determined against mida","exact":"itraconazole"},{"setid":"PMC2883751","drugname":"itraconazole","startOffset":421,"endOffset":433,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" the enzyme source (Table 2), reported IC50 or Ki values of ","suffix":" indicated 17-fold differences [19-22]. Similar results have","exact":"itraconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":847,"endOffset":858,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"nts (Ki) of three triazole anti-fungal drugs (itraconazole, ","suffix":", and voriconazole) for liver microsomal P450 3A5 are higher","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":441,"endOffset":452,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ely broad spectrum. Voriconazole is structurally related to ","suffix":", but its activity and handling by the body are completely d","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":404,"endOffset":415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"me sources [14]. Inhibition constants (Ki) of itraconazole, ","suffix":", and voriconazole were determined against midazolam hydroxy","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":280,"endOffset":291,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"midazolam varied by a factor of 10 between the Ki values of ","suffix":" toward P450 3A4 and P450 3A5 [17, 18]. With human liver mic","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":513,"endOffset":524,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ifferences [19-22]. Similar results have been obtained with ","suffix":" [18-20, 23, 24]. Apparent differences in Ki of fluconazole ","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":572,"endOffset":583,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" fluconazole [18-20, 23, 24]. Apparent differences in Ki of ","suffix":" were reported between liver microsomes that either do or do","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":864,"endOffset":876,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" triazole anti-fungal drugs (itraconazole, fluconazole, and ","suffix":") for liver microsomal P450 3A5 are higher than for liver mi","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":1232,"endOffset":1244,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"itor]unbound / Ki (as recommended by Japanese MHLW Notice). ","suffix":" would be expected to cause approximately a three-fold highe","exact":"Voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":254,"endOffset":266,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"riazole antifungal drug and is a broad spectrum antifungal. ","suffix":" was approved in Europe and the United States in 2002 for th","exact":"Voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":401,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"invasive Aspergillosis and has an extremely broad spectrum. ","suffix":" is structurally related to fluconazole, but its activity an","exact":"Voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":193,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ance and inhibition of triazole antifungal drugs, including ","suffix":", emphasising polymorphic P450 3A5 expression in genotyped l","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":421,"endOffset":433,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Inhibition constants (Ki) of itraconazole, fluconazole, and ","suffix":" were determined against midazolam hydroxylation catalyzed b","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":556,"endOffset":568,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"iver microsomal P450 3A enzymes [14]. Inhibitory effects of ","suffix":" on cyclosporin oxidation were also determined [14]. To pred","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":1065,"endOffset":1077,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"is the inhibition constant [11, 15]. Docking simulations of ","suffix":" and other substrates in a reported structure of P450 3A4 (P","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":178,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"etabolic pathways catalyzed by P450 2C19 and P450 3A4 [16]. ","suffix":" N-oxidation and 4-hydroxylation are catalyzed more efficien","exact":"Voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":295,"endOffset":307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"d more efficiently by P450 3A4 than by P450 3A5 [16]. Using ","suffix":" to inhibit cyclosporin oxidation, it was found that voricon","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":360,"endOffset":372,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"onazole to inhibit cyclosporin oxidation, it was found that ","suffix":" was a weak inhibitor of P450 3A5. Liver microsomes expressi","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":711,"endOffset":723,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"mol min−1 mg−1 protein and 5.43 µmol l−1 in the presence of ","suffix":" (200 µg ml−1= 573 µmol l−1), respectively, suggesting that ","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":783,"endOffset":795,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" (200 µg ml−1= 573 µmol l−1), respectively, suggesting that ","suffix":" inhibits both by competitive and noncompetitive mechanisms ","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":894,"endOffset":906,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"mpetitive mechanisms [25]. Docking simulation revealed that ","suffix":" can adopt an orientation suitable for N-oxidation over the ","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":1002,"endOffset":1014,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"or N-oxidation over the P450 3A4 heme (Figure 1A). However, ","suffix":" could adopt far from the P450 3A5 heme (Figure 1B), resulti","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":1594,"endOffset":1606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"c co-operativity [13], in a mechanism distinct from that of ","suffix":". In our preliminary experiments, thalidomide was hydroxylat","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":1884,"endOffset":1896,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"co-operativity [13]. Why the mechanism is different between ","suffix":" and thalidomide is not known but it might be due to substra","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":681,"endOffset":693,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"d drug-interactions of triazole antifungal drugs, including ","suffix":", are appreciably affected by the CYP3A5 genotypes (Tables 2","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":1341,"endOffset":1353,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"ed that the highest increased AUC caused by co-administered ","suffix":" would be expected to be low in expressers of P450 3A5 (Tabl","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":213,"endOffset":225,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":" drug clearance and the intensity of drug interactions with ","suffix":". P450 3A5 also shows the heterotropic co-operativity phenom","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":345,"endOffset":357,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":"enon in some cases. Increased AUC caused by co-administered ","suffix":" should be anticipated as a potential cause of toxicity, esp","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"tacrolimus","startOffset":532,"endOffset":542,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"e microsomes expressing P450 3A4 (Table 4). Vmax and Km for ","suffix":" metabolism have been reported to be 1.47 nmol min−1 mg−1 pr","exact":"tacrolimus"}],[{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":246,"endOffset":255,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"receptor-positive tumours. Cytochrome P-450 2D6 metabolises ","suffix":" to metabolites that more readily bind the oestrogen recepto","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":461,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"se widely used drugs - when taken concurrently - may reduce ","suffix":"'s prevention of breast cancer recurrence. We studied citalo","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":822,"endOffset":831,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ogen-receptor-positive breast cancer 1985-2001 and who took ","suffix":" for 1, 2, or most often for 5 years. We ascertained prescri","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1141,"endOffset":1150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"least one prescription for the SSRI citalopram while taking ","suffix":" (adjusted conditional odds ratio=0.85, 95% confidence inter","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1259,"endOffset":1268,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"dence interval=0.42, 1.7). We also observed no reduction of ","suffix":" effectiveness among regular citalopram users (⩾30% overlap ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1333,"endOffset":1342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ctiveness among regular citalopram users (⩾30% overlap with ","suffix":" use). These results suggest that concurrent use of citalopr","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":360,"endOffset":369,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"Collaborative Group, 2005). To be pharmacologically active, ","suffix":" must be metabolised to secondary metabolites that bind the ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":475,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"that bind the oestrogen receptor 100-fold more readily than ","suffix":" itself (Malet et al, 1988). Four cytochrome P-450 enzymes (","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":687,"endOffset":696,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"988). CYP2D6 catalyses formation of 4-hydroxytamoxifen from ","suffix":" (Coller et al, 2002) and formation of 4-hydroxy-N-desmethyl","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":211,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t are metabolised by some of the same enzymes that activate ","suffix":". For example, depression is a common comorbidity in breast ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":535,"endOffset":544,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"lised by CYP2D6 (Zanger et al, 2004). SSRI competition with ","suffix":" and N-desmethyltamoxifen for CYP2D6, or direct inhibition o","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":657,"endOffset":666,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ition of CYP2D6 by SSRI, could reduce the production of the ","suffix":" metabolites with high receptor-binding affinity, and thereb","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":735,"endOffset":744,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tes with high receptor-binding affinity, and thereby reduce ","suffix":"'s prevention of breast cancer recurrence. Competition betwe","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":807,"endOffset":816,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"prevention of breast cancer recurrence. Competition between ","suffix":" and the SSRI paroxetine reduced the plasma concentration of","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":139,"endOffset":148,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"o date of the potential for drug-drug interaction to reduce ","suffix":"'s protection against breast cancer recurrence, we examined ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":309,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"h oestrogen-receptor-positive tumours who were treated with ","suffix":" for 1, 2, or most often for 5 years had a higher rate of re","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":211,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"ed the oestrogen receptor protein and who were treated with ","suffix":" for at least 1 year; (b) group II women whose tumour did no","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":344,"endOffset":353,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"press the oestrogen receptor protein, were not treated with ","suffix":", and who survived for at least one year; and (c) group III ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":512,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"excluded from this analysis. Group I women were assigned to ","suffix":" therapy protocols of 1, 2, or 5 years, depending on the gui","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":163,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"opram prescription, we calculated the percentage of time on ","suffix":" when they were simultaneously taking citalopram. We created","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":318,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"ttent citalopram use, defined as citalopram use overlapping ","suffix":" use for more than 0% but less than 30% of the time on tamox","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":382,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"xifen use for more than 0% but less than 30% of the time on ","suffix":" and (b) regular citalopram use, defined as citalopram use o","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":462,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"gular citalopram use, defined as citalopram use overlapping ","suffix":" use for 30% or more of the time on tamoxifen. We chose 30% ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":507,"endOffset":516,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"se overlapping tamoxifen use for 30% or more of the time on ","suffix":". We chose 30% as the overlap boundary to allow sufficient s","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":167,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"he two groups (oestrogen-receptor positive and treated with ","suffix":" or oestrogen-receptor negative and not treated with tamoxif","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":229,"endOffset":238,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"moxifen or oestrogen-receptor negative and not treated with ","suffix":"). We computed the frequency and proportion of cases and con","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":346,"endOffset":355,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ases and controls within categories of assigned protocol of ","suffix":" duration, of citalopram use, of use of other CYP2D6 inhibit","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":475,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"er the effect of citalopram use was modified by duration of ","suffix":" therapy in a stratified analysis. Finally, we adjusted for ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":725,"endOffset":734,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"en (positive oestrogen-receptor expression and treated with ","suffix":") were more likely to be post-menopausal (87%) than were gro","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":872,"endOffset":881,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"negative oestrogen-receptor expression and not treated with ","suffix":"). Group I women were also less likely to receive systemic a","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":224,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ecurrence than women who never used citalopram while taking ","suffix":" (Table 3; OR=0.79, 95% CI=0.40, 1.6). This OR was not subst","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":326,"endOffset":335,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"1.6). This OR was not substantially modified by duration of ","suffix":" therapy (P=0.23 for test of homogeneity; data not shown). T","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":154,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ort the hypothesis that citalopram, taken concurrently with ","suffix":", reduces tamoxifen's protective effect against breast cance","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":173,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"that citalopram, taken concurrently with tamoxifen, reduces ","suffix":"'s protective effect against breast cancer recurrence in ear","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":294,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" centre, which also reported no substantial modification of ","suffix":" effectiveness by concomitant use of SSRI inhibitors of CYP2","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":542,"endOffset":551,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" support the hypothesis that CYP2D6 inhibition would reduce ","suffix":"'s prevention of breast cancer recurrence. It is possible, h","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":682,"endOffset":691,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"t SSRI medications could reduce the plasma concentration of ","suffix":"'s secondary metabolites without reducing its anti-tumorigen","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":822,"endOffset":831,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"one et al, 2004; Ratliff et al, 2004; Stearns et al, 2004). ","suffix":" doses as much as 20-fold lower than the typical US dose of ","exact":"Tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1070,"endOffset":1079,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"imately three-fold reduction in the plasma concentration of ","suffix":"'s secondary metabolites associated with concomitant receipt","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":134,"endOffset":143,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ic question may be whether reduced concentrations of active ","suffix":" metabolites result in substantially reduced occupancy of th","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":316,"endOffset":325,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ated that, in postmenopausal women on a daily dose of 20 mg ","suffix":", tamoxifen and its metabolites occupy 9994 of 10 000 oestro","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":327,"endOffset":336,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"in postmenopausal women on a daily dose of 20 mg tamoxifen, ","suffix":" and its metabolites occupy 9994 of 10 000 oestrogen recepto","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":465,"endOffset":474,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"cating their calculation using the plasma concentrations of ","suffix":" and its metabolites in women with no CYP2D6 variant allele ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":553,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"s in women with no CYP2D6 variant allele (Jin et al, 2005), ","suffix":" and its metabolites would occupy 9999 of 10 000 receptors i","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":772,"endOffset":781,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"-inhibiting SSRI paroxetine. Steady-state concentrations of ","suffix":" and its metabolites may be sufficient to manifest fully tam","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":838,"endOffset":847,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"fen and its metabolites may be sufficient to manifest fully ","suffix":"'s antitumorigenic effect in postmenopausal women regardless","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":468,"endOffset":477,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"pesen et al, 1996). These more potent inhibitors may reduce ","suffix":"'s protection against breast cancer recurrence, but their in","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":197,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"riants (Hayhurst et al, 2001) that affect the metabolism of ","suffix":" (Jin et al, 2005). The combination of genotype and receipt ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":319,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"eceipt of CYP2D6-inhibiting medications has been related to ","suffix":" effectiveness in a previous study (Goetz et al, 2007). We d","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":451,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ot, however, expect ever-receipt of citalopram while taking ","suffix":" to be related to CYP2D6 genotype, as this genotype would be","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1267,"endOffset":1276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"rrence and duration of citalopram prescription while taking ","suffix":". Some non-randomized studies suggest such a relation betwee","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1798,"endOffset":1807,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"l, 2003). Paroxetine is the most potent CYP2D6 inhibitor of ","suffix":" metabolism among the SSRI class (Jin et al, 2005). If CYP2D","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":149,"endOffset":158,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"udy yielded only 17 cases of breast cancer recurrence among ","suffix":"-treated women who had used citalopram while taking tamoxife","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":210,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"amoxifen-treated women who had used citalopram while taking ","suffix":". The study was designed with 80% power to detect an OR of 1","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":223,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"tration advisory committee recently recommended relabelling ","suffix":" with information on gene-drug and drug-drug interactions me","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":497,"endOffset":506,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":" Network note that some SSRI reduce the formation of active ","suffix":" metabolites, that citalopram and venlaflaxine appear to hav","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":586,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"italopram and venlaflaxine appear to have minimal impact on ","suffix":" metabolism, and that 'the clinical impact of these observat","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":751,"endOffset":760,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"ensive Cancer Network, 2008). Breast cancer patients taking ","suffix":" and their physicians may therefore be concerned about SSRI ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":524,"endOffset":534,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"oxifen's prevention of breast cancer recurrence. We studied ","suffix":" use in 184 cases of breast cancer recurrence and 184 matche","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1117,"endOffset":1127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"trols (11%) received at least one prescription for the SSRI ","suffix":" while taking tamoxifen (adjusted conditional odds ratio=0.8","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1297,"endOffset":1307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"erved no reduction of tamoxifen effectiveness among regular ","suffix":" users (⩾30% overlap with tamoxifen use). These results sugg","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1394,"endOffset":1404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"amoxifen use). These results suggest that concurrent use of ","suffix":" does not reduce tamoxifen's prevention of breast cancer rec","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":430,"endOffset":440,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"te of recurrence if they were concomitantly taking the SSRI ","suffix":" or its S-stereoisomer ('citalopram' from here onwards) than","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":554,"endOffset":564,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":") than if they were not. As described in more detail below, ","suffix":" was the most frequently prescribed SSRI in the study popula","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":703,"endOffset":713,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"cluded group II women to estimate the direct association of ","suffix":" prescription with recurrence rate, if any. We further restr","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1076,"endOffset":1086,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"sed to ascertain use of prescription medications, including ","suffix":". Follow-up time began 1 year after the date of breast cance","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":385,"endOffset":395,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":" the SSRI drugs: zimeldine (N06AB02), fluoxetine (N06AB03), ","suffix":" (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), alap","exact":"citalopram"},{"setid":"PMC2527838","drugname":"escitalopram","startOffset":524,"endOffset":536,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"N06AB07), fluvoxamine (N06AB08), etoperidone (N06AB09), and ","suffix":" (N06AB10). We defined citalopram exposure as any prescripti","exact":"escitalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":559,"endOffset":569,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"operidone (N06AB09), and escitalopram (N06AB10). We defined ","suffix":" exposure as any prescription for citalopram (N06AB04) or it","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":127,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":" classified cases and controls as those with no record of a ","suffix":" prescription during their follow-up time (never citalopram)","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":186,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":" citalopram prescription during their follow-up time (never ","suffix":") and those with any record of prescription for citalopram d","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":244,"endOffset":254,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":"r citalopram) and those with any record of prescription for ","suffix":" during their follow-up time (ever citalopram). We used a si","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":289,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":"escription for citalopram during their follow-up time (ever ","suffix":"). We used a similar procedure to classify cases and control","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":210,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"e of time on tamoxifen when they were simultaneously taking ","suffix":". We created categories of (a) intermittent citalopram use, ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":264,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"aking citalopram. We created categories of (a) intermittent ","suffix":" use, defined as citalopram use overlapping tamoxifen use fo","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":291,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"d categories of (a) intermittent citalopram use, defined as ","suffix":" use overlapping tamoxifen use for more than 0% but less tha","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":408,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":" but less than 30% of the time on tamoxifen and (b) regular ","suffix":" use, defined as citalopram use overlapping tamoxifen use fo","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":435,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"ime on tamoxifen and (b) regular citalopram use, defined as ","suffix":" use overlapping tamoxifen use for 30% or more of the time o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":602,"endOffset":612,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"lap boundary to allow sufficient sample size in the regular ","suffix":" subgroup, while also investigating a substantial period of ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":369,"endOffset":379,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"n categories of assigned protocol of tamoxifen duration, of ","suffix":" use, of use of other CYP2D6 inhibitors or substrates, and o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":519,"endOffset":529,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" calculated the number of cases and controls ever receiving ","suffix":", the number of total prescriptions for citalopram summed ov","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":569,"endOffset":579,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"receiving citalopram, the number of total prescriptions for ","suffix":" summed over all cases or controls, and the range of the num","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":230,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"io (OR) in a conditional logistic regression including only ","suffix":" use as the exposure variable and conditioned on the matched","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":432,"endOffset":442,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"actors (Greenland, 2008). We examined whether the effect of ","suffix":" use was modified by duration of tamoxifen therapy in a stra","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":834,"endOffset":844,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" from the conditional logistic regression model associating ","suffix":" use with breast cancer recurrence rate by more than 10% (Gr","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1276,"endOffset":1286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"receptor. Between 3 and 11% of cases and controls ever used ","suffix":" while taking tamoxifen (group I) or during their follow-up ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":201,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":" both groups, SSRI prescriptions were primarily written for ","suffix":" or its S-stereoisomer, escitalopram. For example, 17 of 23 ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"escitalopram","startOffset":235,"endOffset":247,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ere primarily written for citalopram or its S-stereoisomer, ","suffix":". For example, 17 of 23 group I cases (74%) ever prescribed ","exact":"escitalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":349,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":") ever prescribed an SSRI had at least one prescription for ","suffix":", accounting for 86% of the total number of prescriptions. S","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":519,"endOffset":529,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":") ever prescribed an SSRI had at least one prescription for ","suffix":", accounting for 64% of their prescriptions. Sertraline acco","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":200,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" rate of breast cancer recurrence than women who never used ","suffix":" while taking tamoxifen (Table 3; OR=0.79, 95% CI=0.40, 1.6)","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":614,"endOffset":624,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" effects were likewise approximately null within cumulative ","suffix":" prescription categories (intermittent use OR=0.72, 95% CI 0","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":733,"endOffset":743,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"2, 95% CI 0.30, 1.7; regular use OR=1.1, 95% CI 0.37, 3.3). ","suffix":" use also had no substantial effect on recurrence in group I","exact":"Citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":865,"endOffset":875,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"women (adjusted OR=0.78, 95% CI 0.17, 3.6), suggesting that ","suffix":" does not directly affect the risk of breast cancer recurren","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":118,"endOffset":128,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"he results of this study do not support the hypothesis that ","suffix":", taken concurrently with tamoxifen, reduces tamoxifen's pro","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":207,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"t, the majority of SSRI prescriptions in our study were for ","suffix":" or its S-stereoisomer, both originally manufactured by Lund","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":319,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"nufactured by Lundbeck, a company headquartered in Denmark. ","suffix":" is a modest inhibitor of CYP2D6 compared with some other SS","exact":"Citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":427,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"tz et al, 2007). We do not, however, expect ever-receipt of ","suffix":" while taking tamoxifen to be related to CYP2D6 genotype, as","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":570,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"e would be unknown to the patient and provider at the first ","suffix":" prescription. This study's results therefore pertain to the","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":715,"endOffset":725,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" setting. In addition, CYP2D6 genotype is unlikely to cause ","suffix":" prescription, or to share a common causal ancestor, so CYP2","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":953,"endOffset":963,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"be possible that CYP2D6 genotype is related to adherence to ","suffix":" prescription or to long-term maintenance of the prescriptio","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1230,"endOffset":1240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ssociation between breast cancer recurrence and duration of ","suffix":" prescription while taking tamoxifen. Some non-randomized st","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":817,"endOffset":827,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":" have high sensitivity and specificity for ascertainment of ","suffix":" prescriptions in the source population. Furthermore, becaus","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":186,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ancer recurrence among tamoxifen-treated women who had used ","suffix":" while taking tamoxifen. The study was designed with 80% pow","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":525,"endOffset":535,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":" reduce the formation of active tamoxifen metabolites, that ","suffix":" and venlaflaxine appear to have minimal impact on tamoxifen","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":909,"endOffset":919,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"epressants are strongly indicated. Our results suggest that ","suffix":" prescription does not reduce tamoxifen's prevention of brea","exact":"citalopram"},{"setid":"PMC2527838","drugname":"4-hydroxytamoxifen","startOffset":663,"endOffset":681,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" CYP2C9) (Malet et al, 1988). CYP2D6 catalyses formation of ","suffix":" from tamoxifen (Coller et al, 2002) and formation of 4-hydr","exact":"4-hydroxytamoxifen"},{"setid":"PMC2527838","drugname":"paroxetine","startOffset":830,"endOffset":840,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ncer recurrence. Competition between tamoxifen and the SSRI ","suffix":" reduced the plasma concentration of endoxifen in a cross-ov","exact":"paroxetine"},{"setid":"PMC2527838","drugname":"paroxetine","startOffset":407,"endOffset":417,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"dine (N06AB02), fluoxetine (N06AB03), citalopram (N06AB04), ","suffix":" (N06AB05), sertraline (N06AB06), alaproclate (N06AB07), flu","exact":"paroxetine"},{"setid":"PMC2527838","drugname":"paroxetine","startOffset":729,"endOffset":739,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"receptors in women taking the strong CYP2D6-inhibiting SSRI ","suffix":". Steady-state concentrations of tamoxifen and its metabolit","exact":"paroxetine"},{"setid":"PMC2527838","drugname":"paroxetine","startOffset":1702,"endOffset":1712,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" either the occurrence of adverse events or to adherence to ","suffix":" prescription (Murphy et al, 2003). Paroxetine is the most p","exact":"paroxetine"},{"setid":"PMC2527838","drugname":"paroxetine","startOffset":1748,"endOffset":1758,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" adherence to paroxetine prescription (Murphy et al, 2003). ","suffix":" is the most potent CYP2D6 inhibitor of tamoxifen metabolism","exact":"Paroxetine"},{"setid":"PMC2527838","drugname":"advantage","startOffset":933,"endOffset":942,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"enrol in a trial, so the registry provides the data quality ","suffix":" of a clinical trial setting with the generalisability advan","exact":"advantage"},{"setid":"PMC2527838","drugname":"zimeldine","startOffset":342,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"sified in group N06AB by the ATC. These are the SSRI drugs: ","suffix":" (N06AB02), fluoxetine (N06AB03), citalopram (N06AB04), paro","exact":"zimeldine"},{"setid":"PMC2527838","drugname":"fluoxetine","startOffset":363,"endOffset":373,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":" by the ATC. These are the SSRI drugs: zimeldine (N06AB02), ","suffix":" (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), sert","exact":"fluoxetine"},{"setid":"PMC2527838","drugname":"sertraline","startOffset":429,"endOffset":439,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"tine (N06AB03), citalopram (N06AB04), paroxetine (N06AB05), ","suffix":" (N06AB06), alaproclate (N06AB07), fluvoxamine (N06AB08), et","exact":"sertraline"},{"setid":"PMC2527838","drugname":"sertraline","startOffset":574,"endOffset":584,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":" for citalopram, accounting for 64% of their prescriptions. ","suffix":" accounted for the majority of the remaining prescriptions (","exact":"Sertraline"},{"setid":"PMC2527838","drugname":"alaproclate","startOffset":451,"endOffset":462,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"pram (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), ","suffix":" (N06AB07), fluvoxamine (N06AB08), etoperidone (N06AB09), an","exact":"alaproclate"},{"setid":"PMC2527838","drugname":"fluvoxamine","startOffset":474,"endOffset":485,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"ine (N06AB05), sertraline (N06AB06), alaproclate (N06AB07), ","suffix":" (N06AB08), etoperidone (N06AB09), and escitalopram (N06AB10","exact":"fluvoxamine"},{"setid":"PMC2527838","drugname":"etoperidone","startOffset":497,"endOffset":508,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[1]","prefix":"ne (N06AB06), alaproclate (N06AB07), fluvoxamine (N06AB08), ","suffix":" (N06AB09), and escitalopram (N06AB10). We defined citalopra","exact":"etoperidone"}],[{"setid":"PMC2764168","drugname":"tipranavir","startOffset":739,"endOffset":749,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ax of atorvastatin with TPV/r at steady state versus alone. ","suffix":" PK parameters were not affected by single-dose rosuvastatin","exact":"Tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":219,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"d a single 10-mg dose of rosuvastatin on day 1, followed by ","suffix":" 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":714,"endOffset":724,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"/r at steady state) for rosuvastatin and days 12 and 13 for ","suffix":" and ritonavir. A standard 670-kcal (33% fat) breakfast was ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":1096,"endOffset":1106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"nd 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for ","suffix":" and ritonavir and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":1437,"endOffset":1447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"s undertaken. The short-term safety and steady-state PKs of ","suffix":" and ritonavir coadministered with single-dose rosuvastatin ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"0% adherence with study medication. The steady-state PKs of ","suffix":" were assessed on day 19 after ingestion of TPV/r alone and ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":141,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"MS method was used to measure plasma drug concentrations of ","suffix":" and ritonavir (16). In general terms, ritonavir, tipranavir","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":201,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"tipranavir and ritonavir (16). In general terms, ritonavir, ","suffix":", and an IS are extracted from EDTA human plasma by a two-st","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":575,"endOffset":585,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"acid-acetonitrile mobile phase. For the atorvastatin study, ","suffix":" and an IS (PNU-109011) were extracted from 50 μl of heparin","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":415,"endOffset":425,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","prefix":"arisons. The within-subject variability in the steady-state ","suffix":" AUC0-12 was calculated as the percent difference between th","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":739,"endOffset":749,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ax of atorvastatin with TPV/r at steady state versus alone. ","suffix":" PK parameters were not affected by single-dose rosuvastatin","exact":"Tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":571,"endOffset":581,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" increase in plasma t1/2 (20.6 h versus 9.01 h; P < 0.001). ","suffix":" and ritonavir PK parameters were not affected by single-dos","exact":"Tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":385,"endOffset":395,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"orvastatin PK results from one subject and the steady-state ","suffix":" PK results from another subject were excluded from all stat","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":125,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"le-dose atorvastatin did not affect the steady-state PKs of ","suffix":" (Table ​(Table33).\n                                        ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":534,"endOffset":544,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s, Wilmington, DE). Although in vitro studies indicate that ","suffix":" is an inhibitor of CYP2C9, an in vivo cocktail study determ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":641,"endOffset":651,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"o cocktail study determined that the steady-state levels of ","suffix":" (500 mg) plus ritonavir 200 mg twice daily did not affect c","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":1818,"endOffset":1828,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"oncentrations, by 11-fold and 8-fold, respectively (8, 24). ","suffix":", ritonavir, and lopinavir are also BCRP inhibitors in vitro","exact":"Tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":2214,"endOffset":2224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"nhibition of OATP1B1 and BCRP transporters by ritonavir and ","suffix":". Inhibition of OATP1B1 may lead to a decrease in hepatocyte","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":136,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"rmacokinetic (PK) drug-drug interactions between tipranavir-","suffix":" (TPV/r) and rosuvastatin and atorvastatin, we conducted two","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":237,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ose of rosuvastatin on day 1, followed by tipranavir 500 mg-","suffix":" 200 mg twice daily for 11 days (days 3 to 13), with a singl","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":729,"endOffset":738,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ate) for rosuvastatin and days 12 and 13 for tipranavir and ","suffix":". A standard 670-kcal (33% fat) breakfast was served to subj","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1111,"endOffset":1120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for tipranavir and ","suffix":" and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, ","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1452,"endOffset":1461,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"he short-term safety and steady-state PKs of tipranavir and ","suffix":" coadministered with single-dose rosuvastatin (10 mg) were a","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":156,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"sed to measure plasma drug concentrations of tipranavir and ","suffix":" (16). In general terms, ritonavir, tipranavir, and an IS ar","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":190,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"rations of tipranavir and ritonavir (16). In general terms, ","suffix":", tipranavir, and an IS are extracted from EDTA human plasma","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":586,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"asma t1/2 (20.6 h versus 9.01 h; P < 0.001). Tipranavir and ","suffix":" PK parameters were not affected by single-dose rosuvastatin","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":666,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ed that the steady-state levels of tipranavir (500 mg) plus ","suffix":" 200 mg twice daily did not affect concentrations of plasma ","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1830,"endOffset":1839,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s, by 11-fold and 8-fold, respectively (8, 24). Tipranavir, ","suffix":", and lopinavir are also BCRP inhibitors in vitro (19, 27). ","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1979,"endOffset":1988,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ent inhibition of [3H]estradiol-17β-d-glucuronide uptake by ","suffix":" is also observed in OATP1B1-transfected HeLa cells and OATP","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":2200,"endOffset":2209,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"sult of dual inhibition of OATP1B1 and BCRP transporters by ","suffix":" and tipranavir. Inhibition of OATP1B1 may lead to a decreas","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1106,"endOffset":1115,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" of various CYP3A4 and/or Pgp substrates in the presence of ","suffix":" (e.g., digoxin and saquinavir) (22, 26). Similarly near-com","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":173,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tion studies evaluating the effect of another PI, lopinavir-","suffix":" (LPV/r), when coadministered with rosuvastatin at steady st","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":756,"endOffset":765,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ith lopinavir in vitro (27). Coadministration of atazanavir-","suffix":" with rosuvastatin was found to result in a 210% increase in","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":916,"endOffset":925,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" no significant interaction was observed with fosamprenavir-","suffix":" (2). The lack of interaction observed with fosamprenavir-ri","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":983,"endOffset":992,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ir (2). The lack of interaction observed with fosamprenavir-","suffix":" may be due to its low BCRP and OATP1B1 inhibitory potential","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1907,"endOffset":1916,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"17 to 20 September 2000) (5). The combination of saquinavir-","suffix":" 400 mg/400 mg twice daily increased the median atorvastatin","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":2361,"endOffset":2370,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"g once daily for 14 days (11). The combination of darunavir-","suffix":" 300 mg/100 mg twice daily with atorvastatin 10 mg daily res","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":158,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-drug interactions between tipranavir-ritonavir (TPV/r) and ","suffix":" and atorvastatin, we conducted two prospective, open-label,","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":405,"endOffset":417,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":") for the area under the concentration-time curve (AUC) for ","suffix":" and 2.23 (90% CI, 1.83 to 2.72) for the maximum concentrati","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":508,"endOffset":520,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":") for the maximum concentration of drug in serum (Cmax) for ","suffix":" with TPV/r at steady state versus alone. The GM ratio was 9","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":251,"endOffset":263,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" (P = 0.0006) (Fig. ​(Fig.11 and ​and2).2). The GM Cmax for ","suffix":" was 5.78 ng/ml with TPV/r coadministration, a 123% increase","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":797,"endOffset":809,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":". Tipranavir PK parameters were not affected by single-dose ","suffix":" or atorvastatin. Mild gastrointestinal intolerance, headach","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1051,"endOffset":1063,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ed on these interactions, we recommend low initial doses of ","suffix":" (5 mg) and atorvastatin (10 mg), with careful clinical moni","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1133,"endOffset":1145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"d atorvastatin (10 mg), with careful clinical monitoring of ","suffix":"- or atorvastatin-related adverse events when combined with ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1673,"endOffset":1685,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":".g., atorvastatin [Lipitor; Pfizer, Inc., New York, NY] and ","suffix":" [Crestor; AstraZeneca Pharmaceuticals, Wilmington, DE]) are","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"crestor","startOffset":1687,"endOffset":1694,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"tin [Lipitor; Pfizer, Inc., New York, NY] and rosuvastatin [","suffix":"; AstraZeneca Pharmaceuticals, Wilmington, DE]) are recommen","exact":"Crestor"},{"setid":"PMC2764168","drugname":"crestor","startOffset":188,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t a CYP3A4 substrate and it is not extensively metabolized (","suffix":" package insert; AstraZeneca Pharmaceuticals, Wilmington, DE","exact":"Crestor"},{"setid":"PMC2764168","drugname":"crestor","startOffset":424,"endOffset":431,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"tin. This major metabolite is formed principally by CYP2C9 (","suffix":" package insert; AstraZeneca Pharmaceuticals, Wilmington, DE","exact":"Crestor"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":436,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"rug interactions between steady-state TPV/r and single-dose ","suffix":" (\"rosuvastatin study\") and atorvastatin (\"atorvastatin stud","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":451,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"s between steady-state TPV/r and single-dose rosuvastatin (\"","suffix":" study\") and atorvastatin (\"atorvastatin study\").\n          ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":184,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"dy-state PK study. Subjects received a single 10-mg dose of ","suffix":" on day 1, followed by tipranavir 500 mg-ritonavir 200 mg tw","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":322,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ily for 11 days (days 3 to 13), with a single 10-mg dose of ","suffix":" given on day 12. All study drug doses were given under dire","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":678,"endOffset":690,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"f TPV/r) and days 12 to 14 (with TPV/r at steady state) for ","suffix":" and days 12 and 13 for tipranavir and ritonavir. A standard","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1206,"endOffset":1218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h postdose for ","suffix":". A pharmacokinetic comparison of single-dose rosuvastatin w","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1264,"endOffset":1276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"r rosuvastatin. A pharmacokinetic comparison of single-dose ","suffix":" with single-dose rosuvastatin coadministered with TPV/r 500","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1294,"endOffset":1306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"tic comparison of single-dose rosuvastatin with single-dose ","suffix":" coadministered with TPV/r 500 mg/200 mg twice daily at stea","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":157,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"ped and validated by PPD (Richmond, VA) for the analysis of ","suffix":" in human plasma containing dipotassium EDTA. A 200-μl-sampl","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":205,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","prefix":" variation (CV) would range from 20% to 40% for the AUCs of ","suffix":" and atorvastatin. Therefore, a sample size of 20 would prov","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":105,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"                With TPV/r coadministration, the GM AUC for ","suffix":" was 38.6 ng·h/ml, a 37% increase compared with that of rosu","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":173,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"atin was 38.6 ng·h/ml, a 37% increase compared with that of ","suffix":" alone (P = 0.0006) (Fig. ​(Fig.11 and ​and2).2). The GM Cma","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":251,"endOffset":263,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" (P = 0.0006) (Fig. ​(Fig.11 and ​and2).2). The GM Cmax for ","suffix":" was 5.78 ng/ml with TPV/r coadministration, a 123% increase","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":346,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"V/r coadministration, a 123% increase compared with that of ","suffix":" alone (P < 0.001) (Table ​(Table1).1). Rosuvastatin clearan","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":398,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"that of rosuvastatin alone (P < 0.001) (Table ​(Table1).1). ","suffix":" clearance (CL) also was decreased by 27% with TPV/r coadmin","exact":"Rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":643,"endOffset":655,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"nd ritonavir PK parameters were not affected by single-dose ","suffix":" (see Table ​Table33).\n                                     ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1377,"endOffset":1389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"k of hepatotoxicity with the coadministration of TPV/r plus ","suffix":" could not be assessed since all liver enzyme elevations occ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":125,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"g interaction was predicted to be unlikely to occur between ","suffix":" and TPV/r since rosuvastatin is not a known substrate, inhi","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":154,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"o be unlikely to occur between rosuvastatin and TPV/r since ","suffix":" is not a known substrate, inhibitor, or inducer of CYP3A4. ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":239,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"wn substrate, inhibitor, or inducer of CYP3A4. Furthermore, ","suffix":" is not extensively metabolized, with approximately 10% of a","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":355,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"imately 10% of a radiolabeled dose recovered as N-desmethyl ","suffix":". This major metabolite is formed principally by CYP2C9 (Cre","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"crestor","startOffset":188,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t a CYP3A4 substrate and it is not extensively metabolized (","suffix":" package insert; AstraZeneca Pharmaceuticals, Wilmington, DE","exact":"Crestor"},{"setid":"PMC2764168","drugname":"crestor","startOffset":424,"endOffset":431,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"tin. This major metabolite is formed principally by CYP2C9 (","suffix":" package insert; AstraZeneca Pharmaceuticals, Wilmington, DE","exact":"Crestor"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":945,"endOffset":957,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"y, 16 to 18 April 2007). When TPV/r was coadministered with ","suffix":" at steady state, the AUC0-∞ and Cmax of rosuvastatin were i","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":998,"endOffset":1010,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"d with rosuvastatin at steady state, the AUC0-∞ and Cmax of ","suffix":" were increased by 37% and 123%, respectively, after single-","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1075,"endOffset":1087,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" increased by 37% and 123%, respectively, after single-dose ","suffix":". Similarly, concomitant administration of steady-state TPV/","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1313,"endOffset":1325,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ntly higher. The differential effect of TPV/r on the PKs of ","suffix":" and atorvastatin may be due to the difference in the mechan","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":544,"endOffset":556,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"statins (i.e., pravastatin, cerivastatin, atorvastatin, and ","suffix":") (7, 10). BCRP is expressed in many tissue barriers through","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1592,"endOffset":1604,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" was associated with significant increased atorvastatin and ","suffix":" AUC values of 72% and 100%, respectively (13). Cyclosporine","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1721,"endOffset":1733,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ine, an OATP1B1 and BCRP inhibitor, significantly increases ","suffix":" and atorvastatin serum concentrations, by 11-fold and 8-fol","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":2295,"endOffset":2307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"n of OATP1B1 may lead to a decrease in hepatocyte uptake of ","suffix":" and atorvastatin, whereas inhibition of BCRP decreases hepa","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1439,"endOffset":1451,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" resulting in no change in the t1/2. On the other hand, the ","suffix":" t1/2 was increased by approximately twofold. This finding s","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":217,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"r PI, lopinavir-ritonavir (LPV/r), when coadministered with ","suffix":" at steady state. A prospective study conducted with healthy","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":312,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"spective study conducted with healthy volunteers found that ","suffix":" AUC0-∞ and Cmax were increased 2.1- and 4.7-fold, respectiv","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":575,"endOffset":587,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ver, the magnitude of the drug interaction observed between ","suffix":" and LPV/r was severalfold higher. This effect may be due to","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":771,"endOffset":783,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"n vitro (27). Coadministration of atazanavir-ritonavir with ","suffix":" was found to result in a 210% increase in the rosuvastatin ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":830,"endOffset":842,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" rosuvastatin was found to result in a 210% increase in the ","suffix":" AUC; however, no significant interaction was observed with ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":669,"endOffset":681,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"or delavirdine (3, 18). Although the safety and efficacy of ","suffix":" and atorvastatin could not be assessed by these single-dose","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":118,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"n conclusion, we observed a clinically relevant increase in ","suffix":" and atorvastatin concentrations during coadministration of ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":269,"endOffset":281,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" twice daily. Based on these results, a low initial dose of ","suffix":" (5 mg) and atorvastatin (10 mg) is recommended when combine","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":429,"endOffset":441,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[2]","prefix":"tawa Hospital and the Ottawa Health Research Institute. The ","suffix":" study is supported by a GCRC grant (RR-00052) and an invest","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":623,"endOffset":635,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"he GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of ","suffix":" and 8.61 (90% CI, 7.25 to 10.21) for the Cmax of atorvastat","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":685,"endOffset":697,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"orvastatin and 8.61 (90% CI, 7.25 to 10.21) for the Cmax of ","suffix":" with TPV/r at steady state versus alone. Tipranavir PK para","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":813,"endOffset":825,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"parameters were not affected by single-dose rosuvastatin or ","suffix":". Mild gastrointestinal intolerance, headache, and mild reve","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1075,"endOffset":1087,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":", we recommend low initial doses of rosuvastatin (5 mg) and ","suffix":" (10 mg), with careful clinical monitoring of rosuvastatin- ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1150,"endOffset":1162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"0 mg), with careful clinical monitoring of rosuvastatin- or ","suffix":"-related adverse events when combined with TPV/r.\n          ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1618,"endOffset":1630,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"l-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (e.g., ","suffix":" [Lipitor; Pfizer, Inc., New York, NY] and rosuvastatin [Cre","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1927,"endOffset":1939,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"clinically significant drug-drug interactions with PIs (5). ","suffix":" is metabolized extensively by cytochrome P450 3A4 (CYP3A4) ","exact":"Atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":2094,"endOffset":2106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"nhibitory activity for HMG-CoA reductase similar to that of ","suffix":". Approximately 70% of the circulating inhibitory activity f","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1075,"endOffset":1087,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":", we recommend low initial doses of rosuvastatin (5 mg) and ","suffix":" (10 mg), with careful clinical monitoring of rosuvastatin- ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":476,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"V/r and single-dose rosuvastatin (\"rosuvastatin study\") and ","suffix":" (\"atorvastatin study\").\n                                   ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1192,"endOffset":1204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":", 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ","suffix":" (14 samples).\n                                             ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":385,"endOffset":397,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"V/r inhibited the formation of orthohydroxy and parahydroxy ","suffix":" and reduced the AUC0-∞ by 89% (P = 0.002) and 82% (P = 0.00","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1738,"endOffset":1750,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"nd BCRP inhibitor, significantly increases rosuvastatin and ","suffix":" serum concentrations, by 11-fold and 8-fold, respectively (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":2284,"endOffset":2296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"by 1.7- and 2.2-fold, respectively, after administration of ","suffix":" 10 mg once daily for 14 days (11). The combination of darun","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":293,"endOffset":305,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"hese results, a low initial dose of rosuvastatin (5 mg) and ","suffix":" (10 mg) is recommended when combined with TPV/r, with caref","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":205,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"vastatin were assessed on day 1 after ingestion of 40 mg of ","suffix":" alone. From days 14 to 21, subjects received TPV/r 500 mg/2","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":766,"endOffset":778,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"on of TPV/r 500 mg/200 mg twice daily plus a single dose of ","suffix":" 10 mg, as an increase in atorvastatin concentrations was ex","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":804,"endOffset":816,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"plus a single dose of atorvastatin 10 mg, as an increase in ","suffix":" concentrations was expected in combination with steady-stat","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":944,"endOffset":956,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"at 500 mg/200 mg twice daily. Blood samples for analysis of ","suffix":" and hydroxy metabolites were collected on days 1 and 20 in ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":736,"endOffset":748,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"mode. The lower limits of quantitation were 0.225 ng/ml for ","suffix":", 0.250 ng/ml for parahydroxy atorvastatin, and 0.175 ng/ml ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":778,"endOffset":790,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"e 0.225 ng/ml for atorvastatin, 0.250 ng/ml for parahydroxy ","suffix":", and 0.175 ng/ml for orthohydroxy atorvastatin using a 200-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":825,"endOffset":837,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":" parahydroxy atorvastatin, and 0.175 ng/ml for orthohydroxy ","suffix":" using a 200-μl sample.\n                                    ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":555,"endOffset":567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":" formic acid-acetic acid-acetonitrile mobile phase. For the ","suffix":" study, tipranavir and an IS (PNU-109011) were extracted fro","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":117,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","prefix":"    Prior to statistical analysis of the effect of TPV/r on ","suffix":" (day 1 versus day 20), the atorvastatin AUC0-∞ and Cmax wer","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":157,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","prefix":" effect of TPV/r on atorvastatin (day 1 versus day 20), the ","suffix":" AUC0-∞ and Cmax were multiplied by 4 to adjust for the diff","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":670,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"incidentally, the formation of orthohydroxy and parahydroxy ","suffix":" was inhibited. The AUC0-∞ values of these metabolites were ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":239,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","prefix":"d Cmax were multiplied by 4 to adjust for the difference in ","suffix":" dose between day 1 (40 mg) and day 20 (10 mg). No dose adju","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":338,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":"ted as the sum of the time-specific molar concentrations of ","suffix":" (normalized for a 40-mg dose), orthohydroxy atorvastatin, a","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":222,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","prefix":"ould range from 20% to 40% for the AUCs of rosuvastatin and ","suffix":". Therefore, a sample size of 20 would provide >90% power to","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":323,"endOffset":335,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" kg, and a median height of 168 (range, 158 to 189) cm. The ","suffix":" PK results from one subject and the steady-state tipranavir","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":95,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"                          TPV/r increased the dose-adjusted ","suffix":" AUC0-∞ and Cmax by approximately ninefold (Table ​(Table2;2","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":309,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"d almost proportionally, there was no effect on the t1/2 of ","suffix":". TPV/r inhibited the formation of orthohydroxy and parahydr","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":385,"endOffset":397,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"V/r inhibited the formation of orthohydroxy and parahydroxy ","suffix":" and reduced the AUC0-∞ by 89% (P = 0.002) and 82% (P = 0.00","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":161,"endOffset":173,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[1]","prefix":"200 mg twice daily alone and in the presence of single-dose ","suffix":" was well tolerated in this study. There were no study disco","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1187,"endOffset":1199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"of steady-state TPV/r significantly increased the AUC0-∞ of ","suffix":". However, the atorvastatin AUC increase was significantly h","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1214,"endOffset":1226,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ficantly increased the AUC0-∞ of atorvastatin. However, the ","suffix":" AUC increase was significantly higher. The differential eff","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1330,"endOffset":1342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"differential effect of TPV/r on the PKs of rosuvastatin and ","suffix":" may be due to the difference in the mechanisms of interacti","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":526,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s include several statins (i.e., pravastatin, cerivastatin, ","suffix":", and rosuvastatin) (7, 10). BCRP is expressed in many tissu","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1575,"endOffset":1587,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ealthy volunteers was associated with significant increased ","suffix":" and rosuvastatin AUC values of 72% and 100%, respectively (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1738,"endOffset":1750,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"nd BCRP inhibitor, significantly increases rosuvastatin and ","suffix":" serum concentrations, by 11-fold and 8-fold, respectively (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":2312,"endOffset":2324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"lead to a decrease in hepatocyte uptake of rosuvastatin and ","suffix":", whereas inhibition of BCRP decreases hepatobiliary excreti","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ediated interaction, inhibition of first-pass metabolism of ","suffix":", rather than inhibition of its systemic metabolism, may exp","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":264,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"s systemic metabolism, may explain the 8.6-fold increase in ","suffix":" Cmax (an 8.6-fold increase) without an effect on the t1/2. ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":373,"endOffset":385,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"an effect on the t1/2. The absolute oral bioavailability of ","suffix":" is low (14%), which is likely a result of the combined effe","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":589,"endOffset":601,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"drug efflux transporter Pgp (4). Assuming the linear PKs of ","suffix":" (23), coincidentally, the formation of orthohydroxy and par","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":670,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"incidentally, the formation of orthohydroxy and parahydroxy ","suffix":" was inhibited. The AUC0-∞ values of these metabolites were ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":938,"endOffset":950,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"cts on Pgp (5) and may thus increase the bioavailability of ","suffix":", as suggested in the current study. Previous studies have r","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1195,"endOffset":1207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"saquinavir) (22, 26). Similarly near-complete absorption of ","suffix":" in the presence of TPV/r (F ≈ 100%) may explain the observe","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":464,"endOffset":476,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ered with LPV/r (14). Similar to the results of the current ","suffix":" study, the t1/2 was not affected; however, the magnitude of","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1292,"endOffset":1304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"al Scientists [AAPS], November 2008). Increased exposure to ","suffix":" has previously been observed in combination with other HIV ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1484,"endOffset":1496,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"stration with LPV/r 400 mg/100 mg twice daily increased the ","suffix":" (20 mg once daily) AUC0-24 and Cmax by 5.9- and 4.7-fold, r","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1964,"endOffset":1976,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ir-ritonavir 400 mg/400 mg twice daily increased the median ","suffix":" (40 mg) AUC0-24 by 3.5-fold and the AUC0-24 of the total HM","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":2284,"endOffset":2296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"by 1.7- and 2.2-fold, respectively, after administration of ","suffix":" 10 mg once daily for 14 days (11). The combination of darun","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":2402,"endOffset":2414,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ation of darunavir-ritonavir 300 mg/100 mg twice daily with ","suffix":" 10 mg daily resulted in an AUC0-24 that was 15% lower than ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":2489,"endOffset":2501,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"sulted in an AUC0-24 that was 15% lower than the AUC0-24 of ","suffix":" 40 mg daily alone, suggesting an almost fourfold increase i","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":2567,"endOffset":2579,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" daily alone, suggesting an almost fourfold increase in the ","suffix":" AUC0-24 (R. M. W. Hoetelmans, A. Lasure, A. Koester, M. de ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":460,"endOffset":472,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ed metabolism are used concomitantly (21). Several cases of ","suffix":"-associated rhabdomyolysis have been reported in patients us","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":536,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ociated rhabdomyolysis have been reported in patients using ","suffix":" in combination with CYP3A4 inhibitors, such as cyclosporine","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":686,"endOffset":698,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":", 18). Although the safety and efficacy of rosuvastatin and ","suffix":" could not be assessed by these single-dose studies, to mini","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":135,"endOffset":147,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"observed a clinically relevant increase in rosuvastatin and ","suffix":" concentrations during coadministration of TPV/r 500 mg/200 ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":293,"endOffset":305,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"hese results, a low initial dose of rosuvastatin (5 mg) and ","suffix":" (10 mg) is recommended when combined with TPV/r, with caref","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"lipitor","startOffset":1632,"endOffset":1639,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"nzyme A (HMG-CoA) reductase inhibitors (e.g., atorvastatin [","suffix":"; Pfizer, Inc., New York, NY] and rosuvastatin [Crestor; Ast","exact":"Lipitor"},{"setid":"PMC2764168","drugname":"cholesterol","startOffset":376,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"erse effects (AEs) that include increased triglycerides and ","suffix":". NIAID Division of AIDS (DAIDS) grade 3 to 4 cholesterol el","exact":"cholesterol"},{"setid":"PMC2764168","drugname":"cholesterol","startOffset":433,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"nd cholesterol. NIAID Division of AIDS (DAIDS) grade 3 to 4 ","suffix":" elevation (>400 mg/dl) and grade 3 to 4 triglyceride elevat","exact":"cholesterol"},{"setid":"PMC2764168","drugname":"cholesterol","startOffset":653,"endOffset":664,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" PI-treated patients in phase III studies (9). Grade 3 to 4 ","suffix":" elevation was 4.3 versus 0.6/100 patient exposure years, an","exact":"cholesterol"},{"setid":"PMC2764168","drugname":"methylxanthine","startOffset":712,"endOffset":726,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"milk thistle) starting 5 days prior to the first study day. ","suffix":"-containing foods or drinks were not allowed within 72 h pri","exact":"Methylxanthine"},{"setid":"PMC2764168","drugname":"caffeine","startOffset":862,"endOffset":870,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" within 30 min before morning medication administration. No ","suffix":" or food was allowed until 5 h postdose. No grapefruit juice","exact":"caffeine"},{"setid":"PMC2764168","drugname":"edta","startOffset":1016,"endOffset":1020,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" and hydroxy metabolites were collected on days 1 and 20 in ","suffix":"-containing tubes by an indwelling catheter or the venipunct","exact":"EDTA"},{"setid":"PMC2764168","drugname":"edta","startOffset":363,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"as ISs. Briefly, the analytes were extracted from 200 μl of ","suffix":" plasma by solid-phase extraction using C8 cartridges. After","exact":"EDTA"},{"setid":"PMC2764168","drugname":"edta","startOffset":242,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":" terms, ritonavir, tipranavir, and an IS are extracted from ","suffix":" human plasma by a two-step liquid-liquid extraction using a","exact":"EDTA"},{"setid":"PMC2764168","drugname":"dipotassium edta","startOffset":197,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"for the analysis of rosuvastatin in human plasma containing ","suffix":". A 200-μl-sample aliquot was fortified with 200 μl of inter","exact":"dipotassium EDTA"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":372,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"lytes were isolated by protein precipitation with 400 μl of ","suffix":". Sample extraction steps were controlled and automated usin","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":671,"endOffset":683,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"emaining residue was reconstituted with 150 μl of 20:80:0.1 ","suffix":"-water-formic acid (vol/vol/vol). The final extract was anal","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":520,"endOffset":532,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"Polar RP column (Phenomenex) with a formic acid-acetic acid-","suffix":" mobile phase. For the atorvastatin study, tipranavir and an","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"alanine","startOffset":143,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","prefix":"one subject with an asymptomatic DAIDS grade 3 elevation in ","suffix":" aminotransferase, there were no clinically relevant changes","exact":"alanine"},{"setid":"PMC2764168","drugname":"alanine","startOffset":347,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","prefix":"rom the median baseline were observed for triglycerides and ","suffix":" aminotransferase levels, which increased by 1.7-fold and 3.","exact":"alanine"},{"setid":"PMC2764168","drugname":"warfarin","startOffset":737,"endOffset":745,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"00 mg twice daily did not affect concentrations of plasma S-","suffix":", a CYP2C9 substrate (M. Vourvahis, presented at the Eighth ","exact":"warfarin"},{"setid":"PMC2764168","drugname":"pravastatin","startOffset":499,"endOffset":510,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s. These types of substrates include several statins (i.e., ","suffix":", cerivastatin, atorvastatin, and rosuvastatin) (7, 10). BCR","exact":"pravastatin"},{"setid":"PMC2764168","drugname":"cerivastatin","startOffset":512,"endOffset":524,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s of substrates include several statins (i.e., pravastatin, ","suffix":", atorvastatin, and rosuvastatin) (7, 10). BCRP is expressed","exact":"cerivastatin"},{"setid":"PMC2764168","drugname":"nitrofurantoin","startOffset":1249,"endOffset":1263,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" BCRP 1 knockout murine model. The plasma concentrations of ","suffix":", a substrate of BCRP, were increased by fourfold and twofol","exact":"nitrofurantoin"},{"setid":"PMC2764168","drugname":"cyclosporine","startOffset":1652,"endOffset":1664,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"rosuvastatin AUC values of 72% and 100%, respectively (13). ","suffix":", an OATP1B1 and BCRP inhibitor, significantly increases ros","exact":"Cyclosporine"},{"setid":"PMC2764168","drugname":"cyclosporine","startOffset":596,"endOffset":608,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"atorvastatin in combination with CYP3A4 inhibitors, such as ","suffix":" or delavirdine (3, 18). Although the safety and efficacy of","exact":"cyclosporine"},{"setid":"PMC2764168","drugname":"lopinavir","startOffset":1845,"endOffset":1854,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"nd 8-fold, respectively (8, 24). Tipranavir, ritonavir, and ","suffix":" are also BCRP inhibitors in vitro (19, 27). Concentration-d","exact":"lopinavir"},{"setid":"PMC2764168","drugname":"lopinavir","startOffset":163,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ug interaction studies evaluating the effect of another PI, ","suffix":"-ritonavir (LPV/r), when coadministered with rosuvastatin at","exact":"lopinavir"},{"setid":"PMC2764168","drugname":"lopinavir","startOffset":700,"endOffset":709,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" due to the higher inhibitory potency of BCRP observed with ","suffix":" in vitro (27). Coadministration of atazanavir-ritonavir wit","exact":"lopinavir"},{"setid":"PMC2764168","drugname":"estradiol","startOffset":1941,"endOffset":1950,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"n vitro (19, 27). Concentration-dependent inhibition of [3H]","suffix":"-17β-d-glucuronide uptake by ritonavir is also observed in O","exact":"estradiol"},{"setid":"PMC2764168","drugname":"digoxin","startOffset":1123,"endOffset":1130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"4 and/or Pgp substrates in the presence of ritonavir (e.g., ","suffix":" and saquinavir) (22, 26). Similarly near-complete absorptio","exact":"digoxin"},{"setid":"PMC2764168","drugname":"saquinavir","startOffset":1135,"endOffset":1145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" substrates in the presence of ritonavir (e.g., digoxin and ","suffix":") (22, 26). Similarly near-complete absorption of atorvastat","exact":"saquinavir"},{"setid":"PMC2764168","drugname":"saquinavir","startOffset":1896,"endOffset":1906,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"o, Canada, 17 to 20 September 2000) (5). The combination of ","suffix":"-ritonavir 400 mg/400 mg twice daily increased the median at","exact":"saquinavir"},{"setid":"PMC2764168","drugname":"atazanavir","startOffset":745,"endOffset":755,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" observed with lopinavir in vitro (27). Coadministration of ","suffix":"-ritonavir with rosuvastatin was found to result in a 210% i","exact":"atazanavir"},{"setid":"PMC2764168","drugname":"fosamprenavir","startOffset":902,"endOffset":915,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" AUC; however, no significant interaction was observed with ","suffix":"-ritonavir (2). The lack of interaction observed with fosamp","exact":"fosamprenavir"},{"setid":"PMC2764168","drugname":"fosamprenavir","startOffset":969,"endOffset":982,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"enavir-ritonavir (2). The lack of interaction observed with ","suffix":"-ritonavir may be due to its low BCRP and OATP1B1 inhibitory","exact":"fosamprenavir"},{"setid":"PMC2764168","drugname":"nelfinavir","startOffset":2089,"endOffset":2099,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"otal HMG-CoA reductase inhibitory activity by 1.8-fold (5). ","suffix":", a moderately strong inhibitor of CYP3A4, increased the AUC","exact":"Nelfinavir"},{"setid":"PMC2764168","drugname":"darunavir","startOffset":2351,"endOffset":2360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tatin 10 mg once daily for 14 days (11). The combination of ","suffix":"-ritonavir 300 mg/100 mg twice daily with atorvastatin 10 mg","exact":"darunavir"},{"setid":"PMC2764168","drugname":"delavirdine","startOffset":612,"endOffset":623,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"combination with CYP3A4 inhibitors, such as cyclosporine or ","suffix":" (3, 18). Although the safety and efficacy of rosuvastatin a","exact":"delavirdine"}],[{"setid":"PMC1884432","drugname":"rifampicin","startOffset":193,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"s, 10 healthy volunteers received a 5-day pretreatment with ","suffix":" (600 mg daily) or placebo. On day 6, a single 40 mg dose of","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":401,"endOffset":411,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"e of the 10 subjects the AUC(0-∞) of pravastatin during the ","suffix":" phase was 50% or less of that during the placebo phase. Rif","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":468,"endOffset":478,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"cin phase was 50% or less of that during the placebo phase. ","suffix":" had no significant effect on the peak concentration, elimin","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":235,"endOffset":245,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ingle oral dose to healthy subjects. However, the effect of ","suffix":" varied greatly between subjects. The mean rifampicin-induce","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":288,"endOffset":298,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ect of rifampicin varied greatly between subjects. The mean ","suffix":"-induced decrease in pravastatin concentration was considera","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":178,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"P) enzymes both in the intestinal wall and the liver [1-3]. ","suffix":" also induces the expression of some drug transporters, for ","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":427,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"RP2) [5]. Induction of CYP enzymes and drug transporters by ","suffix":" is mediated by the activation of the nuclear pregnane X rec","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":646,"endOffset":656,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ATP-C or LST-1) and OATP8 (LST-2) can mediate the uptake of ","suffix":" into liver cells, and thus facilitate rifampicin mediated P","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":695,"endOffset":705,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" uptake of rifampicin into liver cells, and thus facilitate ","suffix":" mediated PXR activation [8]. Recently we showed that rifamp","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":759,"endOffset":769,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"mpicin mediated PXR activation [8]. Recently we showed that ","suffix":" decreases the total area under the plasma concentration-tim","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":960,"endOffset":970,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"argely unknown. Thus, the extent of any interaction between ","suffix":" and pravastatin cannot be inferred from previous work. The ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1086,"endOffset":1096,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The aim of this study was to examine the possible effect of ","suffix":" on the pharmacokinetics of pravastatin in healthy volunteer","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":408,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"n the phases was 4 weeks. Subjects were given either 600 mg ","suffix":" (Rifarm, Pharmacal, Helsinki, Finland) or matched placebo o","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":696,"endOffset":706,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"h 150 ml water at 9 AM, that is 17 h after the last dose of ","suffix":". The subjects had fasted overnight, and a standard meal was","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":277,"endOffset":287,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" calculated on the mean differences between the placebo and ","suffix":" phases for AUC(0-∞), Cmax and t1/2. Statistical comparisons","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":677,"endOffset":687,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":". The Mann-Whitney U-test was used to compare the effect of ","suffix":" on the AUC(0-∞) of pravastatin and simvastatin acid [9]. Th","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":296,"endOffset":306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ere were large interindividual differences in the effect of ","suffix":". Thus, the AUC(0-∞) of pravastatin decreased in 7 and incre","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":520,"endOffset":530,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" placebo phase or to the gender of the subjects (Figure 2). ","suffix":" tended to decrease the Cmax of pravastatin, on average by 2","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":664,"endOffset":674,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"fference did not reach statistical significance (P = 0.13). ","suffix":" had no statistically significant effect on the tmax (P = 0.","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":889,"endOffset":899,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"on of pravastatin into the urine were largely unaffected by ","suffix":" (P = 0.14 and P = 0.35, respectively).\n                    ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":316,"endOffset":326,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"al protocol (Figure 3) [9]. The difference in the effect of ","suffix":" on the AUC(0-∞) of pravastatin compared to simvastatin acid","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":159,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" pravastatin were moderately decreased by pretreatment with ","suffix":". The mean AUC(0-∞) of pravastatin was decreased by 31%, but","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":346,"endOffset":356,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"e of the 10 subjects the AUC(0-∞) of pravastatin during the ","suffix":" phase was 50% or less of that during the placebo phase. How","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":502,"endOffset":512,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"e plasma concentrations of pravastatin increased during the ","suffix":" phase. The other pharmacokinetic variables studied were not","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":643,"endOffset":653,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" a statistically significant degree. Although the effect of ","suffix":" was statistically significant, the possibility of chance fi","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":551,"endOffset":561,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"sorption, tissue uptake and elimination of substrate drugs. ","suffix":" is known to induce duodenal MRP2 mRNA and MRP2 protein [5],","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":731,"endOffset":741,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"rates of this transporter. Induction of canalicular MRP2 by ","suffix":" might also decrease systemic pravastatin absorption by enha","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":949,"endOffset":959,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"in-pravastatin interaction is a consequence of an effect of ","suffix":" on MRP2 or other transporting proteins. Fromm et al. [5] ob","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1031,"endOffset":1041,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"other transporting proteins. Fromm et al. [5] observed that ","suffix":" induced duodenal MRP2 protein in only 10 out of the 16 subj","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1150,"endOffset":1160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"the 16 subjects [5], which is in line with our results that ","suffix":" only decreased pravastatin AUC in 7 out of 10 subjects (Fig","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1384,"endOffset":1394,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"y in the liver sinusoidal membrane, which decrease cellular ","suffix":" retention and thus could cause interindividual variability ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1682,"endOffset":1692,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"of OATP2-mediated uptake of pravastatin into hepatocytes by ","suffix":" [8]. However, it is likely that the concentrations of rifam","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1747,"endOffset":1757,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"picin [8]. However, it is likely that the concentrations of ","suffix":" in the liver were very low at the time of pravastatin admin","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1853,"endOffset":1863,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ime of pravastatin administration, because the last dose of ","suffix":" was administered 17 h earlier. Accordingly, it is also poss","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":155,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"he predominant pathways of pravastatin metabolism [12], and ","suffix":" is also known to induce the phase II enzymes, such as UDP-g","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":368,"endOffset":378,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ination half-life of pravastatin were largely unaffected by ","suffix":", it is reasonable to assume that the interaction occurred p","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":129,"endOffset":139,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" showed that using an identical protocol, pretreatment with ","suffix":" greatly decreased the AUC(0-∞) of simvastatin and simvastat","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":188,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"28], by about 50% [23]. Preliminary data also indicate that ","suffix":" decreases the AUC of atorvastatin by a mean of 78% compared","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":416,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"y resemble those of simvastatin [31, 32], it is likely that ","suffix":" will induce the metabolism of lovastatin and lovastatin aci","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":606,"endOffset":616,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"s to be least susceptible to the potent inducing effects of ","suffix":", and therefore seems most suited for use in combination wit","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":770,"endOffset":780,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"coprotein. However, the decrease in pravastatin exposure by ","suffix":" might be clinically significant in some individuals, and th","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":264,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"(600 mg daily) or placebo. On day 6, a single 40 mg dose of ","suffix":" was administered orally. Plasma concentrations of pravastat","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":159,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ean total area under the plasma concentration-time curve of ","suffix":" [AUC(0-∞)] was 69% (range 24-220%) of the corresponding val","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":378,"endOffset":389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"−0.4 ng ml−1·h). In five of the 10 subjects the AUC(0-∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":323,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"idual variation. In five of the 10 subjects the AUC(0-∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":151,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"tically significant decrease in the plasma concentration of ","suffix":" given as a single oral dose to healthy subjects. However, t","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":319,"endOffset":330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"y between subjects. The mean rifampicin-induced decrease in ","suffix":" concentration was considerably smaller than that observed p","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":170,"endOffset":181,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"not significantly mediated by CYP enzymes [10-12]. However, ","suffix":" is a substrate of MRP2 and the uptake transporter OATP2 [13","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":466,"endOffset":477,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"d at least tenfold but had no significant effect on that of ","suffix":" [16]. Furthermore, combination therapy with the HIV proteas","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":652,"endOffset":663,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ian AUC(0-24) of simvastatin 30-fold, but decreased that of ","suffix":" by 50% [17]. Pravastatin is a substrate of both influx and ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":677,"endOffset":688,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tin 30-fold, but decreased that of pravastatin by 50% [17]. ","suffix":" is a substrate of both influx and efflux transporters, and ","exact":"Pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":807,"endOffset":818,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" although significant interactions mediated by induction of ","suffix":" metabolism are not likely, the in vivo effects of induction","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":975,"endOffset":986,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" Thus, the extent of any interaction between rifampicin and ","suffix":" cannot be inferred from previous work. The aim of this stud","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":1124,"endOffset":1135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"he possible effect of rifampicin on the pharmacokinetics of ","suffix":" in healthy volunteers, using an identical study design as i","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":527,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"d placebo orally once daily at 4 p.m. for 5 days. On day 6, ","suffix":" (a single Pravachol 40 mg tablet, Bristol-Myers Squibb, New","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravachol","startOffset":549,"endOffset":558,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"daily at 4 p.m. for 5 days. On day 6, pravastatin (a single ","suffix":" 40 mg tablet, Bristol-Myers Squibb, New York, NY) was admin","exact":"Pravachol"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":812,"endOffset":823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ndard meal was served 3 and 7 h after the administration of ","suffix":". Alcohol or strenuous exercise was not allowed for two days","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":157,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"n from a cannulated forearm vein prior to administration of ","suffix":" and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 h later, an","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":752,"endOffset":763,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"oncentration by ke. The renal clearance (CLrenal 0−12 h) of ","suffix":" was calculated from CLrenal 0-12 h = Ae/AUC(0-12), where Ae","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":707,"endOffset":718,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"used to compare the effect of rifampicin on the AUC(0-∞) of ","suffix":" and simvastatin acid [9]. The analysis was performed with S","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":159,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ean total area under the plasma concentration-time curve of ","suffix":" [AUC(0-∞)] was 69% (range 24-220%) of the corresponding val","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":107,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"          During the rifampicin phase, the mean AUC(0-∞) of ","suffix":" was 69% (range 24-220%, P <0.05) of the corresponding value","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":330,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ferences in the effect of rifampicin. Thus, the AUC(0-∞) of ","suffix":" decreased in 7 and increased in 3 of the 10 subjects. This ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":438,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" the 10 subjects. This effect was not related to the AUC of ","suffix":" during the placebo phase or to the gender of the subjects (","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":562,"endOffset":573,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"jects (Figure 2). Rifampicin tended to decrease the Cmax of ","suffix":", on average by 21%, but the difference did not reach statis","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":760,"endOffset":771,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ificant effect on the tmax (P = 0.33) or t1/2 (P = 0.75) of ","suffix":" (Table 2). The renal clearance and the cumulative excretion","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":835,"endOffset":846,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ble 2). The renal clearance and the cumulative excretion of ","suffix":" into the urine were largely unaffected by rifampicin (P = 0","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":346,"endOffset":357,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"e difference in the effect of rifampicin on the AUC(0-∞) of ","suffix":" compared to simvastatin acid was statistically significant ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":192,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"eased by pretreatment with rifampicin. The mean AUC(0-∞) of ","suffix":" was decreased by 31%, but there was considerable interindiv","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":378,"endOffset":389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"−0.4 ng ml−1·h). In five of the 10 subjects the AUC(0-∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":323,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"idual variation. In five of the 10 subjects the AUC(0-∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":469,"endOffset":480,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"se. However, in three subjects the plasma concentrations of ","suffix":" increased during the rifampicin phase. The other pharmacoki","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":191,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"be caused by induction of CYP3A4 or P-glycoprotein, because ","suffix":" is not a substrate of P-glycoprotein, CYP3A4 or other CYP e","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":295,"endOffset":306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"tein, CYP3A4 or other CYP enzymes [10, 11, 19-21]. However, ","suffix":" is a substrate of canalicular multispecific organic anion t","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":771,"endOffset":782,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"canalicular MRP2 by rifampicin might also decrease systemic ","suffix":" absorption by enhancing first-pass biliary excretion. There","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":1176,"endOffset":1187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" is in line with our results that rifampicin only decreased ","suffix":" AUC in 7 out of 10 subjects (Figure 2). There are several a","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":1554,"endOffset":1565,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"onsequent induction [8]. An explanation for the increase in ","suffix":" concentrations in some subjects might be the inhibition of ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":1650,"endOffset":1661,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ubjects might be the inhibition of OATP2-mediated uptake of ","suffix":" into hepatocytes by rifampicin [8]. However, it is likely t","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":1800,"endOffset":1811,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ons of rifampicin in the liver were very low at the time of ","suffix":" administration, because the last dose of rifampicin was adm","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":1949,"endOffset":1960,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"lier. Accordingly, it is also possible that the increase in ","suffix":" concentrations in some subjects was the result of the inher","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":122,"endOffset":133,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ronidation appears to be one of the predominant pathways of ","suffix":" metabolism [12], and rifampicin is also known to induce the","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":329,"endOffset":340,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"s, because the renal clearance and elimination half-life of ","suffix":" were largely unaffected by rifampicin, it is reasonable to ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":312,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ffect was much greater than that on the pharmacokinetics of ","suffix":" observed in the present study. In other work, itraconazole ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":524,"endOffset":535,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"(P < 0.001), whereas the effect on the AUC(0-∞) and Cmax of ","suffix":" was not statistically significant [16]. Furthermore, a 14-d","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":759,"endOffset":770,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"4) of simvastatin acid by 52%, but had no effect on that of ","suffix":" [27]. These results are in agreement with the present findi","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":852,"endOffset":863,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"re in agreement with the present findings and indicate that ","suffix":" is less susceptible to pharmacokinetic interactions than si","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":528,"endOffset":539,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"and lovastatin acid as well. Of the statins studied so far, ","suffix":" appears to be least susceptible to the potent inducing effe","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":746,"endOffset":757,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" of CYP enzymes or P-glycoprotein. However, the decrease in ","suffix":" exposure by rifampicin might be clinically significant in s","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":160,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"small but highly variable effect on the pharmacokinetics of ","suffix":". The dose of pravastatin might need adjustment in some indi","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":185,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" effect on the pharmacokinetics of pravastatin. The dose of ","suffix":" might need adjustment in some individuals if long-term trea","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":898,"endOffset":909,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"AUC) and peak concentration (Cmax) of the HMG-CoA inhibitor ","suffix":" and its acid metabolite to about one tenth of control value","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":609,"endOffset":620,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" ritonavir and saquinavir increased the median AUC(0-24) of ","suffix":" 30-fold, but decreased that of pravastatin by 50% [17]. Pra","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":174,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"treatment with rifampicin greatly decreased the AUC(0-∞) of ","suffix":" and simvastatin acid in all of the 10 subjects studied [9].","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":190,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ifampicin greatly decreased the AUC(0-∞) of simvastatin and ","suffix":" acid in all of the 10 subjects studied [9]. This effect was","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":376,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f the CYP3A4 substrate lovastatin closely resemble those of ","suffix":" [31, 32], it is likely that rifampicin will induce the meta","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"itraconazole","startOffset":357,"endOffset":369,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" interaction potential of the different statin drugs. Thus, ","suffix":" increased the AUC of simvastatin acid at least tenfold but ","exact":"itraconazole"},{"setid":"PMC1884432","drugname":"itraconazole","startOffset":370,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"f pravastatin observed in the present study. In other work, ","suffix":" was found to increase the AUC(0-∞) and Cmax of simvastatin ","exact":"itraconazole"},{"setid":"PMC1884432","drugname":"ritonavir","startOffset":550,"endOffset":559,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"rmore, combination therapy with the HIV protease inhibitors ","suffix":" and saquinavir increased the median AUC(0-24) of simvastati","exact":"ritonavir"},{"setid":"PMC1884432","drugname":"saquinavir","startOffset":564,"endOffset":574,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tion therapy with the HIV protease inhibitors ritonavir and ","suffix":" increased the median AUC(0-24) of simvastatin 30-fold, but ","exact":"saquinavir"},{"setid":"PMC1884432","drugname":"at 10","startOffset":491,"endOffset":496,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"coefficients of variation (CV) were 9.0% at 1 ng ml−1, 2.6% ","suffix":" ng ml−1 and 3.3% at 100 ng ml−1 (n = 7) replicates.\n       ","exact":"at 10"},{"setid":"PMC1884432","drugname":"at 10","startOffset":514,"endOffset":519,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"on (CV) were 9.0% at 1 ng ml−1, 2.6% at 10 ng ml−1 and 3.3% ","suffix":"0 ng ml−1 (n = 7) replicates.\n                              ","exact":"at 10"},{"setid":"PMC1884432","drugname":"atorvastatin","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ary data also indicate that rifampicin decreases the AUC of ","suffix":" by a mean of 78% compared to placebo [30]. Because the phar","exact":"atorvastatin"},{"setid":"PMC1884432","drugname":"lovastatin","startOffset":339,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ause the pharmacokinetic properties of the CYP3A4 substrate ","suffix":" closely resemble those of simvastatin [31, 32], it is likel","exact":"lovastatin"},{"setid":"PMC1884432","drugname":"lovastatin","startOffset":457,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" it is likely that rifampicin will induce the metabolism of ","suffix":" and lovastatin acid as well. Of the statins studied so far,","exact":"lovastatin"},{"setid":"PMC1884432","drugname":"lovastatin","startOffset":472,"endOffset":482,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hat rifampicin will induce the metabolism of lovastatin and ","suffix":" acid as well. Of the statins studied so far, pravastatin ap","exact":"lovastatin"}],[{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":147,"endOffset":158,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"teract with midazolam (CYP3A4 probe substrate). Exposure to ","suffix":" when co-administered with midazolam was slightly decreased ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":279,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"y 11% (95% confidence interval [CI] −28%, 7%) compared with ","suffix":" alone. The following drugs moderately affected rivaroxaban ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":338,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" rivaroxaban alone. The following drugs moderately affected ","suffix":" exposure, but not to a clinically relevant extent: erythrom","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":693,"endOffset":704,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" 42% increase [95% CI 29%, 56%]). A significant increase in ","suffix":" exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":338,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"t [Ki] 0.4 nm) independently of antithrombin [1]. In vitro, ","suffix":" has been shown to inhibit thrombin generation and prolong c","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":483,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"[1, 2]. Results of in vivo animal model studies showed that ","suffix":" was effective in the prevention and treatment of venous thr","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":467,"endOffset":478,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"renal secretion [12]. When comparing the renal clearance of ","suffix":" (approximately 30-40% of its apparent total body clearance ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":643,"endOffset":654,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"ate, taking into account the high plasma protein binding of ","suffix":" (approximately 92-95%), a considerable contribution of acti","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":327,"endOffset":338,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"hways of biotransformation [18]. After a 10 mg oral dose of ","suffix":", the metabolite profile in human plasma shows that unchange","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":400,"endOffset":411,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"the metabolite profile in human plasma shows that unchanged ","suffix":" is the main compound, with no major or active circulating m","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":549,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":" [12]. With a systemic clearance of approximately 10 l h−1, ","suffix":" can be classified as a low clearance drug, lacking relevant","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":867,"endOffset":878,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"[10]. Owing to the involvement of both CYP3A4 and CYP2J2 in ","suffix":" biotransformation and of transport proteins P-gp and Bcrp (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":974,"endOffset":985,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"proteins P-gp and Bcrp (ABCG2) in active renal secretion of ","suffix":", it was important to determine the potential of rivaroxaban","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1034,"endOffset":1045,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"rivaroxaban, it was important to determine the potential of ","suffix":" to interact with drugs that are substrates for, or known in","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":332,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"toconazole and ritonavir, may reduce the renal clearance of ","suffix":" [15]. Further in vitro interaction studies showed that the ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":424,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"ro interaction studies showed that the biotransformation of ","suffix":" was affected by therapeutically relevant concentrations of ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":945,"endOffset":956,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"). Using appropriate probe drugs and in vitro test systems, ","suffix":" itself (at concentrations up to more than 100-fold higher t","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1235,"endOffset":1246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" 11, 15, 17], rendering clinically relevant interactions of ","suffix":" with co-medications unlikely. Clinically relevant drug-drug","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1328,"endOffset":1339,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"nlikely. Clinically relevant drug-drug interactions between ","suffix":" and substrates of CYP enzymes are unlikely, because no sign","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1420,"endOffset":1431,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"P enzymes are unlikely, because no significant influence of ","suffix":" on biotransformation reactions catalysed by relevant CYP is","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":313,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"ne the clinical extent of any potential interaction between ","suffix":" and substrates for, or inhibitors of, CYP3A4 and/or CYP2J2 ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":446,"endOffset":457,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"d the transport proteins P-gp and Bcrp (ABCG2). Previously, ","suffix":" has demonstrated a lack of mutual interaction with the P-gp","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":182,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"e the extent of potential interactions with single doses of ","suffix":" (10 mg or 20 mg) and steady-state ketoconazole (200 mg once","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":604,"endOffset":615,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"the extent of the possible interaction between steady-state ","suffix":" (10 mg once daily) and high dose, steady-state ketoconazole","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":203,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":". In the study investigating potential interactions between ","suffix":" and steady-state ketoconazole 200 mg, subjects received ket","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":815,"endOffset":826,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"e laboratory tests and to determine the pharmacokinetics of ","suffix":" and, where necessary, the pharmacokinetics of the potential","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":132,"endOffset":143,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","prefix":" was undertaken to determine potential interactions between ","suffix":" and a sensitive probe substrate for CYP3A4 alone, midazolam","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":163,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 20 mg alone, a single dose of midazolam 7.5 mg alone or the","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":152,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"o determine the extent of the potential interaction between ","suffix":" and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2),","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"stigated the potential interaction between a single dose of ","suffix":" and steady-state ketoconazole 200 mg once daily. In this op","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":331,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg, alone or with ketoconazole (4 days of oral ketoconaz","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":429,"endOffset":440,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"onazole (4 days of oral ketoconazole 200 mg once daily with ","suffix":" given on day 4). Rivaroxaban was given under fasting condit","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":458,"endOffset":469,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"onazole 200 mg once daily with rivaroxaban given on day 4). ","suffix":" was given under fasting conditions and ketoconazole was giv","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":576,"endOffset":587,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"azole was given with food, except when co-administered with ","suffix":". After completion of this study, a publication suggested th","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":824,"endOffset":835,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"um extent of the potential interaction between steady-state ","suffix":" and steady-state ketoconazole 400 mg once daily. This was a","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":961,"endOffset":972,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"andomized, open label study in which subjects received oral ","suffix":" 10 mg once daily alone for 5 days, with concomitant ketocon","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":246,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"mized, open label study. Subjects received a single dose of ","suffix":" 10 mg on day 1, ritonavir 600 mg twice daily on days 3-7, a","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":481,"endOffset":492,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"alid for the safety analysis. All received a single dose of ","suffix":" 10 mg on day 1 and at least one dose of ritonavir (600 mg).","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":597,"endOffset":608,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"navir (600 mg). Twelve subjects received the combination of ","suffix":" and ritonavir on day 8. However, none of the subjects recei","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":127,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and clarithromycin, classified as a strong inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":160,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg alone, or clarithromycin 500 mg twice daily for a per","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":127,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and erythromycin, classified as a moderate inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg alone, or erythromycin 500 mg three times daily given","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":291,"endOffset":302,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"n for 4 days, with a single 500 mg dose given on day 5 with ","suffix":" 10 mg. All study drugs were administered with food and ther","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":127,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and fluconazole, classified as a potent inhibitor of CYP2C9","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":200,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"nd fluconazole, classified as a potent inhibitor of CYP2C9 (","suffix":" is not metabolized via CYP2C9), a moderate inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 20 mg alone, or fluconazole 400 mg once daily given for 6 d","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":280,"endOffset":291,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"iven for 6 days, with a concomitant administration of 20 mg ","suffix":" given on day 5. All study drugs were administered with food","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":369,"endOffset":380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","prefix":"tervals after drug administration. Quantitative analysis of ","suffix":" concentrations (plasma and urine) was performed using a ful","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":259,"endOffset":270,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"n the ketoconazole 400 mg study, in which multiple doses of ","suffix":" were given. Maximum drug concentration in plasma (Cmax), ti","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":918,"endOffset":929,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"al body clearance, because absolute bioavailability (F) for ","suffix":" is high (>80%) for the 10 mg dose [14] used in most of the ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1012,"endOffset":1023,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":" 10 mg dose [14] used in most of the studies. The amount of ","suffix":" excreted in the urine was used to determine the renal clear","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":282,"endOffset":293,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":", the fraction of free (unbound) drug in plasma (fu, %) for ","suffix":" was determined using equilibrium dialysis of total plasma c","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":589,"endOffset":600,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":" urinary creatinine data collected in parallel to amount of ","suffix":" excreted in the urine. This allowed the splitting of rivaro","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":654,"endOffset":665,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"oxaban excreted in the urine. This allowed the splitting of ","suffix":" CLR into clearance by renal filtration (CLRF, calculated by","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":280,"endOffset":291,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"olized by CYP3A4 to α-hydroxy-midazolam [28], the effect of ","suffix":" on the pharmacokinetics of this CYP3A4-mediated metabolite ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":224,"endOffset":235,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[1]","prefix":"over design, the pharmacokinetic parameters AUC and Cmax of ","suffix":" were analyzed assuming log-normally distributed data. To co","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":325,"endOffset":336,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[1]","prefix":"rmally distributed data. To compare the pharmacokinetics of ","suffix":" in the absence and presence of the potential interacting dr","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"ial designs, the pharmacokinetic parameters AUC and Cmax of ","suffix":" were analyzed assuming log-normally distributed data. Stude","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":546,"endOffset":557,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"ion of the logarithmic results. Derived clearance values of ","suffix":" (CL/F, CLR, CLRS) were analyzed using the same methods.\n   ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":174,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"d its CYP3A4-mediated metabolite, α-hydroxy-midazolam, when ","suffix":" 20 mg and midazolam 7.5 mg were administered alone and in c","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":338,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"e 1. Co-administration with midazolam led to an increase in ","suffix":" median tmax from 1.5 h to 4.0 h and slightly decreased the ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":409,"endOffset":420,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":" median tmax from 1.5 h to 4.0 h and slightly decreased the ","suffix":" mean Cmax by 12% compared with rivaroxaban alone, a change ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"ly decreased the rivaroxaban mean Cmax by 12% compared with ","suffix":" alone, a change that was not statistically significant (90%","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":538,"endOffset":549,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"e that was not statistically significant (90% CI −28%, 7%). ","suffix":" mean AUC remained almost unchanged. Co-administration with ","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":609,"endOffset":620,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":" mean AUC remained almost unchanged. Co-administration with ","suffix":" slightly decreased the mean AUC of midazolam by 11% compare","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":905,"endOffset":916,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"idazolam remained almost the same with co-administration of ","suffix":" and midazolam compared with midazolam alone, but the mean C","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":331,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"tly increased the plasma concentrations of a single dose of ","suffix":" 10 mg compared with rivaroxaban alone. The mean AUC increas","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":363,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"rations of a single dose of rivaroxaban 10 mg compared with ","suffix":" alone. The mean AUC increased by 82% (90% CI 59%, 108%) and","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":551,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"tal (apparent) body clearance of drug from plasma (CL/F) of ","suffix":" was significantly reduced by a mean of 45% (90% CI −52%, −3","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"aban 10 mg (day 5) were compared with those of steady-state ","suffix":" 10 mg in combination with steady-state ketoconazole 400 mg ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":328,"endOffset":339,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"nistration with ketoconazole 400 mg significantly increased ","suffix":" plasma concentrations (Figure 1A). The mean AUC for the act","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":544,"endOffset":555,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"by 72% (90% CI 61%, 83%) with the combination compared with ","suffix":" alone (Table 2). The mean CL/F was significantly decreased ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":323,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"s of ritonavir were compared in the absence and presence of ","suffix":" (days 7 and 8, respectively). Steady-state ritonavir signif","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":432,"endOffset":443,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"state ritonavir significantly increased the AUC and Cmax of ","suffix":". The mean AUC increased by 153% (90% CI 134%, 174%) and the","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":563,"endOffset":574,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":" mean Cmax increased by 55% (90% CI 41%, 69%) compared with ","suffix":" alone (Table 2). Mean plasma concentrations of rivaroxaban ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":622,"endOffset":633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":" rivaroxaban alone (Table 2). Mean plasma concentrations of ","suffix":" were shown to increase with the combined regimen (Figure 1B","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":742,"endOffset":753,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":" (Figure 1B). Ritonavir significantly decreased the CL/F of ","suffix":" by 60% (90% CI −63%, −57%) without affecting the fu of riva","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":809,"endOffset":820,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"aban by 60% (90% CI −63%, −57%) without affecting the fu of ","suffix":". CLRS was significantly reduced by 82% (90% CI −86%, −76%).","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":138,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"inetics of rivaroxaban were compared after a single dose of ","suffix":" 10 mg was administered alone and co-administered with clari","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":399,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (Table 2, Figure 1C). Both the mean AUC and Cmax were signi","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":575,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"and 40% (90% CI 30%, 52%), respectively, in comparison with ","suffix":" alone. Co-administration significantly decreased the mean C","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":653,"endOffset":664,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":" Co-administration significantly decreased the mean CL/F of ","suffix":" from plasma by 35% (90% CI −39%, −31%), whereas mean CLRS w","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":376,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"rythromycin significantly increased the pharmacokinetics of ","suffix":" (Table 2, Figure 1D). The mean AUC and Cmax both significan","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":542,"endOffset":553,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"46%] and 38% [90% CI 21%, 48%], respectively) compared with ","suffix":" alone. The mean CL/F of rivaroxaban was significantly decre","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":578,"endOffset":589,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"ectively) compared with rivaroxaban alone. The mean CL/F of ","suffix":" was significantly decreased by 25% (90% CI −31%, −19%) with","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":138,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"inetics of rivaroxaban were compared after a single dose of ","suffix":" 20 mg was administered alone and co-administered with fluco","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":389,"endOffset":400,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (Table 2, Figure 1E). Both the mean AUC and mean Cmax incre","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":551,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"and 28% [90% CI 12%, 47%], respectively) in comparison with ","suffix":" alone. Co-administration significantly decreased the CL/F o","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":624,"endOffset":635,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"lone. Co-administration significantly decreased the CL/F of ","suffix":" from plasma by 29% (90% CI −36%, −22%) and significantly re","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":272,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"hich was serious, were considered to be possibly related to ","suffix":" alone or a combination involving rivaroxaban. Of these, hea","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":317,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"bly related to rivaroxaban alone or a combination involving ","suffix":". Of these, headache (32 events) and fatigue (13 events) wer","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":144,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ic interaction studies in healthy subjects demonstrate that ","suffix":" does not interact with a probe substrate for CYP3A4 (midazo","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"robe substrate for CYP3A4 (midazolam). Co-administration of ","suffix":" with a moderate CYP3A4 and P-gp inhibitor (erythromycin), a","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":515,"endOffset":526,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ithromycin), led to a statistically significant increase in ","suffix":" exposure. Of note, active renal secretion (CLRS) was reduce","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":840,"endOffset":851,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"tistically significant interaction was demonstrated between ","suffix":" and strong inhibitors of CYP3A4 (and possibly CYP2J2), P-gp","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":150,"endOffset":161,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ban with midazolam had no effect on the pharmacokinetics of ","suffix":", or on the pharmacokinetics of midazolam or its CYP3A4-medi","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":484,"endOffset":495,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no effect on the pharmacokinetics and pharmacodynamics of ","suffix":", or on the pharmacokinetics of digoxin or atorvastatin [25,","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":631,"endOffset":642,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"of interaction confirms previous in vitro observations that ","suffix":" does not induce or inhibit any major CYP isoforms, includin","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":824,"endOffset":835,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ormation is of further value because the concomitant use of ","suffix":" and these drugs is highly likely. Rivaroxaban is now in use","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":870,"endOffset":881,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"mitant use of rivaroxaban and these drugs is highly likely. ","suffix":" is now in use for the prevention of stroke in patients with","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":258,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"bitor, led to a 34% and 38% increase in the AUC and Cmax of ","suffix":", respectively. However, as with other studies reporting sim","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":615,"endOffset":626,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" magnitude to the inter-individual variability expected for ","suffix":" in patients [20, 40]. The decreased clearance and slightly ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":722,"endOffset":733,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" clearance and slightly increased active renal secretion of ","suffix":" when it was co-administered with steady-state erythromycin ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1015,"endOffset":1026,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" renal filtration [CLRF] and CLRS). The interaction between ","suffix":" and another frequently used antibiotic, clarithromycin, cla","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1257,"endOffset":1268,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ential, was also moderate (mean increases of 54% and 40% in ","suffix":" AUC and Cmax, respectively), with a minimal decrease in act","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":123,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"results, combined with in vitro data [15, 17], suggest that ","suffix":" has the potential to interact to a clinically relevant exte","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":583,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"rp (ABCG2). There were significant increases in exposure to ","suffix":" when it was co-administered with ketoconazole and ritonavir","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":805,"endOffset":816,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"y 70% mean inhibition of non-renal (metabolic) clearance of ","suffix":" (derived from data in Table 2) and a 44% mean inhibition of","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1247,"endOffset":1258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"tively) and, as a result, the concomitant administration of ","suffix":" with these drugs should be avoided because of a potential i","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1606,"endOffset":1617,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"titative assumption for the interaction of fluconazole with ","suffix":" was moderate (mean increases of 42% and 28% in rivaroxaban ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":236,"endOffset":247,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"action phenotyping study [16-18], the clearance pathways of ","suffix":" have been quantified to the following average values. The c","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":406,"endOffset":417,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"approximately 18% and CYP2J2 for approximately 14% of total ","suffix":" elimination. In addition to this oxidative biotransformatio","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":891,"endOffset":902,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"cordance with the contributions of the respective routes of ","suffix":" multi-pathway clearance and the inhibitory potential of the","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1108,"endOffset":1119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":" understanding of the clearance and elimination profile for ","suffix":" and its potential for drug-drug interactions when linking i","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1274,"endOffset":1285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"although the studies described here involve single doses of ","suffix":", no relevant accumulation was observed in a multiple dose e","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":1409,"endOffset":1420,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ation study [41]. This indicates that the concentrations of ","suffix":" observed after single dose administration can be considered","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"s P-gp and Bcrp (ABCG2), are involved in the elimination of ","suffix":". Therefore, it was important to determine the clinical exte","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":283,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ne the clinical extent of any potential interaction between ","suffix":" and drugs that are substrates for and/or inhibitors of thes","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":445,"endOffset":456,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"e studies suggest that the oral, direct Factor Xa inhibitor ","suffix":" does not interact to a clinically relevant extent with subs","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":787,"endOffset":798,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":" HIV protease inhibitors. Therefore, the concomitant use of ","suffix":" with these agents should be avoided. The exception may be f","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":185,"endOffset":194,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"bstrate). Exposure to rivaroxaban when co-administered with ","suffix":" was slightly decreased by 11% (95% confidence interval [CI]","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":669,"endOffset":678,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"inhibitors of CYP2J2 [16, 17]. CYP3A4 substrates (including ","suffix":") or moderate to strong inhibitors of CYP3A4 only (erythromy","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":476,"endOffset":485,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"y-state fluconazole (400 mg once daily) or a single dose of ","suffix":" (7.5 mg). An additional study was undertaken to determine t","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":205,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","prefix":" a single dose of rivaroxaban 20 mg alone, a single dose of ","suffix":" 7.5 mg alone or the combination. All study drugs were given","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":202,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"nation with the potential interacting drug. In addition, as ","suffix":" is metabolized by CYP3A4 to α-hydroxy-midazolam [28], the e","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":250,"endOffset":259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"ddition, as midazolam is metabolized by CYP3A4 to α-hydroxy-","suffix":" [28], the effect of rivaroxaban on the pharmacokinetics of ","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":754,"endOffset":763,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[1]","prefix":"nsformation of the logarithmic results. The AUC and Cmax of ","suffix":" (and its CYP3A4-mediated metabolites), in the absence or pr","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":158,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"an, midazolam and its CYP3A4-mediated metabolite, α-hydroxy-","suffix":", when rivaroxaban 20 mg and midazolam 7.5 mg were administe","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":196,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"metabolite, α-hydroxy-midazolam, when rivaroxaban 20 mg and ","suffix":" 7.5 mg were administered alone and in combination are summa","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":306,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"mbination are summarized in Table 1. Co-administration with ","suffix":" led to an increase in rivaroxaban median tmax from 1.5 h to","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":656,"endOffset":665,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"tration with rivaroxaban slightly decreased the mean AUC of ","suffix":" by 11% compared with midazolam alone, but this was not stat","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":687,"endOffset":696,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"ly decreased the mean AUC of midazolam by 11% compared with ","suffix":" alone, but this was not statistically significant (90% CI −","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":844,"endOffset":853,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"virtually unaffected. Conversely, the mean AUC of α-hydroxy-","suffix":" remained almost the same with co-administration of rivaroxa","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":921,"endOffset":930,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"d almost the same with co-administration of rivaroxaban and ","suffix":" compared with midazolam alone, but the mean Cmax was increa","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":945,"endOffset":954,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"o-administration of rivaroxaban and midazolam compared with ","suffix":" alone, but the mean Cmax was increased by 11%. This change ","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":1089,"endOffset":1098,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"ically significant (90% CI −23%, 59%). The tmax and t1/2 of ","suffix":" and its metabolite remained similar in the presence or abse","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":209,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"oxaban does not interact with a probe substrate for CYP3A4 (","suffix":"). Co-administration of rivaroxaban with a moderate CYP3A4 a","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":193,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"rmacokinetics of rivaroxaban, or on the pharmacokinetics of ","suffix":" or its CYP3A4-mediated metabolites. Previous interaction st","exact":"midazolam"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":401,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"aroxaban exposure, but not to a clinically relevant extent: ","suffix":" (moderate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":729,"endOffset":741,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"midazolam) or moderate to strong inhibitors of CYP3A4 only (","suffix":" and clarithromycin) did not reveal any significant interact","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":370,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ady-state clarithromycin (500 mg twice daily), steady-state ","suffix":" (500 mg three times daily), steady-state fluconazole (400 m","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":486,"endOffset":498,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"fter administration of the drug combinations, except in the ","suffix":" interaction study, in which subjects were discharged 72 h a","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":143,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a moderate inhibitor of CYP3A4, and consider","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg three times daily given for 4 days, with a single 50","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":185,"endOffset":197,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"n findings (in the ketoconazole, ritonavir, clarithromycin, ","suffix":" and fluconazole studies), the fraction of free (unbound) dr","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":178,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"nistered alone (day 5) and in combination with steady-state ","suffix":" (500 mg three times daily for 4 days with a single 500 mg d","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":315,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"n day 5) were analyzed. Co-administration with steady-state ","suffix":" significantly increased the pharmacokinetics of rivaroxaban","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":297,"endOffset":309,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"n of rivaroxaban with a moderate CYP3A4 and P-gp inhibitor (","suffix":"), a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":675,"endOffset":687,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ally significant extent with fluconazole but minimally with ","suffix":" and clarithromycin. As expected from in vitro studies [15, ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":129,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"istration of rivaroxaban and the frequently used antibiotic ","suffix":", a moderate CYP inhibitor and weak to moderate P-gp inhibit","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":444,"endOffset":456,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"es in these parameters when drugs were co-administered with ","suffix":" [38, 39], these changes were not considered to be clinicall","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":780,"endOffset":792,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"f rivaroxaban when it was co-administered with steady-state ","suffix":" may be partially explained by the observed mean difference ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":480,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, 46%]), ","suffix":" (strong CYP3A4/moderate P-gp inhibitor; 54% increase [95% C","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":746,"endOffset":760,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"erate to strong inhibitors of CYP3A4 only (erythromycin and ","suffix":") did not reveal any significant interactions (unpublished d","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":320,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":", steady-state ritonavir (600 mg twice daily), steady-state ","suffix":" (500 mg twice daily), steady-state erythromycin (500 mg thr","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":143,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a strong inhibitor of CYP3A4, and considered","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":188,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg twice daily for a period of 4 days under steady-stat","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":169,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"pated interaction findings (in the ketoconazole, ritonavir, ","suffix":", erythromycin and fluconazole studies), the fraction of fre","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":204,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"xaban 10 mg was administered alone and co-administered with ","suffix":" 500 mg after 4 days of pretreatment with clarithromycin 500","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":260,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"ith clarithromycin 500 mg after 4 days of pretreatment with ","suffix":" 500 mg twice daily. Co-administration with clarithromycin s","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":318,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"h clarithromycin 500 mg twice daily. Co-administration with ","suffix":" significantly increased the primary pharmacokinetic paramet","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":451,"endOffset":465,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" strong inhibitor of CYP3A4 and moderate inhibitor of P-gp (","suffix":"), led to a statistically significant increase in rivaroxaba","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":692,"endOffset":706,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"extent with fluconazole but minimally with erythromycin and ","suffix":". As expected from in vitro studies [15, 24, 29, 30], a pron","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":1067,"endOffset":1081,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"between rivaroxaban and another frequently used antibiotic, ","suffix":", classified as a strong inhibitor of CYP3A4 only, but repor","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":571,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oderate P-gp inhibitor; 54% increase [95% CI 44%, 64%]) and ","suffix":" (moderate CYP3A4, possible Bcrp [ABCG2] inhibitor; 42% incr","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":297,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"nhibitors (mainly comprising azole-antimycotics, apart from ","suffix":", and HIV protease inhibitors), which are multi-pathway inhi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":424,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"state erythromycin (500 mg three times daily), steady-state ","suffix":" (400 mg once daily) or a single dose of midazolam (7.5 mg).","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":143,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a potent inhibitor of CYP2C9 (rivaroxaban is","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":189,"endOffset":200,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 20 mg alone, or ","suffix":" 400 mg once daily given for 6 days, with a concomitant admi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":202,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"e ketoconazole, ritonavir, clarithromycin, erythromycin and ","suffix":" studies), the fraction of free (unbound) drug in plasma (fu","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"xaban 20 mg was administered alone and co-administered with ","suffix":" 400 mg after 4 days of pretreatment with fluconazole 400 mg","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":257,"endOffset":268,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"d with fluconazole 400 mg after 4 days of pretreatment with ","suffix":" 400 mg once daily. Co-administration with fluconazole signi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":311,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":" with fluconazole 400 mg once daily. Co-administration with ","suffix":" significantly increased the primary pharmacokinetic paramet","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":372,"endOffset":383,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG2, ","suffix":"), and a strong inhibitor of CYP3A4 and moderate inhibitor o","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":644,"endOffset":655,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ced to a moderate but statistically significant extent with ","suffix":" but minimally with erythromycin and clarithromycin. As expe","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":1402,"endOffset":1413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"leeding [10, 11]. An exception may be the azole-antimycotic ","suffix":", which is classified as a strong CYP2C9 inhibitor with only","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":1589,"endOffset":1600,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"t study, the quantitative assumption for the interaction of ","suffix":" with rivaroxaban was moderate (mean increases of 42% and 28","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":857,"endOffset":868,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"n with these agents should be avoided. The exception may be ","suffix":", which is expected to have less effect on rivaroxaban expos","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":818,"endOffset":830,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"p/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ","suffix":" (158% increase [95% CI 136%, 182%] for a 400 mg once daily ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":270,"endOffset":282,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"that strong inhibitors of P-gp and/or Bcrp (ABCG2), such as ","suffix":" and ritonavir, may reduce the renal clearance of rivaroxaba","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":495,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" was affected by therapeutically relevant concentrations of ","suffix":" and ritonavir, both of which are not only strong inhibitors","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":228,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ngle doses of rivaroxaban (10 mg or 20 mg) and steady-state ","suffix":" (200 mg once daily), steady-state ritonavir (600 mg twice d","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":232,"endOffset":244,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"potential interactions between rivaroxaban and steady-state ","suffix":" 200 mg, subjects received ketoconazole for 72 h as outpatie","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ban and steady-state ketoconazole 200 mg, subjects received ","suffix":" for 72 h as outpatients. Subjects were kept in-house for 72","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":201,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" 200 mg once daily. In this open label, two way crossover st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":364,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"o receive a single dose of rivaroxaban 10 mg, alone or with ","suffix":" (4 days of oral ketoconazole 200 mg once daily with rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":393,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"varoxaban 10 mg, alone or with ketoconazole (4 days of oral ","suffix":" 200 mg once daily with rivaroxaban given on day 4). Rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":509,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":" day 4). Rivaroxaban was given under fasting conditions and ","suffix":" was given with food, except when co-administered with rivar","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"fter completion of this study, a publication suggested that ","suffix":" 400 mg may lead to higher inhibition of CYP 34, which promp","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":853,"endOffset":865,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"teraction between steady-state rivaroxaban and steady-state ","suffix":" 400 mg once daily. This was a non-randomized, open label st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":1025,"endOffset":1037,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"roxaban 10 mg once daily alone for 5 days, with concomitant ","suffix":" 400 mg once daily for a further 5 days. All study drugs wer","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":308,"endOffset":320,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"4-41 years) and their mean weight was 86.4 ± 9.2 kg. In the ","suffix":" 400 mg study, a total of 20 subjects were enrolled. All com","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":205,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"under the plasma concentration-time curve (AUC(0,τ)) in the ","suffix":" 400 mg study, in which multiple doses of rivaroxaban were g","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":144,"endOffset":156,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"erpretation of the anticipated interaction findings (in the ","suffix":", ritonavir, clarithromycin, erythromycin and fluconazole st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":159,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"rivaroxaban 10 mg administered alone or in combination with ","suffix":" 200 mg once daily are shown in Table 2. Co-administration w","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"y are shown in Table 2. Co-administration with steady-state ","suffix":" significantly increased the plasma concentrations of a sing","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"dy-state rivaroxaban 10 mg in combination with steady-state ","suffix":" 400 mg once daily (day 10). Co-administration with ketocona","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":284,"endOffset":296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"conazole 400 mg once daily (day 10). Co-administration with ","suffix":" 400 mg significantly increased rivaroxaban plasma concentra","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":324,"endOffset":336,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"gp and Bcrp (ABCG2). This was confirmed in the studies with ","suffix":" and ritonavir, both strong inhibitors of CYP3A4 (and possib","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":628,"endOffset":640,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"in exposure to rivaroxaban when it was co-administered with ","suffix":" and ritonavir, with a more than two-fold increase in the AU","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":703,"endOffset":715,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d ritonavir, with a more than two-fold increase in the AUC. ","suffix":" 400 mg led to an approximately 70% mean inhibition of non-r","exact":"Ketoconazole"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":287,"endOffset":296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"itors of P-gp and/or Bcrp (ABCG2), such as ketoconazole and ","suffix":", may reduce the renal clearance of rivaroxaban [15]. Furthe","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":512,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"therapeutically relevant concentrations of ketoconazole and ","suffix":", both of which are not only strong inhibitors of CYP3A4 [21","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":275,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"steady-state ketoconazole (200 mg once daily), steady-state ","suffix":" (600 mg twice daily), steady-state clarithromycin (500 mg t","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":145,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" was investigated in a non-randomized, open label study. Sub","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":274,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"jects received a single dose of rivaroxaban 10 mg on day 1, ","suffix":" 600 mg twice daily on days 3-7, and ritonavir 600 mg twice ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":320,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":" mg on day 1, ritonavir 600 mg twice daily on days 3-7, and ","suffix":" 600 mg twice daily plus a single dose of rivaroxaban on day","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":533,"endOffset":542,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"dose of rivaroxaban 10 mg on day 1 and at least one dose of ","suffix":" (600 mg). Twelve subjects received the combination of rivar","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":613,"endOffset":622,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"Twelve subjects received the combination of rivaroxaban and ","suffix":" on day 8. However, none of the subjects received the second","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":691,"endOffset":700,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":". However, none of the subjects received the second dose of ","suffix":" on day 8 because of tolerability issues, which were conside","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":781,"endOffset":790,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"tolerability issues, which were considered to be related to ","suffix":". Four subjects withdrew from the study owing to adverse eve","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":870,"endOffset":879,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"drew from the study owing to adverse events while receiving ","suffix":" alone (see below). Therefore, 12 subjects were valid for th","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":158,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":" the anticipated interaction findings (in the ketoconazole, ","suffix":", clarithromycin, erythromycin and fluconazole studies), the","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":193,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"le dose (day 1) with those of a single dose of steady-state ","suffix":" 600 mg twice daily (day 8). In addition, the pharmacokineti","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":268,"endOffset":277,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"g twice daily (day 8). In addition, the pharmacokinetics of ","suffix":" were compared in the absence and presence of rivaroxaban (d","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":378,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"e of rivaroxaban (days 7 and 8, respectively). Steady-state ","suffix":" significantly increased the AUC and Cmax of rivaroxaban. Th","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":696,"endOffset":705,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"re shown to increase with the combined regimen (Figure 1B). ","suffix":" significantly decreased the CL/F of rivaroxaban by 60% (90%","exact":"Ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":491,"endOffset":500,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"hanges in ECG or vital signs were observed. Subjects taking ","suffix":" exhibited adverse events consistent with its established sa","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":341,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"2). This was confirmed in the studies with ketoconazole and ","suffix":", both strong inhibitors of CYP3A4 (and possibly CYP2J2 base","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":645,"endOffset":654,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"varoxaban when it was co-administered with ketoconazole and ","suffix":", with a more than two-fold increase in the AUC. Ketoconazol","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":909,"endOffset":918,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"nd a 44% mean inhibition of active renal secretion, whereas ","suffix":" led to a reduction of metabolic clearance by approximately ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"thrombin","startOffset":376,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"rombin [1]. In vitro, rivaroxaban has been shown to inhibit ","suffix":" generation and prolong clotting times [1, 2]. Results of in","exact":"thrombin"},{"setid":"PMC3769672","drugname":"digoxin","startOffset":534,"endOffset":541,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":" a lack of mutual interaction with the P-gp probe substrate ","suffix":" [24, 25], as well as with the CYP3A4/P-gp substrate atorvas","exact":"digoxin"},{"setid":"PMC3769672","drugname":"digoxin","startOffset":273,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"3A4-mediated metabolites. Previous interaction studies with ","suffix":" (a pure P-gp substrate with a narrow therapeutic window) an","exact":"digoxin"},{"setid":"PMC3769672","drugname":"digoxin","startOffset":527,"endOffset":534,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"rmacodynamics of rivaroxaban, or on the pharmacokinetics of ","suffix":" or atorvastatin [25, 27]. This lack of interaction confirms","exact":"digoxin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":594,"endOffset":606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"digoxin [24, 25], as well as with the CYP3A4/P-gp substrate ","suffix":" [26, 27]. Here, interaction studies were carried out betwee","exact":"atorvastatin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":342,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"a pure P-gp substrate with a narrow therapeutic window) and ","suffix":" (a substrate of both CYP3A4 and P-gp) in healthy subjects d","exact":"atorvastatin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":538,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"cs of rivaroxaban, or on the pharmacokinetics of digoxin or ","suffix":" [25, 27]. This lack of interaction confirms previous in vit","exact":"atorvastatin"},{"setid":"PMC3769672","drugname":"creatinine","startOffset":409,"endOffset":419,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"ma concentrations at three predefined sampling time points. ","suffix":" clearance (CLcr), as a marker of glomerular filtration, was","exact":"Creatinine"},{"setid":"PMC3769672","drugname":"creatinine","startOffset":502,"endOffset":512,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":" marker of glomerular filtration, was determined from serum ","suffix":" measurements and urinary creatinine data collected in paral","exact":"creatinine"},{"setid":"PMC3769672","drugname":"creatinine","startOffset":538,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"s determined from serum creatinine measurements and urinary ","suffix":" data collected in parallel to amount of rivaroxaban excrete","exact":"creatinine"}],[{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"rial 24 healthy adult volunteers were randomized to receive ","suffix":" 10 mg orally each morning (07.00 h) or evening (18.00 h) fo","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":591,"endOffset":603,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":") vs −29.2% (evening). The steady-state pharmacokinetics of ","suffix":" were very similar following the morning and evening dosing ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":887,"endOffset":899,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" There were no serious adverse events during the trial, and ","suffix":" was well tolerated after morning and evening administration","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"crestor","startOffset":71,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                              Rosuvastatin (","suffix":"®) is a new and highly effective inhibitor of HMG-CoA reduct","exact":"Crestor"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":262,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced reductions in LDL-C, total cholesterol (","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":166,"endOffset":178,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":" the pharmacodynamics and multiple-dose pharmacokinetics of ","suffix":" following morning and evening administration in healthy adu","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":130,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"volunteers were randomized to receive a single oral dose of ","suffix":" (10 mg) each morning (approximately 07.00 h) or evening (ap","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":495,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"required to fast for a minimum of 2 h before and after each ","suffix":" dose, and for at least 12 h (overnight) before collection o","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":195,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"concentrations before administration of the morning dose of ","suffix":" (morning dosing) or before the morning meal (evening dosing","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":407,"endOffset":419,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":" h period before the first dose and after the final dose of ","suffix":" in each treatment period. Heparinized plasma samples and ur","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ial venous blood samples (7 ml) for determination of plasma ","suffix":" concentrations were collected at 0.5 h predose and at fixed","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"6, 8, 10, 12, 18, 24, 48, and 72 h) after administration of ","suffix":" on treatment day 14. Blood samples were also collected at 0","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":708,"endOffset":720,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"tored at −70 °C prior to analysis. Plasma concentrations of ","suffix":" were determined using a validated h.p.l.c./MS assay [24] at","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":836,"endOffset":848,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"] at Quintiles, Edinburgh, UK. Correlation coefficients for ","suffix":" were 0.994-1.00. Mean inaccuracy levels and imprecision val","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":1030,"endOffset":1042,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" 7% and < 8%, respectively. The limit of quantification for ","suffix":" in this trial was 0.2 ng ml−1.\n                            ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":780,"endOffset":792,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"pressed as morning-evening differences with 90% CIs. Plasma ","suffix":" exposure was compared using least square geometric means ge","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":888,"endOffset":900,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"quare geometric means generated by anova of log-transformed ","suffix":" AUC(0,24 h) and Cmax values and expressed as morning/evenin","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":" LDL-C were obtained following once daily administration of ","suffix":" 10 mg in the morning or evening. After 14 days of treatment","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":222,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"y state was attained within 8 days of initiating once-daily ","suffix":" administration (with both morning and evening dosing regime","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":353,"endOffset":365,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"ens). Under steady-state conditions, the mean trough plasma ","suffix":" concentration was approximately 0.6 ng ml−1 in both treatme","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":153,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"n the pharmacokinetic parameters (Cmax and AUC(0,24 h)) for ","suffix":" between the morning and evening dosing regimens was exclude","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":264,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","prefix":"ateral leads), which occurred 3.5 h after the first dose of ","suffix":". The volunteer was asymptomatic and the T-wave abnormality ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":152,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the pharmacodynamics and multiple-dose pharmacokinetics of ","suffix":" following morning and evening administration in healthy vol","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":255,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"administration in healthy volunteers. The results show that ","suffix":" was equally effective in lowering serum LDL-C concentration","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":437,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ing with this finding, the steady-state pharmacokinetics of ","suffix":" were very similar after morning and evening administration.","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":295,"endOffset":307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"n. Atorvastatin appears to be the only statin to share with ","suffix":" the characteristic of dose-time independence for pharmacody","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":416,"endOffset":428,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" pharmacodynamics [26]. The fact that both atorvastatin and ","suffix":" have relatively long plasma half-lives may be of relevance ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":549,"endOffset":561,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"o this common characteristic. However, atorvastatin, unlike ","suffix":", shows diurnal differences in plasma exposure: lower system","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":227,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" in hypercholesterolaemic patients following treatment with ","suffix":" 10 mg once daily for 6 weeks (approximately −48%) [14]. Whi","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":408,"endOffset":420,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ns observed in this trial are consistent with the effect of ","suffix":" on LDL-C, the small reductions in HDL-C and ApoA-I concentr","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":584,"endOffset":596,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"om dose-ranging [14] and Phase-III [15-18] trials show that ","suffix":" (1-80 mg) consistently raises HDL-C in dyslipidaemic patien","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":139,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ults of this trial indicate that the therapeutic benefit of ","suffix":" is not dose-time de-pendent, and that morning or evening ad","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":348,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on in volunteers with fasting serum low-density lipoprotein ","suffix":" (LDL-C) concentrations < 4.14 mmol l−1.\n                   ","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ions of LDL-C (−41.3% [morning] vs −44.2% [evening]), total ","suffix":" (−30.9% vs −31.8%), triglycerides (−17.1% vs −22.7%), and a","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":321,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" rosuvastatin (1-80 mg) produced reductions in LDL-C, total ","suffix":" (TC), and triglycerides (TG), and increases in high-density","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"erapy, and are the most effective agents for reducing serum ","suffix":" concentrations and cardiovascular mortality [1-3]. As compe","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":398,"endOffset":409,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"CoA reductase, statins block an early rate-limiting step in ","suffix":" biosynthesis: the conversion of HMG-CoA to mevalonate [4]. ","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":491,"endOffset":502,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"version of HMG-CoA to mevalonate [4]. Inhibition of hepatic ","suffix":" production results in up-regulation of hepatic low-density ","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":664,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"le for the clearance of circulating low-density lipoprotein ","suffix":" (LDL-C), and reduced hepatic secretion of very-low-density ","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":321,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" rosuvastatin (1-80 mg) produced reductions in LDL-C, total ","suffix":" (TC), and triglycerides (TG), and increases in high-density","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":405,"endOffset":416,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"iglycerides (TG), and increases in high-density lipoprotein ","suffix":" (HDL-C) [14-18].\n                                          ","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"fluvastatin","startOffset":356,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"id-regulating effects of most available statins - including ","suffix":" [10], lovastatin [11], pravastatin [12], and simvastatin [1","exact":"fluvastatin"},{"setid":"PMC1874466","drugname":"lovastatin","startOffset":374,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"cts of most available statins - including fluvastatin [10], ","suffix":" [11], pravastatin [12], and simvastatin [13]- are reported ","exact":"lovastatin"},{"setid":"PMC1874466","drugname":"pravastatin","startOffset":391,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"able statins - including fluvastatin [10], lovastatin [11], ","suffix":" [12], and simvastatin [13]- are reported to be influenced b","exact":"pravastatin"},{"setid":"PMC1874466","drugname":"simvastatin","startOffset":413,"endOffset":424,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ng fluvastatin [10], lovastatin [11], pravastatin [12], and ","suffix":" [13]- are reported to be influenced by the time of dosing, ","exact":"simvastatin"},{"setid":"PMC1874466","drugname":"sodium acetate","startOffset":612,"endOffset":626,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"n. The derived plasma samples were diluted 1 : 1 with 0.1 m ","suffix":" buffer (pH 4.0) and stored at −70 °C prior to analysis. Pla","exact":"sodium acetate"},{"setid":"PMC1874466","drugname":"atorvastatin","startOffset":238,"endOffset":250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"cts following morning compared with evening administration. ","suffix":" appears to be the only statin to share with rosuvastatin th","exact":"Atorvastatin"},{"setid":"PMC1874466","drugname":"atorvastatin","startOffset":399,"endOffset":411,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" independence for pharmacodynamics [26]. The fact that both ","suffix":" and rosuvastatin have relatively long plasma half-lives may","exact":"atorvastatin"},{"setid":"PMC1874466","drugname":"atorvastatin","startOffset":528,"endOffset":540,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"may be of relevance to this common characteristic. However, ","suffix":", unlike rosuvastatin, shows diurnal differences in plasma e","exact":"atorvastatin"}],[{"setid":"PMC2598705","drugname":"simvastatin","startOffset":250,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"the patient and his general practitioner (GP), stating that ","suffix":" is not recommended with his antiretroviral combination, but","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":314,"endOffset":325,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":" and mentioned that her cholesterol was 8.5. Her GP started ","suffix":". The patient took the first dose but stopped after reading ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":269,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"is GP about current medications. Pravastatin was changed to ","suffix":" by his GP 6 years later.\n                                  ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":160,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[5]","prefix":"on protease inhibitors (PIs) have recently been switched to ","suffix":" by GPs. None have suffered adverse consequences, although s","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":195,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"hibit cytochrome P450 (CYP) 3A4 activity, which metabolises ","suffix":" and atorvastatin. Simvastatin exposure is increased by up t","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":225,"endOffset":236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"4 activity, which metabolises simvastatin and atorvastatin. ","suffix":" exposure is increased by up to 3000% by PIs,2 and co‐admini","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":224,"endOffset":235,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":"CYP3A4 metabolism, and reduces the concentrations of active ","suffix":", atorvastatin and pravastatin by 58%, 34% and 40%, respecti","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":184,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"dications where possible, and this is driving the switch to ","suffix":". Simvastatin is also available without prescription in phar","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":197,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"re possible, and this is driving the switch to simvastatin. ","suffix":" is also available without prescription in pharmacies. These","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":477,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"bout potential drug interactions. Where PIs are being used, ","suffix":" must be avoided.\n                                          ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"abacavir","startOffset":86,"endOffset":94,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"                               A 58‐year‐old man was taking ","suffix":", lamivudine, atazanavir and ritonavir. His HIV physician no","exact":"abacavir"},{"setid":"PMC2598705","drugname":"lamivudine","startOffset":96,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"                     A 58‐year‐old man was taking abacavir, ","suffix":", atazanavir and ritonavir. His HIV physician noted raised c","exact":"lamivudine"},{"setid":"PMC2598705","drugname":"lamivudine","startOffset":97,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"                    A 53‐year‐old man was taking stavudine, ","suffix":" and nelfinavir. Pravastatin was started by his HIV physicia","exact":"lamivudine"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":108,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"         A 58‐year‐old man was taking abacavir, lamivudine, ","suffix":" and ritonavir. His HIV physician noted raised cholesterol a","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":111,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"      A 52‐year‐old woman was taking didanosine, efavirenz, ","suffix":" and ritonavir, as well as gliclazide, doxazosin and bendrof","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":123,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"ear‐old man was taking abacavir, lamivudine, atazanavir and ","suffix":". His HIV physician noted raised cholesterol and wrote to th","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":126,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"‐old woman was taking didanosine, efavirenz, atazanavir and ","suffix":", as well as gliclazide, doxazosin and bendrofluazide. A let","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"cholesterol","startOffset":165,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"e, atazanavir and ritonavir. His HIV physician noted raised ","suffix":" and wrote to the patient and his general practitioner (GP),","exact":"cholesterol"},{"setid":"PMC2598705","drugname":"cholesterol","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"ian to her GP listed her medications and mentioned that her ","suffix":" was 8.5. Her GP started simvastatin. The patient took the f","exact":"cholesterol"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"commended with his antiretroviral combination, but low dose ","suffix":" or pravastatin is safe. Simvastatin was prescribed by the G","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":211,"endOffset":223,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" P450 (CYP) 3A4 activity, which metabolises simvastatin and ","suffix":". Simvastatin exposure is increased by up to 3000% by PIs,2 ","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":325,"endOffset":337,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"to 3000% by PIs,2 and co‐administration is contraindicated. ","suffix":" concentrations are increased by a much smaller margin, and ","exact":"Atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":397,"endOffset":409,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" concentrations are increased by a much smaller margin, and ","suffix":" may be used cautiously. Pravastatin and rosuvastatin are no","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":124,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"ar‐old man was taking stavudine, lamivudine and nelfinavir. ","suffix":" was started by his HIV physician, and letters were written ","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"were written regularly to his GP about current medications. ","suffix":" was changed to simvastatin by his GP 6 years later.\n       ","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":434,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"ch smaller margin, and atorvastatin may be used cautiously. ","suffix":" and rosuvastatin are not metabolised by CYP3A4 and are safe","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"didanosine","startOffset":88,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"                             A 52‐year‐old woman was taking ","suffix":", efavirenz, atazanavir and ritonavir, as well as gliclazide","exact":"didanosine"},{"setid":"PMC2598705","drugname":"efavirenz","startOffset":100,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"                 A 52‐year‐old woman was taking didanosine, ","suffix":", atazanavir and ritonavir, as well as gliclazide, doxazosin","exact":"efavirenz"},{"setid":"PMC2598705","drugname":"gliclazide","startOffset":148,"endOffset":158,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"didanosine, efavirenz, atazanavir and ritonavir, as well as ","suffix":", doxazosin and bendrofluazide. A letter from her HIV physic","exact":"gliclazide"},{"setid":"PMC2598705","drugname":"doxazosin","startOffset":160,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"efavirenz, atazanavir and ritonavir, as well as gliclazide, ","suffix":" and bendrofluazide. A letter from her HIV physician to her ","exact":"doxazosin"},{"setid":"PMC2598705","drugname":"bendrofluazide","startOffset":174,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"zanavir and ritonavir, as well as gliclazide, doxazosin and ","suffix":". A letter from her HIV physician to her GP listed her medic","exact":"bendrofluazide"},{"setid":"PMC2598705","drugname":"stavudine","startOffset":86,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"                               A 53‐year‐old man was taking ","suffix":", lamivudine and nelfinavir. Pravastatin was started by his ","exact":"stavudine"},{"setid":"PMC2598705","drugname":"nelfinavir","startOffset":112,"endOffset":122,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"     A 53‐year‐old man was taking stavudine, lamivudine and ","suffix":". Pravastatin was started by his HIV physician, and letters ","exact":"nelfinavir"},{"setid":"PMC2598705","drugname":"nelfinavir","startOffset":121,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" including ritonavir, atazanavir, lopinavir, saquinavir and ","suffix":", inhibit cytochrome P450 (CYP) 3A4 activity, which metaboli","exact":"nelfinavir"},{"setid":"PMC2598705","drugname":"rosuvastatin","startOffset":450,"endOffset":462,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"n, and atorvastatin may be used cautiously. Pravastatin and ","suffix":" are not metabolised by CYP3A4 and are safe to use with PIs.","exact":"rosuvastatin"}],[{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"controlled trial. Healthy male volunteers (n = 14) received ","suffix":" 200 mg or placebo twice daily for 7 days, and rosuvastatin ","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":452,"endOffset":464,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"uctase inhibitors and most (> 85%) of the total inhibitors. ","suffix":" did not affect the proportion of circulating active or tota","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":327,"endOffset":339,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"ly, the present study was conducted to assess the effect of ","suffix":" (a potent CYP3A4 inhibitor [15]) on the pharmacokinetics of","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":274,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":". Volunteers were randomized to receive daily oral doses of ","suffix":" 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":586,"endOffset":598,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"mg (1 × 80-mg encapsulated tablet) with the morning dose of ","suffix":" or placebo. Volunteers then remained in the Clinical Pharma","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":339,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"mples were taken before administration of the first dose of ","suffix":" or placebo on day 1 of the second dosing period. Blood samp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"en before and 2 h after administration of the first dose of ","suffix":" or placebo on days 4, 5, 6 and 7 of each dosing period. Blo","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"drug concentration (Cmax) of rosuvastatin after dosing with ","suffix":" compared with placebo. If less than 12 volunteers had AUC d","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":817,"endOffset":829,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"-CoA reductase inhibitors, and plasma drug concentration of ","suffix":" before and 2 h after administration of the first dose on da","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":98,"endOffset":110,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"                           To examine in vivo the effect of ","suffix":" on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-meth","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"controlled trial. Healthy male volunteers (n = 14) received ","suffix":" 200 mg or placebo twice daily for 7 days, and rosuvastatin ","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":97,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                            Following coadministration with ","suffix":", rosuvastatin geometric least square mean AUC(0,t) and Cmax","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":327,"endOffset":339,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"ly, the present study was conducted to assess the effect of ","suffix":" (a potent CYP3A4 inhibitor [15]) on the pharmacokinetics of","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":274,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":". Volunteers were randomized to receive daily oral doses of ","suffix":" 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":586,"endOffset":598,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"mg (1 × 80-mg encapsulated tablet) with the morning dose of ","suffix":" or placebo. Volunteers then remained in the Clinical Pharma","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":339,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"mples were taken before administration of the first dose of ","suffix":" or placebo on day 1 of the second dosing period. Blood samp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"en before and 2 h after administration of the first dose of ","suffix":" or placebo on days 4, 5, 6 and 7 of each dosing period. Blo","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"drug concentration (Cmax) of rosuvastatin after dosing with ","suffix":" compared with placebo. If less than 12 volunteers had AUC d","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":817,"endOffset":829,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"-CoA reductase inhibitors, and plasma drug concentration of ","suffix":" before and 2 h after administration of the first dose on da","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":183,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"dence interval (CI) for the treatment ratio (rosuvastatin + ","suffix":"/rosuvastatin + placebo) of the geometric least square means","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":187,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"time were similar when rosuvastatin was coadministered with ","suffix":" and placebo (Figure 1). As AUC data from both dosing period","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":636,"endOffset":648,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"the assessment of exposure. Following coadministration with ","suffix":", rosuvastatin glsmean AUC(0,t) and Cmax were unchanged comp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":850,"endOffset":862,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"prespecified interval of 0.7-1.43, so it was concluded that ","suffix":" had no effect on the pharmacokinetics of rosuvastatin.\n    ","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":92,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"                         The gmean plasma concentrations of ","suffix":" before administration of the first dose on days 4-7 (data n","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":318,"endOffset":330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ntained during sampling. The gmean plasma concentrations of ","suffix":" 2 h after administration of the first dose on days 4-7 (452","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":518,"endOffset":530,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ions fell within the range anticipated for a 200-mg dose of ","suffix":".\n                                                    ","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":74,"endOffset":86,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"                                           Rosuvastatin and ","suffix":" were well tolerated when coadministered. There were no seri","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"inistration of rosuvastatin and the potent CYP3A4 inhibitor ","suffix":" did not produce any change in pharmacokinetics of the forme","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":235,"endOffset":247,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"netics of the former. Furthermore, the results suggest that ","suffix":" had no effect on the systemic clearance of rosuvastatin, as","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":640,"endOffset":652,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" exposure would be expected following coadministration with ","suffix":". The potency of ketoconazole to inhibit P-gp has been asses","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":669,"endOffset":681,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ollowing coadministration with ketoconazole. The potency of ","suffix":" to inhibit P-gp has been assessed in cell-based assays and ","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":835,"endOffset":847,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ased on these data, it is likely that the concentrations of ","suffix":" achieved in the present study would have caused a degree of","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"                                             In conclusion, ","suffix":" did not affect the pharmacokinetics of rosuvastatin in heal","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"astatin in healthy subjects. Therefore, coadministration of ","suffix":" and rosuvastatin is unlikely to increase the risk of toxici","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":364,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"Sciences Inc. (Montreal, Quebec, Canada) for performing the ","suffix":" assays, Olise M. Nwose MB BS for his support of this trial,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":187,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"time were similar when rosuvastatin was coadministered with ","suffix":" and placebo (Figure 1). As AUC data from both dosing period","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":636,"endOffset":648,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"the assessment of exposure. Following coadministration with ","suffix":", rosuvastatin glsmean AUC(0,t) and Cmax were unchanged comp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":452,"endOffset":464,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"uctase inhibitors and most (> 85%) of the total inhibitors. ","suffix":" did not affect the proportion of circulating active or tota","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":525,"endOffset":537,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ity (≥ 75%) of the total circulating inhibitors (Figure 2). ","suffix":" did not affect the proportion of circulating active or tota","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":318,"endOffset":330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ntained during sampling. The gmean plasma concentrations of ","suffix":" 2 h after administration of the first dose on days 4-7 (452","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"inistration of rosuvastatin and the potent CYP3A4 inhibitor ","suffix":" did not produce any change in pharmacokinetics of the forme","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":235,"endOffset":247,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"netics of the former. Furthermore, the results suggest that ","suffix":" had no effect on the systemic clearance of rosuvastatin, as","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":208,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ion for, or induction or inhibition of, transport proteins. ","suffix":" is known to have inhibitory effects on the transport protei","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":640,"endOffset":652,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" exposure would be expected following coadministration with ","suffix":". The potency of ketoconazole to inhibit P-gp has been asses","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":669,"endOffset":681,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ollowing coadministration with ketoconazole. The potency of ","suffix":" to inhibit P-gp has been assessed in cell-based assays and ","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":835,"endOffset":847,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ased on these data, it is likely that the concentrations of ","suffix":" achieved in the present study would have caused a degree of","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"astatin in healthy subjects. Therefore, coadministration of ","suffix":" and rosuvastatin is unlikely to increase the risk of toxici","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":364,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"Sciences Inc. (Montreal, Quebec, Canada) for performing the ","suffix":" assays, Olise M. Nwose MB BS for his support of this trial,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" vivo the effect of ketoconazole on the pharmacokinetics of ","suffix":", a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductas","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" ketoconazole 200 mg or placebo twice daily for 7 days, and ","suffix":" 80 mg was coadministered on day 4 of dosing. Plasma concent","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"coadministered on day 4 of dosing. Plasma concentrations of ","suffix":", and active and total HMG-CoA reductase inhibitors were mea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":312,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" 1.016 (0.839, 1.230), 0.954 (0.722, 1.260), respectively). ","suffix":" accounted for essentially all of the circulating active HMG","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"crestor","startOffset":71,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                              Rosuvastatin (","suffix":"®) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A ","exact":"Crestor"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"3], 90% of an orally administered dose of 14C-radiolabelled ","suffix":" was recovered in faeces as unchanged drug, a result consist","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"mes and hepatocytes demonstrated only limited metabolism of ","suffix":" [4], and cytochrome P450 2C9 (CYP2C9) appeared to be the pr","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":582,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":", with minor roles for CYP3A4 and CYP2C19 [4]. In addition, ","suffix":" had no significant inhibitory effect on the major CYP isofo","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"P3A4 metabolism is not an important clearance mechanism for ","suffix":", an in vivo interaction with coadministered drugs that inhi","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":253,"endOffset":265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":". Thus, studies with rats have demonstrated selective hepati","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":337,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ies with rats have demonstrated selective hepatic uptake of ","suffix":" by an active transport process [17], and rosuvastatin was s","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ke of rosuvastatin by an active transport process [17], and ","suffix":" was shown to be a ligand for a liver-specific human organic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" vivo the effect of ketoconazole on the pharmacokinetics of ","suffix":", a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductas","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" ketoconazole 200 mg or placebo twice daily for 7 days, and ","suffix":" 80 mg was coadministered on day 4 of dosing. Plasma concent","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"coadministered on day 4 of dosing. Plasma concentrations of ","suffix":", and active and total HMG-CoA reductase inhibitors were mea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"              Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,t) and Cmax were unchange","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":566,"endOffset":578,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ing active or total inhibitors accounted for by circulating ","suffix":".\n                                                          ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":108,"endOffset":120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                 Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".\n                                                          ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":81,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                    The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                             Elimination of ","suffix":" is primarily via the liver. In a clinical trial [3], 90% of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"3], 90% of an orally administered dose of 14C-radiolabelled ","suffix":" was recovered in faeces as unchanged drug, a result consist","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"mes and hepatocytes demonstrated only limited metabolism of ","suffix":" [4], and cytochrome P450 2C9 (CYP2C9) appeared to be the pr","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":582,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":", with minor roles for CYP3A4 and CYP2C19 [4]. In addition, ","suffix":" had no significant inhibitory effect on the major CYP isofo","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"P3A4 metabolism is not an important clearance mechanism for ","suffix":", an in vivo interaction with coadministered drugs that inhi","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":400,"endOffset":412,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"(a potent CYP3A4 inhibitor [15]) on the pharmacokinetics of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":253,"endOffset":265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":". Thus, studies with rats have demonstrated selective hepati","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":337,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ies with rats have demonstrated selective hepatic uptake of ","suffix":" by an active transport process [17], and rosuvastatin was s","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ke of rosuvastatin by an active transport process [17], and ","suffix":" was shown to be a ligand for a liver-specific human organic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":748,"endOffset":760,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ndication of whether P-gp-mediated transport contributes to ","suffix":" disposition.\n                                              ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":398,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":510,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":255,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":433,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                                   Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":247,"endOffset":259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"n) at Quintiles Scotland Ltd (Edinburgh, UK) [19]. Briefly, ","suffix":" was extracted from the samples by automated solid-phase ext","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":902,"endOffset":914,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"ionspray source. The lower limit of quantification (LOQ) of ","suffix":" was verified as 0.1 ng ml−1. However, because all samples w","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1154,"endOffset":1166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"%, and at 1 ng ml−1 was ≤ 20%. Correlation coefficients for ","suffix":" calibration curves were 0.996-0.999. Mean imprecision value","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":89,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                                The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1268,"endOffset":1280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ard curve. Concentrations are reported as ng equivalents of ","suffix":" ml−1. The lower LOQ was verified as 0.36 ng ml−1 and the co","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":240,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"C) and maximum observed plasma drug concentration (Cmax) of ","suffix":" after dosing with ketoconazole compared with placebo. If le","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":664,"endOffset":676,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" to Cmax (tmax), and terminal elimination half-life (t½) of ","suffix":", area under the plasma concentration-time curve and Cmax of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":168,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (glsmeans) f","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"placebo) of the geometric least square means (glsmeans) for ","suffix":" AUC [or AUC(0,t)] was contained within the interval of 0.7-","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":64,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","prefix":"                                                         As ","suffix":" AUC [or AUC(0,t)] and Cmax were the primary parameters upon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":109,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"        The geometric mean (gmean) plasma concentrations of ","suffix":" over time were similar when rosuvastatin was coadministered","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" concentrations of rosuvastatin over time were similar when ","suffix":" was coadministered with ketoconazole and placebo (Figure 1)","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" of exposure. Following coadministration with ketoconazole, ","suffix":" glsmean AUC(0,t) and Cmax were unchanged compared with plac","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":904,"endOffset":916,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" that ketoconazole had no effect on the pharmacokinetics of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":657,"endOffset":669,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"l HMG-CoA reductase inhibitors accounted for by circulating ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":234,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"indicated that steady state was achieved before dosing with ","suffix":" and was maintained during sampling. The gmean plasma concen","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":77,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                                        Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":291,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                             In contrast to ","suffix":", atorvastatin [5], simvastatin [6], and lovastatin [7] are ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":384,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":700,"endOffset":712,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [3, 4].\n                                                   ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":389,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":" [17, 18]. The identity of the rosuvastatin transporters tha","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":432,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d disposition of rosuvastatin [17, 18]. The identity of the ","suffix":" transporters that interact with rosuvastatin has not been c","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":477,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"dentity of the rosuvastatin transporters that interact with ","suffix":" has not been clearly defined, but if it were a P-gp substra","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ly defined, but if it were a P-gp substrate, an increase in ","suffix":" exposure would be expected following coadministration with ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":966,"endOffset":978,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f P-gp inhibition [16]. Therefore, our results suggest that ","suffix":" is not a ligand for P-gp. This finding is in agreement with","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1087,"endOffset":1099,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"eement with the results of a study that showed no effect of ","suffix":" on the pharmacokinetics of the P-gp substrate digoxin [21].","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":206,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":414,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":510,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":255,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":433,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                                   Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":247,"endOffset":259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"n) at Quintiles Scotland Ltd (Edinburgh, UK) [19]. Briefly, ","suffix":" was extracted from the samples by automated solid-phase ext","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":736,"endOffset":748,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"led water (70 : 30 v/v), and the flow rate was 1 ml min−1). ","suffix":" was detected using a PE-Sciex API 365 triple quadruple mass","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":902,"endOffset":914,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"ionspray source. The lower limit of quantification (LOQ) of ","suffix":" was verified as 0.1 ng ml−1. However, because all samples w","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1154,"endOffset":1166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"%, and at 1 ng ml−1 was ≤ 20%. Correlation coefficients for ","suffix":" calibration curves were 0.996-0.999. Mean imprecision value","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1268,"endOffset":1280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ard curve. Concentrations are reported as ng equivalents of ","suffix":" ml−1. The lower LOQ was verified as 0.36 ng ml−1 and the co","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":240,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"C) and maximum observed plasma drug concentration (Cmax) of ","suffix":" after dosing with ketoconazole compared with placebo. If le","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":664,"endOffset":676,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" to Cmax (tmax), and terminal elimination half-life (t½) of ","suffix":", area under the plasma concentration-time curve and Cmax of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" vivo the effect of ketoconazole on the pharmacokinetics of ","suffix":", a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductas","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" ketoconazole 200 mg or placebo twice daily for 7 days, and ","suffix":" 80 mg was coadministered on day 4 of dosing. Plasma concent","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"coadministered on day 4 of dosing. Plasma concentrations of ","suffix":", and active and total HMG-CoA reductase inhibitors were mea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"              Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,t) and Cmax were unchange","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":566,"endOffset":578,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ing active or total inhibitors accounted for by circulating ","suffix":".\n                                                          ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":108,"endOffset":120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                 Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".\n                                                          ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":81,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                    The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                             Elimination of ","suffix":" is primarily via the liver. In a clinical trial [3], 90% of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"3], 90% of an orally administered dose of 14C-radiolabelled ","suffix":" was recovered in faeces as unchanged drug, a result consist","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"mes and hepatocytes demonstrated only limited metabolism of ","suffix":" [4], and cytochrome P450 2C9 (CYP2C9) appeared to be the pr","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":582,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":", with minor roles for CYP3A4 and CYP2C19 [4]. In addition, ","suffix":" had no significant inhibitory effect on the major CYP isofo","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"P3A4 metabolism is not an important clearance mechanism for ","suffix":", an in vivo interaction with coadministered drugs that inhi","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":400,"endOffset":412,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"(a potent CYP3A4 inhibitor [15]) on the pharmacokinetics of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":253,"endOffset":265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":". Thus, studies with rats have demonstrated selective hepati","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":337,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ies with rats have demonstrated selective hepatic uptake of ","suffix":" by an active transport process [17], and rosuvastatin was s","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ke of rosuvastatin by an active transport process [17], and ","suffix":" was shown to be a ligand for a liver-specific human organic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":748,"endOffset":760,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ndication of whether P-gp-mediated transport contributes to ","suffix":" disposition.\n                                              ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":398,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":510,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":255,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":433,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                                   Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":247,"endOffset":259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"n) at Quintiles Scotland Ltd (Edinburgh, UK) [19]. Briefly, ","suffix":" was extracted from the samples by automated solid-phase ext","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":902,"endOffset":914,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"ionspray source. The lower limit of quantification (LOQ) of ","suffix":" was verified as 0.1 ng ml−1. However, because all samples w","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1154,"endOffset":1166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"%, and at 1 ng ml−1 was ≤ 20%. Correlation coefficients for ","suffix":" calibration curves were 0.996-0.999. Mean imprecision value","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":89,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                                The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1268,"endOffset":1280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ard curve. Concentrations are reported as ng equivalents of ","suffix":" ml−1. The lower LOQ was verified as 0.36 ng ml−1 and the co","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":240,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"C) and maximum observed plasma drug concentration (Cmax) of ","suffix":" after dosing with ketoconazole compared with placebo. If le","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":664,"endOffset":676,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" to Cmax (tmax), and terminal elimination half-life (t½) of ","suffix":", area under the plasma concentration-time curve and Cmax of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":168,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (glsmeans) f","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"placebo) of the geometric least square means (glsmeans) for ","suffix":" AUC [or AUC(0,t)] was contained within the interval of 0.7-","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":64,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","prefix":"                                                         As ","suffix":" AUC [or AUC(0,t)] and Cmax were the primary parameters upon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":109,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"        The geometric mean (gmean) plasma concentrations of ","suffix":" over time were similar when rosuvastatin was coadministered","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" concentrations of rosuvastatin over time were similar when ","suffix":" was coadministered with ketoconazole and placebo (Figure 1)","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" of exposure. Following coadministration with ketoconazole, ","suffix":" glsmean AUC(0,t) and Cmax were unchanged compared with plac","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":904,"endOffset":916,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" that ketoconazole had no effect on the pharmacokinetics of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":657,"endOffset":669,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"l HMG-CoA reductase inhibitors accounted for by circulating ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":234,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"indicated that steady state was achieved before dosing with ","suffix":" and was maintained during sampling. The gmean plasma concen","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":77,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                                        Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":291,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                             In contrast to ","suffix":", atorvastatin [5], simvastatin [6], and lovastatin [7] are ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":384,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":700,"endOffset":712,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [3, 4].\n                                                   ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":389,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":" [17, 18]. The identity of the rosuvastatin transporters tha","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":432,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d disposition of rosuvastatin [17, 18]. The identity of the ","suffix":" transporters that interact with rosuvastatin has not been c","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":477,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"dentity of the rosuvastatin transporters that interact with ","suffix":" has not been clearly defined, but if it were a P-gp substra","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ly defined, but if it were a P-gp substrate, an increase in ","suffix":" exposure would be expected following coadministration with ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":966,"endOffset":978,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f P-gp inhibition [16]. Therefore, our results suggest that ","suffix":" is not a ligand for P-gp. This finding is in agreement with","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1087,"endOffset":1099,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"eement with the results of a study that showed no effect of ","suffix":" on the pharmacokinetics of the P-gp substrate digoxin [21].","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":206,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":414,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" vivo the effect of ketoconazole on the pharmacokinetics of ","suffix":", a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductas","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" ketoconazole 200 mg or placebo twice daily for 7 days, and ","suffix":" 80 mg was coadministered on day 4 of dosing. Plasma concent","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"coadministered on day 4 of dosing. Plasma concentrations of ","suffix":", and active and total HMG-CoA reductase inhibitors were mea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"              Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,t) and Cmax were unchange","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":566,"endOffset":578,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ing active or total inhibitors accounted for by circulating ","suffix":".\n                                                          ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":108,"endOffset":120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                 Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".\n                                                          ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":81,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                    The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                             Elimination of ","suffix":" is primarily via the liver. In a clinical trial [3], 90% of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"3], 90% of an orally administered dose of 14C-radiolabelled ","suffix":" was recovered in faeces as unchanged drug, a result consist","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"mes and hepatocytes demonstrated only limited metabolism of ","suffix":" [4], and cytochrome P450 2C9 (CYP2C9) appeared to be the pr","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":582,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":", with minor roles for CYP3A4 and CYP2C19 [4]. In addition, ","suffix":" had no significant inhibitory effect on the major CYP isofo","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"P3A4 metabolism is not an important clearance mechanism for ","suffix":", an in vivo interaction with coadministered drugs that inhi","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":400,"endOffset":412,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"(a potent CYP3A4 inhibitor [15]) on the pharmacokinetics of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":253,"endOffset":265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":". Thus, studies with rats have demonstrated selective hepati","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":337,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ies with rats have demonstrated selective hepatic uptake of ","suffix":" by an active transport process [17], and rosuvastatin was s","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ke of rosuvastatin by an active transport process [17], and ","suffix":" was shown to be a ligand for a liver-specific human organic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":748,"endOffset":760,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ndication of whether P-gp-mediated transport contributes to ","suffix":" disposition.\n                                              ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":398,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":510,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":255,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":433,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                                   Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":247,"endOffset":259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"n) at Quintiles Scotland Ltd (Edinburgh, UK) [19]. Briefly, ","suffix":" was extracted from the samples by automated solid-phase ext","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":902,"endOffset":914,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"ionspray source. The lower limit of quantification (LOQ) of ","suffix":" was verified as 0.1 ng ml−1. However, because all samples w","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1154,"endOffset":1166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"%, and at 1 ng ml−1 was ≤ 20%. Correlation coefficients for ","suffix":" calibration curves were 0.996-0.999. Mean imprecision value","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":89,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                                The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1268,"endOffset":1280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ard curve. Concentrations are reported as ng equivalents of ","suffix":" ml−1. The lower LOQ was verified as 0.36 ng ml−1 and the co","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":240,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"C) and maximum observed plasma drug concentration (Cmax) of ","suffix":" after dosing with ketoconazole compared with placebo. If le","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":664,"endOffset":676,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" to Cmax (tmax), and terminal elimination half-life (t½) of ","suffix":", area under the plasma concentration-time curve and Cmax of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":168,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (glsmeans) f","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"placebo) of the geometric least square means (glsmeans) for ","suffix":" AUC [or AUC(0,t)] was contained within the interval of 0.7-","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":64,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","prefix":"                                                         As ","suffix":" AUC [or AUC(0,t)] and Cmax were the primary parameters upon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":109,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"        The geometric mean (gmean) plasma concentrations of ","suffix":" over time were similar when rosuvastatin was coadministered","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" concentrations of rosuvastatin over time were similar when ","suffix":" was coadministered with ketoconazole and placebo (Figure 1)","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" of exposure. Following coadministration with ketoconazole, ","suffix":" glsmean AUC(0,t) and Cmax were unchanged compared with plac","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":904,"endOffset":916,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" that ketoconazole had no effect on the pharmacokinetics of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":657,"endOffset":669,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"l HMG-CoA reductase inhibitors accounted for by circulating ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":234,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"indicated that steady state was achieved before dosing with ","suffix":" and was maintained during sampling. The gmean plasma concen","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":77,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                                        Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":291,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                             In contrast to ","suffix":", atorvastatin [5], simvastatin [6], and lovastatin [7] are ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":384,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":700,"endOffset":712,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [3, 4].\n                                                   ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":389,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":" [17, 18]. The identity of the rosuvastatin transporters tha","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":432,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d disposition of rosuvastatin [17, 18]. The identity of the ","suffix":" transporters that interact with rosuvastatin has not been c","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":477,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"dentity of the rosuvastatin transporters that interact with ","suffix":" has not been clearly defined, but if it were a P-gp substra","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ly defined, but if it were a P-gp substrate, an increase in ","suffix":" exposure would be expected following coadministration with ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":966,"endOffset":978,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f P-gp inhibition [16]. Therefore, our results suggest that ","suffix":" is not a ligand for P-gp. This finding is in agreement with","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1087,"endOffset":1099,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"eement with the results of a study that showed no effect of ","suffix":" on the pharmacokinetics of the P-gp substrate digoxin [21].","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":206,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":414,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".\n                                                    ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"placebo) of the geometric least square means (glsmeans) for ","suffix":" AUC [or AUC(0,t)] was contained within the interval of 0.7-","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":109,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"        The geometric mean (gmean) plasma concentrations of ","suffix":" over time were similar when rosuvastatin was coadministered","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" concentrations of rosuvastatin over time were similar when ","suffix":" was coadministered with ketoconazole and placebo (Figure 1)","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" of exposure. Following coadministration with ketoconazole, ","suffix":" glsmean AUC(0,t) and Cmax were unchanged compared with plac","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":312,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" 1.016 (0.839, 1.230), 0.954 (0.722, 1.260), respectively). ","suffix":" accounted for essentially all of the circulating active HMG","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":736,"endOffset":748,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"led water (70 : 30 v/v), and the flow rate was 1 ml min−1). ","suffix":" was detected using a PE-Sciex API 365 triple quadruple mass","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" ketoconazole 200 mg or placebo twice daily for 7 days, and ","suffix":" 80 mg was coadministered on day 4 of dosing. Plasma concent","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"              Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,t) and Cmax were unchange","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"3], 90% of an orally administered dose of 14C-radiolabelled ","suffix":" was recovered in faeces as unchanged drug, a result consist","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":582,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":", with minor roles for CYP3A4 and CYP2C19 [4]. In addition, ","suffix":" had no significant inhibitory effect on the major CYP isofo","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"ke of rosuvastatin by an active transport process [17], and ","suffix":" was shown to be a ligand for a liver-specific human organic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":510,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":247,"endOffset":259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"n) at Quintiles Scotland Ltd (Edinburgh, UK) [19]. Briefly, ","suffix":" was extracted from the samples by automated solid-phase ext","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1154,"endOffset":1166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"%, and at 1 ng ml−1 was ≤ 20%. Correlation coefficients for ","suffix":" calibration curves were 0.996-0.999. Mean imprecision value","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":664,"endOffset":676,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" to Cmax (tmax), and terminal elimination half-life (t½) of ","suffix":", area under the plasma concentration-time curve and Cmax of","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" of exposure. Following coadministration with ketoconazole, ","suffix":" glsmean AUC(0,t) and Cmax were unchanged compared with plac","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":384,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":432,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d disposition of rosuvastatin [17, 18]. The identity of the ","suffix":" transporters that interact with rosuvastatin has not been c","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ly defined, but if it were a P-gp substrate, an increase in ","suffix":" exposure would be expected following coadministration with ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":966,"endOffset":978,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f P-gp inhibition [16]. Therefore, our results suggest that ","suffix":" is not a ligand for P-gp. This finding is in agreement with","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":206,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":234,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"indicated that steady state was achieved before dosing with ","suffix":" and was maintained during sampling. The gmean plasma concen","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":291,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":384,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":389,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"cesses may have a role in the absorption and disposition of ","suffix":" [17, 18]. The identity of the rosuvastatin transporters tha","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":432,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d disposition of rosuvastatin [17, 18]. The identity of the ","suffix":" transporters that interact with rosuvastatin has not been c","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":477,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"dentity of the rosuvastatin transporters that interact with ","suffix":" has not been clearly defined, but if it were a P-gp substra","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ly defined, but if it were a P-gp substrate, an increase in ","suffix":" exposure would be expected following coadministration with ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":966,"endOffset":978,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f P-gp inhibition [16]. Therefore, our results suggest that ","suffix":" is not a ligand for P-gp. This finding is in agreement with","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":1087,"endOffset":1099,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"eement with the results of a study that showed no effect of ","suffix":" on the pharmacokinetics of the P-gp substrate digoxin [21].","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":206,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"cholesterol","startOffset":187,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in ","suffix":" biosynthesis, and is effective for the treatment of patient","exact":"cholesterol"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":105,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"            Some of the other HMG-CoA reductase inhibitors (","suffix":" [5], simvastatin [6], and lovastatin [7]) are cleared prima","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":373,"endOffset":385,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"g CYP3A4 activity. It has been shown that the metabolism of ","suffix":" [8-10], simvastatin [11, 12], and lovastatin [13, 14] is in","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":404,"endOffset":416,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ts metabolites may be affected. For example, in the case of ","suffix":", following coadministration with itraconazole, the mean AUC","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":587,"endOffset":599,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ased 1.6- and 1.7-fold, respectively; the mean AUC(0,72) of ","suffix":" acid and lactone was increased 3.2- and 4.1-fold, respectiv","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"simvastatin","startOffset":123,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"f the other HMG-CoA reductase inhibitors (atorvastatin [5], ","suffix":" [6], and lovastatin [7]) are cleared primarily by metabolis","exact":"simvastatin"},{"setid":"PMC1884190","drugname":"simvastatin","startOffset":394,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":" has been shown that the metabolism of atorvastatin [8-10], ","suffix":" [11, 12], and lovastatin [13, 14] is inhibited by erythromy","exact":"simvastatin"},{"setid":"PMC1884190","drugname":"lovastatin","startOffset":144,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"eductase inhibitors (atorvastatin [5], simvastatin [6], and ","suffix":" [7]) are cleared primarily by metabolism involving CYP3A4. ","exact":"lovastatin"},{"setid":"PMC1884190","drugname":"lovastatin","startOffset":420,"endOffset":430,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"etabolism of atorvastatin [8-10], simvastatin [11, 12], and ","suffix":" [13, 14] is inhibited by erythromycin and itraconazole, lea","exact":"lovastatin"},{"setid":"PMC1884190","drugname":"lovastatin","startOffset":125,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ast to rosuvastatin, atorvastatin [5], simvastatin [6], and ","suffix":" [7] are cleared primarily by metabolism involving CYP3A4 an","exact":"lovastatin"},{"setid":"PMC1884190","drugname":"erythromycin","startOffset":456,"endOffset":468,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"mvastatin [11, 12], and lovastatin [13, 14] is inhibited by ","suffix":" and itraconazole, leading to increased serum/plasma drug co","exact":"erythromycin"},{"setid":"PMC1884190","drugname":"itraconazole","startOffset":473,"endOffset":485,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"], and lovastatin [13, 14] is inhibited by erythromycin and ","suffix":", leading to increased serum/plasma drug concentrations and ","exact":"itraconazole"},{"setid":"PMC1884190","drugname":"itraconazole","startOffset":450,"endOffset":462,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"n the case of atorvastatin, following coadministration with ","suffix":", the mean AUC(0,72) of the active and total inhibitors was ","exact":"itraconazole"},{"setid":"PMC1884190","drugname":"alanine","startOffset":417,"endOffset":424,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" haematology, or urinalysis results, or if total bilirubin, ","suffix":" aminotransferase, aspartate aminotransferase, alkaline phos","exact":"alanine"},{"setid":"PMC1884190","drugname":"caffeine","startOffset":311,"endOffset":319,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" of rosuvastatin in each dosing period), the consumption of ","suffix":"-containing drinks/food and smoking (none permitted from mid","exact":"caffeine"},{"setid":"PMC1884190","drugname":"heparin","startOffset":460,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" Blood samples were collected into tubes containing lithium ","suffix":" anticoagulant and centrifuged within 30 min. Plasma was the","exact":"heparin"},{"setid":"PMC1884190","drugname":"sodium acetate","startOffset":572,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" Plasma was then harvested from the samples, mixed 1:1 with ","suffix":" buffer 0.1 m pH 4.0, and stored at −70°C until assay.\n     ","exact":"sodium acetate"},{"setid":"PMC1884190","drugname":"acetonitrile","startOffset":388,"endOffset":400,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" drug-related components were isolated from plasma by using ","suffix":" : acetone (95 : 5) to precipitate plasma proteins. The supe","exact":"acetonitrile"},{"setid":"PMC1884190","drugname":"acetone","startOffset":403,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"omponents were isolated from plasma by using acetonitrile : ","suffix":" (95 : 5) to precipitate plasma proteins. The supernatant wa","exact":"acetone"},{"setid":"PMC1884190","drugname":"mevalonolactone","startOffset":973,"endOffset":988,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"as separated from the substrate, after lactonization to 14C-","suffix":" by hydrochloric acid, on a small ion-exchange column. The e","exact":"mevalonolactone"},{"setid":"PMC1884190","drugname":"mevalonolactone","startOffset":1097,"endOffset":1112,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"lumn. The effluent from the column (which contained the 14C-","suffix":") was collected into scintillation vials and counted. The re","exact":"mevalonolactone"},{"setid":"PMC1884190","drugname":"edta","startOffset":271,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" period. Blood samples were collected into tubes containing ","suffix":" anticoagulant and centrifuged. Plasma was then harvested fr","exact":"EDTA"}],[{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":662,"endOffset":674,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tin concentration (adjusted R2 = 0.56 for the final model). ","suffix":" concentration was associated with SLCO1B1 c.388A>G (p < 0.0","exact":"Atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":260,"endOffset":272,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" incorporating genomic and clinical variables to avoid high ","suffix":" and rosuvastatin levels is described; further study will de","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":167,"endOffset":179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"London Health Sciences Center (LHSC, London, Canada) taking ","suffix":" or rosuvastatin daily to participate. Patients were exclude","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":261,"endOffset":273,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" to participate. Patients were excluded if they were taking ","suffix":" or rosuvastatin in an alternate day dosing regimen, or if t","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":362,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ate day dosing regimen, or if they had not taken their last ","suffix":" or rosuvastatin dose within 24 hours of their clinic visit ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":479,"endOffset":491,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"r clinic visit and blood draw. All patients had been taking ","suffix":" or rosuvastatin at the same dose for at least six weeks pri","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":266,"endOffset":278,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ated in 300 μL acetonitrile containing internal standard d5-","suffix":" or d6-rosuvastatin, and centrifuged at 14,000 rpm for 20 mi","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":617,"endOffset":629,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"dient to ratio of 10:90. Concentrations of rosuvastatin and ","suffix":" were measured by liquid chromatography-mass spectrometry (L","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":719,"endOffset":731,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"249G>A (rs2273697); and ABCG2 c.421C>A (rs2231142). For the ","suffix":" group, polymorphisms in the drug metabolizing enzymes CYP3A","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":289,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":"8A>G, and ABCG2 c.421C>A, respectively. For log-transformed ","suffix":" concentration, the effect sizes detectable with a power of ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":246,"endOffset":258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"ax of the statin were included (1.5 hours and 4.0 hours for ","suffix":" and rosuvastatin, respectively11). Different genetic models","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":257,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"models. The 90th percentile was determined by adjusting the ","suffix":" or rosuvastatin concentrations measured in our population t","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":439,"endOffset":451,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"of the blood sampling across the population (11.5 hours for ","suffix":" and 12.9 hours for rosuvastatin). For covariates that were ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":741,"endOffset":753,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"lation height and weight (body mass index of 29.0 kg/m2 for ","suffix":" and 30.1 kg/m2 rosuvastatin), and for atorvastatin, average","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":792,"endOffset":804,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"g/m2 for atorvastatin and 30.1 kg/m2 rosuvastatin), and for ","suffix":", average 4β-hydroxycholesterol concentration (22 ng/ml). Ag","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"l, 299 patients were enrolled in the study, with 134 taking ","suffix":" and 165 patients on rosuvastatin therapy. Of these patients","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":303,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"rapy. Of these patients, 3 taking rosuvastatin and 6 taking ","suffix":" had undetectable statin levels, and were excluded from furt","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ld or higher variability between patients on the same daily ","suffix":" dose (Figure 1B). In patients taking 10, 20, 40, or 80 mg a","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":234,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"n dose (Figure 1B). In patients taking 10, 20, 40, or 80 mg ","suffix":" daily, mean plasma concentration of atorvastatin was 0.9 ng","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":283,"endOffset":295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", or 80 mg atorvastatin daily, mean plasma concentration of ","suffix":" was 0.9 ng/mL (SD 1.0), 2.0 ng/mL (1.7), 3.0 ng/mL (3.5), a","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":434,"endOffset":446,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":" respectively. There was a significant difference in plasma ","suffix":" concentration between those taking 20 mg, 40 mg, or 80 mg v","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":119,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"  Multiple linear regression analysis indicated that plasma ","suffix":" concentration was higher in individuals with the SLCO1B1 c.","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":426,"endOffset":438,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"(p < 0.01). In addition, age was a significant predictor of ","suffix":" level (p < 0.01) (Table 2). The adjusted R2 value of the mo","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":850,"endOffset":862,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"ted for an additional 30% of the explainable variability in ","suffix":" concentration. A list of CYP3A inhibitors and inducers pres","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":948,"endOffset":960,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"CYP3A inhibitors and inducers prescribed to patients taking ","suffix":" is provided in Supplemental Table 6. Similar results were o","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":1163,"endOffset":1175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" following variables were not significantly associated with ","suffix":" concentration: gender, ethnicity, BMI, and SLCO1B3, SLCO2B1","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":208,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"1) and rosuvastatin was 3.4 μg/mL (2.2). In patients taking ","suffix":", lathosterol concentration was lower in patients taking a h","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":294,"endOffset":306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"concentration was lower in patients taking a higher dose of ","suffix":" (p < 0.01), however, there was no significant association b","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":389,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"here was no significant association between rosuvastatin or ","suffix":" concentrations and lathosterol concentration detected in th","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":665,"endOffset":677,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"usted R2 value of the model of lathosterol concentration in ","suffix":"-treated patients was 0.08; for rosuvastatin-treated patient","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":246,"endOffset":258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"s (n = 579). The first cohort contained 224 patients taking ","suffix":" and 37 patients taking rosuvastatin in the context of routi","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"n the U.S.; the second cohort contained 121 patients taking ","suffix":" and 198 patients taking rosuvastatin treated in a lipid cli","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":116,"endOffset":128,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"     Among 67 patients on high-dose rosuvastatin (40 mg) or ","suffix":" (80 mg), nearly 50% exceeded the maximum dose recommended b","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":298,"endOffset":310,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"developing intolerance. Of the 16 patients taking high-dose ","suffix":" (80 mg) within our cohort derived from an EMR-linked bioban","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":463,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"nded dose, and only 7 of these patients were still on 80 mg ","suffix":" one year later. Conversely, all (7 of 7) subjects predicted","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":595,"endOffset":607,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":" by our algorithm to tolerate 80 mg were still on high-dose ","suffix":" one year later, however, this result was not statistically ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":173,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"drug transporter polymorphisms and plasma concentrations of ","suffix":" and rosuvastatin in a real world population. We found a mar","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":765,"endOffset":777,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" transporter ABCG2. In contrast, explainable variability in ","suffix":" level is almost equally divided between two polymorphisms i","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":990,"endOffset":1002,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ng our findings together, we propose a dosing algorithm for ","suffix":" and rosuvastatin that, based on our data regarding the asso","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":556,"endOffset":568,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"B1 SNPs had higher plasma concentrations of such statins as ","suffix":", rosuvastatin, simvastatin, pravastatin, and pitavastatin19","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":1209,"endOffset":1221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" studies to be associated with a trend towards lower plasma ","suffix":" level22, 24. Interestingly, the SEARCH study showed a link ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":442,"endOffset":454,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" low 4β-hydroxycholesterol level was associated with higher ","suffix":" but not rosuvastatin concentration. Rosuvastatin concentrat","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":805,"endOffset":817,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ction with higher creatine kinase levels in patients taking ","suffix":", suggesting these individuals are prone to more severe myop","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":1072,"endOffset":1084,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"A inhibitors and statins metabolized by CYP3A, particularly ","suffix":" and simvastatin. The US Food and Drug Administration (US FD","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"as a significant factor in predicting the concentrations of ","suffix":" and rosuvastatin in patients. Age has been recognized as a ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":256,"endOffset":268,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"nhibition37-38. In our population, plasma concentrations of ","suffix":" and rosuvastatin did not correlate with lathosterol levels.","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":118,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"t the highest available dose, nearly 50% of patients taking ","suffix":" or rosuvastatin exceeded the maximum genotype-based dose re","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":561,"endOffset":573,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":" most useful when a patient is starting the highest dose of ","suffix":" or rosuvastatin, bearing in mind that SLCO1B1 c.521 T>C var","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":593,"endOffset":605,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"(p < 0.001) and ABCG2 c.421C>A (p < 0.01) were important to ","suffix":" concentration (adjusted R2 = 0.56 for the final model). Ato","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":277,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"nomic and clinical variables to avoid high atorvastatin and ","suffix":" levels is described; further study will determine if this a","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":183,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"iences Center (LHSC, London, Canada) taking atorvastatin or ","suffix":" daily to participate. Patients were excluded if they were t","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":277,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" Patients were excluded if they were taking atorvastatin or ","suffix":" in an alternate day dosing regimen, or if they had not take","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":378,"endOffset":390,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"egimen, or if they had not taken their last atorvastatin or ","suffix":" dose within 24 hours of their clinic visit and blood draw. ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":495,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"nd blood draw. All patients had been taking atorvastatin or ","suffix":" at the same dose for at least six weeks prior to participat","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":285,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"onitrile containing internal standard d5-atorvastatin or d6-","suffix":", and centrifuged at 14,000 rpm for 20 minutes at 4 °C. The ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":600,"endOffset":612,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"70:30, with a gradient to ratio of 10:90. Concentrations of ","suffix":" and atorvastatin were measured by liquid chromatography-mas","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":864,"endOffset":876,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":") and CYP3A5 (rs776746) were also assessed. Patients in the ","suffix":" group were also genotyped for CYP2C9 *2 (rs1799853) and CYP","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":263,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"were included (1.5 hours and 4.0 hours for atorvastatin and ","suffix":", respectively11). Different genetic models-dominant, co-dom","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":273,"endOffset":285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":" percentile was determined by adjusting the atorvastatin or ","suffix":" concentrations measured in our population to the concentrat","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":471,"endOffset":483,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":" population (11.5 hours for atorvastatin and 12.9 hours for ","suffix":"). For covariates that were not significant in the model, we","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":769,"endOffset":781,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"dy mass index of 29.0 kg/m2 for atorvastatin and 30.1 kg/m2 ","suffix":"), and for atorvastatin, average 4β-hydroxycholesterol conce","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":227,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"the study, with 134 taking atorvastatin and 165 patients on ","suffix":" therapy. Of these patients, 3 taking rosuvastatin and 6 tak","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":277,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"tients on rosuvastatin therapy. Of these patients, 3 taking ","suffix":" and 6 taking atorvastatin had undetectable statin levels, a","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":409,"endOffset":421,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"nd were excluded from further analysis. Two patients taking ","suffix":" were excluded from lathosterol-related analysis, due to ina","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":223,"endOffset":235,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"me dose (Figure 1A). In patients taking 5, 10, 20, or 40 mg ","suffix":" daily, mean plasma concentration of rosuvastatin was 1.6 ng","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":272,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":", or 40 mg rosuvastatin daily, mean plasma concentration of ","suffix":" was 1.6 ng/mL (SD 1.8), 3.5 ng/mL (2.9), 6.3 ng/mL (5.3), a","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" respectively. There was a significant difference in plasma ","suffix":" concentration between those taking 5 mg vs. 10 mg, 20 mg or","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":147,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ociation of clinical and pharmacogenetic variables with the ","suffix":" levels observed, we performed multiple linear regression an","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":411,"endOffset":423,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":". Multiple linear regression analysis indicated that plasma ","suffix":" concentration was higher in individuals with the reduced fu","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":666,"endOffset":678,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ism ABCG2 c.421A (p < 0.05). Age also contributed to plasma ","suffix":" level (p < 0.01) (Table 2). The adjusted R2 value of the mo","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":609,"endOffset":621,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"uced similar results (Supplemental Table 5). In contrast to ","suffix":", the genetic component of the model contributed only 38% of","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" in patients taking atorvastatin was 3.9 μg/mL (SD 2.1) and ","suffix":" was 3.4 μg/mL (2.2). In patients taking atorvastatin, latho","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":373,"endOffset":385,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":".01), however, there was no significant association between ","suffix":" or atorvastatin concentrations and lathosterol concentratio","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"n combination with plasma statin concentration. We examined ","suffix":" acid concentrations in patients taking 40 mg rosuvastatin d","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":345,"endOffset":357,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"d rosuvastatin acid concentrations in patients taking 40 mg ","suffix":" daily, for whom no higher dose or more potent statin is ava","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":681,"endOffset":693,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"nts who were not at target LDL-C (n = 12) had a mean plasma ","suffix":" concentration of 9.183 ng/mL (SD 1.6; 13.6 hours post dose)","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":132,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[1]","prefix":", we summarize recommendations for maximum atorvastatin and ","suffix":" doses, based on a patient's age and transporter genotype, a","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":282,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"ned 224 patients taking atorvastatin and 37 patients taking ","suffix":" in the context of routine clinical care at a large academic","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":460,"endOffset":472,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"ed 121 patients taking atorvastatin and 198 patients taking ","suffix":" treated in a lipid clinic at a large academic center in Can","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":243,"endOffset":255,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[2]","prefix":"mmarized in Figure 3. We observed that patients taking 5 mg ","suffix":" were older than those taking 10 mg and 40 mg (p < 0.05). Th","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":190,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"polymorphisms and plasma concentrations of atorvastatin and ","suffix":" in a real world population. We found a marked, 45-fold inte","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":558,"endOffset":570,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"level. Indeed, nearly 90% of the explainable variability in ","suffix":" concentration can be accounted for by two reduced function ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":1007,"endOffset":1019,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ogether, we propose a dosing algorithm for atorvastatin and ","suffix":" that, based on our data regarding the association between t","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":570,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"gher plasma concentrations of such statins as atorvastatin, ","suffix":", simvastatin, pravastatin, and pitavastatin19-22. Important","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":927,"endOffset":939,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"lso been associated with reduced LDL-C lowering response to ","suffix":" therapy23. The other SLCO1B1 polymorphism genotyped, c.388A","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":") efflux transporter ABCG2 have been associated with higher ","suffix":" concentration in healthy volunteers25 and recently, with im","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":362,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"3, 27. The effect of reduced activity ABCG2 polymorphism on ","suffix":" concentration suggests increased statin exposure is the mec","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":482,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"Asian countries such as Japan, the maximum approved dose of ","suffix":" is 20 mg/day compared with 40 mg/day in North American and ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":596,"endOffset":608,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"orth American and European countries. Since the increase in ","suffix":" exposure is not strictly related to environment 24, physici","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":463,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"terol level was associated with higher atorvastatin but not ","suffix":" concentration. Rosuvastatin concentration was also not asso","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":491,"endOffset":503,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ith higher atorvastatin but not rosuvastatin concentration. ","suffix":" concentration was also not associated with CYP2C9 *2 and CY","exact":"Rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":641,"endOffset":653,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" consistent with previous studies which have indicated that ","suffix":" is predominantly eliminated unchanged30. Previous reports h","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":168,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"factor in predicting the concentrations of atorvastatin and ","suffix":" in patients. Age has been recognized as a clinical risk fac","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":405,"endOffset":417,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"creased exposure to atorvastatin35, but not rosuvastatin36. ","suffix":" clearance, however, is partially mediated by tubular secret","exact":"Rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":273,"endOffset":285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"n our population, plasma concentrations of atorvastatin and ","suffix":" did not correlate with lathosterol levels. This suggests st","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":134,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ailable dose, nearly 50% of patients taking atorvastatin or ","suffix":" exceeded the maximum genotype-based dose recommended by our","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":577,"endOffset":589,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"n a patient is starting the highest dose of atorvastatin or ","suffix":", bearing in mind that SLCO1B1 c.521 T>C variant carriers in","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":366,"endOffset":378,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"statin transporter polymorphisms. In the clinical review of ","suffix":" originally submitted to the US FDA, all patients with serio","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":509,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"events for whom drug levels were available (n = 6) had high ","suffix":" concentrations (> 50 ng/mL; http://www.accessdata.fda.gov/d","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"crestor","startOffset":612,"endOffset":619,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"tp://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_","suffix":"_Medr_P4.pdf). The FDA recently updated advice on statin ris","exact":"Crestor"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":292,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"by lowering plasma concentration of low-density lipoprotein ","suffix":" (LDL-C)1. A recent report indicates that 25% of Americans o","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":463,"endOffset":474,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ss the efficacy of statin-mediated inhibition of endogenous ","suffix":" synthesis, as well as its relationship to statin concentrat","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":699,"endOffset":710,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"to 80 mg one week prior to blood sampling to achieve better ","suffix":" lowering. The study was conducted between August 2009 and M","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":140,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"as measured by the enzymatic colorimetric method, using the ","suffix":" E kit from Wako (Richmond, VA). Samples were measured in tr","exact":"Cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":520,"endOffset":531,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" analysis, due to inability to measure lathosterol or total ","suffix":". A list of the concomitant medications observed in our popu","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":1087,"endOffset":1098,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" when 4β-hydroxycholesterol levels were normalized by total ","suffix":". The following variables were not significantly associated ","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":530,"endOffset":541,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"tion. In both groups, lathosterol was associated with total ","suffix":", and was higher in patients taking ezetimibe (Table 3). The","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":282,"endOffset":293,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ve. 4β-hydroxycholesterol is produced by CYP3A enzymes from ","suffix":", and has been proposed to be a marker of CYP3A activity in ","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":490,"endOffset":501,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"rmining the inhibition of HMG-CoA reductase. Ezetimibe is a ","suffix":" absorption inhibitor that has been previously associated wi","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":221,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ada). Plasma aliquots of 100 μL were precipitated in 300 μL ","suffix":" containing internal standard d5-atorvastatin or d6-rosuvast","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":503,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" phases 0.05% formic acid in water and 0.05% formic acid in ","suffix":", starting at a ratio of 70:30, with a gradient to ratio of ","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":1595,"endOffset":1607,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"parated and eluted with a gradient from 80% to 98% methanol:","suffix":" (1:1). The transition used for lathosterol was m/z 555.3 to","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"ethanol","startOffset":637,"endOffset":644,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"asma or standard curve were saponified in 1 mL of 1M KOH in ","suffix":" for 1 hour at 37 °C. The samples were extracted twice, in 7","exact":"ethanol"},{"setid":"PMC3922121","drugname":"triethylamine","startOffset":970,"endOffset":983,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"opyridine, 12 mg picolinic acid, 225 μL pyridine, and 30 μL ","suffix":". Samples were incubated with the derivatization reagents at","exact":"triethylamine"},{"setid":"PMC3922121","drugname":"as 2","startOffset":971,"endOffset":975,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"ere coded as 1, and homozygous variant genotypes were coded ","suffix":". Regression analysis was performed by a step-wise search. A","exact":"as 2"},{"setid":"PMC3922121","drugname":"ezetimibe","startOffset":1357,"endOffset":1366,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"omitant medications or presence of the specific medications ","suffix":", niacin, and fibrate were assessed for their contribution t","exact":"ezetimibe"},{"setid":"PMC3922121","drugname":"ezetimibe","startOffset":577,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"d with total cholesterol, and was higher in patients taking ","suffix":" (Table 3). The adjusted R2 value of the model of lathostero","exact":"ezetimibe"},{"setid":"PMC3922121","drugname":"ezetimibe","startOffset":475,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":" factor in determining the inhibition of HMG-CoA reductase. ","suffix":" is a cholesterol absorption inhibitor that has been previou","exact":"Ezetimibe"},{"setid":"PMC3922121","drugname":"ezetimibe","startOffset":657,"endOffset":666,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"rved that lathosterol level is increased in patients taking ","suffix":" even when they are concurrently taking statins, which limit","exact":"ezetimibe"},{"setid":"PMC3922121","drugname":"niacin","startOffset":1368,"endOffset":1374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"ications or presence of the specific medications ezetimibe, ","suffix":", and fibrate were assessed for their contribution to the mo","exact":"niacin"},{"setid":"PMC3922121","drugname":"simvastatin","startOffset":584,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ncentrations of such statins as atorvastatin, rosuvastatin, ","suffix":", pravastatin, and pitavastatin19-22. Importantly, a genome-","exact":"simvastatin"},{"setid":"PMC3922121","drugname":"simvastatin","startOffset":753,"endOffset":764,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"between susceptibility to biochemical myopathy on high-dose ","suffix":" and a common reduced-function variant in SLCO1B1, namely c.","exact":"simvastatin"},{"setid":"PMC3922121","drugname":"simvastatin","startOffset":1319,"endOffset":1330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"H study showed a link between this SNP and reduced risk for ","suffix":"-associated myopathy4. In our population, the SLCO1B1 c.521T","exact":"simvastatin"},{"setid":"PMC3922121","drugname":"simvastatin","startOffset":1089,"endOffset":1100,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"statins metabolized by CYP3A, particularly atorvastatin and ","suffix":". The US Food and Drug Administration (US FDA) recommendatio","exact":"simvastatin"},{"setid":"PMC3922121","drugname":"pravastatin","startOffset":597,"endOffset":608,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"of such statins as atorvastatin, rosuvastatin, simvastatin, ","suffix":", and pitavastatin19-22. Importantly, a genome-wide analysis","exact":"pravastatin"}],[{"setid":"PMC3571969","drugname":"cholesterol","startOffset":470,"endOffset":481,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"nation may be also required to achieve target lipid levels (","suffix":", LDL-C, triglycerides, HDL-C), which appears to confer addi","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":377,"endOffset":388,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"evel (349 mg/dL), CK was in the normal range (121 U/l), but ","suffix":" showed further increase (310.5 mg/dL). Taking the lipid lev","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"ond control. This time both the values of triglycerides and ","suffix":" showed improvement, 154.1 and 249.8 mg/dL, respectively. Ho","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":585,"endOffset":596,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"es (AST: 131.3; ALT: 95.5 U/l), and in LDH (386 U/l). Serum ","suffix":" level remained elevated (257.2 mg/dL), triglycerides reache","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":369,"endOffset":380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","prefix":"transaminases were normal, dyslipidaemia was reduced (total ","suffix":" and triglycerides levels were 238.3 and 216.1 mg/dL, respec","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":673,"endOffset":684,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"-fold higher triglyceride and the moderately elevated total ","suffix":" at the beginning. Third, unfortunately at the first blood t","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":752,"endOffset":763,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"beginning. Third, unfortunately at the first blood test LDL-","suffix":" could not have been evaluated because of the disturbing eff","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":895,"endOffset":906,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"d triglyceride. Later at the control blood tests only total ","suffix":" was measured. LDL-cholesterol is an essential parameter of ","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":925,"endOffset":936,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"ontrol blood tests only total cholesterol was measured. LDL-","suffix":" is an essential parameter of cardiovascular risk stratifica","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":133,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"syndrome; TG: Triglyceride; HDL-C: High-density lipoprotein ","suffix":"; ESC/EAS: European Society of Cardiology and the European A","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":708,"endOffset":719,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"es and lack of lifestyle modification possibilities, 160 mg ","suffix":" per day was applied. The patient was also informed about th","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":229,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","prefix":"was probably the atrovastatin as compared with gemfibrozil, ","suffix":" were found to be less prone to make complications when used","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":369,"endOffset":380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","prefix":" with statins [28]. However, the pathophysiological role of ","suffix":" or the exaggerating effect in the extent of CK elevation ca","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":440,"endOffset":451,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"lyzed by the UDP-glucuronosyltransferase-2B7 (UGT2B7) [33]. ","suffix":" is also glucuronidated by this enzyme [34]. Thus a varenicl","exact":"Fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":515,"endOffset":526,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"also glucuronidated by this enzyme [34]. Thus a varenicline-","suffix":" interaction is theoretically possible. In our case, 3 weeks","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":775,"endOffset":786,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"2-week dose of varenicline where in the second week he took ","suffix":" and atorvastatin, as well. The symptoms started two weeks a","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":466,"endOffset":477,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"general practitioner sometimes limit our success. Secondly, ","suffix":" was administered first instead of atrovastatin. This choice","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"nebivolol","startOffset":458,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"tension started 10 years ago and was controlled with 2.5 mg ","suffix":" per day. He was a blue-collar worker in a storehouse, and s","exact":"nebivolol"},{"setid":"PMC3571969","drugname":"nebivolol","startOffset":240,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[18]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[18]","prefix":"through CYP 450. [4] Although the aromatic hydroxylation of ","suffix":" takes place in CYP 2D6 [35], a single nucleotid polymorphis","exact":"nebivolol"},{"setid":"PMC3571969","drugname":"nebivolol","startOffset":494,"endOffset":503,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[18]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[18]","prefix":"scle effects [36]. Although interaction between statins and ","suffix":" has not been published yet, nebivolol might have influenced","exact":"nebivolol"},{"setid":"PMC3571969","drugname":"nebivolol","startOffset":532,"endOffset":541,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[18]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[18]","prefix":"n between statins and nebivolol has not been published yet, ","suffix":" might have influenced the development of rhabdomyolysis in ","exact":"nebivolol"},{"setid":"PMC3571969","drugname":"nebivolol","startOffset":538,"endOffset":547,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"h lipid lowering medications. The incidental interaction of ","suffix":" with statins or fibrates is also need to be clarified in th","exact":"nebivolol"},{"setid":"PMC3571969","drugname":"alanine","startOffset":594,"endOffset":601,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"s, like creatine kinase (CK), aspartate transaminase (AST), ","suffix":" transaminase (ALT) and gamma glutamyl transpeptidase (GGT) ","exact":"alanine"},{"setid":"PMC3571969","drugname":"alanine","startOffset":283,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ety; CK: Creatine kinase; AST: Aspartate transaminase; ALT: ","suffix":" transaminases; GGT: Gamma glutamyl transpeptidase; LDH: Lac","exact":"Alanine"},{"setid":"PMC3571969","drugname":"urea","startOffset":760,"endOffset":764,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"/l, 23 U/l and 36 U/l, respectively). Renal function (blood ","suffix":" nitrogen: 7.6 mmol/l, serum creatinine: 97 μmol/L, glomerul","exact":"urea"},{"setid":"PMC3571969","drugname":"creatinine","startOffset":793,"endOffset":803,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ly). Renal function (blood urea nitrogen: 7.6 mmol/l, serum ","suffix":": 97 μmol/L, glomerular filtration rate: >60 ml/min) was als","exact":"creatinine"},{"setid":"PMC3571969","drugname":"aspirin","startOffset":208,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"ate regarding taking the prescribed medications (except for ","suffix":", because of bad family experience). About lifestyle modific","exact":"aspirin"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":854,"endOffset":865,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"-effects of the lipid-lowering therapy. Because of smoking, ","suffix":" therapy was prescribed as well, as the patient previously f","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":157,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"ithout any symptoms, and mentioned that he had begun taking ","suffix":" only one week earlier. Laboratory parameters revealed the e","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":179,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":" the three types of medicines together (statin, fibrate and ","suffix":") only one week long. He did not smoke since then. The irreg","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"ibrate therapy-induced rhabdomyolysis could be connected to ","suffix":" intake. The theoretical background of this interaction is b","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":320,"endOffset":331,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"brach et al., who found two metabolites in human excreta of ","suffix":": one of them is the N-carbamoylglucuronide, catalyzed by th","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":503,"endOffset":514,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"ofibrate is also glucuronidated by this enzyme [34]. Thus a ","suffix":"-fenofibrate interaction is theoretically possible. In our c","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":648,"endOffset":659,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"fter starting the fibrate therapy the patient began to take ","suffix":", and one week later atorvastatin. He took altogether a 2-we","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":730,"endOffset":741,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"eek later atorvastatin. He took altogether a 2-week dose of ","suffix":" where in the second week he took fenofibrate and atorvastat","exact":"varenicline"},{"setid":"PMC3571969","drugname":"atorvastatin","startOffset":538,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"r risk of the patient due to MetS into consideration, 20 mg ","suffix":" per day was added to the therapy. Similarly, a control labo","exact":"atorvastatin"},{"setid":"PMC3571969","drugname":"atorvastatin","startOffset":680,"endOffset":692,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"y the patient began to take varenicline, and one week later ","suffix":". He took altogether a 2-week dose of varenicline where in t","exact":"atorvastatin"},{"setid":"PMC3571969","drugname":"atorvastatin","startOffset":791,"endOffset":803,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"arenicline where in the second week he took fenofibrate and ","suffix":", as well. The symptoms started two weeks after the stop of ","exact":"atorvastatin"},{"setid":"PMC3571969","drugname":"lactate","startOffset":223,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"vated, while GGT remained in the normal range (38 U/l). The ","suffix":" dehydrogenase (LDH) level was also increased, 463 U/l. Stat","exact":"lactate"},{"setid":"PMC3571969","drugname":"lactate","startOffset":347,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ine transaminases; GGT: Gamma glutamyl transpeptidase; LDH: ","suffix":" dehydrogenase; CYP: Cytochrome P enzyme; GFR: Glomerular fi","exact":"Lactate"},{"setid":"PMC3571969","drugname":"thyroid-stimulating hormone","startOffset":796,"endOffset":823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"normalities, and the thyroid function test was also normal (","suffix":" 1.42 μU/ml). As the patient remained asymptomatic, and the ","exact":"thyroid-stimulating hormone"},{"setid":"PMC3571969","drugname":"gemfibrozil","startOffset":216,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","prefix":" cause of it was probably the atrovastatin as compared with ","suffix":", fenofibrate were found to be less prone to make complicati","exact":"gemfibrozil"}],[{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":208,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ess, and tenderness after starting treatment with high dose ","suffix":" while on simvastatin. The patient had acute renal failure a","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":330,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"failure and rhabdomyolysis which resolved with cessation of ","suffix":", simvastatin, ezetimibe, diuretics and olmesartan. All drug","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":410,"endOffset":421,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin, ezetimibe, diuretics and olmesartan. All drugs except ","suffix":" and ezetimibe, simvastatin were resumed, and the patient wa","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":250,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ating levels of simvastatin. Given the high likelihood that ","suffix":" will be co-administered with statins and renally active med","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":416,"endOffset":427,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"reased glucagon production. The most common side effects of ","suffix":" include headache and pharyngitis, and few serious adverse e","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":880,"endOffset":891,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" in renal insufficiency. Single dose studies suggested that ","suffix":" may be used in the setting of renal insufficiency, but data","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":673,"endOffset":684,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ibe 10 mg daily was added without incident. He began taking ","suffix":" 50 mg daily 6 weeks prior to presentation, increasing his d","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":798,"endOffset":809,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" his dose 3 weeks later to 100 mg daily. One week after the ","suffix":" dose was increased, he noted the onset of pain and tenderne","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1287,"endOffset":1298,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"cute renal failure, and olmesartan, bumetanide, metolazone, ","suffix":", simvastatin, and ezetimibe were all stopped. His creatine ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1522,"endOffset":1533,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" resumed all medications except simvastatin, ezetimibe, and ","suffix":". He later started lovastatin which was increased to a dose ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":402,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"of myopathy. At presentation, the patient was taking 100 mg ","suffix":", double the recommended dose given his renal function. (1) ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":502,"endOffset":513,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" given his renal function. (1) High serum concentrations of ","suffix":" were achieved following single doses in healthy patients wi","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":690,"endOffset":701,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"g half-life was observed to decrease and renal clearance of ","suffix":" was preserved. (2) However, both the maximum serum concentr","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":793,"endOffset":804,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"h the maximum serum concentration and terminal half-life of ","suffix":" are increased in renal insufficiency, and the maximum recom","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1140,"endOffset":1151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" at sub-lethal doses, (3) suggesting that elevated doses of ","suffix":" may result in renal injury in humans. We suspect that initi","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1220,"endOffset":1231,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"lt in renal injury in humans. We suspect that initiation of ","suffix":" and escalation of dose in this patient may have produced pr","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1309,"endOffset":1320,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" dose in this patient may have produced prolonged, elevated ","suffix":" levels resulting in decreased renal function and precipitat","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":269,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"shed data regarding the safety of chronic administration of ","suffix":" with renal insufficiency in humans, but analysis of reports","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":351,"endOffset":362,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" insufficiency in humans, but analysis of reports involving ","suffix":" submitted through the FDA's Adverse Event Reporting System ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":644,"endOffset":655,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" and 2 deaths. In 91/96 (95%) cases involving renal injury, ","suffix":" was designated as the 'primary suspected' drug. Patients' c","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":757,"endOffset":768,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" drug. Patients' condition improved with discontinuation of ","suffix":" in 20 cases and returned on rechallenge in 1 case. In 40/96","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":229,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fter starting treatment with high dose sitagliptin while on ","suffix":". The patient had acute renal failure and rhabdomyolysis whi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":343,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"habdomyolysis which resolved with cessation of sitagliptin, ","suffix":", ezetimibe, diuretics and olmesartan. All drugs except sita","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":437,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"and olmesartan. All drugs except sitagliptin and ezetimibe, ","suffix":" were resumed, and the patient was subsequently started on l","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":206,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ipitated rhabdomyolysis by increasing circulating levels of ","suffix":". Given the high likelihood that sitagliptin will be co-admi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":477,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"tolazone, amiodarone, bumetanide, glipizide, levothyroxine, ","suffix":", and ezetimibe. Four months prior to presentation, his simv","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":544,"endOffset":555,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"atin, and ezetimibe. Four months prior to presentation, his ","suffix":" dose had been increased from 40 to 80 mg daily and ezetimib","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":1300,"endOffset":1311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ilure, and olmesartan, bumetanide, metolazone, sitagliptin, ","suffix":", and ezetimibe were all stopped. His creatine kinase levels","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":1494,"endOffset":1505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"o baseline within 7 days. He resumed all medications except ","suffix":", ezetimibe, and sitagliptin. He later started lovastatin wh","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":311,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"s had been stable for months, and the patient had tolerated ","suffix":" and ezetemibe for at least 4 months prior to the onset of s","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":356,"endOffset":365,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" which resolved with cessation of sitagliptin, simvastatin, ","suffix":", diuretics and olmesartan. All drugs except sitagliptin and","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":426,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" diuretics and olmesartan. All drugs except sitagliptin and ","suffix":", simvastatin were resumed, and the patient was subsequently","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":494,"endOffset":503,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"one, bumetanide, glipizide, levothyroxine, simvastatin, and ","suffix":". Four months prior to presentation, his simvastatin dose ha","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":607,"endOffset":616,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"vastatin dose had been increased from 40 to 80 mg daily and ","suffix":" 10 mg daily was added without incident. He began taking sit","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":1317,"endOffset":1326,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"rtan, bumetanide, metolazone, sitagliptin, simvastatin, and ","suffix":" were all stopped. His creatine kinase levels fell, his symp","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":1507,"endOffset":1516,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"thin 7 days. He resumed all medications except simvastatin, ","suffix":", and sitagliptin. He later started lovastatin which was inc","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":381,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ation of sitagliptin, simvastatin, ezetimibe, diuretics and ","suffix":". All drugs except sitagliptin and ezetimibe, simvastatin we","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":382,"endOffset":392,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" 204 μmol/L. His medications included aspirin, clopidogrel, ","suffix":", carvedilol, insulin, metolazone, amiodarone, bumetanide, g","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":1251,"endOffset":1261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"o hospital with rhabdomyolysis and acute renal failure, and ","suffix":", bumetanide, metolazone, sitagliptin, simvastatin, and ezet","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"lovastatin","startOffset":1552,"endOffset":1562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"t simvastatin, ezetimibe, and sitagliptin. He later started ","suffix":" which was increased to a dose of 10 mg daily without recurr","exact":"lovastatin"},{"setid":"PMC2602841","drugname":"glucagon","startOffset":272,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" IV enzyme thereby prolonging the post-prandial activity of ","suffix":"-like-peptide-1 (GLP-1). This results in increased insulin s","exact":"glucagon"},{"setid":"PMC2602841","drugname":"glucagon","startOffset":363,"endOffset":371,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":". This results in increased insulin secretion and decreased ","suffix":" production. The most common side effects of sitagliptin inc","exact":"glucagon"},{"setid":"PMC2602841","drugname":"insulin","startOffset":331,"endOffset":338,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" glucagon-like-peptide-1 (GLP-1). This results in increased ","suffix":" secretion and decreased glucagon production. The most commo","exact":"insulin"},{"setid":"PMC2602841","drugname":"insulin","startOffset":406,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ions included aspirin, clopidogrel, olmesartan, carvedilol, ","suffix":", metolazone, amiodarone, bumetanide, glipizide, levothyroxi","exact":"insulin"},{"setid":"PMC2602841","drugname":"vildagliptin","startOffset":717,"endOffset":729,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" organ of toxicity, and approval of its nearest competitor, ","suffix":", by the Federal Drug Administration (FDA) has been delayed ","exact":"vildagliptin"},{"setid":"PMC2602841","drugname":"creatinine","startOffset":309,"endOffset":319,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"al fibrillation, and chronic kidney disease with a baseline ","suffix":" of 204 μmol/L. His medications included aspirin, clopidogre","exact":"creatinine"},{"setid":"PMC2602841","drugname":"creatinine","startOffset":1109,"endOffset":1119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"les in both legs. Laboratory tests revealed urea 43 mmol/L, ","suffix":" 398 μmol/L, and creatine kinase 22,000 IU/L. The patient wa","exact":"creatinine"},{"setid":"PMC2602841","drugname":"aspirin","startOffset":360,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"baseline creatinine of 204 μmol/L. His medications included ","suffix":", clopidogrel, olmesartan, carvedilol, insulin, metolazone, ","exact":"aspirin"},{"setid":"PMC2602841","drugname":"clopidogrel","startOffset":369,"endOffset":380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"creatinine of 204 μmol/L. His medications included aspirin, ","suffix":", olmesartan, carvedilol, insulin, metolazone, amiodarone, b","exact":"clopidogrel"},{"setid":"PMC2602841","drugname":"carvedilol","startOffset":394,"endOffset":404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" His medications included aspirin, clopidogrel, olmesartan, ","suffix":", insulin, metolazone, amiodarone, bumetanide, glipizide, le","exact":"carvedilol"},{"setid":"PMC2602841","drugname":"metolazone","startOffset":415,"endOffset":425,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"uded aspirin, clopidogrel, olmesartan, carvedilol, insulin, ","suffix":", amiodarone, bumetanide, glipizide, levothyroxine, simvasta","exact":"metolazone"},{"setid":"PMC2602841","drugname":"metolazone","startOffset":1275,"endOffset":1285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"olysis and acute renal failure, and olmesartan, bumetanide, ","suffix":", sitagliptin, simvastatin, and ezetimibe were all stopped. ","exact":"metolazone"},{"setid":"PMC2602841","drugname":"amiodarone","startOffset":427,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":", clopidogrel, olmesartan, carvedilol, insulin, metolazone, ","suffix":", bumetanide, glipizide, levothyroxine, simvastatin, and eze","exact":"amiodarone"},{"setid":"PMC2602841","drugname":"bumetanide","startOffset":439,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"l, olmesartan, carvedilol, insulin, metolazone, amiodarone, ","suffix":", glipizide, levothyroxine, simvastatin, and ezetimibe. Four","exact":"bumetanide"},{"setid":"PMC2602841","drugname":"bumetanide","startOffset":1263,"endOffset":1273,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ith rhabdomyolysis and acute renal failure, and olmesartan, ","suffix":", metolazone, sitagliptin, simvastatin, and ezetimibe were a","exact":"bumetanide"},{"setid":"PMC2602841","drugname":"glipizide","startOffset":451,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"n, carvedilol, insulin, metolazone, amiodarone, bumetanide, ","suffix":", levothyroxine, simvastatin, and ezetimibe. Four months pri","exact":"glipizide"},{"setid":"PMC2602841","drugname":"levothyroxine","startOffset":462,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ol, insulin, metolazone, amiodarone, bumetanide, glipizide, ","suffix":", simvastatin, and ezetimibe. Four months prior to presentat","exact":"levothyroxine"},{"setid":"PMC2602841","drugname":"urea","startOffset":1093,"endOffset":1097,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"he proximal muscles in both legs. Laboratory tests revealed ","suffix":" 43 mmol/L, creatinine 398 μmol/L, and creatine kinase 22,00","exact":"urea"}],[{"setid":"PMC3477350","drugname":"rifampicin","startOffset":219,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ived a single dose of dabigatran etexilate 150 mg on day 1, ","suffix":" 600 mg once daily on days 2-8, and single doses of dabigatr","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":279,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" administration of dabigatran etexilate following 7 days of ","suffix":" (treatment B) decreased the geometric mean (gMean) area und","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":156,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"to determine whether, and to what extent, the P-gp inducer, ","suffix":", affects the plasma exposure of dabigatran by investigating","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":259,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"dabigatran by investigating the effect of multiple doses of ","suffix":" 600 mg once daily on the PK parameters of dabigatran follow","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":550,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"preted as normal activity levels of P-gp after induction by ","suffix":". The doses selected for investigation reflect standard clin","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":634,"endOffset":644,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"lected for investigation reflect standard clinical doses of ","suffix":" and dabigatran etexilate, and were expected to allow an ade","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":798,"endOffset":808,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"meters of dabigatran after P-gp induction. The induction by ","suffix":" was to be confirmed further by measurement of a surrogate e","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":146,"endOffset":156,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":" to determine the safety and tolerability of dabigatran and ","suffix":" coadministration, and to determine the duration of the effe","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":256,"endOffset":266,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"duration of the effect of P-gp induction after cessation of ","suffix":" treatment. If an interaction between rifampicin and dabigat","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":304,"endOffset":314,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"essation of rifampicin treatment. If an interaction between ","suffix":" and dabigatran was observed, it was expected that this woul","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":302,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"en as single doses, either alone or after multiple doses of ","suffix":", or after cessation of rifampicin. Twenty-four subjects wer","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":336,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"r after multiple doses of rifampicin, or after cessation of ","suffix":". Twenty-four subjects were to be enrolled, with at least ei","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":203,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"inistered as 150 mg hydroxypropyl methylcellulose capsules. ","suffix":" was administered as the commercially available Rifa® 600 mg","exact":"Rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":336,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":" administered on day 1 (reference); period 2 (treatment B), ","suffix":" 600 mg once daily administered for 7 days (days 2-8) in the","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":449,"endOffset":459,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"(days 2-8) in the evening at 20.00 h, with the last dose of ","suffix":" given 12 h before dabigatran etexilate 150 mg administered ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":646,"endOffset":656,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"ran etexilate 150 mg administered on day 16 after 7 days of ","suffix":" washout (test 2); and period 4 (treatment D), a single dose","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":260,"endOffset":270,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"al or hormonal disorders, risk of bleeding, previous use of ","suffix":" or other P-gp or CYP450 inhibitors/inducers within 4 weeks ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":340,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"dose of dabigatran etexilate 150 mg after multiple doses of ","suffix":" 600 mg) vs. reference treatment A (single dose of dabigatra","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":440,"endOffset":450,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"nt A (single dose of dabigatran etexilate 150 mg before any ","suffix":" treatment), with α-adjustment of the 90% confidence interva","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":205,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"exilate 150 mg after 7 days of washout since last intake of ","suffix":" 600 mg) and reference treatment A, and between treatment D ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":332,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"ycortisol to cortisol as a marker of induction of CYP3A4 by ","suffix":" and an evaluation of safety were other secondary end-points","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":450,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"n in the morning after subjects had received three doses of ","suffix":" during treatment B and before administration of dabigatran ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":469,"endOffset":479,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"rtisol) at all spiked concentrations. Induction of CYP3A by ","suffix":" was assessed by the change in the ratio of 6β-hydroxycortis","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":585,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"-hydroxycortisol/cortisol after a 7 day treatment of 600 mg ","suffix":" once daily and after cessation of rifampicin, compared with","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":630,"endOffset":640,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"ment of 600 mg rifampicin once daily and after cessation of ","suffix":", compared with the ratio at baseline before the administrat","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":584,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"late 150 mg for 4 days (1 day in each treatment period) and ","suffix":" 600 mg for 7 days (period 2); the other two subjects receiv","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":167,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"n etexilate alone), the administration of the P-gp inducer, ","suffix":", over 7 days (treatment B) resulted in a significant reduct","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":140,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"max) and the terminal half-life (t1/2) were not affected by ","suffix":" administration. The tmax, t1/2, mean residence time after o","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":157,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"tran etexilate after a 7 day washout after the last dose of ","suffix":" (treatment C, day 16), AUC0-∞ and Cmax values were reduced ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":493,"endOffset":503,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"%) for Cmax. Fourteen days after the last administration of ","suffix":" (treatment D, day 23), the AUC0-∞ and Cmax values were redu","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":231,"endOffset":241,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[5]","prefix":"male subjects in the trial. Following the administration of ","suffix":" over 7 days, the reduction in total dabigatran exposure was","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":240,"endOffset":250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"tween total and free dabigatran AUC0-∞ was not modulated by ","suffix":" administration. Furthermore, the prodrug (dabigatran etexil","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":307,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":" 22.0 (48.5), indicating CYP450 3A induction as a result of ","suffix":" administration. The urinary 6β-hydroxycortisol/cortisol rat","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":223,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"%) subjects during treatment with dabigatran etexilate plus ","suffix":" and two (8.3%) subjects during treatment with rifampicin al","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":280,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"us rifampicin and two (8.3%) subjects during treatment with ","suffix":" alone (Table 4). In addition, one subject (4.5%; 1 of 22) r","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":182,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"s, with headache the most common (dabigatran, two subjects; ","suffix":", one subject; and dabigatran plus rifampicin, three subject","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":227,"endOffset":237,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":" two subjects; rifampicin, one subject; and dabigatran plus ","suffix":", three subjects). No other AEs were reported during treatme","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":419,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"hyperhidrosis (one subject each) during the dabigatran plus ","suffix":" period; dizziness, nausea, oropharyngeal pain, vomiting and","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":528,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"al pain, vomiting and fatigue (one subject each) during the ","suffix":" alone period; and nausea (one subject) during the washout a","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":376,"endOffset":386,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" by P-gp inhibitors [23]. In this study, a 1 week course of ","suffix":", a potent inducer of P-gp, decreased exposure to dabigatran","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":278,"endOffset":288,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"dy investigated dabigatran etexilate 150 mg with or without ","suffix":" 600 mg once daily. These doses were selected because they r","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":430,"endOffset":440,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ical doses, and the plasma concentrations of dabigatran and ","suffix":" in this trial represent clinically relevant drug exposure. ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":532,"endOffset":542,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"lly relevant drug exposure. The selected dosing regimen for ","suffix":" (7 day treatment with cessation of treatment the evening, i","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":759,"endOffset":769,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"of P-gp without interference of inhibiting effects, because ","suffix":" was stopped after the last dose given in the evening before","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":427,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ealthy volunteers. Within 7 days following the cessation of ","suffix":" administration, the bioavailability of total dabigatran ret","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":287,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"nted to dissipate in about 2 weeks after discontinuation of ","suffix":" [25]. Indeed, in this trial, the urinary 6β-hydroxycortisol","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":528,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"line levels 2 weeks after discontinuation of treatment with ","suffix":". The effect on dabigatran was highly comparable, which seem","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":403,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"-∞ of aliskiren or a 58% reduction in Cmax of digoxin after ","suffix":" treatment, the renal clearance and half-life of these drugs","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":153,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"e absorbed mainly in the duodenum. The pronounced effect of ","suffix":" on dabigatran kinetics might, thus, be due to a remarkable ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":295,"endOffset":305,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"duodenal P-gp expression (about a threefold increase) after ","suffix":", as reported ex vivo[27] and in vitro[26]. An approximately","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":321,"endOffset":331,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"ferences in exposure to total dabigatran, administration of ","suffix":" for 7 days resulted in a similar percentage reduction in to","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":199,"endOffset":209,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"was well tolerated when given alone and in combination with ","suffix":". The results were in line with the known safety profile of ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":132,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"two-thirds in dabigatran exposure due to a 1 week course of ","suffix":" has clinically relevant consequences. Patients undergoing o","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":378,"endOffset":388,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"rapeutic concentrations of dabigatran if they have received ","suffix":" immediately before surgery. Dabigatran etexilate is also in","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":670,"endOffset":680,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"e significant decrease in dabigatran exposure observed with ","suffix":" is likely to decrease the potential for stroke prevention. ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":767,"endOffset":777,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"potential for stroke prevention. Concomitant treatment with ","suffix":" and dabigatran should be avoided in these patients. The eff","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":1212,"endOffset":1222,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"ng warfarin clearance, such as carbamazepine, barbiturates, ","suffix":" and chronic alcohol [30]. Furthermore, the new factor Xa in","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":1363,"endOffset":1373,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"and apixaban are expected to be affected by inducers of the ","suffix":" type because their clearance is dependent to a large extent","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":349,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ealthy volunteers. Within 7 days following the cessation of ","suffix":" administration, the bioavailability returned almost to base","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":500,"endOffset":510,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":" the potential for reduced systemic exposure to dabigatran, ","suffix":" and other P-gp inducers (e.g. carbamazepine and St John's w","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":173,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"lycoprotein inducer, rifampicin, on the pharmacokinetics of ","suffix":" following oral administration of the prodrug, dabigatran et","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":439,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"e (AUC0-∞) and maximal plasma concentration (Cmax) of total ","suffix":" by 67 and 65.5%, respectively. The time to peak and the ter","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":775,"endOffset":785,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":", 44.1%) for Cmax, indicating a significant effect on total ","suffix":" exposure (total pharmacologically active dabigatran represe","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":827,"endOffset":837,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"n total dabigatran exposure (total pharmacologically active ","suffix":" represents the sum of nonconjugated dabigatran and dabigatr","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":874,"endOffset":884,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"cally active dabigatran represents the sum of nonconjugated ","suffix":" and dabigatran glucuronide). After a 7 day (treatment C) or","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":889,"endOffset":899,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"bigatran represents the sum of nonconjugated dabigatran and ","suffix":" glucuronide). After a 7 day (treatment C) or 14 day washout","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":998,"endOffset":1008,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" C) or 14 day washout (treatment D), the AUC0-∞ and Cmax of ","suffix":" were reduced by 18 and 20%, and by 15 and 20%, respectively","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":198,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"diates, BIBR 1087 SE and BIBR 951 BS, to the active moiety, ","suffix":", a direct and reversible thrombin inhibitor. Dabigatran is ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":254,"endOffset":264,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ty, dabigatran, a direct and reversible thrombin inhibitor. ","suffix":" is partly conjugated with activated glucuronic acid to form","exact":"Dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":374,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"id to form a pharmacologically equipotent glucuronide. Free ","suffix":" and total dabigatran (sum of free and glucuronidated dabiga","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":395,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"logically equipotent glucuronide. Free dabigatran and total ","suffix":" (sum of free and glucuronidated dabigatran) reach peak plas","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":438,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"gatran and total dabigatran (sum of free and glucuronidated ","suffix":") reach peak plasma concentrations after approximately 1.5 h","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":154,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"re not metabolized by the cytochrome P450 (CYP) system, and ","suffix":" does not affect the metabolism of other drugs that utilize ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":336,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"nical studies have shown that dabigatran etexilate (but not ","suffix":") is a P-glycoprotein (P-gp) substrate, and therefore the bi","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":423,"endOffset":433,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"tein (P-gp) substrate, and therefore the bioavailability of ","suffix":" following oral administration of dabigatran etexilate may b","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":199,"endOffset":209,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"he P-gp inducer, rifampicin, affects the plasma exposure of ","suffix":" by investigating the effect of multiple doses of rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":312,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"ses of rifampicin 600 mg once daily on the PK parameters of ","suffix":" following a single dose of 150 mg dabigatran etexilate. The","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":458,"endOffset":468,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"uated the time course of a return to normal availability of ","suffix":", which could be interpreted as normal activity levels of P-","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":748,"endOffset":758,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" to allow an adequate determination of the PK parameters of ","suffix":" after P-gp induction. The induction by rifampicin was to be","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":131,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"objectives were to determine the safety and tolerability of ","suffix":" and rifampicin coadministration, and to determine the durat","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":319,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"ampicin treatment. If an interaction between rifampicin and ","suffix":" was observed, it was expected that this would lead to decre","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":190,"endOffset":200,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"e (AUC0-∞) and maximal plasma concentration (Cmax) of total ","suffix":" (free plus conjugated). The primary comparison was between ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":122,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"he secondary PK end-points included AUC0-∞ and Cmax of free ","suffix":", and Cmax and time from dosing to maximal plasma concentrat","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":212,"endOffset":222,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"from dosing to maximal plasma concentration (tmax) of total ","suffix":". The ratio of urinary concentrations of 6β-hydroxycortisol ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":332,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"atment period. Plasma concentrations of free, nonconjugated ","suffix":", total dabigatran [sum of free and conjugated dabigatran (m","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":350,"endOffset":360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sma concentrations of free, nonconjugated dabigatran, total ","suffix":" [sum of free and conjugated dabigatran (measured after alka","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":389,"endOffset":399,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ed dabigatran, total dabigatran [sum of free and conjugated ","suffix":" (measured after alkaline cleavage of conjugates)], the prod","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":169,"endOffset":179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" 2000g-4000g for 10 minutes); for the determination of free ","suffix":", 50 µl of plasma was aliquoted, diluted with 50 µl 0.2 m am","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":334,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"ked with 40 µl internal standard solution (100 ng ml−1[13C6]","suffix":"), mixed and centrifuged. For the determination of total dab","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":401,"endOffset":411,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"ran), mixed and centrifuged. For the determination of total ","suffix":", 50 µl of plasma was aliquoted, spiked with 40 µl internal ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":198,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","prefix":" the inaccuracy was at maximum −5.37% (at 3 ng ml−1 nominal ","suffix":" concentration), and the imprecision was always <9%. The lim","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":509,"endOffset":519,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":" rifampicin during treatment B and before administration of ","suffix":" in each respective treatment period. Thus, morning spot uri","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":132,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"of the plasma concentration-time profiles of free and total ","suffix":" were highly comparable, as shown in Figure 2. The PK parame","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":216,"endOffset":226,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"omparable, as shown in Figure 2. The PK parameters of total ","suffix":" after administration of dabigatran etexilate 150 mg, with a","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":266,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"esulted in a significant reduction in the exposure to total ","suffix":" (67% reduction in AUC0-∞ and 65.5% reduction in Cmax) on da","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":140,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"f free dabigatran followed the same trend as those of total ","suffix":" (Figure 2b), and the ratio between total and free dabigatra","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":201,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"abigatran (Figure 2b), and the ratio between total and free ","suffix":" AUC0-∞ was not modulated by rifampicin administration. Furt","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":412,"endOffset":422,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"R 951 BS and BIBR 1087 SE) were affected in the same way as ","suffix":" (Table 3). As the concentrations (only Cmax could be evalua","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":156,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"re nervous system disorders, with headache the most common (","suffix":", two subjects; rifampicin, one subject; and dabigatran plus","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":211,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"mon (dabigatran, two subjects; rifampicin, one subject; and ","suffix":" plus rifampicin, three subjects). No other AEs were reporte","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":305,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"subjects). No other AEs were reported during treatment with ","suffix":" alone. Other AEs reported were vertigo and hyperhidrosis (o","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":403,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"ere vertigo and hyperhidrosis (one subject each) during the ","suffix":" plus rifampicin period; dizziness, nausea, oropharyngeal pa","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":130,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"nvestigations have shown that dabigatran etexilate (but not ","suffix":" or its intermediate metabolites) is a substrate for the eff","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":290,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"Previous investigations suggest that the bioavailability of ","suffix":" may be affected by P-gp inhibitors [23]. In this study, a 1","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":415,"endOffset":425,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d standard clinical doses, and the plasma concentrations of ","suffix":" and rifampicin in this trial represent clinically relevant ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":830,"endOffset":840,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"was stopped after the last dose given in the evening before ","suffix":" administration. A single dose of dabigatran etexilate was c","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":197,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"cant and relevant reduction in the bioavailability of total ","suffix":" (67 and 65.5% reduction in AUC0-∞ and Cmax values of total ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":267,"endOffset":277,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" (67 and 65.5% reduction in AUC0-∞ and Cmax values of total ","suffix":", respectively) after administering a single oral dose of 15","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":483,"endOffset":493,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" of rifampicin administration, the bioavailability of total ","suffix":" returned almost to baseline values. Pharmacokinetic paramet","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":554,"endOffset":564,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"discontinuation of treatment with rifampicin. The effect on ","suffix":" was highly comparable, which seems physiologically reasonab","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":167,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"nly in the duodenum. The pronounced effect of rifampicin on ","suffix":" kinetics might, thus, be due to a remarkable increase in du","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":640,"endOffset":650,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"reover, recent in vitro data have clearly demonstrated that ","suffix":" has no affinity to any efflux (P-gp, BCRP and MRP2) or upta","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":913,"endOffset":923,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"etexilate as substrate [29]. The reduced bioavailability of ","suffix":" after P-gp induction contrasts with the effect observed (an","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":1011,"endOffset":1021,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"sts with the effect observed (an increase in exposure) when ","suffix":" is administered with a P-gp inhibitor. For example, the adm","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":291,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"d. Although there were sex differences in exposure to total ","suffix":", administration of rifampicin for 7 days resulted in a simi","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":345,"endOffset":355,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"romboembolism may not achieve therapeutic concentrations of ","suffix":" if they have received rifampicin immediately before surgery","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":636,"endOffset":646,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":" for dabigatran etexilate [13], the significant decrease in ","suffix":" exposure observed with rifampicin is likely to decrease the","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":782,"endOffset":792,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"troke prevention. Concomitant treatment with rifampicin and ","suffix":" should be avoided in these patients. The effect of concomit","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":488,"endOffset":498,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"es. Owing to the potential for reduced systemic exposure to ","suffix":", rifampicin and other P-gp inducers (e.g. carbamazepine and","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":181,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"y in healthy volunteers. Subjects received a single dose of ","suffix":" 150 mg on day 1, rifampicin 600 mg once daily on days 2-8, ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":178,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" alone; treatment A), administration of dabigatran etexilate","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":238,"endOffset":258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"dabigatran etexilate alone; treatment A), administration of ","suffix":" following 7 days of rifampicin (treatment B) decreased the ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":296,"endOffset":316,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"roke prevention in patients with atrial fibrillation [7-9]. ","suffix":" is administered orally, is not associated with clinically r","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":306,"endOffset":326,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":". However, preclinical and clinical studies have shown that ","suffix":" (but not dabigatran) is a P-glycoprotein (P-gp) substrate, ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":467,"endOffset":487,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"availability of dabigatran following oral administration of ","suffix":" may be altered by P-gp inhibitors [17, 18]. For example, it","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":357,"endOffset":377,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" parameters of dabigatran following a single dose of 150 mg ","suffix":". The study also evaluated the time course of a return to no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":649,"endOffset":669,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"stigation reflect standard clinical doses of rifampicin and ","suffix":", and were expected to allow an adequate determination of th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":218,"endOffset":238,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" given as single doses, either alone or after multiple doses","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":249,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":" four treatment periods (Figure 1): period 1 (treatment A), ","suffix":" 150 mg administered on day 1 (reference); period 2 (treatme","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":478,"endOffset":498,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"20.00 h, with the last dose of rifampicin given 12 h before ","suffix":" 150 mg administered on day 9 (test 1); period 3 (treatment ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":579,"endOffset":599,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"on day 9 (test 1); period 3 (treatment C), a single dose of ","suffix":" 150 mg administered on day 16 after 7 days of rifampicin wa","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":720,"endOffset":740,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"hout (test 2); and period 4 (treatment D), a single dose of ","suffix":" 150 mg administered on day 23 after 14 days of rifampicin w","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":169,"endOffset":189,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"between days −21 and −1. Washout periods between subsequent ","suffix":" doses were included between the study days (days 1, 9, 16 a","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":288,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":" primary comparison was between treatment B (single dose of ","suffix":" 150 mg after multiple doses of rifampicin 600 mg) vs. refer","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":401,"endOffset":421,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ifampicin 600 mg) vs. reference treatment A (single dose of ","suffix":" 150 mg before any rifampicin treatment), with α-adjustment ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":132,"endOffset":152,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"parisons were performed between treatment C (single dose of ","suffix":" 150 mg after 7 days of washout since last intake of rifampi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":291,"endOffset":311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erence treatment A, and between treatment D (single dose of ","suffix":" 150 mg after 14 days washout after the last intake of rifam","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":240,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"24 and 34 h after administration of a single dose of 150 mg ","suffix":" in each treatment period. Plasma concentrations of free, no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":464,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sured after alkaline cleavage of conjugates)], the prodrug, ","suffix":", and the intermediate metabolites, BIBR 1087 SE and BIBR 95","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":325,"endOffset":345,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","prefix":"limit of quantification was also 1 ng ml−1 for the prodrug (","suffix":") and the intermediate metabolites, BIBR 1087 SE and BIBR 95","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":508,"endOffset":528,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"The 22 subjects who completed treatment as planned received ","suffix":" 150 mg for 4 days (1 day in each treatment period) and rifa","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":657,"endOffset":677,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"0 mg for 7 days (period 2); the other two subjects received ","suffix":" 150 mg for 2 days (1 day in the first two treatment periods","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":98,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"                       Relative to the reference treatment (","suffix":" alone), the administration of the P-gp inducer, rifampicin,","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":293,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"ted by rifampicin administration. Furthermore, the prodrug (","suffix":") and the intermediate metabolites (BIBR 951 BS and BIBR 108","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":125,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" alone, four (16.7%) subjects during treatment with dabigatr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":197,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"texilate alone, four (16.7%) subjects during treatment with ","suffix":" plus rifampicin and two (8.3%) subjects during treatment wi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":234,"endOffset":254,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ly for most patients [7, 8]. The present study investigated ","suffix":" 150 mg with or without rifampicin 600 mg once daily. These ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":637,"endOffset":657,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" treatment the evening, i.e. 12 h, before administration of ","suffix":") allowed for a test of maximal induction of P-gp without in","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":874,"endOffset":894,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" evening before dabigatran administration. A single dose of ","suffix":" was considered to be representative of the effect following","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":342,"endOffset":362,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"pectively) after administering a single oral dose of 150 mg ","suffix":" in healthy volunteers. Within 7 days following the cessatio","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":454,"endOffset":474,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"lity by P-gp induction may be physiologically plausible for ","suffix":", whose absorption (besides solubility limitations) is solel","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":842,"endOffset":862,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"nd that among intestinal transporters, P-gp only recognized ","suffix":" as substrate [29]. The reduced bioavailability of dabigatra","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":118,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"he overall safety profile of all treatments was favourable. ","suffix":" was well tolerated when given alone and in combination with","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":233,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"uences. Patients undergoing orthopaedic surgery who receive ","suffix":" for the prevention of venous thromboembolism may not achiev","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":417,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"f they have received rifampicin immediately before surgery. ","suffix":" is also indicated for stroke prevention in patients with at","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":581,"endOffset":601,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"dose-response in stroke reduction has been demonstrated for ","suffix":" [13], the significant decrease in dabigatran exposure obser","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":874,"endOffset":894,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"these patients. The effect of concomitant administration of ","suffix":" with other P-gp inducers, such as carbamazepine, diphenylhy","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":264,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"t reduction in the bioavailability of a single oral dose of ","suffix":" in healthy volunteers. Within 7 days following the cessatio","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":83,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"                                      Dabigatran etexilate (","suffix":"®; Boehringer Ingelheim Pharma GmbH & Co. KG) was administer","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"thrombin","startOffset":234,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":", to the active moiety, dabigatran, a direct and reversible ","suffix":" inhibitor. Dabigatran is partly conjugated with activated g","exact":"thrombin"},{"setid":"PMC3477350","drugname":"glucuronic acid","startOffset":301,"endOffset":316,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n inhibitor. Dabigatran is partly conjugated with activated ","suffix":" to form a pharmacologically equipotent glucuronide. Free da","exact":"glucuronic acid"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":909,"endOffset":917,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"nt of a surrogate end-point, the urinary 6β-hydroxycortisol/","suffix":" ratio. This ratio is thought to reflect the CYP3A activity ","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":285,"endOffset":293,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"he ratio of urinary concentrations of 6β-hydroxycortisol to ","suffix":" as a marker of induction of CYP3A4 by rifampicin and an eva","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":84,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"                                     The 6β-hydroxycortisol/","suffix":" ratio, an established marker of human hepatic CYP450 3A ind","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":248,"endOffset":256,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":", France. The calibration curves for 6β-hydroxycortisol and ","suffix":" ranged between 1-1000 and 10-3000 ng ml−1, respectively. Th","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":407,"endOffset":415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"curacy and imprecision of <11 (6β-hydroxycortisol) and 13% (","suffix":") at all spiked concentrations. Induction of CYP3A by rifamp","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":542,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"s assessed by the change in the ratio of 6β-hydroxycortisol/","suffix":" after a 7 day treatment of 600 mg rifampicin once daily and","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":113,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"        Compared with day 1, the urinary 6β-hydroxycortisol/","suffix":" ratio on day 9 was increased approximately 5.6-fold, from a","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":215,"endOffset":223,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"oximately 5.6-fold, from a gMean (gCV %) 6β-hydroxycortisol/","suffix":" ratio of 3.92 (65.3) to 22.0 (48.5), indicating CYP450 3A i","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":356,"endOffset":364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":" result of rifampicin administration. The urinary 6β-hydroxy","suffix":"/cortisol ratio was still slightly elevated on day 16 (∼1.2-","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":365,"endOffset":373,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"f rifampicin administration. The urinary 6β-hydroxycortisol/","suffix":" ratio was still slightly elevated on day 16 (∼1.2-fold), bu","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":176,"endOffset":184,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d CYP3A, as shown by an elevated urinary 6β-hydroxycortisol/","suffix":" ratio [24]. Such induction has been documented to dissipate","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":358,"endOffset":366,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"[25]. Indeed, in this trial, the urinary 6β-hydroxycortisol/","suffix":" ratio was found to be only 1.2-fold higher than baseline va","exact":"cortisol"},{"setid":"PMC3477350","drugname":"digoxin","startOffset":229,"endOffset":236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"agnitude or only slightly exceeded the effects reported for ","suffix":" [27], a prototypical P-gp substrate, or aliskiren [28]. Int","exact":"digoxin"},{"setid":"PMC3477350","drugname":"digoxin","startOffset":389,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"on in the AUC0-∞ of aliskiren or a 58% reduction in Cmax of ","suffix":" after rifampicin treatment, the renal clearance and half-li","exact":"digoxin"},{"setid":"PMC3477350","drugname":"aliskiren","startOffset":277,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"eported for digoxin [27], a prototypical P-gp substrate, or ","suffix":" [28]. Interestingly, despite a 56% reduction in the AUC0-∞ ","exact":"aliskiren"},{"setid":"PMC3477350","drugname":"aliskiren","startOffset":349,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"8]. Interestingly, despite a 56% reduction in the AUC0-∞ of ","suffix":" or a 58% reduction in Cmax of digoxin after rifampicin trea","exact":"aliskiren"},{"setid":"PMC3477350","drugname":"ketoconazole","startOffset":1122,"endOffset":1134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"or example, the administration of the strong P-gp inhibitor ","suffix":" increased the AUC0-∞ and Cmax of dabigatran by approximatel","exact":"ketoconazole"},{"setid":"PMC3477350","drugname":"carbamazepine","startOffset":929,"endOffset":942,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"n of dabigatran etexilate with other P-gp inducers, such as ","suffix":", diphenylhydantoin and St John's wort has not been tested. ","exact":"carbamazepine"},{"setid":"PMC3477350","drugname":"carbamazepine","startOffset":1183,"endOffset":1196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"tered with compounds increasing warfarin clearance, such as ","suffix":", barbiturates, rifampicin and chronic alcohol [30]. Further","exact":"carbamazepine"},{"setid":"PMC3477350","drugname":"carbamazepine","startOffset":541,"endOffset":554,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ure to dabigatran, rifampicin and other P-gp inducers (e.g. ","suffix":" and St John's wort) are not recommended for use with dabiga","exact":"carbamazepine"},{"setid":"PMC3477350","drugname":"diphenylhydantoin","startOffset":944,"endOffset":961,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":" etexilate with other P-gp inducers, such as carbamazepine, ","suffix":" and St John's wort has not been tested. However, it should ","exact":"diphenylhydantoin"},{"setid":"PMC3477350","drugname":"vitamin k","startOffset":1040,"endOffset":1049,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":" has not been tested. However, it should be emphasized that ","suffix":" antagonists, such as warfarin, show comparable liabilities ","exact":"vitamin K"},{"setid":"PMC3477350","drugname":"warfarin","startOffset":1071,"endOffset":1079,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"it should be emphasized that vitamin K antagonists, such as ","suffix":", show comparable liabilities when coadministered with compo","exact":"warfarin"},{"setid":"PMC3477350","drugname":"warfarin","startOffset":1155,"endOffset":1163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"e liabilities when coadministered with compounds increasing ","suffix":" clearance, such as carbamazepine, barbiturates, rifampicin ","exact":"warfarin"},{"setid":"PMC3477350","drugname":"rivaroxaban","startOffset":1291,"endOffset":1302,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"nic alcohol [30]. Furthermore, the new factor Xa inhibitors ","suffix":" and apixaban are expected to be affected by inducers of the","exact":"rivaroxaban"},{"setid":"PMC3477350","drugname":"apixaban","startOffset":1307,"endOffset":1315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":". Furthermore, the new factor Xa inhibitors rivaroxaban and ","suffix":" are expected to be affected by inducers of the rifampicin t","exact":"apixaban"}],[{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":197,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose of racemic warfarin 25 mg alone and after 8 days of ","suffix":" 10 mg once daily. Assessments included exposure (AUC0-last)","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":468,"endOffset":479,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"nder the curve (INRAUC(0-last)). The effects of warfarin on ","suffix":" steady-state pharmacokinetics and the safety of ambrisentan","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":528,"endOffset":539,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ambrisentan steady-state pharmacokinetics and the safety of ","suffix":"/warfarin co-administration were assessed. Data are presente","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":240,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"07.7) or S-warfarin (101.6; 90% CI 98.4, 105.0). Similarly, ","suffix":" had no significant effects on the Cmax of R-warfarin (91.6;","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":590,"endOffset":601,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"). In addition, co-administration of warfarin did not alter ","suffix":" steady-state pharmacokinetics. Adverse events were infreque","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":393,"endOffset":404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" metabolism by affecting the activity of CYP3A4 and CYP2C9. ","suffix":" is a once-daily, orally active, propanoic acid-based, recep","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":541,"endOffset":552,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"A) selective ERA that is approved for the treatment of PAH. ","suffix":" has been shown to improve exercise capacity, delay time to ","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":762,"endOffset":773,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"patients with PAH [10-12]. Unlike bosentan and sitaxsentan, ","suffix":" does not induce or inhibit CYP2C9 or CYP3A4 and is therefor","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":998,"endOffset":1009,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"was undertaken to evaluate the effects of multiple doses of ","suffix":" on the pharmacokinetics and pharmacodynamics of a single ra","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":1178,"endOffset":1189,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"effects of warfarin on the steady-state pharmacokinetics of ","suffix":". In addition, the safety and tolerability of ambrisentan an","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":194,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":" dependence, bleeding disorders, sensitivity to warfarin or ","suffix":", or significant allergies. Subjects were also excluded if t","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":253,"endOffset":264,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tic and/or pharmacodynamic interaction of multiple doses of ","suffix":" with a single dose of warfarin in healthy subjects (Figure ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":547,"endOffset":558,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":". On days 5 to 16, subjects received a single daily dose of ","suffix":" 10 mg (Gilead Sciences, Inc., formerly Myogen, Inc., Westmi","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":696,"endOffset":707,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"n day 13, subjects were administered a single 10-mg dose of ","suffix":" together with a single 25-mg dose of warfarin. All study me","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":334,"endOffset":345,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ","suffix":" pharmacokinetic assessments were collected relative to the ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":423,"endOffset":434,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ssessments were collected relative to the day 12 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":537,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ","suffix":" concentrations were determined from samples collected at tr","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":1190,"endOffset":1201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"quantification of 1.0 ng ml−1[13]. Plasma concentrations of ","suffix":" were determined by a validated LC/MS/MS method with a lower","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":1323,"endOffset":1334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"imit of quantification of 5.0 ng ml−1. The precision of the ","suffix":" assay was <15% as indicated by the percent coefficient of v","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":1472,"endOffset":1483,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ccuracy of the assay was within 15% of the actual value for ","suffix":". Pharmacokinetic analyses were performed using WinNonlin™ P","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":1672,"endOffset":1683,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", CA, USA). Estimated plasma pharmacokinetic parameters for ","suffix":" and warfarin enantiomers included area under the concentrat","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":1971,"endOffset":1982,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"determined for the steady-state pharmacokinetic analysis of ","suffix":". Prothrombin times, presented as INR, were characterized us","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":237,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") vs. day 1 (warfarin alone) were summarized for the natural","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":216,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") vs. day 12 (ambrisentan alone) were summarized for the nat","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":241,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" differences of day 13 (warfarin + ambrisentan) vs. day 12 (","suffix":" alone) were summarized for the natural logarithms of ambris","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":306,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"sentan alone) were summarized for the natural logarithms of ","suffix":" Cmin,ss,Cmax,ss and AUC0-τ,ss. These comparisons were repor","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":250,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":" to detect a 6% difference in INR between day 13 (warfarin +","suffix":") and day 1 (warfarin alone), and a >90% probability that th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":357,"endOffset":368,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"eceived two doses of racemic warfarin 25 mg and 12 doses of ","suffix":" 10 mg; therefore, all were included in the safety, pharmaco","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":124,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"re were no clinically relevant effects of multiple doses of ","suffix":" on the concentration-time profiles of R-and S-warfarin (Fig","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":486,"endOffset":497,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"perimposable in the presence (day 13) or absence (day 1) of ","suffix":". Following multiple doses of ambrisentan, the observed mean","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":527,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"absence (day 1) of ambrisentan. Following multiple doses of ","suffix":", the observed mean AUC0-last values for R-and S-warfarin in","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":125,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"nistration of warfarin in the presence of multiple doses of ","suffix":" (Figure 3) resulted in a 14.7% decrease in INRmax (85.3; 95","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":153,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ct on the steady-state plasma concentration-time profile of ","suffix":" (Figure 4). In the presence of warfarin, steady-state ambri","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":219,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"entan (Figure 4). In the presence of warfarin, steady-state ","suffix":" Cmax and Cmin decreased by 2.0% (98.0; 90% CI 87.6, 109.5) ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":492,"endOffset":503,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"sed by 12.2% (87.8; 90% CI 83.9, 91.8). The 90% CIs for all ","suffix":" pharmacokinetic parameters were within the predefined no ef","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":341,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"predefined equivalence criteria of 80-125%, suggesting that ","suffix":" did not have a clinically relevant effect on warfarin metab","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":241,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" by CYP pathways. In addition,in vitro studies suggest that ","suffix":" does not alter the expression or activity of CYP enzymes, t","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":431,"endOffset":442,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"er agents metabolized by CYP family members. In this study, ","suffix":" decreased INRmax and INRAUC(0-last) by 14.7 and 7.0%, respe","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":919,"endOffset":930,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"or prothrombin time. The lack of a drug interaction between ","suffix":" and warfarin has been corroborated in ambrisentan clinical ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":969,"endOffset":980,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"n between ambrisentan and warfarin has been corroborated in ","suffix":" clinical studies that permitted the use of warfarin or warf","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":514,"endOffset":525,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"egarding the safety profile of chronic co-administration of ","suffix":" and warfarin. Of note, clinical studies in patients with PA","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":671,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":" above, have demonstrated that chronic co-administration of ","suffix":" and warfarin does not appear to be associated with any spec","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":1033,"endOffset":1044,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"dow; therefore, caution should be exercised when initiating ","suffix":" therapy in patients receiving warfarin.\n                   ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":156,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":321,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"0-last) and maximum plasma concentration (Cmax) for R-and S-","suffix":", and International Normalized Ratio maximum observed value ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":456,"endOffset":464,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":") and area under the curve (INRAUC(0-last)). The effects of ","suffix":" on ambrisentan steady-state pharmacokinetics and the safety","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":540,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"steady-state pharmacokinetics and the safety of ambrisentan/","suffix":" co-administration were assessed. Data are presented as geom","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":126,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"mbrisentan had no significant effects on the AUC0-last of R-","suffix":" [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-war","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":191,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"rin [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-","suffix":" (101.6; 90% CI 98.4, 105.0). Similarly, ambrisentan had no ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":296,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ly, ambrisentan had no significant effects on the Cmax of R-","suffix":" (91.6; 90% CI 86.2, 97.4) or S-warfarin (89.9; 90% CI 84.8,","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":336,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ts on the Cmax of R-warfarin (91.6; 90% CI 86.2, 97.4) or S-","suffix":" (89.9; 90% CI 84.8, 95.3). Consistent with these observatio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":567,"endOffset":575,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"93.0; 90% CI 90.8, 95.3). In addition, co-administration of ","suffix":" did not alter ambrisentan steady-state pharmacokinetics. Ad","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":195,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":184,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"haracteristic of PAH [2]; therefore, anticoagulants such as ","suffix":" are commonly administered to prevent thrombus formation in ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":313,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"his patient population [4]. The pharmacodynamic response to ","suffix":" includes increased prothrombin time (PT), which is often ex","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":437,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"n expressed as an International Normalized Ratio (INR) [5]. ","suffix":" is administered as a racemic mixture of R(+) and S(-) enant","exact":"Warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":648,"endOffset":656,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"R-enantiomer with respect to coagulation activity [6]. Both ","suffix":" enantiomers are metabolized in the liver by cytochrome P450","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":737,"endOffset":745,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"bolized in the liver by cytochrome P450 (CYP) isoenzymes: R-","suffix":" is primarily metabolized by CYP1A2 and CYP3A4, whereas S-wa","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":803,"endOffset":811,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"in is primarily metabolized by CYP1A2 and CYP3A4, whereas S-","suffix":" is primarily metabolized by CYP2C9 [7]. Concomitant therapi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":949,"endOffset":957,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"enzyme activities may alter the pharmacokinetic exposure of ","suffix":" and significantly affect clotting time as measured by INR. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":325,"endOffset":333,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"PAH [[8], [9]; however, both drugs have been shown to alter ","suffix":" metabolism by affecting the activity of CYP3A4 and CYP2C9. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":880,"endOffset":888,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"d is therefore unlikely to have drug-drug interactions with ","suffix":" and other CYP-metabolized drugs [11]. This study was undert","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1083,"endOffset":1091,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cokinetics and pharmacodynamics of a single racemic dose of ","suffix":", as well as to assess the effects of warfarin on the steady","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1129,"endOffset":1137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cemic dose of warfarin, as well as to assess the effects of ","suffix":" on the steady-state pharmacokinetics of ambrisentan. In add","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":287,"endOffset":295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (Figure 1). Following a screening perio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":421,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"1 days, subjects were administered a single dose of racemic ","suffix":" 25 mg (Bristol-Myers Squibb, Princeton, NJ, USA) on day 1. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":745,"endOffset":753,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"mg dose of ambrisentan together with a single 25-mg dose of ","suffix":". All study medications were administered under fasted condi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":122,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":202,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1002,"endOffset":1010,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"n at -20°C until analysis. Plasma concentrations of R-and S-","suffix":" were determined by a validated liquid chromatography tandem","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1688,"endOffset":1696,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"mated plasma pharmacokinetic parameters for ambrisentan and ","suffix":" enantiomers included area under the concentration-time curv","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":119,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"  To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":305,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.\n                    ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":156,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":321,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"0-last) and maximum plasma concentration (Cmax) for R-and S-","suffix":", and International Normalized Ratio maximum observed value ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":456,"endOffset":464,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":") and area under the curve (INRAUC(0-last)). The effects of ","suffix":" on ambrisentan steady-state pharmacokinetics and the safety","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":540,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"steady-state pharmacokinetics and the safety of ambrisentan/","suffix":" co-administration were assessed. Data are presented as geom","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":126,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"mbrisentan had no significant effects on the AUC0-last of R-","suffix":" [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-war","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":191,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"rin [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-","suffix":" (101.6; 90% CI 98.4, 105.0). Similarly, ambrisentan had no ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":296,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ly, ambrisentan had no significant effects on the Cmax of R-","suffix":" (91.6; 90% CI 86.2, 97.4) or S-warfarin (89.9; 90% CI 84.8,","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":336,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ts on the Cmax of R-warfarin (91.6; 90% CI 86.2, 97.4) or S-","suffix":" (89.9; 90% CI 84.8, 95.3). Consistent with these observatio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":567,"endOffset":575,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"93.0; 90% CI 90.8, 95.3). In addition, co-administration of ","suffix":" did not alter ambrisentan steady-state pharmacokinetics. Ad","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":195,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":184,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"haracteristic of PAH [2]; therefore, anticoagulants such as ","suffix":" are commonly administered to prevent thrombus formation in ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":313,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"his patient population [4]. The pharmacodynamic response to ","suffix":" includes increased prothrombin time (PT), which is often ex","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":648,"endOffset":656,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"R-enantiomer with respect to coagulation activity [6]. Both ","suffix":" enantiomers are metabolized in the liver by cytochrome P450","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":737,"endOffset":745,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"bolized in the liver by cytochrome P450 (CYP) isoenzymes: R-","suffix":" is primarily metabolized by CYP1A2 and CYP3A4, whereas S-wa","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":803,"endOffset":811,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"in is primarily metabolized by CYP1A2 and CYP3A4, whereas S-","suffix":" is primarily metabolized by CYP2C9 [7]. Concomitant therapi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":949,"endOffset":957,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"enzyme activities may alter the pharmacokinetic exposure of ","suffix":" and significantly affect clotting time as measured by INR. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":325,"endOffset":333,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"PAH [[8], [9]; however, both drugs have been shown to alter ","suffix":" metabolism by affecting the activity of CYP3A4 and CYP2C9. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":880,"endOffset":888,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"d is therefore unlikely to have drug-drug interactions with ","suffix":" and other CYP-metabolized drugs [11]. This study was undert","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1083,"endOffset":1091,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cokinetics and pharmacodynamics of a single racemic dose of ","suffix":", as well as to assess the effects of warfarin on the steady","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1129,"endOffset":1137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cemic dose of warfarin, as well as to assess the effects of ","suffix":" on the steady-state pharmacokinetics of ambrisentan. In add","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1251,"endOffset":1259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"In addition, the safety and tolerability of ambrisentan and ","suffix":" co-administration were evaluated.\n                         ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":287,"endOffset":295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (Figure 1). Following a screening perio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":421,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"1 days, subjects were administered a single dose of racemic ","suffix":" 25 mg (Bristol-Myers Squibb, Princeton, NJ, USA) on day 1. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":745,"endOffset":753,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"mg dose of ambrisentan together with a single 25-mg dose of ","suffix":". All study medications were administered under fasted condi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":122,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":202,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1002,"endOffset":1010,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"n at -20°C until analysis. Plasma concentrations of R-and S-","suffix":" were determined by a validated liquid chromatography tandem","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1688,"endOffset":1696,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"mated plasma pharmacokinetic parameters for ambrisentan and ","suffix":" enantiomers included area under the concentration-time curv","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":108,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"             The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":119,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"  To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":226,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) vs. day 1 (warfarin alone) were summarized f","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":261,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"e differences of day 13 (warfarin + ambrisentan) vs. day 1 (","suffix":" alone) were summarized for the natural logarithms of Cmax a","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":354,"endOffset":362,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"or the natural logarithms of Cmax and AUC0-last for R-and S-","suffix":", and the natural logarithms of INRmax and INRAUC(0-last). T","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1044,"endOffset":1052,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"ferences in tmax between treatment days for INR and R-and S-","suffix":" concentrations.\n                                           ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":97,"endOffset":105,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"                        To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":205,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) vs. day 12 (ambrisentan alone) were summariz","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":240,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":274,"endOffset":282,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":326,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"according to the protocol and received two doses of racemic ","suffix":" 25 mg and 12 doses of ambrisentan 10 mg; therefore, all wer","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration-time profiles of R-and S-","suffix":" (Figure 2). Both R-and S-warfarin were detectable at the fi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":216,"endOffset":224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"-time profiles of R-and S-warfarin (Figure 2). Both R-and S-","suffix":" were detectable at the first postdose sampling time (0.5 h)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":388,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ately 1 h postdose. The concentration-time profiles of both ","suffix":" enantiomers were virtually superimposable in the presence (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":587,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ambrisentan, the observed mean AUC0-last values for R-and S-","suffix":" increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6%","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":882,"endOffset":890,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"respectively (Table 1). The 90% CIs of the GMRs for R-and S-","suffix":" Cmax were within the predefined 80-125% no effect boundarie","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":79,"endOffset":87,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"                                          Administration of ","suffix":" in the presence of multiple doses of ambrisentan (Figure 3)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":69,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"                                                    Racemic ","suffix":" had little effect on the steady-state plasma concentration-","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":196,"endOffset":204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"-time profile of ambrisentan (Figure 4). In the presence of ","suffix":", steady-state ambrisentan Cmax and Cmin decreased by 2.0% (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC0-last,Cmax) and pharmacodynamic (INR) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":398,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"at ambrisentan did not have a clinically relevant effect on ","suffix":" metabolism or the resulting therapeutic effects of warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":458,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"warfarin metabolism or the resulting therapeutic effects of ","suffix":". Nonetheless, warfarin is a drug with a narrow therapeutic ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":481,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"the resulting therapeutic effects of warfarin. Nonetheless, ","suffix":" is a drug with a narrow therapeutic index, so that even sli","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":80,"endOffset":88,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                     Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":376,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"wo enzymes are also primarily responsible for metabolism of ","suffix":". Bosentan, which is primarily metabolized by CYP2C9 and CYP","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":559,"endOffset":567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"es. As a result, co-administration of bosentan with racemic ","suffix":" in healthy subjects decreased the systemic exposure (AUC) t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":876,"endOffset":884,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" experience with concomitant administration of bosentan and ","suffix":" in patients with PAH does not appear to result in any clini","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":977,"endOffset":985,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"pear to result in any clinically relevant changes in INR or ","suffix":" dose [17]. Sitaxsentan also has an interaction with warfari","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1038,"endOffset":1046,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"arfarin dose [17]. Sitaxsentan also has an interaction with ","suffix":" due to sitaxsentan-mediated inhibition of CYP2C9 that incre","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1143,"endOffset":1151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"on of CYP2C9 that increases the pharmacokinetic exposure of ","suffix":", prolonging its effects on coagulation [16]. The increase i","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1313,"endOffset":1321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tration requires substantial reduction in the daily dose of ","suffix":". For example, an 80% reduction in warfarin dose was require","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1356,"endOffset":1364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"he daily dose of warfarin. For example, an 80% reduction in ","suffix":" dose was required during the clinical studies of sitaxsenta","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":560,"endOffset":568,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"pectively, with a nominal increase in AUC0-last for R-and S-","suffix":" of 4.7 and 1.6%, respectively. The mechanism of these minor","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":845,"endOffset":853,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"re unlikely to result in any clinically relevant effects on ","suffix":" dose or prothrombin time. The lack of a drug interaction be","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":935,"endOffset":943,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ime. The lack of a drug interaction between ambrisentan and ","suffix":" has been corroborated in ambrisentan clinical studies that ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1024,"endOffset":1032,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"d in ambrisentan clinical studies that permitted the use of ","suffix":" or warfarin-like anticoagulants as concomitant medications ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1036,"endOffset":1044,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ntan clinical studies that permitted the use of warfarin or ","suffix":"-like anticoagulants as concomitant medications [10].\n      ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":93,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"                        In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":225,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":530,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":687,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":925,"endOffset":933,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"olunteers are consistent with that conclusion. Nonetheless, ","suffix":" is a drug with a narrow therapeutic window; therefore, caut","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1075,"endOffset":1083,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d when initiating ambrisentan therapy in patients receiving ","suffix":".\n                                                    ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":261,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"e differences of day 13 (warfarin + ambrisentan) vs. day 1 (","suffix":" alone) were summarized for the natural logarithms of Cmax a","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":354,"endOffset":362,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"or the natural logarithms of Cmax and AUC0-last for R-and S-","suffix":", and the natural logarithms of INRmax and INRAUC(0-last). T","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":305,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.\n                    ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":156,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":321,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"0-last) and maximum plasma concentration (Cmax) for R-and S-","suffix":", and International Normalized Ratio maximum observed value ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":456,"endOffset":464,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":") and area under the curve (INRAUC(0-last)). The effects of ","suffix":" on ambrisentan steady-state pharmacokinetics and the safety","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":540,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"steady-state pharmacokinetics and the safety of ambrisentan/","suffix":" co-administration were assessed. Data are presented as geom","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":126,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"mbrisentan had no significant effects on the AUC0-last of R-","suffix":" [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-war","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":191,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"rin [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-","suffix":" (101.6; 90% CI 98.4, 105.0). Similarly, ambrisentan had no ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":296,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ly, ambrisentan had no significant effects on the Cmax of R-","suffix":" (91.6; 90% CI 86.2, 97.4) or S-warfarin (89.9; 90% CI 84.8,","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":336,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ts on the Cmax of R-warfarin (91.6; 90% CI 86.2, 97.4) or S-","suffix":" (89.9; 90% CI 84.8, 95.3). Consistent with these observatio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":567,"endOffset":575,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"93.0; 90% CI 90.8, 95.3). In addition, co-administration of ","suffix":" did not alter ambrisentan steady-state pharmacokinetics. Ad","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":195,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":184,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"haracteristic of PAH [2]; therefore, anticoagulants such as ","suffix":" are commonly administered to prevent thrombus formation in ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":313,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"his patient population [4]. The pharmacodynamic response to ","suffix":" includes increased prothrombin time (PT), which is often ex","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":648,"endOffset":656,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"R-enantiomer with respect to coagulation activity [6]. Both ","suffix":" enantiomers are metabolized in the liver by cytochrome P450","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":737,"endOffset":745,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"bolized in the liver by cytochrome P450 (CYP) isoenzymes: R-","suffix":" is primarily metabolized by CYP1A2 and CYP3A4, whereas S-wa","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":803,"endOffset":811,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"in is primarily metabolized by CYP1A2 and CYP3A4, whereas S-","suffix":" is primarily metabolized by CYP2C9 [7]. Concomitant therapi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":949,"endOffset":957,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"enzyme activities may alter the pharmacokinetic exposure of ","suffix":" and significantly affect clotting time as measured by INR. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":325,"endOffset":333,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"PAH [[8], [9]; however, both drugs have been shown to alter ","suffix":" metabolism by affecting the activity of CYP3A4 and CYP2C9. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":880,"endOffset":888,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"d is therefore unlikely to have drug-drug interactions with ","suffix":" and other CYP-metabolized drugs [11]. This study was undert","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1083,"endOffset":1091,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cokinetics and pharmacodynamics of a single racemic dose of ","suffix":", as well as to assess the effects of warfarin on the steady","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1129,"endOffset":1137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cemic dose of warfarin, as well as to assess the effects of ","suffix":" on the steady-state pharmacokinetics of ambrisentan. In add","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1251,"endOffset":1259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"In addition, the safety and tolerability of ambrisentan and ","suffix":" co-administration were evaluated.\n                         ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":287,"endOffset":295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (Figure 1). Following a screening perio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":421,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"1 days, subjects were administered a single dose of racemic ","suffix":" 25 mg (Bristol-Myers Squibb, Princeton, NJ, USA) on day 1. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":745,"endOffset":753,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"mg dose of ambrisentan together with a single 25-mg dose of ","suffix":". All study medications were administered under fasted condi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":122,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":202,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1002,"endOffset":1010,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"n at -20°C until analysis. Plasma concentrations of R-and S-","suffix":" were determined by a validated liquid chromatography tandem","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1688,"endOffset":1696,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"mated plasma pharmacokinetic parameters for ambrisentan and ","suffix":" enantiomers included area under the concentration-time curv","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":108,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"             The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":119,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"  To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":226,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) vs. day 1 (warfarin alone) were summarized f","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":261,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"e differences of day 13 (warfarin + ambrisentan) vs. day 1 (","suffix":" alone) were summarized for the natural logarithms of Cmax a","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":354,"endOffset":362,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"or the natural logarithms of Cmax and AUC0-last for R-and S-","suffix":", and the natural logarithms of INRmax and INRAUC(0-last). T","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1044,"endOffset":1052,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"ferences in tmax between treatment days for INR and R-and S-","suffix":" concentrations.\n                                           ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":97,"endOffset":105,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"                        To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":205,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) vs. day 12 (ambrisentan alone) were summariz","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":240,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":274,"endOffset":282,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":326,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"according to the protocol and received two doses of racemic ","suffix":" 25 mg and 12 doses of ambrisentan 10 mg; therefore, all wer","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration-time profiles of R-and S-","suffix":" (Figure 2). Both R-and S-warfarin were detectable at the fi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":216,"endOffset":224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"-time profiles of R-and S-warfarin (Figure 2). Both R-and S-","suffix":" were detectable at the first postdose sampling time (0.5 h)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":388,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ately 1 h postdose. The concentration-time profiles of both ","suffix":" enantiomers were virtually superimposable in the presence (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":587,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ambrisentan, the observed mean AUC0-last values for R-and S-","suffix":" increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6%","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":882,"endOffset":890,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"respectively (Table 1). The 90% CIs of the GMRs for R-and S-","suffix":" Cmax were within the predefined 80-125% no effect boundarie","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":79,"endOffset":87,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"                                          Administration of ","suffix":" in the presence of multiple doses of ambrisentan (Figure 3)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":69,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"                                                    Racemic ","suffix":" had little effect on the steady-state plasma concentration-","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":196,"endOffset":204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"-time profile of ambrisentan (Figure 4). In the presence of ","suffix":", steady-state ambrisentan Cmax and Cmin decreased by 2.0% (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC0-last,Cmax) and pharmacodynamic (INR) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":398,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"at ambrisentan did not have a clinically relevant effect on ","suffix":" metabolism or the resulting therapeutic effects of warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":458,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"warfarin metabolism or the resulting therapeutic effects of ","suffix":". Nonetheless, warfarin is a drug with a narrow therapeutic ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":481,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"the resulting therapeutic effects of warfarin. Nonetheless, ","suffix":" is a drug with a narrow therapeutic index, so that even sli","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":80,"endOffset":88,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                     Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":376,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"wo enzymes are also primarily responsible for metabolism of ","suffix":". Bosentan, which is primarily metabolized by CYP2C9 and CYP","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":559,"endOffset":567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"es. As a result, co-administration of bosentan with racemic ","suffix":" in healthy subjects decreased the systemic exposure (AUC) t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":876,"endOffset":884,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" experience with concomitant administration of bosentan and ","suffix":" in patients with PAH does not appear to result in any clini","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":977,"endOffset":985,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"pear to result in any clinically relevant changes in INR or ","suffix":" dose [17]. Sitaxsentan also has an interaction with warfari","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1038,"endOffset":1046,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"arfarin dose [17]. Sitaxsentan also has an interaction with ","suffix":" due to sitaxsentan-mediated inhibition of CYP2C9 that incre","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1143,"endOffset":1151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"on of CYP2C9 that increases the pharmacokinetic exposure of ","suffix":", prolonging its effects on coagulation [16]. The increase i","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1313,"endOffset":1321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tration requires substantial reduction in the daily dose of ","suffix":". For example, an 80% reduction in warfarin dose was require","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1356,"endOffset":1364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"he daily dose of warfarin. For example, an 80% reduction in ","suffix":" dose was required during the clinical studies of sitaxsenta","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":560,"endOffset":568,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"pectively, with a nominal increase in AUC0-last for R-and S-","suffix":" of 4.7 and 1.6%, respectively. The mechanism of these minor","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":845,"endOffset":853,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"re unlikely to result in any clinically relevant effects on ","suffix":" dose or prothrombin time. The lack of a drug interaction be","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":935,"endOffset":943,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ime. The lack of a drug interaction between ambrisentan and ","suffix":" has been corroborated in ambrisentan clinical studies that ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1024,"endOffset":1032,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"d in ambrisentan clinical studies that permitted the use of ","suffix":" or warfarin-like anticoagulants as concomitant medications ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1036,"endOffset":1044,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ntan clinical studies that permitted the use of warfarin or ","suffix":"-like anticoagulants as concomitant medications [10].\n      ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":93,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"                        In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":225,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":530,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":687,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":925,"endOffset":933,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"olunteers are consistent with that conclusion. Nonetheless, ","suffix":" is a drug with a narrow therapeutic window; therefore, caut","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1075,"endOffset":1083,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d when initiating ambrisentan therapy in patients receiving ","suffix":".\n                                                    ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":305,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.\n                    ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":156,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":321,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"0-last) and maximum plasma concentration (Cmax) for R-and S-","suffix":", and International Normalized Ratio maximum observed value ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":456,"endOffset":464,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":") and area under the curve (INRAUC(0-last)). The effects of ","suffix":" on ambrisentan steady-state pharmacokinetics and the safety","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":540,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"steady-state pharmacokinetics and the safety of ambrisentan/","suffix":" co-administration were assessed. Data are presented as geom","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":126,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"mbrisentan had no significant effects on the AUC0-last of R-","suffix":" [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-war","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":191,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"rin [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-","suffix":" (101.6; 90% CI 98.4, 105.0). Similarly, ambrisentan had no ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":296,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ly, ambrisentan had no significant effects on the Cmax of R-","suffix":" (91.6; 90% CI 86.2, 97.4) or S-warfarin (89.9; 90% CI 84.8,","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":336,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ts on the Cmax of R-warfarin (91.6; 90% CI 86.2, 97.4) or S-","suffix":" (89.9; 90% CI 84.8, 95.3). Consistent with these observatio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":567,"endOffset":575,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"93.0; 90% CI 90.8, 95.3). In addition, co-administration of ","suffix":" did not alter ambrisentan steady-state pharmacokinetics. Ad","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":195,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":184,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"haracteristic of PAH [2]; therefore, anticoagulants such as ","suffix":" are commonly administered to prevent thrombus formation in ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":313,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"his patient population [4]. The pharmacodynamic response to ","suffix":" includes increased prothrombin time (PT), which is often ex","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":648,"endOffset":656,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"R-enantiomer with respect to coagulation activity [6]. Both ","suffix":" enantiomers are metabolized in the liver by cytochrome P450","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":737,"endOffset":745,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"bolized in the liver by cytochrome P450 (CYP) isoenzymes: R-","suffix":" is primarily metabolized by CYP1A2 and CYP3A4, whereas S-wa","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":803,"endOffset":811,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"in is primarily metabolized by CYP1A2 and CYP3A4, whereas S-","suffix":" is primarily metabolized by CYP2C9 [7]. Concomitant therapi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":949,"endOffset":957,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"enzyme activities may alter the pharmacokinetic exposure of ","suffix":" and significantly affect clotting time as measured by INR. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":325,"endOffset":333,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"PAH [[8], [9]; however, both drugs have been shown to alter ","suffix":" metabolism by affecting the activity of CYP3A4 and CYP2C9. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":880,"endOffset":888,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"d is therefore unlikely to have drug-drug interactions with ","suffix":" and other CYP-metabolized drugs [11]. This study was undert","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1083,"endOffset":1091,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cokinetics and pharmacodynamics of a single racemic dose of ","suffix":", as well as to assess the effects of warfarin on the steady","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1129,"endOffset":1137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"cemic dose of warfarin, as well as to assess the effects of ","suffix":" on the steady-state pharmacokinetics of ambrisentan. In add","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1251,"endOffset":1259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"In addition, the safety and tolerability of ambrisentan and ","suffix":" co-administration were evaluated.\n                         ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":287,"endOffset":295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (Figure 1). Following a screening perio","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":421,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"1 days, subjects were administered a single dose of racemic ","suffix":" 25 mg (Bristol-Myers Squibb, Princeton, NJ, USA) on day 1. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":745,"endOffset":753,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"mg dose of ambrisentan together with a single 25-mg dose of ","suffix":". All study medications were administered under fasted condi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":122,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":202,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1002,"endOffset":1010,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"n at -20°C until analysis. Plasma concentrations of R-and S-","suffix":" were determined by a validated liquid chromatography tandem","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1688,"endOffset":1696,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"mated plasma pharmacokinetic parameters for ambrisentan and ","suffix":" enantiomers included area under the concentration-time curv","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":108,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"             The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":119,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"  To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":226,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) vs. day 1 (warfarin alone) were summarized f","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":261,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"e differences of day 13 (warfarin + ambrisentan) vs. day 1 (","suffix":" alone) were summarized for the natural logarithms of Cmax a","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":354,"endOffset":362,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"or the natural logarithms of Cmax and AUC0-last for R-and S-","suffix":", and the natural logarithms of INRmax and INRAUC(0-last). T","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1044,"endOffset":1052,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"ferences in tmax between treatment days for INR and R-and S-","suffix":" concentrations.\n                                           ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":97,"endOffset":105,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"                        To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":205,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) vs. day 12 (ambrisentan alone) were summariz","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":240,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":274,"endOffset":282,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":326,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"according to the protocol and received two doses of racemic ","suffix":" 25 mg and 12 doses of ambrisentan 10 mg; therefore, all wer","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration-time profiles of R-and S-","suffix":" (Figure 2). Both R-and S-warfarin were detectable at the fi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":216,"endOffset":224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"-time profiles of R-and S-warfarin (Figure 2). Both R-and S-","suffix":" were detectable at the first postdose sampling time (0.5 h)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":388,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ately 1 h postdose. The concentration-time profiles of both ","suffix":" enantiomers were virtually superimposable in the presence (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":587,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ambrisentan, the observed mean AUC0-last values for R-and S-","suffix":" increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6%","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":882,"endOffset":890,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"respectively (Table 1). The 90% CIs of the GMRs for R-and S-","suffix":" Cmax were within the predefined 80-125% no effect boundarie","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":79,"endOffset":87,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"                                          Administration of ","suffix":" in the presence of multiple doses of ambrisentan (Figure 3)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":69,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"                                                    Racemic ","suffix":" had little effect on the steady-state plasma concentration-","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":196,"endOffset":204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"-time profile of ambrisentan (Figure 4). In the presence of ","suffix":", steady-state ambrisentan Cmax and Cmin decreased by 2.0% (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC0-last,Cmax) and pharmacodynamic (INR) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":398,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"at ambrisentan did not have a clinically relevant effect on ","suffix":" metabolism or the resulting therapeutic effects of warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":458,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"warfarin metabolism or the resulting therapeutic effects of ","suffix":". Nonetheless, warfarin is a drug with a narrow therapeutic ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":481,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"the resulting therapeutic effects of warfarin. Nonetheless, ","suffix":" is a drug with a narrow therapeutic index, so that even sli","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":80,"endOffset":88,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                     Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":376,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"wo enzymes are also primarily responsible for metabolism of ","suffix":". Bosentan, which is primarily metabolized by CYP2C9 and CYP","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":559,"endOffset":567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"es. As a result, co-administration of bosentan with racemic ","suffix":" in healthy subjects decreased the systemic exposure (AUC) t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":876,"endOffset":884,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" experience with concomitant administration of bosentan and ","suffix":" in patients with PAH does not appear to result in any clini","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":977,"endOffset":985,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"pear to result in any clinically relevant changes in INR or ","suffix":" dose [17]. Sitaxsentan also has an interaction with warfari","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1038,"endOffset":1046,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"arfarin dose [17]. Sitaxsentan also has an interaction with ","suffix":" due to sitaxsentan-mediated inhibition of CYP2C9 that incre","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1143,"endOffset":1151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"on of CYP2C9 that increases the pharmacokinetic exposure of ","suffix":", prolonging its effects on coagulation [16]. The increase i","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1313,"endOffset":1321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tration requires substantial reduction in the daily dose of ","suffix":". For example, an 80% reduction in warfarin dose was require","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1356,"endOffset":1364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"he daily dose of warfarin. For example, an 80% reduction in ","suffix":" dose was required during the clinical studies of sitaxsenta","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":560,"endOffset":568,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"pectively, with a nominal increase in AUC0-last for R-and S-","suffix":" of 4.7 and 1.6%, respectively. The mechanism of these minor","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":845,"endOffset":853,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"re unlikely to result in any clinically relevant effects on ","suffix":" dose or prothrombin time. The lack of a drug interaction be","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":935,"endOffset":943,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ime. The lack of a drug interaction between ambrisentan and ","suffix":" has been corroborated in ambrisentan clinical studies that ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1024,"endOffset":1032,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"d in ambrisentan clinical studies that permitted the use of ","suffix":" or warfarin-like anticoagulants as concomitant medications ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1036,"endOffset":1044,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ntan clinical studies that permitted the use of warfarin or ","suffix":"-like anticoagulants as concomitant medications [10].\n      ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":93,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"                        In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":225,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":530,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":687,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":925,"endOffset":933,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"olunteers are consistent with that conclusion. Nonetheless, ","suffix":" is a drug with a narrow therapeutic window; therefore, caut","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1075,"endOffset":1083,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d when initiating ambrisentan therapy in patients receiving ","suffix":".\n                                                    ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":240,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":274,"endOffset":282,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":326,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"according to the protocol and received two doses of racemic ","suffix":" 25 mg and 12 doses of ambrisentan 10 mg; therefore, all wer","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration-time profiles of R-and S-","suffix":" (Figure 2). Both R-and S-warfarin were detectable at the fi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":216,"endOffset":224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"-time profiles of R-and S-warfarin (Figure 2). Both R-and S-","suffix":" were detectable at the first postdose sampling time (0.5 h)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":388,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ately 1 h postdose. The concentration-time profiles of both ","suffix":" enantiomers were virtually superimposable in the presence (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":587,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ambrisentan, the observed mean AUC0-last values for R-and S-","suffix":" increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6%","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":882,"endOffset":890,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"respectively (Table 1). The 90% CIs of the GMRs for R-and S-","suffix":" Cmax were within the predefined 80-125% no effect boundarie","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":196,"endOffset":204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"-time profile of ambrisentan (Figure 4). In the presence of ","suffix":", steady-state ambrisentan Cmax and Cmin decreased by 2.0% (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC0-last,Cmax) and pharmacodynamic (INR) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":398,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"at ambrisentan did not have a clinically relevant effect on ","suffix":" metabolism or the resulting therapeutic effects of warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":458,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"warfarin metabolism or the resulting therapeutic effects of ","suffix":". Nonetheless, warfarin is a drug with a narrow therapeutic ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":481,"endOffset":489,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"the resulting therapeutic effects of warfarin. Nonetheless, ","suffix":" is a drug with a narrow therapeutic index, so that even sli","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":376,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"wo enzymes are also primarily responsible for metabolism of ","suffix":". Bosentan, which is primarily metabolized by CYP2C9 and CYP","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":559,"endOffset":567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"es. As a result, co-administration of bosentan with racemic ","suffix":" in healthy subjects decreased the systemic exposure (AUC) t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":876,"endOffset":884,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" experience with concomitant administration of bosentan and ","suffix":" in patients with PAH does not appear to result in any clini","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":977,"endOffset":985,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"pear to result in any clinically relevant changes in INR or ","suffix":" dose [17]. Sitaxsentan also has an interaction with warfari","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1038,"endOffset":1046,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"arfarin dose [17]. Sitaxsentan also has an interaction with ","suffix":" due to sitaxsentan-mediated inhibition of CYP2C9 that incre","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1143,"endOffset":1151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"on of CYP2C9 that increases the pharmacokinetic exposure of ","suffix":", prolonging its effects on coagulation [16]. The increase i","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1313,"endOffset":1321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tration requires substantial reduction in the daily dose of ","suffix":". For example, an 80% reduction in warfarin dose was require","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1356,"endOffset":1364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"he daily dose of warfarin. For example, an 80% reduction in ","suffix":" dose was required during the clinical studies of sitaxsenta","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":560,"endOffset":568,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"pectively, with a nominal increase in AUC0-last for R-and S-","suffix":" of 4.7 and 1.6%, respectively. The mechanism of these minor","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":845,"endOffset":853,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"re unlikely to result in any clinically relevant effects on ","suffix":" dose or prothrombin time. The lack of a drug interaction be","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":935,"endOffset":943,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ime. The lack of a drug interaction between ambrisentan and ","suffix":" has been corroborated in ambrisentan clinical studies that ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1024,"endOffset":1032,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"d in ambrisentan clinical studies that permitted the use of ","suffix":" or warfarin-like anticoagulants as concomitant medications ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":225,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":530,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":687,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":925,"endOffset":933,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"olunteers are consistent with that conclusion. Nonetheless, ","suffix":" is a drug with a narrow therapeutic window; therefore, caut","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":1075,"endOffset":1083,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d when initiating ambrisentan therapy in patients receiving ","suffix":".\n                                                    ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"prothrombin","startOffset":341,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"The pharmacodynamic response to warfarin includes increased ","suffix":" time (PT), which is often expressed as an International Nor","exact":"prothrombin"},{"setid":"PMC2686069","drugname":"prothrombin","startOffset":1984,"endOffset":1995,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"r the steady-state pharmacokinetic analysis of ambrisentan. ","suffix":" times, presented as INR, were characterized using area unde","exact":"Prothrombin"},{"setid":"PMC2686069","drugname":"prothrombin","startOffset":862,"endOffset":873,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"sult in any clinically relevant effects on warfarin dose or ","suffix":" time. The lack of a drug interaction between ambrisentan an","exact":"prothrombin"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":165,"endOffset":173,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"ged as a promising class of therapeutic agents for PAH [4]. ","suffix":" and sitaxsentan are sulphonamide-based ERAs that have prove","exact":"Bosentan"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":736,"endOffset":744,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"ulmonary haemodynamics in patients with PAH [10-12]. Unlike ","suffix":" and sitaxsentan, ambrisentan does not induce or inhibit CYP","exact":"bosentan"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":136,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ith warfarin have been previously demonstrated for the ERAs ","suffix":" and sitaxsentan [9,14-16]. These interactions have been att","exact":"bosentan"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":268,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ted to alterations in the activity of CYP2C9 and CYP3A4 for ","suffix":" and CYP2C9 for sitaxsentan, and these two enzymes are also ","exact":"bosentan"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":386,"endOffset":394,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":" are also primarily responsible for metabolism of warfarin. ","suffix":", which is primarily metabolized by CYP2C9 and CYP3A4, also ","exact":"Bosentan"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":537,"endOffset":545,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ctivity of these enzymes. As a result, co-administration of ","suffix":" with racemic warfarin in healthy subjects decreased the sys","exact":"bosentan"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":863,"endOffset":871,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ver, clinical experience with concomitant administration of ","suffix":" and warfarin in patients with PAH does not appear to result","exact":"bosentan"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":731,"endOffset":739,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ely to be due to CYP inhibition or induction. Compared with ","suffix":", the smaller effects observed in this study are unlikely to","exact":"bosentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":178,"endOffset":189,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"ising class of therapeutic agents for PAH [4]. Bosentan and ","suffix":" are sulphonamide-based ERAs that have proven effective in t","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":749,"endOffset":760,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"odynamics in patients with PAH [10-12]. Unlike bosentan and ","suffix":", ambrisentan does not induce or inhibit CYP2C9 or CYP3A4 an","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":149,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"have been previously demonstrated for the ERAs bosentan and ","suffix":" [9,14-16]. These interactions have been attributed to alter","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":292,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"e activity of CYP2C9 and CYP3A4 for bosentan and CYP2C9 for ","suffix":", and these two enzymes are also primarily responsible for m","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":997,"endOffset":1008,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"y clinically relevant changes in INR or warfarin dose [17]. ","suffix":" also has an interaction with warfarin due to sitaxsentan-me","exact":"Sitaxsentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":1054,"endOffset":1065,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"]. Sitaxsentan also has an interaction with warfarin due to ","suffix":"-mediated inhibition of CYP2C9 that increases the pharmacoki","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":1231,"endOffset":1242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ects on coagulation [16]. The increase in INR observed with ","suffix":" co-administration requires substantial reduction in the dai","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":1414,"endOffset":1425,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"n warfarin dose was required during the clinical studies of ","suffix":" to prevent excessive anticoagulation and the potential for ","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"caffeine","startOffset":463,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"e nontobacco users, and agreed to discontinue the intake of ","suffix":", alcohol, grapefruit products, liver, and leafy green veget","exact":"caffeine"},{"setid":"PMC2686069","drugname":"alanine","startOffset":694,"endOffset":701,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" within normal limits, serum aspartate aminotransferase and ","suffix":" aminotransferase concentrations <1x the upper limit of norm","exact":"alanine"}],[{"setid":"PMC3703233","drugname":"dabigatran","startOffset":396,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fourth day, or the same treatments in the reverse sequence. ","suffix":" plasma concentration and ecarin clotting time (ECT) were me","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":183,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ion process with two compartments. The relationship between ","suffix":" concentration and ECT was implemented as a linear function.","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":124,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" The model proposed effectively describes the complex PK of ","suffix":" and takes into account drug-drug interactions with P-gp act","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":365,"endOffset":375,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"red prodrug that is rapidly converted into the active drug, ","suffix":", by a serum esterase. It exerts its activity by direct comp","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":798,"endOffset":808,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" side, could be involved in the excretion of DE in the gut. ","suffix":" is not metabolized by the cytochrome P450 enzyme system and","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":129,"endOffset":139,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"h other anticoagulant drugs, such as vitamin K antagonists, ","suffix":" has a low potential for drug-drug interactions. However, it","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":377,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"y, decrease or increase its bioavailability. An increase in ","suffix":" area under the concentration vs. time curve (AUC), ranging ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":149,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"elop a PK/PD model to assess drug-drug interactions between ","suffix":" and P-gp modulators, using clarithromycin, a strong inhibit","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":276,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" administration for measurement of plasma concentrations of ","suffix":". All analyses were performed on venous blood samples collec","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":266,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"t step consisted in identifying the structural PK model for ","suffix":" without clarithromycin. The second step comprised the estim","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":128,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"t PK/PD model corresponded to a linear relationship between ","suffix":" concentration and its anticoagulant effect, based on the EC","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":172,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","prefix":"he baseline ECT value and CDabi the plasma concentration of ","suffix":". Random effect was tested only on K. The error model was pr","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":419,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":" to 0.725 (CV%). The modification of the absorption rate of ","suffix":" and its variability in the presence of clarithromycin is il","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":151,"endOffset":161,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"el to describe the pharmacokinetics and pharmacodynamics of ","suffix":" in healthy volunteers was a two compartment model with an a","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":653,"endOffset":663,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"otransformation of the drug's oral etexilate form to active ","suffix":". In a recent follow-up subanalysis of the RE-LY study (atri","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":145,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"model effectively describes the complex pharmacokinetics of ","suffix":", allowing drug-drug interactions related to P-gp modulation","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":287,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":" into account. Using this model, we showed that exposure to ","suffix":" is increased by 50% in the presence of clarithromycin and i","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":242,"endOffset":256,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"an etexilate (DE) and in the second treatment period 500 mg ","suffix":" twice daily during 3 days and then 300 mg DE plus 500 mg cl","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":314,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"in twice daily during 3 days and then 300 mg DE plus 500 mg ","suffix":" on the fourth day, or the same treatments in the reverse se","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":382,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"n the objective function. The concomitant administration of ","suffix":" induced a significant change only in DE bioavailability, wh","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":508,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"lity, which increased from 6.5% to 10.1% in the presence of ","suffix":". Clarithromycin increased peak concentration and AUC by 60.","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":524,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"eased from 6.5% to 10.1% in the presence of clarithromycin. ","suffix":" increased peak concentration and AUC by 60.2% and 49.1% res","exact":"Clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":693,"endOffset":707,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ere excluded. Subjects with known hypersensitivity to DE or ","suffix":", or who had taken any medicine during the week before the s","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":179,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"eive either first DE alone and then a combination of DE and ","suffix":", or first the combination treatment and then DE alone. The ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":516,"endOffset":530,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ehringer Ingelheim, Ingelheim, Germany). During the DE plus ","suffix":" treatment period, volunteers received on the first 3 days 5","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":596,"endOffset":610,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ment period, volunteers received on the first 3 days 500 mg ","suffix":" (Zeclar®, 500 mg tablet, Abott France, France) twice daily ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":753,"endOffset":767,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"). On the 4th day they received 300 mg of DE plus 500 mg of ","suffix":" at t0 (07.30 h). The clarithromycin administration regimen ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":789,"endOffset":803,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"mg of DE plus 500 mg of clarithromycin at t0 (07.30 h). The ","suffix":" administration regimen was chosen on the grounds of its rel","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":285,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" identifying the structural PK model for dabigatran without ","suffix":". The second step comprised the estimation of PK/PD paramete","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":501,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"al variability (IOV) on the full data set (with and without ","suffix":"). Finally, drug-drug interaction was investigated applying ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":353,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"nd structural parameters. The concomitant administration of ","suffix":", was included as a categorical covariate in the absorption ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":284,"endOffset":298,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"lue; range 2.8-12.1) to 10.1% (4.1-26.9) in the presence of ","suffix":", the inter-individual variability of F increasing from 0.38","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":469,"endOffset":483,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"n rate of dabigatran and its variability in the presence of ","suffix":" is illustrated in Figure ​Figure1.1. The impact of clarithr","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":535,"endOffset":549,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"hromycin is illustrated in Figure ​Figure1.1. The impact of ","suffix":" on peak concentration was an increase of 60.2% from (median","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":654,"endOffset":668,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"2% from (median, min-max) 174.4 μg l−1 (92.3-310.0) without ","suffix":" to 279.4 μg l−1 (71.6-782.1) with clarithromycin. On AUC, a","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":703,"endOffset":717,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"0) without clarithromycin to 279.4 μg l−1 (71.6-782.1) with ","suffix":". On AUC, an increase of 49.1% was observed from 1220.5 μg l","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":805,"endOffset":819,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"1% was observed from 1220.5 μg l−1 h (586.5-2227.2) without ","suffix":" to 1820.4 μg l−1 h (521.0-5000.2) with clarithromycin.\n    ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":307,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"riability in DE bioavailability observed in the presence of ","suffix":" (38.6 vs. 72.5%) in our study, the effect of clarithromycin","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":367,"endOffset":381,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"clarithromycin (38.6 vs. 72.5%) in our study, the effect of ","suffix":" differing substantially from one volunteer to another (Figu","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":337,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"posure to dabigatran is increased by 50% in the presence of ","suffix":" and is characterized by substantial variability. In contras","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"thrombin","startOffset":457,"endOffset":465,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" It exerts its activity by direct competitive inhibition of ","suffix":". DE has a bioavailability of 6.5% due to a complex absorpti","exact":"thrombin"},{"setid":"PMC3703233","drugname":"amiodarone","startOffset":520,"endOffset":530,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" to over 200%, has been reported after co-administration of ","suffix":", ketoconazole, quinidine or verapamil 5. Some of these drug","exact":"amiodarone"},{"setid":"PMC3703233","drugname":"ketoconazole","startOffset":532,"endOffset":544,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"%, has been reported after co-administration of amiodarone, ","suffix":", quinidine or verapamil 5. Some of these drug-drug interact","exact":"ketoconazole"},{"setid":"PMC3703233","drugname":"quinidine","startOffset":546,"endOffset":555,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ported after co-administration of amiodarone, ketoconazole, ","suffix":" or verapamil 5. Some of these drug-drug interactions are st","exact":"quinidine"},{"setid":"PMC3703233","drugname":"verapamil","startOffset":559,"endOffset":568,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"co-administration of amiodarone, ketoconazole, quinidine or ","suffix":" 5. Some of these drug-drug interactions are strong enough t","exact":"verapamil"},{"setid":"PMC3703233","drugname":"fibrinogen","startOffset":420,"endOffset":430,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"zed ratio, activated partial thromboplastin time (aPPT) and ","suffix":" level. Volunteers with renal insufficiency, hepatic insuffi","exact":"fibrinogen"},{"setid":"PMC3703233","drugname":"fibrinogen","startOffset":341,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"a, median aPPT (range) was 1.04 (0.9-1.15) s, median plasma ","suffix":" concentration 2.25 (1.6-3) g l−1 and median plasma creatini","exact":"fibrinogen"},{"setid":"PMC3703233","drugname":"pradaxa","startOffset":428,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", at time zero (t0: 07.30 h), a 300 mg oral dose of DE (two ","suffix":"® 150 mg capsules; Boehringer Ingelheim, Ingelheim, Germany)","exact":"Pradaxa"},{"setid":"PMC3703233","drugname":"creatinine","startOffset":403,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"brinogen concentration 2.25 (1.6-3) g l−1 and median plasma ","suffix":" concentration 77 (72-95) μmol l−1.\n                        ","exact":"creatinine"},{"setid":"PMC3703233","drugname":"creatinine","startOffset":147,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ariates tested (weight, body mass index, body surface area, ","suffix":" clearance) was associated with a significant decrease in th","exact":"creatinine"}],[{"setid":"PMC3195022","drugname":"fluconazole","startOffset":391,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-way crossover study investigated the effect of concomitant ","suffix":" on voriconazole pharmacokinetics in 10 subjects: 8 extensiv","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":588,"endOffset":599,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"sted of 4-day voriconazole-only and 5-day voriconazole-plus-","suffix":" treatments, separated by a 14-day washout. Voriconazole pha","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":918,"endOffset":929,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"drug interaction should antifungal therapy be switched from ","suffix":" to voriconazole, following various simulated lag times for ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1036,"endOffset":1047,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ag times for the switch. In CYP2C19 extensive metabolizers, ","suffix":" increased the maximum plasma concentration and the area und","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1279,"endOffset":1290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":", however, voriconazole pharmacokinetics were unaffected by ","suffix":". The simulations based on pharmacokinetic modeling predicte","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1427,"endOffset":1438,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"azole was started 6, 12, 24, or 36 h after the last dose of ","suffix":", the voriconazole AUC ratios (sequential therapy versus vor","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1628,"endOffset":1639,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"14, respectively. This suggests that the remaining systemic ","suffix":" would result in a marked drug interaction with voriconazole","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1795,"endOffset":1806,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were observed during coadministration, concomitant use of ","suffix":" and voriconazole is not recommended. Frequent monitoring fo","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":380,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"erapy. However, voriconazole may be used sequentially after ","suffix":" in clinical practice. This situation is most likely to aris","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":494,"endOffset":505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"st likely to arise in hematology patients who are receiving ","suffix":" prophylaxis for the prevention of invasive Candida infectio","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":824,"endOffset":835,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"invasive Candida infections later confirmed to be caused by ","suffix":"-resistant strains. The rationale for a therapeutic switch f","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":899,"endOffset":910,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"istant strains. The rationale for a therapeutic switch from ","suffix":" to voriconazole is supported by in vitro and in vivo data s","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1020,"endOffset":1031,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ivo data showing good activity of voriconazole against many ","suffix":"-resistant Candida strains, even though there is some azole ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":339,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" life-threatening fungal infections requiring a switch from ","suffix":" to voriconazole, it may not be feasible to delay voriconazo","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":450,"endOffset":461,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" to delay voriconazole therapy to allow sufficient time for ","suffix":" washout. The elimination half-life of fluconazole is approx","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":500,"endOffset":511,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" time for fluconazole washout. The elimination half-life of ","suffix":" is approximately 30 h in adults (16), and fluconazole level","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":554,"endOffset":565,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"fe of fluconazole is approximately 30 h in adults (16), and ","suffix":" levels with the potential for inhibiting CYP2C19 activity m","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":155,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"e pharmacokinetics of voriconazole when coadministered with ","suffix":" to assess the maximal impact of fluconazole-mediated CYP2C1","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":199,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"ministered with fluconazole to assess the maximal impact of ","suffix":"-mediated CYP2C19 inhibition on voriconazole levels. A physi","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":190,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"zole-only treatment and a 5-day period of voriconazole-plus-","suffix":" combination treatment, separated by a 14-day washout phase.","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":577,"endOffset":588,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"ery 12 h on days 2 and 3 and a single 200-mg dose on day 4. ","suffix":" was administered as a single loading dose of 400 mg orally ","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":703,"endOffset":714,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"mpared between voriconazole alone and the voriconazole-plus-","suffix":" combination. All statistical analyses were performed using ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":165,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ithin Simcyp were utilized. The inhibition constant (Ki) of ","suffix":" for the CYP2C19 enzyme used for simulating drug-drug intera","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":296,"endOffset":307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ction was 2.1 μM (31). The literature reports Ki values for ","suffix":"-mediated CYP3A4 inhibition ranging from 1.9 to 63 μM; there","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":317,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"e, dosing interval, and dosing duration of voriconazole and ","suffix":" in the simulation were identical to those used in the clini","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":573,"endOffset":584,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"es of 200 mg each), or voriconazole was coadministered with ","suffix":" (first fluconazole dose of 400 mg and subsequent doses of 2","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":592,"endOffset":603,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":" or voriconazole was coadministered with fluconazole (first ","suffix":" dose of 400 mg and subsequent doses of 200 mg each every 24","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":702,"endOffset":713,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":" 200 mg each every 24 h). For simulating sequential dosing, ","suffix":" dosing remained the same, while voriconazole administration","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":181,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":") received voriconazole alone followed by voriconazole plus ","suffix":", and five (mean age, 24 years; age range, 22 to 27 years) r","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ears; age range, 22 to 27 years) received voriconazole plus ","suffix":" followed by voriconazole alone. The mean weights in the two","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":251,"endOffset":262,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ons of voriconazole were increased when coadministered with ","suffix":" compared with voriconazole alone, while in PMs, the concent","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":448,"endOffset":459,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":" In EMs, Cmax and AUC12 values increased significantly when ","suffix":" was coadministered with voriconazole compared with when vor","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":315,"endOffset":326,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":" parameters ranged from 18.7 to 34.9% for voriconazole plus ","suffix":", whereas they ranged from 37.8 to 62.0% for voriconazole al","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":397,"endOffset":408,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":" EMs, these simulations predicted ratios (voriconazole plus ","suffix":" versus fluconazole alone) of 2.65 (95% CI, 1.33 to 5.85) an","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":416,"endOffset":427,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ions predicted ratios (voriconazole plus fluconazole versus ","suffix":" alone) of 2.65 (95% CI, 1.33 to 5.85) and 1.40 (95% CI, 1.1","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":416,"endOffset":427,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ions predicted ratios (voriconazole plus fluconazole versus ","suffix":" alone) of 2.65 (95% CI, 1.33 to 5.85) and 1.40 (95% CI, 1.1","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":183,"endOffset":194,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" sequential dosing of voriconazole following termination of ","suffix":" therapy. The doses of both drugs remained the same as in th","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":407,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"time intervals (6, 12, 24, and 36 h) after the last dose of ","suffix":". Accordingly, fluconazole was given at a dose of 400 mg on ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":433,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" and 36 h) after the last dose of fluconazole. Accordingly, ","suffix":" was given at a dose of 400 mg on day 1, followed by 200 mg ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":939,"endOffset":950,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"d could result in higher voriconazole concentrations due to ","suffix":"-mediated interaction. The predicted Cmax and AUC values for","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1061,"endOffset":1072,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"alues for voriconazole and their ratios (voriconazole after ","suffix":" versus voriconazole alone) are presented in Table 3. The pr","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1296,"endOffset":1307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"re higher when this antifungal was given sequentially after ","suffix":" than when voriconazole was given alone. For instance, the v","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1455,"endOffset":1466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"51 when voriconazole was started 6 h after the last dose of ","suffix":", indicating a significant drug interaction. This effect dim","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1865,"endOffset":1876,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"he simulation results suggest that the inhibitory effect of ","suffix":" on voriconazole metabolism would last for at least 24 h aft","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":611,"endOffset":622,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"vents were reported during treatment with voriconazole plus ","suffix":" (14 versus 11 treatment-related adverse events). No apparen","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":135,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s clinical study suggest that concomitant administration of ","suffix":" and voriconazole significantly increases plasma voriconazol","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":349,"endOffset":360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"armacokinetics of voriconazole appeared to be unaffected by ","suffix":" in that population. This observation is not surprising, sin","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1137,"endOffset":1148,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"mulations of sequential use suggested that the influence of ","suffix":" on systemic levels of voriconazole would persist for at lea","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"2C9 and CPY2C19, as well as a moderate inhibitor of CYP3A4. ","suffix":"'s effect on voriconazole pharmacokinetics is probably due t","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":797,"endOffset":808,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"dose when coadministered with omeprazole (17). In contrast, ","suffix":" inhibits CYP2C19 and CYP3A4 with Kis of 2.1 μM and 25.2 μM ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":249,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"etics was reduced when voriconazole was coadministered with ","suffix":" compared with the variability in pharmacokinetics when vori","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":415,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"is presumably occurred because the inhibition of CYP2C19 by ","suffix":" caused EM subjects to behave in a similar fashion to PM sub","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":583,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"the systemic exposure to voriconazole when given along with ","suffix":" observed in EMs did not exceed that observed in PMs. In cli","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":814,"endOffset":825,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"of these results, it is tempting to deduce that concomitant ","suffix":" could be used as a booster to achieve therapeutic levels of","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1200,"endOffset":1211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"equire additional consideration. First, the optimum dose of ","suffix":" needed to boost voriconazole levels is currently unknown. S","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1278,"endOffset":1289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" to boost voriconazole levels is currently unknown. Second, ","suffix":" alters the shape of the concentration-time curve and marked","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1643,"endOffset":1654,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" (23), especially if the patient has not responded to prior ","suffix":" therapy. Finally, there is also a greater likelihood that p","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1884,"endOffset":1895,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"gent alone. Concomitant administration of voriconazole with ","suffix":" is therefore not recommended at present until additional do","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":154,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"erns were noted during coadministration of voriconazole and ","suffix":" in healthy volunteers in the present study. However, elevat","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":542,"endOffset":553,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ssociated with a higher incidence of adverse events (13). A ","suffix":"-mediated increase in voriconazole levels would put patients","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":711,"endOffset":722,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"The PBPK model predicted that in a sequential use scenario, ","suffix":" would continue to have a substantial effect on voriconazole","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":824,"endOffset":835,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ct on voriconazole pharmacokinetics for at least 24 h after ","suffix":" discontinuation. However, it should be noted that voriconaz","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1002,"endOffset":1013,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"hat the plasma voriconazole levels seen on the first day of ","suffix":"-voriconazole sequential therapy are expected to be below th","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1155,"endOffset":1166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"te. This would diminish some of the risks associated with a ","suffix":"-mediated increase in voriconazole levels during sequential ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1379,"endOffset":1390,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"le-associated adverse events during overlapping exposure to ","suffix":", especially if the affected patients receive additional con","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":135,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" results of this study show that concomitantly administered ","suffix":" significantly increases plasma levels of voriconazole. Ther","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":232,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"lasma levels of voriconazole. Therefore, concomitant use of ","suffix":" and voriconazole is not recommended until it has been furth","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"nts is advisable if voriconazole is used sequentially after ","suffix":", especially when voriconazole is initiated within 24 h of t","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ice, antifungal therapy may be switched from fluconazole to ","suffix":"; such sequential use poses the potential for drug interacti","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":274,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ue to cytochrome P450 2C19 (CYP2C19)-mediated inhibition of ","suffix":" metabolism. This open-label, randomized, two-way crossover ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":406,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"study investigated the effect of concomitant fluconazole on ","suffix":" pharmacokinetics in 10 subjects: 8 extensive metabolizers a","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":542,"endOffset":554,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" poor metabolizers of CYP2C19. The study consisted of 4-day ","suffix":"-only and 5-day voriconazole-plus-fluconazole treatments, se","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":570,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"9. The study consisted of 4-day voriconazole-only and 5-day ","suffix":"-plus-fluconazole treatments, separated by a 14-day washout.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":643,"endOffset":655,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"plus-fluconazole treatments, separated by a 14-day washout. ","suffix":" pharmacokinetics were determined by noncompartmental analys","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":933,"endOffset":945,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"n should antifungal therapy be switched from fluconazole to ","suffix":", following various simulated lag times for the switch. In C","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1155,"endOffset":1167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"the area under the plasma concentration-time curve (AUC) of ","suffix":" by 57% and 178%, respectively. In poor metabolizers, howeve","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1230,"endOffset":1242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 57% and 178%, respectively. In poor metabolizers, however, ","suffix":" pharmacokinetics were unaffected by fluconazole. The simula","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1360,"endOffset":1372,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lations based on pharmacokinetic modeling predicted that if ","suffix":" was started 6, 12, 24, or 36 h after the last dose of fluco","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1444,"endOffset":1456,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 6, 12, 24, or 36 h after the last dose of fluconazole, the ","suffix":" AUC ratios (sequential therapy versus voriconazole only) af","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1495,"endOffset":1507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ole, the voriconazole AUC ratios (sequential therapy versus ","suffix":" only) after the first dose would be 1.51, 1.41, 1.28, and 1","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1687,"endOffset":1699,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" fluconazole would result in a marked drug interaction with ","suffix":" for ≥24 h. Although no safety issues were observed during c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1811,"endOffset":1823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"during coadministration, concomitant use of fluconazole and ","suffix":" is not recommended. Frequent monitoring for voriconazole-re","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1868,"endOffset":1880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"nd voriconazole is not recommended. Frequent monitoring for ","suffix":"-related adverse events is advisable if voriconazole is used","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":454,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"s for a substantial part of the intersubject variability in ","suffix":" pharmacokinetics (22, 29, 30). Voriconazole metabolism may ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":498,"endOffset":510,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" variability in voriconazole pharmacokinetics (22, 29, 30). ","suffix":" metabolism may also be influenced by the concomitant admini","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":336,"endOffset":348,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"d be administered together as combination therapy. However, ","suffix":" may be used sequentially after fluconazole in clinical prac","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":631,"endOffset":643,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" who subsequently develop invasive aspergillosis, for which ","suffix":" is regarded the treatment of choice (18, 26, 28). To a less","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":914,"endOffset":926,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" The rationale for a therapeutic switch from fluconazole to ","suffix":" is supported by in vitro and in vivo data showing good acti","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":994,"endOffset":1006,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"orted by in vitro and in vivo data showing good activity of ","suffix":" against many fluconazole-resistant Candida strains, even th","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1133,"endOffset":1145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ere is some azole cross-resistance (14, 15, 21). In Europe, ","suffix":" is specifically approved for the treatment of fluconazole-r","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":145,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"C19 inhibitor (27), and its systemic presence could inhibit ","suffix":" metabolism and potentially increase the frequency of vorico","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":211,"endOffset":223,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"nazole metabolism and potentially increase the frequency of ","suffix":"-related adverse events. In the treatment of serious and lif","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":354,"endOffset":366,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ng fungal infections requiring a switch from fluconazole to ","suffix":", it may not be feasible to delay voriconazole therapy to al","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":400,"endOffset":412,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"luconazole to voriconazole, it may not be feasible to delay ","suffix":" therapy to allow sufficient time for fluconazole washout. T","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":117,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"To examine these issues, we studied the pharmacokinetics of ","suffix":" when coadministered with fluconazole to assess the maximal ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":242,"endOffset":254,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"aximal impact of fluconazole-mediated CYP2C19 inhibition on ","suffix":" levels. A physiologically based pharmacokinetic (PBPK) mode","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":422,"endOffset":434,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"xtent/magnitude of the drug interaction in situations where ","suffix":" therapy is initiated after various lag times following fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"he study was divided into two treatments, a 4-day period of ","suffix":"-only treatment and a 5-day period of voriconazole-plus-fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":172,"endOffset":184,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"period of voriconazole-only treatment and a 5-day period of ","suffix":"-plus-fluconazole combination treatment, separated by a 14-d","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":403,"endOffset":415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" All treatments were administered orally in a fasted state. ","suffix":" was given as a loading dose of 400 mg orally twice daily (e","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":251,"endOffset":263,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"48 h after dosing on day 4. Plasma samples were assayed for ","suffix":" by a previously validated method using automated solid-phas","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":620,"endOffset":632,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" extensive metabolizers (EMs) or poor metabolizers (PMs) of ","suffix":" and was compared between voriconazole alone and the voricon","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":658,"endOffset":670,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"metabolizers (PMs) of voriconazole and was compared between ","suffix":" alone and the voriconazole-plus-fluconazole combination. Al","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":685,"endOffset":697,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"onazole and was compared between voriconazole alone and the ","suffix":"-plus-fluconazole combination. All statistical analyses were","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":310,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"Simcyp Ltd., Sheffield, United Kingdom). A Simcyp model for ","suffix":" was developed using the physicochemical properties, in vitr","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"th sexes. The dose, dosing interval, and dosing duration of ","suffix":" and fluconazole in the simulation were identical to those u","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":412,"endOffset":424,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"identical to those used in the clinical study. Accordingly, ","suffix":" alone was dosed every 12 h for 4 days (first two doses of 4","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":536,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"ses of 400 mg and subsequent five doses of 200 mg each), or ","suffix":" was coadministered with fluconazole (first fluconazole dose","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":746,"endOffset":758,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"uential dosing, fluconazole dosing remained the same, while ","suffix":" administration was initiated at times of 6, 12, and 24 h fo","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":132,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ts (mean age, 29 years; age range, 24 to 43 years) received ","suffix":" alone followed by voriconazole plus fluconazole, and five (","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ge, 24 to 43 years) received voriconazole alone followed by ","suffix":" plus fluconazole, and five (mean age, 24 years; age range, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":260,"endOffset":272,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ve (mean age, 24 years; age range, 22 to 27 years) received ","suffix":" plus fluconazole followed by voriconazole alone. The mean w","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":302,"endOffset":314,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"7 years) received voriconazole plus fluconazole followed by ","suffix":" alone. The mean weights in the two groups were 70 kg (range","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"le by metabolizer type and by treatment group. As expected, ","suffix":" concentrations in PMs were markedly higher than those in EM","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":286,"endOffset":298,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"re markedly higher than those in EMs. The Cmax and AUC12 of ","suffix":" in PMs were approximately 2.7- and 2.5-fold higher, respect","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":198,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"cokinetics in EMs and PMs. In EMs, plasma concentrations of ","suffix":" were increased when coadministered with fluconazole compare","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":277,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ncreased when coadministered with fluconazole compared with ","suffix":" alone, while in PMs, the concentration-time profiles were s","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":484,"endOffset":496,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ased significantly when fluconazole was coadministered with ","suffix":" compared with when voriconazole was administered alone (Tab","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":516,"endOffset":528,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ole was coadministered with voriconazole compared with when ","suffix":" was administered alone (Table 2). In PMs, the pharmacokinet","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":133,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" Cmaxs and AUCs in EMs (Table 2). In this group, the coeffic","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":227,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":" (Table 2). In this group, the coefficient of variations in ","suffix":" pharmacokinetic parameters ranged from 18.7 to 34.9% for vo","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":297,"endOffset":309,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"le pharmacokinetic parameters ranged from 18.7 to 34.9% for ","suffix":" plus fluconazole, whereas they ranged from 37.8 to 62.0% fo","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"rmacokinetic parameters were used to build a PBPK model for ","suffix":" using Simcyp. Figure 2 shows the predicted plasma concentra","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":237,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"cyp. Figure 2 shows the predicted plasma concentrations for ","suffix":" in EMs and PMs using a dosing regimen identical to that use","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":379,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"linical study. For EMs, these simulations predicted ratios (","suffix":" plus fluconazole versus fluconazole alone) of 2.65 (95% CI,","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":502,"endOffset":514,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":" (95% CI, 1.33 to 5.85) and 1.40 (95% CI, 1.14 to 2.20) for ","suffix":" AUCt and Cmax, respectively. However, no significant effect","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":145,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" carried out to evaluate the effect of sequential dosing of ","suffix":" following termination of fluconazole therapy. The doses of ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":296,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" the same as in the clinical study, with the exception that ","suffix":" was initiated sequentially at various time intervals (6, 12","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":535,"endOffset":547,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"on day 1, followed by 200 mg every 24 h on days 2 to 5, and ","suffix":" was initiated sequentially at doses of 400 mg every 12 h on","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":764,"endOffset":776,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"est from these simulations were the Cmax and AUC values for ","suffix":" after the first loading dose of 400 mg, since this represen","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":904,"endOffset":916,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"e the maintenance dose of 200 mg and could result in higher ","suffix":" concentrations due to fluconazole-mediated interaction. The","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1011,"endOffset":1023,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"mediated interaction. The predicted Cmax and AUC values for ","suffix":" and their ratios (voriconazole after fluconazole versus vor","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1042,"endOffset":1054,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"cted Cmax and AUC values for voriconazole and their ratios (","suffix":" after fluconazole versus voriconazole alone) are presented ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1080,"endOffset":1092,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"ole and their ratios (voriconazole after fluconazole versus ","suffix":" alone) are presented in Table 3. The predicted Cmaxs were c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1221,"endOffset":1233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" for both treatments; however, the predicted AUC values for ","suffix":" were higher when this antifungal was given sequentially aft","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1318,"endOffset":1330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"tifungal was given sequentially after fluconazole than when ","suffix":" was given alone. For instance, the voriconazole AUC ratio w","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1366,"endOffset":1378,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"e than when voriconazole was given alone. For instance, the ","suffix":" AUC ratio was 1.51 when voriconazole was started 6 h after ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1403,"endOffset":1415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"one. For instance, the voriconazole AUC ratio was 1.51 when ","suffix":" was started 6 h after the last dose of fluconazole, indicat","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1880,"endOffset":1892,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"esults suggest that the inhibitory effect of fluconazole on ","suffix":" metabolism would last for at least 24 h after the last dose","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":593,"endOffset":605,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ly fewer adverse events were reported during treatment with ","suffix":" plus fluconazole (14 versus 11 treatment-related adverse ev","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" suggest that concomitant administration of fluconazole and ","suffix":" significantly increases plasma voriconazole concentrations ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":195,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"fluconazole and voriconazole significantly increases plasma ","suffix":" concentrations in CYP2C19 EMs. Although the sample size was","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":307,"endOffset":319,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" the sample size was small for PMs, the pharmacokinetics of ","suffix":" appeared to be unaffected by fluconazole in that population","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1171,"endOffset":1183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ted that the influence of fluconazole on systemic levels of ","suffix":" would persist for at least 24 h after the last dose of fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" as a moderate inhibitor of CYP3A4. Fluconazole's effect on ","suffix":" pharmacokinetics is probably due to its inhibition of CPY2C","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":278,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"inetics is probably due to its inhibition of CPY2C19, since ","suffix":" metabolism is mainly mediated by CYP2C19, followed by CYP3A","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":616,"endOffset":628,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" study, concomitant omeprazole increased the average AUC of ","suffix":" by about 40% (32); however, the magnitude of this increase ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":724,"endOffset":736,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"nitude of this increase does not require adjustments in the ","suffix":" dose when coadministered with omeprazole (17). In contrast,","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":165,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"an volunteers, the considerable intersubject variability in ","suffix":" pharmacokinetics was reduced when voriconazole was coadmini","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":212,"endOffset":224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"riability in voriconazole pharmacokinetics was reduced when ","suffix":" was coadministered with fluconazole compared with the varia","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":316,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"zole compared with the variability in pharmacokinetics when ","suffix":" was administered alone. This presumably occurred because th","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":548,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"cts in this respect. Nevertheless, the systemic exposure to ","suffix":" when given along with fluconazole observed in EMs did not e","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":670,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" did not exceed that observed in PMs. In clinical practice, ","suffix":" is administered to both EMs and PMs at an identical dose. O","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":886,"endOffset":898,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"could be used as a booster to achieve therapeutic levels of ","suffix":" with doses lower than those currently recommended, to allow","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":970,"endOffset":982,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"lower than those currently recommended, to allow once-daily ","suffix":" dosing, or to reduce the intersubject variability in vorico","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1036,"endOffset":1048,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"nazole dosing, or to reduce the intersubject variability in ","suffix":" pharmacokinetics. Although this approach seems attractive, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1228,"endOffset":1240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ion. First, the optimum dose of fluconazole needed to boost ","suffix":" levels is currently unknown. Second, fluconazole alters the","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1362,"endOffset":1374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"hape of the concentration-time curve and markedly increases ","suffix":" trough concentrations, which have been linked to a higher i","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1446,"endOffset":1458,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"entrations, which have been linked to a higher incidence of ","suffix":"-associated toxicity (24). Third, an additional microbiologi","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1866,"endOffset":1878,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"than with either agent alone. Concomitant administration of ","suffix":" with fluconazole is therefore not recommended at present un","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":2036,"endOffset":2048,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e conducted to evaluate the efficacy and safety of specific ","suffix":"-plus-fluconazole dosing regimens in the relevant therapeuti","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"icant safety concerns were noted during coadministration of ","suffix":" and fluconazole in healthy volunteers in the present study.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":228,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" healthy volunteers in the present study. However, elevated ","suffix":" plasma levels are associated with an increased likelihood o","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":404,"endOffset":416,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" in hepatic enzymes (5, 24). Therapeutic drug monitoring of ","suffix":" suggests that trough concentrations greater than 6 μg/ml ma","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":575,"endOffset":587,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" of adverse events (13). A fluconazole-mediated increase in ","suffix":" levels would put patients at risk of exceeding this thresho","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":770,"endOffset":782,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" fluconazole would continue to have a substantial effect on ","suffix":" pharmacokinetics for at least 24 h after fluconazole discon","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":886,"endOffset":898,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"uconazole discontinuation. However, it should be noted that ","suffix":" accumulates after multiple dosing (7) and that the plasma v","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":957,"endOffset":969,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"e accumulates after multiple dosing (7) and that the plasma ","suffix":" levels seen on the first day of fluconazole-voriconazole se","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1014,"endOffset":1026,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ma voriconazole levels seen on the first day of fluconazole-","suffix":" sequential therapy are expected to be below those seen at s","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1188,"endOffset":1200,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"he risks associated with a fluconazole-mediated increase in ","suffix":" levels during sequential use in clinical practice. However,","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1309,"endOffset":1321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"e. However, it is prudent to regularly monitor patients for ","suffix":"-associated adverse events during overlapping exposure to fl","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1503,"endOffset":1515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"nal concomitant drugs that inhibit CYP isozymes involved in ","suffix":" metabolism. This is not an unlikely scenario, given the oft","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":188,"endOffset":200,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"stered fluconazole significantly increases plasma levels of ","suffix":". Therefore, concomitant use of fluconazole and voriconazole","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"voriconazole. Therefore, concomitant use of fluconazole and ","suffix":" is not recommended until it has been further evaluated in c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":360,"endOffset":372,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"rther evaluated in clinical trials. Frequent monitoring for ","suffix":"-related adverse events is advisable if voriconazole is used","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":412,"endOffset":424,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ing for voriconazole-related adverse events is advisable if ","suffix":" is used sequentially after fluconazole, especially when vor","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"advantage","startOffset":190,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"f the combination of both drugs does not appear to offer an ","suffix":" over use of the single agents (23); therefore, it is unlike","exact":"advantage"},{"setid":"PMC3195022","drugname":"acetaminophen","startOffset":513,"endOffset":526,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"taken any prescribed or over-the-counter medication (except ","suffix":") within 3 weeks of starting the study; had received any exp","exact":"acetaminophen"},{"setid":"PMC3195022","drugname":"omeprazole","startOffset":411,"endOffset":421,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":", with CYP2C9 appearing to play only a minimal role (3, 9). ","suffix":" is another potent competitive inhibitor of CYP2C19 (Ki, 3.1","exact":"Omeprazole"},{"setid":"PMC3195022","drugname":"omeprazole","startOffset":576,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"on CYP3A4 (Ki, 84 μM) (6). In a previous study, concomitant ","suffix":" increased the average AUC of voriconazole by about 40% (32)","exact":"omeprazole"},{"setid":"PMC3195022","drugname":"omeprazole","startOffset":767,"endOffset":777,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"justments in the voriconazole dose when coadministered with ","suffix":" (17). In contrast, fluconazole inhibits CYP2C19 and CYP3A4 ","exact":"omeprazole"}],[{"setid":"PMC3900249","drugname":"amiodarone","startOffset":298,"endOffset":308,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ange in warfarin dose requirement. To evaluate the roles of ","suffix":" and its circulating metabolites in this highly variable inh","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":334,"endOffset":344,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"(3′-OHMDEA), N,N-didesethylamiodarone (DDEA) and deaminated ","suffix":" (DAA). Another potential product of AMIO metabolism is the ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":243,"endOffset":253,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":" dose change required to maintain an INR of 2.0 - 3.0 after ","suffix":" was added or discontinued in a cohort of patients undergoin","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":416,"endOffset":426,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":" fraction. The plasma free fractions for the metabolites of ","suffix":" - MDEA, 3′-OHMDEA, DDEA, ODAA and DAA, which varied from ~0","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":338,"endOffset":348,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"in which an out-of-range INR was attributed to the warfarin-","suffix":" drug interaction were identified. These incidents were asso","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":442,"endOffset":452,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":" These incidents were associated with 163 episodes in which ","suffix":" was added or discontinued in patients taking warfarin, or i","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":524,"endOffset":534,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"r discontinued in patients taking warfarin, or in which the ","suffix":" dose was changed. Of these 163 episodes, 90 were excluded f","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":668,"endOffset":678,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ue to either unstable warfarin therapy prior to addition of ","suffix":" (n=40), an interaction due to change in amiodarone dose (n=","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":719,"endOffset":729,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ition of amiodarone (n=40), an interaction due to change in ","suffix":" dose (n=27); warfarin and amiodarone having been initiated ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":756,"endOffset":766,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ction due to change in amiodarone dose (n=27); warfarin and ","suffix":" having been initiated concurrently (n=14), the duration of ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":846,"endOffset":856,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ed concurrently (n=14), the duration of concurrent warfarin/","suffix":" therapy being less than 1 month (n=6) or no records availab","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":345,"endOffset":355,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","prefix":"ing us with blood samples from patients undergoing warfarin/","suffix":" therapy. This work was supported by the National Institutes","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":246,"endOffset":254,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ion/elimination of amiodarone resulted in a 6-65% change in ","suffix":" dose requirement. To evaluate the roles of amiodarone and i","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":627,"endOffset":635,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"l standards. KI's were determined for the inhibition of (S)-","suffix":" 7-hydroxylation in human liver microsomes, by parent drug a","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":777,"endOffset":785,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"exhibits is its potentiation of the anticoagulant effect of ","suffix":", which greatly increases the patient's risk of hemorrhage (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":199,"endOffset":207,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"F). Stroke is a major concern in patients with AF and since ","suffix":" is the preferred treatment for stroke prevention, AMIO is t","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":303,"endOffset":311,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ke prevention, AMIO is therefore often co-administered with ","suffix":" (14). An interaction always occurs between these two drugs ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":428,"endOffset":436,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"gs (15, 16) that typically necessitates a dose reduction in ","suffix":" of 25-40% depending on the amiodarone maintenance dose (15,","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":173,"endOffset":181,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"rated that AMIO inhibits the clearance of both (S)- and (R)-","suffix":" (17) and decreases the formation clearances of (S)-warfarin","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":233,"endOffset":241,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"warfarin (17) and decreases the formation clearances of (S)-","suffix":" metabolites to a greater extent than (R)-warfarin metabolit","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":283,"endOffset":291,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"es of (S)-warfarin metabolites to a greater extent than (R)-","suffix":" metabolites (18). However, AMIO proved to be a relatively w","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":372,"endOffset":380,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"wever, AMIO proved to be a relatively weak inhibitor of (S)-","suffix":" metabolism in human liver microsomes (HLM) (18) and AMIO's ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":694,"endOffset":702,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" major P450 that terminates the pharmacological activity of ","suffix":" (21). Moreover, MDEA is present in human plasma at a concen","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":1100,"endOffset":1108,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"vations prompt the hypothesis that a major mechanism of the ","suffix":"-AMIO interaction is inhibition of CYP2C9-mediated (S)-warfa","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":531,"endOffset":539,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"ore of these minor AMIO metabolites could contribute to the ","suffix":" drug interaction and, in fact, several close analogs of ODA","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":175,"endOffset":183,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"spective study was performed to determine mean and range of ","suffix":" dose change required to maintain an INR of 2.0 - 3.0 after ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":322,"endOffset":330,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"d or discontinued in a cohort of patients undergoing stable ","suffix":" therapy. Next, stabilized plasma concentrations, [I], of AM","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":460,"endOffset":468,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"e of its circulating metabolites were determined in several ","suffix":" patients undergoing combination therapy. In order to measur","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":846,"endOffset":854,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"s metabolites to measure the KI against CYP2C9-mediated (S)-","suffix":" 7-hydroxylation in HLM. To best assess the likelihood of an","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":239,"endOffset":247,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ers of our analysis for an out of range INR attributed to a ","suffix":"-AMIO drug interaction which occurred upon either addition o","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":367,"endOffset":375,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"r elimination of AMIO therapy to patients undergoing stable ","suffix":" treatment. Results of the analysis are described in Table 1","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":456,"endOffset":464,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"f the analysis are described in Table 1. The mean change in ","suffix":" dose required to maintain an INR of 2-3 was 25.6%. Warfarin","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":516,"endOffset":524,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"warfarin dose required to maintain an INR of 2-3 was 25.6%. ","suffix":" dosing change requirements were highly variable, with a ran","exact":"Warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":256,"endOffset":264,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"s in the plasma of clinical patients undergoing concomitant ","suffix":" and AMIO therapy (Figure 2). Blood was drawn from three pat","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":539,"endOffset":547,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"ound 8 weeks after addition of AMIO therapy to a stabilized ","suffix":" regime (Figure 3), therefore, average drug and metabolite p","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":200,"endOffset":208,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"tion and to measure the KI values for the inhibition of (S)-","suffix":" metabolism by AMIO and its metabolites, in pooled HLM. Both","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":360,"endOffset":368,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"e 4B) were found to be purely competitive inhibitors of (S)-","suffix":" 7-hydroxylation, with KI's of 0.032 ± 0.006 and 2.0 ± 0.3 μ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":521,"endOffset":529,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":", DDEA and 3′-OHMDEA all appeared to be mixed inhibitors of ","suffix":" metabolism in HLM (Figure 4C-F). The respective KI values f","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":169,"endOffset":177,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"mpounds were carried out in the presence of either 4 μM (S)-","suffix":", for studies in HLM, or 2 μg/mL rac-warfarin (approximate p","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":214,"endOffset":222,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"ither 4 μM (S)-warfarin, for studies in HLM, or 2 μg/mL rac-","suffix":" (approximate physiological concentration), for studies in h","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":295,"endOffset":303,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" physiological concentration), for studies in human plasma. ","suffix":" was found not to affect metabolite protein binding in eithe","exact":"Warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":312,"endOffset":320,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" in vitro KI (apparent), measured for the inhibition of (S)-","suffix":" 7-hydroxylation in HLM, was calculated to be 0.028, 0.20, 1","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":183,"endOffset":191,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"bition of the P450 enzymes responsible for the clearance of ","suffix":", mainly CYP2C9 (18). In patient studies, we confirmed (i) t","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":312,"endOffset":320,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"e wide inter-individual variability in the magnitude of the ","suffix":"-AMIO interaction reported initially by Kerin et al., (15), ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":227,"endOffset":235,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"5.9, 5.2, 0.053, 0.032 and 2.0 μM for the inhibition of (S)-","suffix":" 7-hydroxylation by AMIO, MDEA, 3′-OHMDEA, DDEA, ODAA and DA","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":378,"endOffset":386,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"A, and the alcohol, DAA, were competitive inhibitors of (S)-","suffix":" metabolism in HLM while the amine compounds AMIO, MDEA, 3′-","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":491,"endOffset":499,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"AMIO, MDEA, 3′-OHMDEA and DDEA were mixed inhibitors of (S)-","suffix":" 7-hydroxylation (Figure 4). Ohyama, et al., previously repo","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":642,"endOffset":650,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"mpetitive inhibitor and MDEA to be a mixed inhibitor of (S)-","suffix":" metabolism in microsomes derived from human B-lymphoblastoi","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":960,"endOffset":968,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":"judged as unlikely to contribute to the potentiation of the ","suffix":" anticoagulant effect. Also, though warfarin binds very stro","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":1004,"endOffset":1012,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":"ntiation of the warfarin anticoagulant effect. Also, though ","suffix":" binds very strongly to plasma (fu(serum) = 0.008) (37), the","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":106,"endOffset":114,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"           The overall change in intrinsic clearance of (S)-","suffix":" caused by the drug interaction with AMIO can be predicted a","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":165,"endOffset":173,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"ntration vs time curve (AUC) is therefore predicted for (S)-","suffix":" clearance based on the sum of the [I]/KI ratios of the pare","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":101,"endOffset":109,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"                The actual increase in the mean AUC for (S)-","suffix":" caused by the drug interaction with AMIO has been reported ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":204,"endOffset":212,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"h AMIO has been reported to range from 27 to 110% in single ","suffix":" dose studies carried out in small groups (n = 5 or 6) of he","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":440,"endOffset":448,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"continuation of AMIO therapy results in a 6 - 65% change in ","suffix":" dose requirement is in good agreement with this clearance d","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":398,"endOffset":406,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"bolite to potentiate the anticoagulant effect when AMIO and ","suffix":" are given in combination, even though AMIO plasma concentra","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":216,"endOffset":224,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"patient anticoagulation management for 3129 patients taking ","suffix":". During this 6 year period, a total of 230 incidents in whi","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":329,"endOffset":337,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ncidents in which an out-of-range INR was attributed to the ","suffix":"-amiodarone drug interaction were identified. These incident","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":498,"endOffset":506,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ich amiodarone was added or discontinued in patients taking ","suffix":", or in which the amiodarone dose was changed. Of these 163 ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":630,"endOffset":638,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"odes, 90 were excluded from analysis due to either unstable ","suffix":" therapy prior to addition of amiodarone (n=40), an interact","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":743,"endOffset":751,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"0), an interaction due to change in amiodarone dose (n=27); ","suffix":" and amiodarone having been initiated concurrently (n=14), t","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":837,"endOffset":845,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"n initiated concurrently (n=14), the duration of concurrent ","suffix":"/amiodarone therapy being less than 1 month (n=6) or no reco","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":529,"endOffset":537,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":" patients resulted in a 33, 40 or 71% reduction in required ","suffix":" dose. All patients gave informed consent for the study whic","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":410,"endOffset":418,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"v/v of a 100x concentrated methanolic inhibitor stock and S-","suffix":", added as substrate (at 1, 4 or 16 μM final concentration),","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":93,"endOffset":101,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"                            HLMs were preincubated with (S)-","suffix":", inhibitor and buffer at 37°C and 70 rpm in a water bath fo","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":336,"endOffset":344,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","prefix":"in providing us with blood samples from patients undergoing ","suffix":"/amiodarone therapy. This work was supported by the National","exact":"warfarin"},{"setid":"PMC3900249","drugname":"theophylline","startOffset":537,"endOffset":549,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"her with a wide range of other therapeutic agents including ","suffix":" (8), flecainide (9), cyclosporine A (10, 11) and dextrometh","exact":"theophylline"},{"setid":"PMC3900249","drugname":"flecainide","startOffset":555,"endOffset":565,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"nge of other therapeutic agents including theophylline (8), ","suffix":" (9), cyclosporine A (10, 11) and dextromethorphan (12). How","exact":"flecainide"},{"setid":"PMC3900249","drugname":"cyclosporine a","startOffset":571,"endOffset":585,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"rapeutic agents including theophylline (8), flecainide (9), ","suffix":" (10, 11) and dextromethorphan (12). However, the most commo","exact":"cyclosporine A"},{"setid":"PMC3900249","drugname":"dextromethorphan","startOffset":599,"endOffset":615,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eophylline (8), flecainide (9), cyclosporine A (10, 11) and ","suffix":" (12). However, the most common, as well as potentially the ","exact":"dextromethorphan"},{"setid":"PMC3900249","drugname":"ethane","startOffset":849,"endOffset":855,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"e both derived from unlabeled ODAA utilizing 1,2-dibromo-d4-","suffix":" as the deuterium source (Scheme 1B). These procedures provi","exact":"ethane"},{"setid":"PMC3900249","drugname":"phenol","startOffset":307,"endOffset":313,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"tion by AMIO, MDEA, 3′-OHMDEA, DDEA, ODAA and DAA. Both the ","suffix":", ODAA, and the alcohol, DAA, were competitive inhibitors of","exact":"phenol"},{"setid":"PMC3900249","drugname":"diclofenac","startOffset":1103,"endOffset":1113,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"9) found AMIO and MDEA to be (weak) MBIs of CYP2C9-mediated ","suffix":" 4′-hydroxylation, both exhibiting KI's of inactivation of ~","exact":"diclofenac"},{"setid":"PMC3900249","drugname":"potassium phosphate","startOffset":522,"endOffset":541,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":" concentration), made up to 200 μL total volume with 100 mM ","suffix":" buffer, pH 7.4. The concentrations of inhibitor used in the","exact":"potassium phosphate"}],[{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":195,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","prefix":" sampling for pharmacokinetics on day 3. Subjects took only ","suffix":" 1250 mg twice daily on days 4-12. On days 13-15, subjects c","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":274,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","prefix":"twice daily on days 4-12. On days 13-15, subjects continued ","suffix":" and reinitiated pravastatin. Plasma samples were collected ","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":344,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","prefix":"ions were also lower when pravastatin was administered with ","suffix":". Median values for the maximum plasma concentrations were 2","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":431,"endOffset":441,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"gly, even in this study, the short-course administration of ","suffix":" in healthy HIV-seronegative subjects was associated with a ","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":182,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"us drug-drug interactions, is associated with dyslipidemia. ","suffix":" is the preferred statin prescribed for HIV-associated dysli","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":301,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","prefix":"n days 13-15, subjects continued nelfinavir and reinitiated ","suffix":". Plasma samples were collected over 24 h for the calculatio","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":377,"endOffset":388,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[4]","prefix":"sma samples were collected over 24 h for the calculation of ","suffix":" area under the concentration-time curve for 0-24 h on days ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":206,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","prefix":"or analysis. The median within-subject percentage change in ","suffix":" AUC was a decrease of 46.5%. Pravastatin maximum plasma con","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":247,"endOffset":258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","prefix":"rcentage change in pravastatin AUC was a decrease of 46.5%. ","suffix":" maximum plasma concentrations were also lower when pravasta","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":310,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[5]","prefix":"vastatin maximum plasma concentrations were also lower when ","suffix":" was administered with nelfinavir. Median values for the max","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":155,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[6]","prefix":"ravastatin and nelfinavir led to a substantial reduction in ","suffix":" plasma concentrations. Higher doses of pravastatin may need","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":206,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[6]","prefix":"ction in pravastatin plasma concentrations. Higher doses of ","suffix":" may need to be prescribed in order to achieve optimal lipid","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":622,"endOffset":633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"tin exposure was also increased by CYP3A4 inhibitors [2,3]. ","suffix":" was likely to be safe when coadministered with ritonavir/sa","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":765,"endOffset":776,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ause, instead of an increase, we observed a 50% decrease in ","suffix":" area under the concentration-time curve (AUC). Although we ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":853,"endOffset":864,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"oncentration-time curve (AUC). Although we also showed that ","suffix":" did not alter NFV pharmacokinetics, we did not examine the ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":941,"endOffset":952,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"V pharmacokinetics, we did not examine the effect of NFV on ","suffix":" pharmacokinetics. More recently, we have demonstrated that ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":118,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"he mechanism by which these drugs reduce plasma exposure to ","suffix":" is unknown, but this drug-drug interaction is of concern be","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" drug-drug interaction is of concern because a reduction in ","suffix":" plasma concentration may adversely affect the drug's abilit","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":551,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"n inhibitor of CYP3A4 but an inducer of other CYP isoforms. ","suffix":" metabolism is complex, utilizing both oxidative and conjuga","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":785,"endOffset":796,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ines the hypothesis that NFV would have a similar effect on ","suffix":" pharmacokinetics as ritonavir/saquinavir.\n                 ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":279,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" examine the effect of efavirenz on the pharmacokinetics of ","suffix":", atorvastatin, and simvastatin and the effect of NFV on the","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":371,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"imvastatin and the effect of NFV on the pharmacokinetics of ","suffix":". The efavirenz-statin interactions were recently published ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":523,"endOffset":534,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ed here address the effect of NFVon the pharmacokinetics of ","suffix":". At the time of this study design, NFV was the most commonl","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":170,"endOffset":181,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"y in the morning for the first 3 days and on the fourth day ","suffix":" was administered under observation. Blood samples were obta","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":346,"endOffset":357,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"5, 1, 2, 3, 4, 6, 8, 12, and 24 h after administration, for ","suffix":" pharmacokinetics. On days 4 through 12, subjects took NFV 1","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":508,"endOffset":519,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"On days 13 through 15, subjects continued NFV and restarted ","suffix":" with the morning dose of NFV. On day 16, pravastatin and NF","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":561,"endOffset":572,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"tarted pravastatin with the morning dose of NFV. On day 16, ","suffix":" and NFV doses were administered under observation and sampl","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":664,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" under observation and samples were collected over 24 h for ","suffix":" pharmacokinetics. Fasting serum total cholesterol, triglyce","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":853,"endOffset":864,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"s, was used to test the null hypothesis of no difference in ","suffix":" exposure before initiation of NFV versus after dosing to st","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":1051,"endOffset":1062,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"centrations of statins may be associated with toxicity [7]. ","suffix":" exposure when taken with NFV relative to when taken alone, ","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":174,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ravastatin with and without NFV are shown in Fig. 1. Median ","suffix":" AUC values on days 3 and 16 were 86.5 and 46.8 ng·h/ml, res","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":481,"endOffset":492,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"d the 90% CI around the geometric mean ratio was 0.46-0.65. ","suffix":" Cmax values were also lower when pravastatin was administer","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":526,"endOffset":537,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"was 0.46-0.65. Pravastatin Cmax values were also lower when ","suffix":" was administered with NFV. Median Cmax values were 27.9 and","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":344,"endOffset":355,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"on signed rank test). Median (mean) changes after 3 days of ","suffix":" administration were -200 mg/l (mean, -195) from day 0 to da","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":524,"endOffset":535,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"y 16, for a median difference in within-subject response to ","suffix":" of 28 mg/l (P = 0.436, Wilcoxon signed rank). The percentag","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":717,"endOffset":728,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ause the baseline LDL was increased by NFV. After 3 days of ","suffix":" administration, the median changes were -19.7% (mean, -19.8","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":913,"endOffset":924,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"y 16, for a median difference in within-subject response to ","suffix":" of 6.7% (mean, 5.5). This difference was not statistically ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":199,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"abolism by P4503A4 and results from studies suggesting that ","suffix":" is safe and tolerable in patients taking potent antiretrovi","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":367,"endOffset":378,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"dy, we demonstrated that ritonavir/saquinavir decreased the ","suffix":" median AUC by 50% [2]. In this study, NFV administration to","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":476,"endOffset":487,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" NFV administration to steady state reduced the exposure to ","suffix":" by a median of 46.5%. Similarly, we have also demonstrated ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":581,"endOffset":592,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"we have also demonstrated that efavirenz reduces the AUC of ","suffix":" [4].This reduction in exposure may compromise the effective","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":660,"endOffset":671,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s reduction in exposure may compromise the effectiveness of ","suffix":" in patients taking certain PI drugs or efavirenz. Although ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":793,"endOffset":804,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"r study was not adequately powered nor designed to evaluate ","suffix":"'s effectiveness in lowering LDL, we did note a trend sugges","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":151,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" concentrations are reduced is not known. The metabolism of ","suffix":" is complex. Induction of non-CYP3A4 oxidation or glucuronid","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":266,"endOffset":277,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"on or glucuronidation may result in more rapid clearance of ","suffix":". In addition, hepatic transporter OATP1B1 may participate i","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":455,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ces both CYP isoforms as well as some transporters, reduced ","suffix":" exposure by a mean of 30% without affecting Cmax [14]. Howe","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":610,"endOffset":621,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"rs itraconazole and mibefradil had no significant effect on ","suffix":" AUC [15]. Gemfibrozil as well as ciclosporin have been show","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":695,"endOffset":706,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"fibrozil as well as ciclosporin have been shown to increase ","suffix":" exposure during concomitant administration, pointing to pro","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":202,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" shown mixed results. For example, in a randomized trial of ","suffix":" versus fenofibrate for combined HIV-associated dyslipidemia","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":312,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"sociated dyslipidemia, only 36% of subjects receiving 40 mg ","suffix":" daily met the LDL goal (median 20% decrease) and 18% met th","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":523,"endOffset":534,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"domized, open-label study comparing lipid-lowering therapy (","suffix":" or bezafibrate) with a switch from PI drug to non-nucleosid","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":775,"endOffset":786,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rides of 45.8%, 39.5%, and 41.2%, respectively, after 20 mg ","suffix":" daily for 12 months. Interestingly, 55% of subjects receivi","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":849,"endOffset":860,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ily for 12 months. Interestingly, 55% of subjects receiving ","suffix":" had normal total cholesterol at 12 months. Benesic and coll","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":975,"endOffset":986,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" colleagues [20] reported results for patients treated with ","suffix":" or fluvastatin. In 13 pravastatin-treated subjects (11 taki","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":1009,"endOffset":1020,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"for patients treated with pravastatin or fluvastatin. In 13 ","suffix":"-treated subjects (11 taking 10 mg pravastatin), a decrease ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":1055,"endOffset":1066,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"statin. In 13 pravastatin-treated subjects (11 taking 10 mg ","suffix":"), a decrease in total cholesterol levels (from 7.12 to 6.29","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":1224,"endOffset":1235,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" reported. The reduction of LDL level was only 14.4% in the ","suffix":" group, without a significant reduction in triglycerides. No","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":273,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"in and atorvastatin. The observed near 50% reduction in the ","suffix":" median AUC and a trend toward less reduction in LDL when co","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":395,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"L when coadministered with NFV suggest that higher doses of ","suffix":" may need to be prescribed to achieve optimal lipid-lowering","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":521,"endOffset":532,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ering activity. It remains unclear what the optimal dose of ","suffix":" is to achieve maximal lipid-lowering activity safely in HIV","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":726,"endOffset":737,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hat greater improvements in lipid levels may be observed if ","suffix":" doses are adjusted in the setting of agents that are known ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":387,"endOffset":398,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"known as statins. In a previous study, we demonstrated that ","suffix":" should not be used with ritonavir/saquinavir because of the","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":310,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"z on the pharmacokinetics of pravastatin, atorvastatin, and ","suffix":" and the effect of NFV on the pharmacokinetics of pravastati","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"iretroviral therapy, given its safety profile compared with ","suffix":" and atorvastatin. The observed near 50% reduction in the pr","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":423,"endOffset":432,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"y, we demonstrated that simvastatin should not be used with ","suffix":"/saquinavir because of the large increases in plasma concent","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":681,"endOffset":690,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" Pravastatin was likely to be safe when coadministered with ","suffix":"/saquinavir because, instead of an increase, we observed a 5","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":404,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" PI drugs in clinical use that is not usually combined with ","suffix":", but NFV has a similar effect on the CYP enzymes as ritonav","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":466,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tonavir, but NFV has a similar effect on the CYP enzymes as ","suffix":" in that it is an inhibitor of CYP3A4 but an inducer of othe","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":817,"endOffset":826,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ld have a similar effect on pravastatin pharmacokinetics as ","suffix":"/saquinavir.\n                                               ","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":332,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"l therapy [10]. In our previous study, we demonstrated that ","suffix":"/saquinavir decreased the pravastatin median AUC by 50% [2].","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":433,"endOffset":443,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"nstrated that simvastatin should not be used with ritonavir/","suffix":" because of the large increases in plasma concentrations fro","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":691,"endOffset":701,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"in was likely to be safe when coadministered with ritonavir/","suffix":" because, instead of an increase, we observed a 50% decrease","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":342,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"[10]. In our previous study, we demonstrated that ritonavir/","suffix":" decreased the pravastatin median AUC by 50% [2]. In this st","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":553,"endOffset":565,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ations from inhibition of CYP3A4 metabolism [2]. Similarly, ","suffix":" exposure was also increased by CYP3A4 inhibitors [2,3]. Pra","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":292,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"effect of efavirenz on the pharmacokinetics of pravastatin, ","suffix":", and simvastatin and the effect of NFV on the pharmacokinet","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"apy, given its safety profile compared with simvastatin and ","suffix":". The observed near 50% reduction in the pravastatin median ","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":1061,"endOffset":1070,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"rated that a non-nucleoside reverse transcriptase inhibitor ","suffix":", which is a CYP3A4 inducer, also reduced the plasma exposur","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":242,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"study. The primary objectives were to examine the effect of ","suffix":" on the pharmacokinetics of pravastatin, atorvastatin, and s","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":552,"endOffset":561,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" median of 46.5%. Similarly, we have also demonstrated that ","suffix":" reduces the AUC of pravastatin [4].This reduction in exposu","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":711,"endOffset":720,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"eness of pravastatin in patients taking certain PI drugs or ","suffix":". Although our study was not adequately powered nor designed","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":298,"endOffset":309,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tion may adversely affect the drug's ability to lower serum ","suffix":" effectively. NFV is one of the few PI drugs in clinical use","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":714,"endOffset":725,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" 24 h for pravastatin pharmacokinetics. Fasting serum total ","suffix":", triglycerides, and high density lipoprotein concentrations","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":685,"endOffset":696,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ors, Calza and colleagues [19] reported reductions in total ","suffix":", LDL, and triglycerides of 45.8%, 39.5%, and 41.2%, respect","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":878,"endOffset":889,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"gly, 55% of subjects receiving pravastatin had normal total ","suffix":" at 12 months. Benesic and colleagues [20] reported results ","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":1089,"endOffset":1100,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"subjects (11 taking 10 mg pravastatin), a decrease in total ","suffix":" levels (from 7.12 to 6.29 mmol/l) after 12 weeks of therapy","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"alanine","startOffset":542,"endOffset":549,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"wo had grade 2 gastrointestinal complaints, one had grade 3 ","suffix":" aminotransferase and grade 2 aspartate aminotransferase on ","exact":"alanine"},{"setid":"PMC1459289","drugname":"rifampin","startOffset":375,"endOffset":383,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"P1B1 may participate in increased drug elimination [11-13]. ","suffix":", which induces both CYP isoforms as well as some transporte","exact":"Rifampin"},{"setid":"PMC1459289","drugname":"itraconazole","startOffset":553,"endOffset":565,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"without affecting Cmax [14]. However, the CYP3A4 inhibitors ","suffix":" and mibefradil had no significant effect on pravastatin AUC","exact":"itraconazole"},{"setid":"PMC1459289","drugname":"mibefradil","startOffset":570,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" Cmax [14]. However, the CYP3A4 inhibitors itraconazole and ","suffix":" had no significant effect on pravastatin AUC [15]. Gemfibro","exact":"mibefradil"},{"setid":"PMC1459289","drugname":"gemfibrozil","startOffset":632,"endOffset":643,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"befradil had no significant effect on pravastatin AUC [15]. ","suffix":" as well as ciclosporin have been shown to increase pravasta","exact":"Gemfibrozil"},{"setid":"PMC1459289","drugname":"ciclosporin","startOffset":655,"endOffset":666,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"cant effect on pravastatin AUC [15]. Gemfibrozil as well as ","suffix":" have been shown to increase pravastatin exposure during con","exact":"ciclosporin"},{"setid":"PMC1459289","drugname":"fenofibrate","startOffset":221,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"s. For example, in a randomized trial of pravastatin versus ","suffix":" for combined HIV-associated dyslipidemia, only 36% of subje","exact":"fenofibrate"},{"setid":"PMC1459289","drugname":"bezafibrate","startOffset":538,"endOffset":549,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"abel study comparing lipid-lowering therapy (pravastatin or ","suffix":") with a switch from PI drug to non-nucleoside reverse trans","exact":"bezafibrate"},{"setid":"PMC1459289","drugname":"fluvastatin","startOffset":990,"endOffset":1001,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"] reported results for patients treated with pravastatin or ","suffix":". In 13 pravastatin-treated subjects (11 taking 10 mg pravas","exact":"fluvastatin"}],[{"setid":"PMC3681953","drugname":"simvastatin","startOffset":726,"endOffset":737,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"rome P450 3A4 (CYP3A4) and CYP3A5 in the gut and liver, and ","suffix":" is mainly metabolized by CYP3A4 and CYP3A5 but also by CYP2","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":459,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"tic wild-type patients taking stable doses of atorvastatin, ","suffix":", or lovastatin for optimal lipid control [6]. Another study","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":253,"endOffset":264,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"cent clinical studies suggest a more significant role [11]. ","suffix":" exposure was higher for CYP3A5*3 homozygotes compared with ","exact":"Simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"ys only a secondary role in the metabolism of atorvastatin, ","suffix":", and lovastatin. Nonetheless, our current investigation int","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":366,"endOffset":377,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"Median, first quartile, and third quartile of atorvastatin, ","suffix":", and lovastatin dose were determined for each combined geno","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":656,"endOffset":667,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":". Potency differences were accounted for by normalizing the ","suffix":" and lovastatin doses to atorvastatin-equivalent doses (i.e.","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":729,"endOffset":740,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"nd lovastatin doses to atorvastatin-equivalent doses (i.e., ","suffix":" and lovastatin have 83% and 58% the potency, respectively, ","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":941,"endOffset":952,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"each dose level are listed in Table 2. For atorvastatin and ","suffix":", the highest percentages of individuals in the PM group app","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":1295,"endOffset":1306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" from expected (0.33, 0.33, 0.33) for both atorvastatin and ","suffix":", p = 0.034 and p = 1.7E-6, respectively. The proportions fo","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":1419,"endOffset":1430,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ions for EMs were significantly different from expected for ","suffix":" only, p = 0.04.\n                                           ","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":259,"endOffset":270,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":" was inferior to the single-gene approach for atorvastatin, ","suffix":", and for the combined statin analysis: the p-values for the","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":483,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ively, for atorvastatin; 0.036 and 0.185, respectively, for ","suffix":"; and 0.014 and 0.044, respectively, for the combined statin","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":351,"endOffset":361,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"g optimal lipid control for atorva statin, simvastatin, and ","suffix":". CYP3A4/5 combined genotype approaches have proved useful i","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":620,"endOffset":630,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"action studies are largely lacking [2, 3]. Atorvastatin and ","suffix":" are primarily metabolized by cytochrome P450 3A4 (CYP3A4) a","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":475,"endOffset":485,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"tients taking stable doses of atorvastatin, simvastatin, or ","suffix":" for optimal lipid control [6]. Another study reported a sig","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":227,"endOffset":237,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"ry role in the metabolism of atorvastatin, simvastatin, and ","suffix":". Nonetheless, our current investigation intends to use the ","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":383,"endOffset":393,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"rtile, and third quartile of atorvastatin, simvastatin, and ","suffix":" dose were determined for each combined genotype group. As u","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":672,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ences were accounted for by normalizing the simvastatin and ","suffix":" doses to atorvastatin-equivalent doses (i.e., simvastatin a","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":745,"endOffset":755,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ses to atorvastatin-equivalent doses (i.e., simvastatin and ","suffix":" have 83% and 58% the potency, respectively, of atorvastatin","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":755,"endOffset":767,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for ","suffix":", simvastatin, and the combined statin analysis, respectivel","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":603,"endOffset":615,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"d gene-gene interaction studies are largely lacking [2, 3]. ","suffix":" and lovastatin are primarily metabolized by cytochrome P450","exact":"Atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":311,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"CYP3A5 were determined to be responsible for 85% and 15% of ","suffix":" metabolism, respectively, in a reported in vitro study. Non","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":445,"endOffset":457,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ed by homozygotic wild-type patients taking stable doses of ","suffix":", simvastatin, or lovastatin for optimal lipid control [6]. ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":530,"endOffset":542,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"dy determined that drug exposure of the biologically active ","suffix":" acid metabolite was not significantly influenced by CYP3A5 ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"3A5 likely plays only a secondary role in the metabolism of ","suffix":", simvastatin, and lovastatin. Nonetheless, our current inve","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":352,"endOffset":364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"notype group. Median, first quartile, and third quartile of ","suffix":", simvastatin, and lovastatin dose were determined for each ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":692,"endOffset":704,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" for by normalizing the simvastatin and lovastatin doses to ","suffix":"-equivalent doses (i.e., simvastatin and lovastatin have 83%","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":924,"endOffset":936,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"otype groups for each dose level are listed in Table 2. For ","suffix":" and simvastatin, the highest percentages of individuals in ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":1278,"endOffset":1290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"icantly different from expected (0.33, 0.33, 0.33) for both ","suffix":" and simvastatin, p = 0.034 and p = 1.7E-6, respectively. Th","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":245,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"3A4/5 approach was inferior to the single-gene approach for ","suffix":", simvastatin, and for the combined statin analysis: the p-v","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":434,"endOffset":446,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ruskal-Wallis model were 0.129 and 0.166, respectively, for ","suffix":"; 0.036 and 0.185, respectively, for simvastatin; and 0.014 ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"tacrolimus","startOffset":336,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"r predicting response to certain CYP3A substrates including ","suffix":" and cyclosporine [8 - 10]. The combined genotype analysis i","exact":"tacrolimus"},{"setid":"PMC3681953","drugname":"cyclosporine","startOffset":351,"endOffset":363,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"sponse to certain CYP3A substrates including tacrolimus and ","suffix":" [8 - 10]. The combined genotype analysis involves categoriz","exact":"cyclosporine"}],[{"setid":"PMC2722908","drugname":"warfarin","startOffset":396,"endOffset":404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"eloped and used an algorithm for estimating the appropriate ","suffix":" dose that is based on both clinical and genetic data from a","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":439,"endOffset":447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"culating the percentage of patients whose predicted dose of ","suffix":" was within 20% of the actual stable therapeutic dose; we al","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":196,"endOffset":204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"tified larger proportions of patients who required 21 mg of ","suffix":" or less per week and of those who required 49 mg or more pe","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":151,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ic algorithm for estimating the appropriate initial dose of ","suffix":" produces recommendations that are significantly closer to t","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":424,"endOffset":432,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" the 46.2% of the population that required 21 mg or less of ","suffix":" per week or 49 mg or more per week for therapeutic anticoag","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":243,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"drug in the United States in 2004.1 The appropriate dose of ","suffix":" is difficult to establish because it can vary by a factor o","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":338,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" to the variability among patients in dose requirements for ","suffix":".3-18 In 2007, the Food and Drug Administration added pharma","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":435,"endOffset":443,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"rug Administration added pharmacogenetic information to the ","suffix":" product label19 but did not propose a specific method for u","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":941,"endOffset":949,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"e United States23 and Europe to test whether algorithms for ","suffix":" dosage that use genetic information improve the outcomes fo","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":1156,"endOffset":1164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"le dose). We developed a pharmacogenetic dose algorithm for ","suffix":" with the use of a large and diverse data set that included ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":289,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"tic data for a total of 5700 patients who were treated with ","suffix":". These data were curated (i.e., collected, formatted, and s","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":141,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" clinical factors that have previously been associated with ","suffix":" therapy and that were available from the information receiv","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":327,"endOffset":335,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" on demographic characteristics, the primary indication for ","suffix":" treatment, the stable therapeutic dose of warfarin, the tre","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":378,"endOffset":386,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"tion for warfarin treatment, the stable therapeutic dose of ","suffix":", the treatment INR (the INR achieved with a stable warfarin","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":438,"endOffset":446,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"warfarin, the treatment INR (the INR achieved with a stable ","suffix":" dose), the target INR (the desired INR), the use of concomi","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":1366,"endOffset":1374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"dy. The outcome variable was the stable therapeutic dose of ","suffix":", defined as the steady-state dose that led to stable antico","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":194,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"site, for a total of 4043 patients who had a stable dose of ","suffix":" and a target INR of 2 to 3) as the \"derivation cohort\" for ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":877,"endOffset":885,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","prefix":"de genetic factors and a model with a fixed dose of 5 mg of ","suffix":" per day. The clinical model was built with the use of the s","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":482,"endOffset":490,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[4]","prefix":"culating the percentage of patients whose predicted dose of ","suffix":" was within 20% of the actual stable therapeutic dose. In ad","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":1371,"endOffset":1379,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ion 7 in Supplementary Appendix 1; a graph of the predicted ","suffix":" dose based on the pharmacogenetic algorithm as compared wit","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":451,"endOffset":459,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"e 2 and Table 3. For patients who required 21 mg or less of ","suffix":" per week (33.9% of the total cohort), the pharmacogenetic a","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":169,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"significantly better predictions of the appropriate dose of ","suffix":" than either the clinical algorithm or a fixed-dose approach","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":352,"endOffset":360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"proaches were noted among patients whose stable therapeutic ","suffix":" doses were 21 mg or less per week and among those whose sta","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":134,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" not address the issue of whether a precise initial dose of ","suffix":" translates into improved clinical end points, such as a red","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":147,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" of pharmacogenetic dose prediction as compared with actual ","suffix":" dose (Section 8 in Supplementary Appendix 1) suggests that ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":319,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" predictably among patients who required very high doses of ","suffix":" (>70 mg per week). The common genetic markers explored in o","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":439,"endOffset":447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"red in our study primarily explain increased sensitivity to ","suffix":", not increased resistance. Mutations of VKORC1 have been as","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":535,"endOffset":543,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"Mutations of VKORC1 have been associated with resistance to ","suffix":", but these mutations are rare except in Ethiopian and certa","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":530,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rs32 that could help predict the stable therapeutic dose of ","suffix":". However, the percentage of dose variability among patients","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":1599,"endOffset":1607,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tudy represents the typical population that is treated with ","suffix":" - namely, the elderly. Only 6% of the cohort was younger th","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":178,"endOffset":186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"patients, we developed a pharmacogenetic dose algorithm for ","suffix":" that uses genotypes from two genes (VKORC1 and CYP2C9) and ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":376,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"cogenetic algorithm predicts the stable therapeutic dose of ","suffix":" better than a fixed-dose approach and better than a clinica","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":790,"endOffset":798,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"efit seen in patients ultimately requiring 21 mg or less of ","suffix":" per week and in those requiring 49 mg or more per week. The","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":695,"endOffset":703,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[2]","prefix":"polymorphisms in CYP4F2 with the stable therapeutic dose of ","suffix":" (a patent that has been licensed by the Marshfield Clinic t","exact":"warfarin"},{"setid":"PMC2722908","drugname":"vitamin k","startOffset":1030,"endOffset":1039,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"nvestigator. Several potentially important variables (e.g., ","suffix":" intake and smoking status) were not consistently available ","exact":"vitamin K"},{"setid":"PMC2722908","drugname":"vitamin k","startOffset":224,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"clude potentially important factors such as smoking status, ","suffix":" intake, or alcohol consumption, as well as other genetic fa","exact":"vitamin K"},{"setid":"PMC2722908","drugname":"lasso","startOffset":858,"endOffset":863,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"te adaptive regression splines, least-angle regression, and ","suffix":", in addition to ordinary linear regression. Logarithmic and","exact":"Lasso"},{"setid":"PMC2722908","drugname":"amiodarone","startOffset":800,"endOffset":810,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"eristics, genotype combinations, race, and use or nonuse of ","suffix":" (an important interacting drug). These data show the way in","exact":"amiodarone"}],[{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":670,"endOffset":681,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"efficacy and toxicity. To determine if co-administration of ","suffix":" with rosuvastatin alters plasma rosuvastatin exposure, an o","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. Advers","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":274,"endOffset":285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":281,"endOffset":292,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":306,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":313,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":274,"endOffset":285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":281,"endOffset":292,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":306,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":313,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":365,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ncluding chronic liver disease and hepatitis C virus [1-3]. ","suffix":" binds to the transmembrane domain of the thrombopoietin rec","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":205,"endOffset":216,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" 1B1 (OATP1B1) and breast cancer resistance protein (BCRP). ","suffix":" was also identified as a BCRP substrate in vitro. OATP1B1 i","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":293,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"itten, informed consent. Subjects received rosuvastatin and ","suffix":" orally in the following sequence: day 1, rosuvastatin 10 mg","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":399,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"day 1, rosuvastatin 10 mg single dose; day 6 through day 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":437,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" day 6 through day 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. This s","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":901,"endOffset":912,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"ons. Plasma PK samples collected on day 10 were assayed for ","suffix":" using a validated analytical method based on protein precip","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":1089,"endOffset":1100,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"liquot of plasma, the lower limit of quantification for the ","suffix":" assay was 100 ng ml−1 and the higher limit of quantificatio","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":307,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[5]","prefix":"osuvastatin when administered alone or co-administered with ","suffix":". Cmax and the first time to reach Cmax (tmax) were the actu","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":209,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","prefix":"mated for the combination regimen only. In addition, plasma ","suffix":" trough concentrations collected on day 10 prior to administ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":539,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"to give point and interval estimates for the ratios. Plasma ","suffix":" and rosuvastatin PK parameters were summarized by treatment","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":283,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"ministration of rosuvastatin alone (Table 4). The impact of ","suffix":" on plasma rosuvastatin exposure differed by race. Plasma ro","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":678,"endOffset":689,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"n and by race for each treatment in Figure 1. The impact of ","suffix":" on plasma rosuvastatin exposure appeared to differ by gende","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":415,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"sian male) with the c.421AA genotype had the highest plasma ","suffix":" AUC(0,τ) (247 µg ml−1 h), but the exposure was similar to t","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":761,"endOffset":772,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":" non-Asian group, women had approximately 46% higher plasma ","suffix":" AUC(0,τ) (126 vs. 86 µg ml−1 h) and 37% higher Cmax (9.48 v","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":869,"endOffset":880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"sian male) with the c.421AA genotype had the highest plasma ","suffix":" AUC(0,τ) (247 µg ml−1 h), the exposure was similar to the h","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":118,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"   For the overall population, the geometric mean of plasma ","suffix":" Cmax was 8.00 µg ml−1 and AUC(0,τ) was 102 µg ml−1 h, and p","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":195,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"was 8.00 µg ml−1 and AUC(0,τ) was 102 µg ml−1 h, and plasma ","suffix":" exposures were similar between Asian and non-Asian subjects","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":415,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"sian male) with the c.421AA genotype had the highest plasma ","suffix":" AUC(0,τ) (247 µg ml−1 h), but the exposure was similar to t","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":869,"endOffset":880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"sian male) with the c.421AA genotype had the highest plasma ","suffix":" AUC(0,τ) (247 µg ml−1 h), the exposure was similar to the h","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":617,"endOffset":628,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"with the c.421CC genotype. When races were combined, plasma ","suffix":" exposure was similar between males and females (Table 5), b","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":761,"endOffset":772,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":" non-Asian group, women had approximately 46% higher plasma ","suffix":" AUC(0,τ) (126 vs. 86 µg ml−1 h) and 37% higher Cmax (9.48 v","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":865,"endOffset":876,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"and 37% higher Cmax (9.48 vs. 6.94 µg ml−1). Median (range) ","suffix":" trough concentrations of 2.98 µg ml−1 (1.14-6.97 µg ml−1) c","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":497,"endOffset":508,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"re observed in several subjects following administration of ","suffix":". At the follow-up visit, 16 subjects (38%) had platelet cou","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":205,"endOffset":216,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" both OATP1B1 and BCRP with IC50s of 2.7 µm (1.19 µg ml−1). ","suffix":" concentrations achieved clinically are higher than this IC5","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":925,"endOffset":936,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" central finding of the study was that co-administration of ","suffix":" 75 mg once daily with a single dose of rosuvastatin 10 mg i","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":915,"endOffset":926,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ters [14]. It was anticipated that inhibition of OATP1B1 by ","suffix":" would have a lesser effect on plasma rosuvastatin exposure ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":324,"endOffset":335,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"able that the increased rosuvastatin exposure observed with ","suffix":" co-administration is due to inhibition of both transporters","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"O1B1) and/or BCRP (ABCG2) polymorphisms, the results of the ","suffix":"-rosuvastatin interaction study may be extended to other sta","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":324,"endOffset":335,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"nded to other statins. In subjects who were co-administered ","suffix":" and rosuvastatin, increased rosuvastatin Cmax (mean 103% in","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":559,"endOffset":570,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"ducing a subject's dose of statin when co-administered with ","suffix":". Monitoring side effects, clinical chemistry, and lipid con","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":682,"endOffset":693,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"ipid concentrations is warranted in subjects receiving both ","suffix":" and a statin. As noted by other investigators, most clinica","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":145,"endOffset":156,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"n plasma eltrombopag PK was not formally assessed. However, ","suffix":" trough concentrations collected prior to co-administration ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":363,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ation of a single dose of rosuvastatin. In addition, plasma ","suffix":" exposure for the 75 mg once daily regimen (in combination w","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":511,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" of rosuvastatin) was generally as expected based on plasma ","suffix":" exposures observed in other eltrombopag studies [20-22]. Th","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":551,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ted based on plasma eltrombopag exposures observed in other ","suffix":" studies [20-22]. Therefore, there does not appear to be a s","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":275,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"tudies that have shown approximately two-fold higher plasma ","suffix":" exposures in Asian vs. non-Asian subjects [21, 22]. In thes","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":597,"endOffset":608,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"the non-Asian population, female subjects had higher plasma ","suffix":" exposure, which is consistent with previous reports [22]. E","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":667,"endOffset":678,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"g exposure, which is consistent with previous reports [22]. ","suffix":" is a BCRP substrate and plasma eltrombopag exposure was sim","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":710,"endOffset":721,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"us reports [22]. Eltrombopag is a BCRP substrate and plasma ","suffix":" exposure was similar between c.421CC and c.421CA genotypes.","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":415,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"sian male) with the c.421AA genotype had the highest plasma ","suffix":" AUC(0,τ) (247 µg ml−1 h), but the exposure was similar to t","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":869,"endOffset":880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"sian male) with the c.421AA genotype had the highest plasma ","suffix":" AUC(0,τ) (247 µg ml−1 h), the exposure was similar to the h","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":274,"endOffset":285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":281,"endOffset":292,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":306,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":313,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":294,"endOffset":306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"(BCRP) in vitro. OATP1B1 is important for hepatic uptake of ","suffix":" and inhibition of this transporter could reduce cholesterol","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":558,"endOffset":570,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" of this transporter could increase both hepatic and plasma ","suffix":" concentrations, resulting in increased efficacy and toxicit","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":687,"endOffset":699,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"city. To determine if co-administration of eltrombopag with ","suffix":" alters plasma rosuvastatin exposure, an open-label study wa","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":714,"endOffset":726,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"ministration of eltrombopag with rosuvastatin alters plasma ","suffix":" exposure, an open-label study was conducted in 42 healthy a","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":127,"endOffset":139,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"bjects received rosuvastatin and eltrombopag orally: day 1, ","suffix":" 10 mg single dose; days 6 to 9, eltrombopag 75 mg once dail","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":243,"endOffset":255,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. Adverse event assessments were performed","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":174,"endOffset":186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"n increased geometric mean (90% confidence interval) plasma ","suffix":" AUC(0,∞) by 55% (42%, 69%) and Cmax by 103% (82%, 126%) in ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"s of eltrombopag on rosuvastatin PK, log transformed plasma ","suffix":" AUC(0,∞) and Cmax were analyzed separately by analysis of v","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","prefix":"tivariate analyses of the relationship between day 1 plasma ","suffix":" AUC(0,∞) and Cmax and potential covariates was completed. T","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"P < 0.05) were retained as significant predictors of plasma ","suffix":" AUC(0,∞) and Cmax in the final multivariate models where ge","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":400,"endOffset":412,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"ined in the final model as significant predictors of plasma ","suffix":" AUC(0,∞) and Cmax where genotype by approach 3 was tested. ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":129,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"istration of eltrombopag with rosuvastatin increased plasma ","suffix":" AUC(0,∞) by 55% and Cmax by 103% in the overall study popul","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":305,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"statin alone (Table 4). The impact of eltrombopag on plasma ","suffix":" exposure differed by race. Plasma rosuvastatin AUC(0,∞) inc","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":352,"endOffset":364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"ag on plasma rosuvastatin exposure differed by race. Plasma ","suffix":" AUC(0,∞) increased by 88% and Cmax increased 165% in non-As","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":438,"endOffset":450,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ions regarding the relationship between genotype and plasma ","suffix":" exposure. Plasma rosuvastatin AUC(0,∞) vs. genotype combina","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":468,"endOffset":480,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"p between genotype and plasma rosuvastatin exposure. Plasma ","suffix":" AUC(0,∞) vs. genotype combination (approach 2) are displaye","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":1012,"endOffset":1024,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"y with a single dose of rosuvastatin 10 mg increased plasma ","suffix":" Cmax by 103% and AUC(0,∞) by 55% in the overall study popul","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":714,"endOffset":726,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"ministration of eltrombopag with rosuvastatin alters plasma ","suffix":" exposure, an open-label study was conducted in 42 healthy a","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":419,"endOffset":431,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"eductase inhibitors (statins) [5]. OATP1B1 is important for ","suffix":" disposition as demonstrated by genetic polymorphism, where ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":570,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"omozygous OATP1B1 (SLCO1B1) c.521CC genotype had 65% higher ","suffix":" mean area under the curve (AUC(0,48 h)) than those with the","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":827,"endOffset":839,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"SLCO1B1*15/*15) has also been associated with higher plasma ","suffix":" exposure [7]. BCRP is an efflux transporter that transports","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":997,"endOffset":1009,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"so limits intestinal drug absorption. BCRP is important for ","suffix":" disposition as demonstrated by genetic polymorphism, where ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":1184,"endOffset":1196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"homozygous c.421AA genotypes had approximately two-fold the ","suffix":" AUC(0,∞) compared with those with the homozygous c.421CC (c","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":276,"endOffset":288,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"jects provided written, informed consent. Subjects received ","suffix":" and eltrombopag orally in the following sequence: day 1, ro","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":346,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"in and eltrombopag orally in the following sequence: day 1, ","suffix":" 10 mg single dose; day 6 through day 9, eltrombopag 75 mg o","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":470,"endOffset":482,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. This study was designed and monitored in","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":499,"endOffset":511,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"6, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after single dose ","suffix":" administration on days 1 and 10. A blood sample was obtaine","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":123,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"asma PK samples collected on days 1 and 10 were assayed for ","suffix":" using a validated analytical method based on solid phase ex","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"liquot of plasma, the lower limit of quantification for the ","suffix":" assay was 0.2 ng ml−1 and the higher limit of quantificatio","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":246,"endOffset":258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[5]","prefix":"ting from dosing and extrapolated to infinity (AUC(0,∞)) of ","suffix":" when administered alone or co-administered with eltrombopag","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":290,"endOffset":302,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","prefix":"ncentrations collected on day 10 prior to administration of ","suffix":" and 24 h after rosuvastatin co-administration were measured","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"s of eltrombopag on rosuvastatin PK, log transformed plasma ","suffix":" AUC(0,∞) and Cmax were analyzed separately by analysis of v","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":555,"endOffset":567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"d interval estimates for the ratios. Plasma eltrombopag and ","suffix":" PK parameters were summarized by treatment and by race and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":659,"endOffset":671,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"y treatment and by race and gender within treatment. Plasma ","suffix":" concentration-time profiles were plotted by treatment, race","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":751,"endOffset":763,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"profiles were plotted by treatment, race and gender. Plasma ","suffix":" AUC(0,∞) was plotted by genotype combination (approach 2 as","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":971,"endOffset":983,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"alyses. Similar to the primary statistical analysis, plasma ","suffix":" PK values were compared between treatments for subgroups ba","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","prefix":"tivariate analyses of the relationship between day 1 plasma ","suffix":" AUC(0,∞) and Cmax and potential covariates was completed. T","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"P < 0.05) were retained as significant predictors of plasma ","suffix":" AUC(0,∞) and Cmax in the final multivariate models where ge","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":400,"endOffset":412,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"ined in the final model as significant predictors of plasma ","suffix":" AUC(0,∞) and Cmax where genotype by approach 3 was tested. ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":732,"endOffset":744,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"subjects were female). Asian participants had a 109% higher ","suffix":" AUC(0,∞) and a 139% higher Cmax compared with non-Asian sub","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":815,"endOffset":827,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"nd a 139% higher Cmax compared with non-Asian subjects when ","suffix":" was administered alone (Table 4). Within the non-Asian popu","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":930,"endOffset":942,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"he non-Asian population, female participants had 50% higher ","suffix":" AUC(0,∞) and 84% higher Cmax compared with male subjects wh","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":129,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"istration of eltrombopag with rosuvastatin increased plasma ","suffix":" AUC(0,∞) by 55% and Cmax by 103% in the overall study popul","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":239,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"he overall study population compared with administration of ","suffix":" alone (Table 4). The impact of eltrombopag on plasma rosuva","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":305,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"statin alone (Table 4). The impact of eltrombopag on plasma ","suffix":" exposure differed by race. Plasma rosuvastatin AUC(0,∞) inc","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":352,"endOffset":364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"ag on plasma rosuvastatin exposure differed by race. Plasma ","suffix":" AUC(0,∞) increased by 88% and Cmax increased 165% in non-As","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":538,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"ax increased 61% in Asian subjects (Table 4). Median plasma ","suffix":" concentration-time profiles are displayed for the overall p","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":700,"endOffset":712,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":" treatment in Figure 1. The impact of eltrombopag on plasma ","suffix":" exposure appeared to differ by gender within the non-Asian ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"bined genotype scores (approach 3) of 2-3 had higher plasma ","suffix":" exposures than subjects with scores of 0-1, and there was a","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":240,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"scores of 0-1, and there was also a trend for higher plasma ","suffix":" exposures for subjects in category 4 (approach 2). However,","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":438,"endOffset":450,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ions regarding the relationship between genotype and plasma ","suffix":" exposure. Plasma rosuvastatin AUC(0,∞) vs. genotype combina","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":468,"endOffset":480,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"p between genotype and plasma rosuvastatin exposure. Plasma ","suffix":" AUC(0,∞) vs. genotype combination (approach 2) are displaye","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":985,"endOffset":997,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":" µg ml−1) collected on day 10 prior to co-administration of ","suffix":" were similar to trough concentrations of 3.22 µg ml−1 (1.22","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":334,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"C50 value (Table 5), and OATP1B1 and BCRP are important for ","suffix":" disposition. Statins are widely used cholesterol-lowering a","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":976,"endOffset":988,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ation of eltrombopag 75 mg once daily with a single dose of ","suffix":" 10 mg increased plasma rosuvastatin Cmax by 103% and AUC(0,","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":1012,"endOffset":1024,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"y with a single dose of rosuvastatin 10 mg increased plasma ","suffix":" Cmax by 103% and AUC(0,∞) by 55% in the overall study popul","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":327,"endOffset":339,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"previous data, Asian race was associated with higher plasma ","suffix":" exposure, with Asian subjects having approximately twice th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":467,"endOffset":479,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"re as non-Asian subjects enrolled in the current study when ","suffix":" was given alone. Interestingly, the non-Asian group studied","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":747,"endOffset":759,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ubjects. The observed interindividual variability in plasma ","suffix":" exposure could be due to different genetic polymorphisms th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":964,"endOffset":976,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"OATP1B1 by eltrombopag would have a lesser effect on plasma ","suffix":" exposure in Asian subjects compared with non-Asian subjects","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":228,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"15/*15) have not been associated with racial differences in ","suffix":" PK, but have been associated with rosuvastatin PK variabili","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":275,"endOffset":287,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"fferences in rosuvastatin PK, but have been associated with ","suffix":" PK variability in White subjects [7]. BCRP C421A polymorphi","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":377,"endOffset":389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"cts [7]. BCRP C421A polymorphisms have been associated with ","suffix":" PK variability as well [8]. The study was not designed to s","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":727,"endOffset":739,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"s, which have not been independently associated with plasma ","suffix":" exposure, were relatively evenly distributed across the enr","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":947,"endOffset":959,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"tely, genotype was not significantly associated with plasma ","suffix":" exposure when race, gender and body weight were included in","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":1199,"endOffset":1211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"tion between haplotype and genotype combinations and plasma ","suffix":" exposure when race, gender and body weight were included in","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":231,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"phisms in both transporters are known to be associated with ","suffix":" exposure, it is probable that the increased rosuvastatin ex","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"th rosuvastatin exposure, it is probable that the increased ","suffix":" exposure observed with eltrombopag co-administration is due","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":436,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"f both transporters. Inhibition of OATP1B1 increases plasma ","suffix":" exposure by reducing the hepatic uptake; in this scenario, ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":508,"endOffset":520,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":" exposure by reducing the hepatic uptake; in this scenario, ","suffix":" efficacy may be reduced and toxicity may be increased. In c","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":625,"endOffset":637,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"increased. In contrast, inhibition of BCRP increases plasma ","suffix":" exposure by enhancing rosuvastatin absorption and/or by inh","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":660,"endOffset":672,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"of BCRP increases plasma rosuvastatin exposure by enhancing ","suffix":" absorption and/or by inhibiting rosuvastatin elimination in","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":705,"endOffset":717,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e by enhancing rosuvastatin absorption and/or by inhibiting ","suffix":" elimination in the bile; in this scenario rosuvastatin effi","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":760,"endOffset":772,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ting rosuvastatin elimination in the bile; in this scenario ","suffix":" efficacy and toxicity may both be increased. In vitro evide","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":855,"endOffset":867,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"may both be increased. In vitro evidence also suggests that ","suffix":" is a substrate for other hepatic uptake transporters includ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":471,"endOffset":483,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":") 521CC genotype had 1.65- to 3.21-fold higher exposures of ","suffix":", pravastatin, simvastatin, lovastatin and atorvastatin than","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":1036,"endOffset":1048,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"into the bile. BCRP polymorphisms have been associated with ","suffix":", atorvastatin, fluvastatin and simvastatin lactone (but not","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":222,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":" BCRP (ABCG2) polymorphisms, the results of the eltrombopag-","suffix":" interaction study may be extended to other statins. In subj","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":340,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"atins. In subjects who were co-administered eltrombopag and ","suffix":", increased rosuvastatin Cmax (mean 103% increase) and AUC(0","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":364,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"ere co-administered eltrombopag and rosuvastatin, increased ","suffix":" Cmax (mean 103% increase) and AUC(0,∞) (mean 55% increase) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":219,"endOffset":231,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ough concentrations collected prior to co-administration of ","suffix":" were similar to trough concentrations collected 24 h after ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":329,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" collected 24 h after co-administration of a single dose of ","suffix":". In addition, plasma eltrombopag exposure for the 75 mg onc","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":455,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"mg once daily regimen (in combination with a single dose of ","suffix":") was generally as expected based on plasma eltrombopag expo","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":115,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"  Plasma eltrombopag exposures collected in the presence of ","suffix":" were similar between Asian and non-Asian subjects. This is ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":119,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":" conclusion, concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure. The th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"cholesterol","startOffset":355,"endOffset":366,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"osuvastatin and inhibition of this transporter could reduce ","suffix":"-lowering efficacy and increase the risk of exposure-depende","exact":"cholesterol"},{"setid":"PMC3162661","drugname":"cholesterol","startOffset":384,"endOffset":395,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"rtant for rosuvastatin disposition. Statins are widely used ","suffix":"-lowering agents [13] and are generally used as chronic ther","exact":"cholesterol"},{"setid":"PMC3162661","drugname":"gemfibrozil","startOffset":149,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"er-mediated drug interactions, such as its interaction with ","suffix":" and cyclosporin [11, 12]. The objective of this study was t","exact":"gemfibrozil"},{"setid":"PMC3162661","drugname":"cyclosporin","startOffset":165,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" interactions, such as its interaction with gemfibrozil and ","suffix":" [11, 12]. The objective of this study was to evaluate the i","exact":"cyclosporin"},{"setid":"PMC3162661","drugname":"pravastatin","startOffset":485,"endOffset":496,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"pe had 1.65- to 3.21-fold higher exposures of rosuvastatin, ","suffix":", simvastatin, lovastatin and atorvastatin than those with t","exact":"pravastatin"},{"setid":"PMC3162661","drugname":"simvastatin","startOffset":498,"endOffset":509,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"to 3.21-fold higher exposures of rosuvastatin, pravastatin, ","suffix":", lovastatin and atorvastatin than those with the homozygous","exact":"simvastatin"},{"setid":"PMC3162661","drugname":"simvastatin","startOffset":1080,"endOffset":1091,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"associated with rosuvastatin, atorvastatin, fluvastatin and ","suffix":" lactone (but not acid), but not pravastatin or pitavastatin","exact":"simvastatin"},{"setid":"PMC3162661","drugname":"lovastatin","startOffset":511,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"higher exposures of rosuvastatin, pravastatin, simvastatin, ","suffix":" and atorvastatin than those with the homozygous 521TT (cont","exact":"lovastatin"},{"setid":"PMC3162661","drugname":"atorvastatin","startOffset":526,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"s of rosuvastatin, pravastatin, simvastatin, lovastatin and ","suffix":" than those with the homozygous 521TT (control) genotypes [6","exact":"atorvastatin"},{"setid":"PMC3162661","drugname":"atorvastatin","startOffset":1050,"endOffset":1062,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":" BCRP polymorphisms have been associated with rosuvastatin, ","suffix":", fluvastatin and simvastatin lactone (but not acid), but no","exact":"atorvastatin"},{"setid":"PMC3162661","drugname":"fluvastatin","startOffset":622,"endOffset":633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ozygous 521TT (control) genotypes [6, 16, 17]. In contrast, ","suffix":" exposure was not different among the T521C genotypes, furth","exact":"fluvastatin"},{"setid":"PMC3162661","drugname":"fluvastatin","startOffset":745,"endOffset":756,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"s, further suggesting that OATP1B1 may not be important for ","suffix":" disposition. BCRP is highly expressed on the apical membran","exact":"fluvastatin"},{"setid":"PMC3162661","drugname":"fluvastatin","startOffset":1064,"endOffset":1075,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"hisms have been associated with rosuvastatin, atorvastatin, ","suffix":" and simvastatin lactone (but not acid), but not pravastatin","exact":"fluvastatin"}],[{"setid":"PMC1490169","drugname":"warfarin","startOffset":123,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ducted a retrospective cohort study of patients with stable ","suffix":" doses and INRs who received a prescription for terazosin, a","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":430,"endOffset":438,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"osen as our control because of its lack of interaction with ","suffix":".9 Participants were included if 2 inclusion INRs (the last ","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":921,"endOffset":929,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"mmencing it. Subjects were excluded if they had a change in ","suffix":" dosing or initiated or changed a scheduled medication that ","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":1015,"endOffset":1023,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"anged a scheduled medication that is known to interact with ","suffix":" during or after collection of their inclusion INRs. As need","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":1168,"endOffset":1176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ed if the medication was not commonly felt to interact with ","suffix":" based on an accepted text of drug interactions.10 Patients ","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":435,"endOffset":443,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"years old. There were no differences in the indications for ","suffix":" use (P=.779). Azithromycin and TMP/SMX were prescribed prim","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":199,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"azithromycin, levofloxacin, or TMP/SMX was added to chronic ","suffix":" therapy in patients who were acutely ill. Prior studies are","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":342,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ndomization. Yamreudeewong et al.16 completed a study of 18 ","suffix":" users who required levofloxacin daily for 5 to 10 days for ","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":117,"endOffset":125,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"It is well known that sulfa-based antibiotics interact with ","suffix":", but the incidence has not been adequately studied.5 Compar","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":507,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ted 11 subjects who were neither acutely ill nor on chronic ","suffix":" and concluded that TMP/SMX potentiates the prothrombin effe","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":144,"endOffset":152,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"gths. We eliminated patients who did not have both a stable ","suffix":" dose and a stable level of anticoagulant intensity and limi","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":1014,"endOffset":1022,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ty to our findings. Terazosin is known not to interact with ","suffix":", while TMP/SMX has a well-described interaction.5,9 Anchori","exact":"warfarin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":148,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"udy of patients using warfarin who initiated an antibiotic (","suffix":", levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"   The mean change in INR was −0.15 for terazosin, 0.51 for ","suffix":", 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean IN","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":356,"endOffset":368,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"dence of supratherapeutic INR was 5% for terazosin, 31% for ","suffix":", 33% for levofloxacin, and 69% for TMP/SMX. The incidence o","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":478,"endOffset":490,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"ncidence of absolute INR >4.0 was 0% for terazosin, 16% for ","suffix":", 19% for levofloxacin, and 44% for TMP/SMX.\n               ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":114,"endOffset":126,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"           Among acutely ill outpatients, oral antibiotics (","suffix":", levofloxacin, and TMP/SMX) increase the incidence and degr","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":315,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"n increases in INR of 0.51, 0.85, and 1.76 were seen in the ","suffix":", levofloxacin, and TMP/SMX groups. Elevations in INR beyond","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":120,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":190,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n doses and INRs who received a prescription for terazosin, ","suffix":", levofloxacin, or TMP/SMX for clinical indications between ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":142,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ptions for terazosin in 333 patients, 273 prescriptions for ","suffix":" in 158 patients, 370 prescriptions for levofloxacin in 258 ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":315,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":722,"endOffset":734,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" patients had INRs drawn between days 15 and 30. Thirty-two ","suffix":", 27 levofloxacin, and 16 TMP/SMX patients were included in ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":245,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ysis. The median time to follow-up was 17.5 (terazosin), 7 (","suffix":"), 6 (levofloxacin), and 6 (TMP/SMX) days. Men constituted 9","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":458,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"o differences in the indications for warfarin use (P=.779). ","suffix":" and TMP/SMX were prescribed primarily for pulmonary infecti","exact":"Azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":831,"endOffset":843,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"tinine in the patients with renal failure was 2.3 mg/dL for ","suffix":", 2.0 mg/dL for levofloxacin, and 2.5 mg/dL for TMP/SMX.\n   ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"idence and degree of warfarin interaction from terazosin to ","suffix":" to levofloxacin to TMP/SMX was found (Table 2). Overall, th","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"n increases in INR of 0.51, 0.85, and 1.76 were seen in the ","suffix":", levofloxacin, and TMP/SMX groups. Elevations in INR beyond","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":549,"endOffset":561,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"beyond therapeutic levels were seen in 5% (terazosin), 31% (","suffix":"), 33% (levofloxacin), and 69% (TMP/SMX) of patients. The P-","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":789,"endOffset":801,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"d as elevations beyond 4, were seen in 0% (terazosin), 16% (","suffix":"), 19% (levofloxacin), and 44% (TMP/SMX). The P-value was si","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":942,"endOffset":954,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" versus terazosin, with a nonsignificant trend between both ","suffix":" and levofloxacin versus terazosin. Even more significant ri","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":139,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"icant increase in the incidence of overanticoagulation when ","suffix":", levofloxacin, or TMP/SMX was added to chronic warfarin the","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":157,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no significant differences in INR after the initiation of ","suffix":" for clinical indications compared with terazosin9 or felodi","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":260,"endOffset":272,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"red with terazosin9 or felodipine.11 However, only 19 of 43 ","suffix":" subjects had a follow-up INR within 15 days, with the remai","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":713,"endOffset":725,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ease. Chronic renal disease was seen more frequently in the ","suffix":" and levofloxacin groups than the TMP/SMX and terazosin grou","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":120,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"s using warfarin who initiated an antibiotic (azithromycin, ","suffix":", or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin f","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":145,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for ","suffix":", and 1.76 for TMP/SMX. These mean INR changes in the antibi","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":378,"endOffset":390,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"tic INR was 5% for terazosin, 31% for azithromycin, 33% for ","suffix":", and 69% for TMP/SMX. The incidence of absolute INR >4.0 wa","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":500,"endOffset":512,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for ","suffix":", and 44% for TMP/SMX.\n                                     ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":128,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"ng acutely ill outpatients, oral antibiotics (azithromycin, ","suffix":", and TMP/SMX) increase the incidence and degree of overanti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":329,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":437,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" INR of 0.51, 0.85, and 1.76 were seen in the azithromycin, ","suffix":", and TMP/SMX groups. Elevations in INR beyond therapeutic l","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":134,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":722,"endOffset":734,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"e outpatients for 3 commonly used antibiotics-azithromycin, ","suffix":", and trimethoprim/sulfamethoxazole (TMP/SMX).\n             ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":204,"endOffset":216,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Rs who received a prescription for terazosin, azithromycin, ","suffix":", or TMP/SMX for clinical indications between January 1998 a","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons for azithromycin in 158 patients, 370 prescriptions for ","suffix":" in 258 patients, and 151 prescriptions for TMP/SMX in 120 p","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":329,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":739,"endOffset":751,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s drawn between days 15 and 30. Thirty-two azithromycin, 27 ","suffix":", and 16 TMP/SMX patients were included in the trial (Table ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":263,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ime to follow-up was 17.5 (terazosin), 7 (azithromycin), 6 (","suffix":"), and 6 (TMP/SMX) days. Men constituted 97% of all patients","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":540,"endOffset":552,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"MX were prescribed primarily for pulmonary infections while ","suffix":" was used most often for urinary tract infections. Terazosin","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":859,"endOffset":871,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"renal failure was 2.3 mg/dL for azithromycin, 2.0 mg/dL for ","suffix":", and 2.5 mg/dL for TMP/SMX.\n                               ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":166,"endOffset":178,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e of warfarin interaction from terazosin to azithromycin to ","suffix":" to TMP/SMX was found (Table 2). Overall, the mean INR incre","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":437,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" INR of 0.51, 0.85, and 1.76 were seen in the azithromycin, ","suffix":", and TMP/SMX groups. Elevations in INR beyond therapeutic l","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":569,"endOffset":581,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"evels were seen in 5% (terazosin), 31% (azithromycin), 33% (","suffix":"), and 69% (TMP/SMX) of patients. The P-value for all 3 anti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":809,"endOffset":821,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"nd 4, were seen in 0% (terazosin), 16% (azithromycin), 19% (","suffix":"), and 44% (TMP/SMX). The P-value was significant for TMP/SM","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":959,"endOffset":971,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":", with a nonsignificant trend between both azithromycin and ","suffix":" versus terazosin. Even more significant rises in INR were c","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":153,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" in the incidence of overanticoagulation when azithromycin, ","suffix":", or TMP/SMX was added to chronic warfarin therapy in patien","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":370,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"t al.16 completed a study of 18 warfarin users who required ","suffix":" daily for 5 to 10 days for infectious indications. No diffe","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":730,"endOffset":742,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"al disease was seen more frequently in the azithromycin and ","suffix":" groups than the TMP/SMX and terazosin groups; however, the ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":134,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"trimethoprim","startOffset":179,"endOffset":191,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"who initiated an antibiotic (azithromycin, levofloxacin, or ","suffix":"/sulfamethoxazole (TMP/SMX)) or terazosin for clinical indic","exact":"trimethoprim"},{"setid":"PMC1490169","drugname":"trimethoprim","startOffset":740,"endOffset":752,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"3 commonly used antibiotics-azithromycin, levofloxacin, and ","suffix":"/sulfamethoxazole (TMP/SMX).\n                               ","exact":"trimethoprim"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":192,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" an antibiotic (azithromycin, levofloxacin, or trimethoprim/","suffix":" (TMP/SMX)) or terazosin for clinical indications between Ja","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":753,"endOffset":769,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ed antibiotics-azithromycin, levofloxacin, and trimethoprim/","suffix":" (TMP/SMX).\n                                                ","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":192,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" an antibiotic (azithromycin, levofloxacin, or trimethoprim/","suffix":" (TMP/SMX)) or terazosin for clinical indications between Ja","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":753,"endOffset":769,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ed antibiotics-azithromycin, levofloxacin, and trimethoprim/","suffix":" (TMP/SMX).\n                                                ","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":223,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":102,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"                       The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":271,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":337,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":459,"endOffset":468,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":179,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":354,"endOffset":363,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"t a university-affiliated Veteran's Affairs Medical Center. ","suffix":" was chosen as our control because of its lack of interactio","exact":"Terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":567,"endOffset":576,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" within 30 days prior to the introduction of the antibiotic/","suffix":") were within±0.2 of the therapeutic range and within 0.5 of","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":796,"endOffset":805,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"tic medications. The time frame was extended to 30 days for ","suffix":", as INRs are generally not followed as closely after commen","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":304,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":587,"endOffset":596,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":230,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":603,"endOffset":612,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ofloxacin was used most often for urinary tract infections. ","suffix":" was nearly always prescribed for symptomatic benign prostat","exact":"Terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":137,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (Table","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":293,"endOffset":302,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"increased significantly for all 3 antibiotics compared with ","suffix":". While the INR decreased slightly for terazosin (−0.15), me","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":341,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"mpared with terazosin. While the INR decreased slightly for ","suffix":" (−0.15), mean increases in INR of 0.51, 0.85, and 1.76 were","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":532,"endOffset":541,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"levations in INR beyond therapeutic levels were seen in 5% (","suffix":"), 31% (azithromycin), 33% (levofloxacin), and 69% (TMP/SMX)","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":656,"endOffset":665,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"/SMX) of patients. The P-value for all 3 antibiotics versus ","suffix":" was <.05. More clinically significant elevations of INR, de","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":772,"endOffset":781,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ns of INR, denoted as elevations beyond 4, were seen in 0% (","suffix":"), 16% (azithromycin), 19% (levofloxacin), and 44% (TMP/SMX)","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":890,"endOffset":899,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"% (TMP/SMX). The P-value was significant for TMP/SMX versus ","suffix":", with a nonsignificant trend between both azithromycin and ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":979,"endOffset":988,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ant trend between both azithromycin and levofloxacin versus ","suffix":". Even more significant rises in INR were consistently seen ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":771,"endOffset":780,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":896,"endOffset":905,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":974,"endOffset":983,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"itive (TMP/SMX) control to confer validity to our findings. ","suffix":" is known not to interact with warfarin, while TMP/SMX has a","exact":"Terazosin"},{"setid":"PMC1490169","drugname":"creatinine","startOffset":767,"endOffset":777,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"se was common while chronic liver disease was not. The mean ","suffix":" in the patients with renal failure was 2.3 mg/dL for azithr","exact":"creatinine"},{"setid":"PMC1490169","drugname":"felodipine","startOffset":223,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"omycin for clinical indications compared with terazosin9 or ","suffix":".11 However, only 19 of 43 azithromycin subjects had a follo","exact":"felodipine"}],[{"setid":"PMC90851","drugname":"cholesterol","startOffset":207,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"evaluated. Metabolic laboratory parameters, including total ","suffix":", low-density lipoproteins (LDL), triglycerides, glucose, in","exact":"cholesterol"},{"setid":"PMC90851","drugname":"cholesterol","startOffset":1172,"endOffset":1183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":" 10 days. Mean baseline values and percent changes in total ","suffix":", LDL, and triglycerides on days 14 and 28 were calculated f","exact":"cholesterol"},{"setid":"PMC90851","drugname":"cholesterol","startOffset":516,"endOffset":527,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rations in the liver. It was interesting to observe similar ","suffix":"-lowering effects of atorvastatin and simvastatin in the pre","exact":"cholesterol"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":725,"endOffset":735,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"e study was performed to determine the interactions between ","suffix":", a protease inhibitor, and two HMG-CoA reductase inhibitors","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1004,"endOffset":1014,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atin (20 mg once a day) for the first 14 days of the study. ","suffix":" (1,250 mg twice a day) was added on days 15 to 28. Pharmaco","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1163,"endOffset":1173,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"med on days 14 and 28. The study drugs were well tolerated. ","suffix":" increased the steady-state area under the plasma concentrat","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1514,"endOffset":1524,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"n nor simvastatin appeared to alter the pharmacokinetics of ","suffix":". It is recommended that coadministration of simvastatin wit","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1586,"endOffset":1596,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"It is recommended that coadministration of simvastatin with ","suffix":" should be avoided, whereas atorvastatin should be used with","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":445,"endOffset":455,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"h Conf. Retrovir. Opportunistic Infect., abstr LB 6, 2000). ","suffix":", like the other protease inhibitors, is an inhibitor of CYP","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":582,"endOffset":592,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"though it is not as strong a CYP3A4 inhibitor as ritonavir. ","suffix":" is a widely prescribed protease inhibitor. It is therefore ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":690,"endOffset":700,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"itor. It is therefore important to study the interaction of ","suffix":" and HMG-CoA reductase inhibitors. Two HMG-CoA reductase inh","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":185,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" study to determine the pharmacokinetic interaction between ","suffix":" and atorvastatin or nelfinavir and simvastatin in healthy v","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":216,"endOffset":226,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"okinetic interaction between nelfinavir and atorvastatin or ","suffix":" and simvastatin in healthy volunteers. Thirty-two subjects ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":265,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"d 2, subjects received atorvastatin calcium (10 mg QD) plus ","suffix":" (Viracept; 1,250 mg twice a day [BID]) for an additional 14","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":232,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" In period 2, subjects received simvastatin (20 mg QD) plus ","suffix":" (1,250 mg BID) for an additional 14 days (days 15 to 28). A","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":121,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"Trough samples (7 ml) were collected prior to initiation of ","suffix":" on day 14 and prior to dosing on days 20 and 25. Serial blo","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":368,"endOffset":378,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"asma samples (0.25 ml) containing various concentrations of ","suffix":" and AG1402 were mixed with an internal standard [6,7-dimeth","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1121,"endOffset":1131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":" column at 30°C with a flow rate of 1.5 ml and detection of ","suffix":" and AG1402 via UV detection at 220 nm. The typical elution ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1200,"endOffset":1210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"02 via UV detection at 220 nm. The typical elution times of ","suffix":", AG1402, and the internal standard were 14.5, 6, and 11 min","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1367,"endOffset":1377,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"ated within a concentration range of 0.05 to 10.0 μg/ml for ","suffix":" and AG1402. The standard curves were linear with R2 values ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1448,"endOffset":1458,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":". The standard curves were linear with R2 values of >0.997. ","suffix":" and AG1402 were stable (<20% loss from the baseline) for at","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1623,"endOffset":1633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"ecision (percent coefficient of variation) of the assay for ","suffix":" and AG1402 was ≤7.2 and 6.6%, respectively. The accuracy (d","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1752,"endOffset":1762,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"deviation from the nominal concentrations) of the assay for ","suffix":" and AG1402 was −16.0 to −6.6% and −5.9 to −1.7%, respective","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1623,"endOffset":1633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"ecision (percent coefficient of variation) of the assay for ","suffix":" and AG1402 was ≤7.2 and 6.6%, respectively. The accuracy (d","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1752,"endOffset":1762,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"deviation from the nominal concentrations) of the assay for ","suffix":" and AG1402 was −16.0 to −6.6% and −5.9 to −1.7%, respective","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":381,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"vastatin and simvastatin and time zero to 12 h postdose for ","suffix":" and AG1402). The geometric mean and its associated 95% CI o","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":513,"endOffset":523,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"the Cmax were calculated for atorvastatin, simvastatin, and ","suffix":". The ratio and its associated 90% CI of the geometric mean ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":667,"endOffset":677,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"atorvastatin and simvastatin in the presence and absence of ","suffix":" were also calculated. Analysis of variance was used to comp","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":850,"endOffset":860,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"atorvastatin and simvastatin in the absence and presence of ","suffix":", with the exception of Tmax, which was analyzed by a nonpar","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":967,"endOffset":977,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"d by a nonparametric method. Pharmacokinetic parameters for ","suffix":" and AG1402 were compared to results from previous studies w","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1074,"endOffset":1084,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"from previous studies with healthy volunteers who had taken ","suffix":" (1,250 mg BID) for at least 10 days. Mean baseline values a","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":304,"endOffset":314,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":". One Caucasian male in treatment group 1 (atorvastatin and ","suffix":") developed a rash, requested withdrawal from the study, and","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":624,"endOffset":634,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"en days 20 to 25 in period 2. Mean trough concentrations of ","suffix":" on days 15, 20, 25, and 28 were 0 (0), 2.4 (1.9), 3.0 (2.3)","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":150,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ime profiles of atorvastatin in the absence and presence of ","suffix":" are presented in Fig. ​Fig.1.1. Following the 14 days of at","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":456,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ml, respectively (Table ​(Table1).1). After the addition of ","suffix":" at 1,250 mg BID to the atorvastatin regimen, the geometric ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":149,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"time profiles of simvastatin in the absence and presence of ","suffix":" are presented in Fig. ​Fig.2.2. Following the 14 days of si","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":452,"endOffset":462,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"ml, respectively (Table ​(Table1).1). After the addition of ","suffix":" at 1,250 mg BID to the simvastatin regimen, the geometric m","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":134,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":" means of the AUCτ (time zero to 12 h postdose) and Cmax of ","suffix":" in the presence of atorvastatin were 44 (95% CI, 35 to 54) ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":305,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"l, respectively. The geometric mean of the AUCτ and Cmax of ","suffix":" in the presence of simvastatin were 38 (range, 31 to 47) μg","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":457,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":" 4.3 to 6.1) μg/ml, respectively. The median Tmax values of ","suffix":" in the presence of atorvastatin and simvastatin were 5.0 (r","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":642,"endOffset":652,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tively. The geometric mean ratios of the AG1402 AUCτ to the ","suffix":" AUCτ were 0.35 (95% CI, 0.25 to 0.48) and 0.31 (95% CI, 0.2","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":882,"endOffset":892,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":" the Cmax, the Tmax, or the ratio of the AG1402 AUCτ to the ","suffix":" AUCτ between these two groups (P > 0.05).\n                 ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":971,"endOffset":981,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"increase in simvastatin levels was related to the levels of ","suffix":" in plasma. Linear regression of the simvastatin AUC ratio (","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2285,"endOffset":2295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ase in atorvastatin levels was not related to the levels of ","suffix":" in plasma. Factors such as the nelfinavir AUC, the atorvast","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2327,"endOffset":2337,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" to the levels of nelfinavir in plasma. Factors such as the ","suffix":" AUC, the atorvastatin AUC in the absence of nelfinavir, gen","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":294,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ase), respectively, and the ratio of the AG1402 AUCτ to the ","suffix":" AUCτ ranged from 0.2 to 0.4. The pharmacokinetic parameters","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":642,"endOffset":652,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tively. The geometric mean ratios of the AG1402 AUCτ to the ","suffix":" AUCτ were 0.35 (95% CI, 0.25 to 0.48) and 0.31 (95% CI, 0.2","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":882,"endOffset":892,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":" the Cmax, the Tmax, or the ratio of the AG1402 AUCτ to the ","suffix":" AUCτ between these two groups (P > 0.05).\n                 ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":971,"endOffset":981,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"increase in simvastatin levels was related to the levels of ","suffix":" in plasma. Linear regression of the simvastatin AUC ratio (","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2285,"endOffset":2295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ase in atorvastatin levels was not related to the levels of ","suffix":" in plasma. Factors such as the nelfinavir AUC, the atorvast","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2327,"endOffset":2337,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" to the levels of nelfinavir in plasma. Factors such as the ","suffix":" AUC, the atorvastatin AUC in the absence of nelfinavir, gen","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":294,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ase), respectively, and the ratio of the AG1402 AUCτ to the ","suffix":" AUCτ ranged from 0.2 to 0.4. The pharmacokinetic parameters","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":372,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"onsidered treatment-related adverse events, most related to ","suffix":" treatment. The most frequently reported adverse event was d","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":529,"endOffset":539,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons. In this study, we investigated the interaction between ","suffix":" and two HMG-CoA reductase inhibitors, simvastatin and atorv","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":127,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s of this study indicate that administration of 1,250 mg of ","suffix":" BID increases the steady-state simvastatin equivalent conce","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":446,"endOffset":456,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ed 505 and 517%, respectively, with the coadministration of ","suffix":". All of the subjects in the simvastatin arm showed an incre","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":574,"endOffset":584,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"rease in the simvastatin equivalent AUCτ in the presence of ","suffix":", with a range of 145 to 1,524% (Fig. ​(Fig.3),3), suggestin","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":680,"endOffset":690,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":". ​(Fig.3),3), suggesting a consistent inhibitory effect of ","suffix":" on simvastatin metabolism. Two subjects had a greater than ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":822,"endOffset":832,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ease in the simvastatin AUC, and they also had the greatest ","suffix":" AUCs (78 and 104 μg·h/ml, respectively), suggesting that th","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":971,"endOffset":981,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"increase in simvastatin levels was related to the levels of ","suffix":" in plasma. Linear regression of the simvastatin AUC ratio (","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1082,"endOffset":1092,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"astatin AUC ratio (the ratio of the AUC of simvastatin plus ","suffix":" to that of simvastatin alone) versus the nelfinavir AUC in ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1134,"endOffset":1144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"in plus nelfinavir to that of simvastatin alone) versus the ","suffix":" AUC in the individual subjects also demonstrated a high cor","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1255,"endOffset":1265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" high correlation between the simvastatin AUC ratio and the ","suffix":" AUC with an R2 value of 0.81. Other factors, such as the si","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1357,"endOffset":1367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ther factors, such as the simvastatin AUC in the absence of ","suffix":", gender, and race, were not related to the simvastatin AUC ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1467,"endOffset":1477,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"the simvastatin AUC ratio. These results suggested that the ","suffix":" level was a major determinant of the change in simvastatin ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1708,"endOffset":1718,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"nly 74 and 122%, respectively, with the coadministration of ","suffix":". Fourteen of the 15 subjects in the atorvastatin arm showed","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1850,"endOffset":1860,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" in the AUCτ of atorvastatin equivalents in the presence of ","suffix":", with a range of −3 to 361% (Fig. ​(Fig.3),3), suggesting a","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1960,"endOffset":1970,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":".3),3), suggesting a fairly consistent inhibitory effect of ","suffix":" on atorvastatin metabolism. Two subjects had a greater-than","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2088,"endOffset":2098,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"an-threefold increase in atorvastatin. However, the AUCs of ","suffix":" (42 and 60 μg·h/ml, respectively) in these two subjects wer","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2285,"endOffset":2295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ase in atorvastatin levels was not related to the levels of ","suffix":" in plasma. Factors such as the nelfinavir AUC, the atorvast","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2327,"endOffset":2337,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" to the levels of nelfinavir in plasma. Factors such as the ","suffix":" AUC, the atorvastatin AUC in the absence of nelfinavir, gen","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2382,"endOffset":2392,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" the nelfinavir AUC, the atorvastatin AUC in the absence of ","suffix":", gender, and race were not related to the atorvastatin AUC ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2503,"endOffset":2513,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"atin AUC ratio. The difference in the inhibitory effects of ","suffix":" on simvastatin and atorvastatin was not unexpected. Simvast","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":176,"endOffset":186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"astatin is likely due mainly to the inhibition of CYP3A4 by ","suffix":" since the in vitro and in vivo drug metabolism of these com","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":298,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"hese compounds is well established. Inhibition of CYP3A4 by ","suffix":" could occur at the gastrointestinal wall, which would have ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":662,"endOffset":672,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"10, 23, 24) and in vivo (5, 10) studies have suggested that ","suffix":", atorvastatin, and simvastatin may also be substrates/inhib","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":805,"endOffset":815,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"efflux pump P-glycoprotein. Inhibition of P-glycoprotein by ","suffix":" may increase the oral absorption of atorvastatin and simvas","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":403,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rvastatin and simvastatin caused by the coadministration of ","suffix":" may not reflect the change in drug concentrations in the li","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"atorvastatin and simvastatin in the presence and absence of ","suffix":" (Table ​(Table2)2) despite a significant increase in the sy","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":774,"endOffset":784,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"simvastatin. These results may suggest different effects of ","suffix":" on the systemic and liver pharmacokinetics of atorvastatin ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":295,"endOffset":305,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hronic coadministration of atorvastatin or simvastatin with ","suffix":" in HIV-positive patients. The greater-than-500% increase in","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":415,"endOffset":425,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ncrease in the simvastatin concentration in the presence of ","suffix":" was quite extensive and may increase the risk of skeletal m","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":572,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" is recommended that simvastatin not be coadministered with ","suffix":". Nelfinavir had a more moderate effect on atorvastatin conc","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":584,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ded that simvastatin not be coadministered with nelfinavir. ","suffix":" had a more moderate effect on atorvastatin concentrations. ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":99,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"                  In previous studies, the AUCτ and Cmax of ","suffix":" after administration of 1,250 mg BID to healthy volunteers ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":642,"endOffset":652,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tively. The geometric mean ratios of the AG1402 AUCτ to the ","suffix":" AUCτ were 0.35 (95% CI, 0.25 to 0.48) and 0.31 (95% CI, 0.2","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":882,"endOffset":892,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":" the Cmax, the Tmax, or the ratio of the AG1402 AUCτ to the ","suffix":" AUCτ between these two groups (P > 0.05).\n                 ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":971,"endOffset":981,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"increase in simvastatin levels was related to the levels of ","suffix":" in plasma. Linear regression of the simvastatin AUC ratio (","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2285,"endOffset":2295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ase in atorvastatin levels was not related to the levels of ","suffix":" in plasma. Factors such as the nelfinavir AUC, the atorvast","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":2327,"endOffset":2337,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" to the levels of nelfinavir in plasma. Factors such as the ","suffix":" AUC, the atorvastatin AUC in the absence of nelfinavir, gen","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":294,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ase), respectively, and the ratio of the AG1402 AUCτ to the ","suffix":" AUCτ ranged from 0.2 to 0.4. The pharmacokinetic parameters","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":368,"endOffset":378,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"τ ranged from 0.2 to 0.4. The pharmacokinetic parameters of ","suffix":" and AG1402 in this study were similar to those in a previou","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":556,"endOffset":566,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"tatin and simvastatin did not alter the pharmacokinetics of ","suffix":" and its active metabolite. These results were not unexpecte","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":251,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"ecommended for long-term coadministration with simvastatin. ","suffix":" also increased systemic exposure to atorvastatin moderately","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"viracept","startOffset":277,"endOffset":285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"s received atorvastatin calcium (10 mg QD) plus nelfinavir (","suffix":"; 1,250 mg twice a day [BID]) for an additional 14 days (day","exact":"Viracept"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":797,"endOffset":809,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"a protease inhibitor, and two HMG-CoA reductase inhibitors, ","suffix":" and simvastatin, in healthy volunteers. Thirty-two healthy ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1283,"endOffset":1295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"concentration-time curve during one dosing period (AUCτ) of ","suffix":" 74% and the maximum concentration (Cmax) of atorvastatin 12","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1340,"endOffset":1352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"of atorvastatin 74% and the maximum concentration (Cmax) of ","suffix":" 122% and increased the AUCτ of simvastatin 505% and the Cma","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1443,"endOffset":1455,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" simvastatin 505% and the Cmax of simvastatin 517%. Neither ","suffix":" nor simvastatin appeared to alter the pharmacokinetics of n","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":639,"endOffset":651,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" lovastatin approximately fivefold but increased the AUC of ","suffix":" only 60% (16, 17). The greatly elevated concentrations of s","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":313,"endOffset":325,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"been shown to increase the concentration of simvastatin and ","suffix":" (C. Fichtenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7t","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":796,"endOffset":808,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"wo HMG-CoA reductase inhibitors were chosen for this study. ","suffix":" was studied because it is the most prescribed HMG-CoA reduc","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":200,"endOffset":212,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"mine the pharmacokinetic interaction between nelfinavir and ","suffix":" or nelfinavir and simvastatin in healthy volunteers. Thirty","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"for atorvastatin equivalent concentrations (as the total of ","suffix":" acid and its active metabolites) or simvastatin equivalent ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":453,"endOffset":465,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"tional Life Sciences, Inc. (Saint-Laurent, Quebec, Canada). ","suffix":" or simvastatin was isolated from 0.25 ml of human plasma by","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":595,"endOffset":607,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"recipitation with acetonitrile/acetone (95:5, vol/vol). The ","suffix":" or simvastatin equivalent concentration was estimated by in","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":858,"endOffset":870,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"factor. Since it was an enzyme inhibition assay, all of the ","suffix":" or simvastatin and its active metabolites in plasma capable","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":990,"endOffset":1002,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":" of inhibiting HMG-CoA reductase was quantified. Therefore, ","suffix":" or simvastatin concentrations were expressed as atorvastati","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1051,"endOffset":1063,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"torvastatin or simvastatin concentrations were expressed as ","suffix":" or simvastatin equivalents. The standard curves were linear","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1158,"endOffset":1170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"andard curves were linear with R2 values of >0.997 for both ","suffix":" and simvastatin. This method was validated within concentra","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1268,"endOffset":1280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"dated within concentration ranges of 0.18 to 7.35 ng/ml for ","suffix":" and 0.3 to 15.2 ng/ml for simvastatin. The precision levels","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1393,"endOffset":1405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":" levels (percent coefficient of variation) of the assay for ","suffix":" and simvastatin were ≤11.3 and 25.4%, respectively. The acc","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1539,"endOffset":1551,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"deviation from the nominal concentrations) of the assay for ","suffix":" and simvastatin were within 0.1 to 3.7% and −6.4 to 3.4%, r","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1539,"endOffset":1551,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"deviation from the nominal concentrations) of the assay for ","suffix":" and simvastatin were within 0.1 to 3.7% and −6.4 to 3.4%, r","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":317,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"riod (AUCτ) were calculated (time zero to 24 h postdose for ","suffix":" and simvastatin and time zero to 12 h postdose for nelfinav","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":482,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"n and its associated 95% CI of the Cmax were calculated for ","suffix":", simvastatin, and nelfinavir. The ratio and its associated ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":607,"endOffset":619,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"ciated 90% CI of the geometric mean of the AUCτ and Cmax of ","suffix":" and simvastatin in the presence and absence of nelfinavir w","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":790,"endOffset":802,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"to compare logarithmically transformed parameter values for ","suffix":" and simvastatin in the absence and presence of nelfinavir, ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"nd three females). One Caucasian male in treatment group 1 (","suffix":" and nelfinavir) developed a rash, requested withdrawal from","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":472,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ic analysis. The mean (standard deviation [SD]) ages of the ","suffix":" and simvastatin groups were 31.5 (5.0) and 38.3 (9.7) years","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":594,"endOffset":606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"9.7) years, respectively. The mean (SD) body weights of the ","suffix":" and simvastatin groups were 74 (12) and 72 (9) kg, respecti","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":78,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"                                           Mean (SD) trough ","suffix":" equivalent concentrations on days 1, 5, 10, 14, 20, 25, and","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":493,"endOffset":505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" ng-eq/ml. These results indicated that the steady state of ","suffix":" and simvastatin was reached on day 5 in period 1 and betwee","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":106,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"               The mean (SD) concentration-time profiles of ","suffix":" in the absence and presence of nelfinavir are presented in ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":218,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ir are presented in Fig. ​Fig.1.1. Following the 14 days of ","suffix":" dosing at 10 mg QD, the geometric mean AUCτ and Cmax for at","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"in dosing at 10 mg QD, the geometric mean AUCτ and Cmax for ","suffix":" equivalents (sum of atorvastatin acid and active metabolite","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":321,"endOffset":333,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ric mean AUCτ and Cmax for atorvastatin equivalents (sum of ","suffix":" acid and active metabolites) were 77 ng-eq·h/ml and 7.4 ng-","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":490,"endOffset":502,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"1). After the addition of nelfinavir at 1,250 mg BID to the ","suffix":" regimen, the geometric mean steady-state AUCτ and Cmax for ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":562,"endOffset":574,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":" regimen, the geometric mean steady-state AUCτ and Cmax for ","suffix":" equivalents were 134 ng-eq·h/ml and 16.4 ng-eq/ml, respecti","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":164,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"to 12 h postdose) and Cmax of nelfinavir in the presence of ","suffix":" were 44 (95% CI, 35 to 54) μg·h/ml and 5.7 (95% CI, 4.8 to ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":487,"endOffset":499,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"ly. The median Tmax values of nelfinavir in the presence of ","suffix":" and simvastatin were 5.0 (range, 2.0 to 8.0) and 5.0 (range","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":742,"endOffset":754,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"to 0.48) and 0.31 (95% CI, 0.22 to 0.42) in the presence of ","suffix":" and simvastatin, respectively. There was no difference in t","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":594,"endOffset":606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"navir and two HMG-CoA reductase inhibitors, simvastatin and ","suffix":", because of the potential for drug interaction and the pote","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":733,"endOffset":745,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"f the coadministration of these drugs. Both simvastatin and ","suffix":" are extensively metabolized by humans, and a number of acti","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":906,"endOffset":918,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" The active metabolites account for most of the activity of ","suffix":" and simvastatin. The enzyme inhibition assay used in this s","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":250,"endOffset":262,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"t concentrations extensively and increases the steady-state ","suffix":" equivalent concentrations moderately. The geometric mean AU","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1594,"endOffset":1606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"in levels. In contrast, the geometric mean AUCτ and Cmax of ","suffix":"-associated HMG-CoA inhibitors increased only 74 and 122%, r","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1755,"endOffset":1767,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"istration of nelfinavir. Fourteen of the 15 subjects in the ","suffix":" arm showed an increase in the AUCτ of atorvastatin equivale","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1806,"endOffset":1818,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s in the atorvastatin arm showed an increase in the AUCτ of ","suffix":" equivalents in the presence of nelfinavir, with a range of ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":1974,"endOffset":1986,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ting a fairly consistent inhibitory effect of nelfinavir on ","suffix":" metabolism. Two subjects had a greater-than-threefold incre","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":2053,"endOffset":2065,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"lism. Two subjects had a greater-than-threefold increase in ","suffix":". However, the AUCs of nelfinavir (42 and 60 μg·h/ml, respec","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":2232,"endOffset":2244,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"arly high, suggesting that the magnitude of the increase in ","suffix":" levels was not related to the levels of nelfinavir in plasm","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":2347,"endOffset":2359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"lfinavir in plasma. Factors such as the nelfinavir AUC, the ","suffix":" AUC in the absence of nelfinavir, gender, and race were not","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":2435,"endOffset":2447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"nce of nelfinavir, gender, and race were not related to the ","suffix":" AUC ratio. The difference in the inhibitory effects of nelf","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":2533,"endOffset":2545,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" in the inhibitory effects of nelfinavir on simvastatin and ","suffix":" was not unexpected. Simvastatin appears to be very sensitiv","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":2793,"endOffset":2805,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"arkedly, whereas itraconazole had only a moderate effect on ","suffix":" equivalents (16, 17). This difference may be explained by t","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":425,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ve a major effect on the bioavailability of simvastatin and ","suffix":", and/or at the liver, which would have an effect on the bio","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":550,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"the bioavailability and elimination rate of simvastatin and ","suffix":". In addition, a number of in vitro (4, 10, 23, 24) and in v","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":674,"endOffset":686,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"and in vivo (5, 10) studies have suggested that nelfinavir, ","suffix":", and simvastatin may also be substrates/inhibitors of the e","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":852,"endOffset":864,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"coprotein by nelfinavir may increase the oral absorption of ","suffix":" and simvastatin and contribute to the observed clinical int","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":340,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tion period. The increase in the systemic concentrations of ","suffix":" and simvastatin caused by the coadministration of nelfinavi","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":548,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"eresting to observe similar cholesterol-lowering effects of ","suffix":" and simvastatin in the presence and absence of nelfinavir (","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":697,"endOffset":709,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" despite a significant increase in the systemic exposure of ","suffix":" and simvastatin. These results may suggest different effect","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":262,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"are difficult to extrapolate to chronic coadministration of ","suffix":" or simvastatin with nelfinavir in HIV-positive patients. Th","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":625,"endOffset":637,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d with nelfinavir. Nelfinavir had a more moderate effect on ","suffix":" concentrations. The recommended doses of atorvastatin are 1","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":679,"endOffset":691,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ct on atorvastatin concentrations. The recommended doses of ","suffix":" are 10 to 80 mg/day. Thus, the 10-mg dose of atorvastatin s","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":737,"endOffset":749,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f atorvastatin are 10 to 80 mg/day. Thus, the 10-mg dose of ","suffix":" should be started and titrated with caution to achieve the ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":489,"endOffset":501,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"a previous studies with healthy volunteers, suggesting that ","suffix":" and simvastatin did not alter the pharmacokinetics of nelfi","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":632,"endOffset":644,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ts active metabolite. These results were not unexpected, as ","suffix":" and simvastatin are weak CYP3A4 inhibitors and their concen","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":298,"endOffset":310,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"simvastatin. Nelfinavir also increased systemic exposure to ","suffix":" moderately and should be coadministered with atorvastatin w","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"r excellent statistical analysis of the data and the Pfizer ","suffix":" Team for valuable suggestions for the study.\n              ","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin calcium","startOffset":894,"endOffset":914,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"thy volunteers. Thirty-two healthy subjects received either ","suffix":" (10 mg once a day) or simvastatin (20 mg once a day) for th","exact":"atorvastatin calcium"},{"setid":"PMC90851","drugname":"lipitor","startOffset":114,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"       In period 1, subjects received atorvastatin calcium (","suffix":"; 10 mg once a day [QD]) in the morning for the first 14 day","exact":"Lipitor"},{"setid":"PMC90851","drugname":"atorvastatin calcium","startOffset":228,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" first 14 days of the study. In period 2, subjects received ","suffix":" (10 mg QD) plus nelfinavir (Viracept; 1,250 mg twice a day ","exact":"atorvastatin calcium"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":814,"endOffset":825,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"tor, and two HMG-CoA reductase inhibitors, atorvastatin and ","suffix":", in healthy volunteers. Thirty-two healthy subjects receive","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":937,"endOffset":948,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" received either atorvastatin calcium (10 mg once a day) or ","suffix":" (20 mg once a day) for the first 14 days of the study. Nelf","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1384,"endOffset":1395,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ation (Cmax) of atorvastatin 122% and increased the AUCτ of ","suffix":" 505% and the Cmax of simvastatin 517%. Neither atorvastatin","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1417,"endOffset":1428,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" and increased the AUCτ of simvastatin 505% and the Cmax of ","suffix":" 517%. Neither atorvastatin nor simvastatin appeared to alte","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1460,"endOffset":1471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" and the Cmax of simvastatin 517%. Neither atorvastatin nor ","suffix":" appeared to alter the pharmacokinetics of nelfinavir. It is","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1569,"endOffset":1580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s of nelfinavir. It is recommended that coadministration of ","suffix":" with nelfinavir should be avoided, whereas atorvastatin sho","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":362,"endOffset":373,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"eases the levels of HMG-CoA reductase inhibitors in plasma. ","suffix":" and lovastatin appear to be especially sensitive to P450 3A","exact":"Simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":564,"endOffset":575,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ration and area under the concentration-time curve (AUC) of ","suffix":" and lovastatin approximately fivefold but increased the AUC","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":710,"endOffset":721,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"n only 60% (16, 17). The greatly elevated concentrations of ","suffix":" and lovastatin caused by itraconazole or other CYP3A4 inhib","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":297,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"s ritonavir has been shown to increase the concentration of ","suffix":" and atorvastatin (C. Fichtenbaum, J. Gerber, S. Rosenkranz ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":888,"endOffset":899,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" it is the most prescribed HMG-CoA reductase inhibitor, and ","suffix":" was studied because it is particularly susceptible to CYP3A","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":231,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ction between nelfinavir and atorvastatin or nelfinavir and ","suffix":" in healthy volunteers. Thirty-two subjects were enrolled in","exact":"simvastatin"},{"setid":"PMC90851","drugname":"zocor","startOffset":105,"endOffset":110,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"                In period 1, subjects received simvastatin (","suffix":"; 20 mg QD) in the morning for the first 14 days of the stud","exact":"Zocor"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" first 14 days of the study. In period 2, subjects received ","suffix":" (20 mg QD) plus nelfinavir (1,250 mg BID) for an additional","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":199,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"e total of atorvastatin acid and its active metabolites) or ","suffix":" equivalent concentrations (as the total of simvastatin acid","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":469,"endOffset":480,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"nces, Inc. (Saint-Laurent, Quebec, Canada). Atorvastatin or ","suffix":" was isolated from 0.25 ml of human plasma by protein precip","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":611,"endOffset":622,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"h acetonitrile/acetone (95:5, vol/vol). The atorvastatin or ","suffix":" equivalent concentration was estimated by inhibition of the","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":874,"endOffset":885,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":" was an enzyme inhibition assay, all of the atorvastatin or ","suffix":" and its active metabolites in plasma capable of inhibiting ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1006,"endOffset":1017,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"MG-CoA reductase was quantified. Therefore, atorvastatin or ","suffix":" concentrations were expressed as atorvastatin or simvastati","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1067,"endOffset":1078,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"imvastatin concentrations were expressed as atorvastatin or ","suffix":" equivalents. The standard curves were linear with R2 values","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1175,"endOffset":1186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"e linear with R2 values of >0.997 for both atorvastatin and ","suffix":". This method was validated within concentration ranges of 0","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1307,"endOffset":1318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"18 to 7.35 ng/ml for atorvastatin and 0.3 to 15.2 ng/ml for ","suffix":". The precision levels (percent coefficient of variation) of","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1410,"endOffset":1421,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"coefficient of variation) of the assay for atorvastatin and ","suffix":" were ≤11.3 and 25.4%, respectively. The accuracy levels (de","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1556,"endOffset":1567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"e nominal concentrations) of the assay for atorvastatin and ","suffix":" were within 0.1 to 3.7% and −6.4 to 3.4%, respectively.\n   ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1556,"endOffset":1567,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"e nominal concentrations) of the assay for atorvastatin and ","suffix":" were within 0.1 to 3.7% and −6.4 to 3.4%, respectively.\n   ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":334,"endOffset":345,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"calculated (time zero to 24 h postdose for atorvastatin and ","suffix":" and time zero to 12 h postdose for nelfinavir and AG1402). ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":496,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"ciated 95% CI of the Cmax were calculated for atorvastatin, ","suffix":", and nelfinavir. The ratio and its associated 90% CI of the","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":624,"endOffset":635,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"the geometric mean of the AUCτ and Cmax of atorvastatin and ","suffix":" in the presence and absence of nelfinavir were also calcula","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":807,"endOffset":818,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[12]/p[1]","prefix":"thmically transformed parameter values for atorvastatin and ","suffix":" in the absence and presence of nelfinavir, with the excepti","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":489,"endOffset":500,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"mean (standard deviation [SD]) ages of the atorvastatin and ","suffix":" groups were 31.5 (5.0) and 38.3 (9.7) years, respectively. ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":".2), and 3.3 (3.3) ng-eq/ml, respectively. Mean (SD) trough ","suffix":" equivalent concentrations on days 1, 5, 10, 14, 20, 25, and","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":510,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"results indicated that the steady state of atorvastatin and ","suffix":" was reached on day 5 in period 1 and between days 20 to 25 ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":106,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"               The mean (SD) concentration-time profiles of ","suffix":" in the absence and presence of nelfinavir are presented in ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":217,"endOffset":228,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"ir are presented in Fig. ​Fig.2.2. Following the 14 days of ","suffix":" dosing at 20 mg QD, the geometric mean AUCτ and Cmax for si","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":286,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"in dosing at 20 mg QD, the geometric mean AUCτ and Cmax for ","suffix":" equivalents (sum of simvastatin acid and active metabolites","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":486,"endOffset":497,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"1). After the addition of nelfinavir at 1,250 mg BID to the ","suffix":" regimen, the geometric mean AUCτ and Cmax for simvastatin e","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":544,"endOffset":555,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"e simvastatin regimen, the geometric mean AUCτ and Cmax for ","suffix":" equivalents were 255 ng-eq·h/ml and 45.7 ng-eq/ml, respecti","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":335,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":" mean of the AUCτ and Cmax of nelfinavir in the presence of ","suffix":" were 38 (range, 31 to 47) μg·h/ml and 5.1 (95% CI, 4.3 to 6","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":504,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"ax values of nelfinavir in the presence of atorvastatin and ","suffix":" were 5.0 (range, 2.0 to 8.0) and 5.0 (range, 2.0 to 6.0) h,","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":759,"endOffset":770,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":" (95% CI, 0.22 to 0.42) in the presence of atorvastatin and ","suffix":", respectively. There was no difference in the AUCτ, the Cma","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":578,"endOffset":589,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on between nelfinavir and two HMG-CoA reductase inhibitors, ","suffix":" and atorvastatin, because of the potential for drug interac","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":717,"endOffset":728,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" the potential of the coadministration of these drugs. Both ","suffix":" and atorvastatin are extensively metabolized by humans, and","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":923,"endOffset":934,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"olites account for most of the activity of atorvastatin and ","suffix":". The enzyme inhibition assay used in this study measured th","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"on of 1,250 mg of nelfinavir BID increases the steady-state ","suffix":" equivalent concentrations extensively and increases the ste","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":337,"endOffset":348,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"centrations moderately. The geometric mean AUCτ and Cmax of ","suffix":"-associated HMG-CoA inhibitors increased 505 and 517%, respe","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":485,"endOffset":496,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" coadministration of nelfinavir. All of the subjects in the ","suffix":" arm showed an increase in the simvastatin equivalent AUCτ i","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":527,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"e subjects in the simvastatin arm showed an increase in the ","suffix":" equivalent AUCτ in the presence of nelfinavir, with a range","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":694,"endOffset":705,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" suggesting a consistent inhibitory effect of nelfinavir on ","suffix":" metabolism. Two subjects had a greater than 10-fold increas","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":774,"endOffset":785,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"sm. Two subjects had a greater than 10-fold increase in the ","suffix":" AUC, and they also had the greatest nelfinavir AUCs (78 and","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":923,"endOffset":934,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ectively), suggesting that the magnitude of the increase in ","suffix":" levels was related to the levels of nelfinavir in plasma. L","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1018,"endOffset":1029,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"he levels of nelfinavir in plasma. Linear regression of the ","suffix":" AUC ratio (the ratio of the AUC of simvastatin plus nelfina","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1065,"endOffset":1076,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ssion of the simvastatin AUC ratio (the ratio of the AUC of ","suffix":" plus nelfinavir to that of simvastatin alone) versus the ne","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1104,"endOffset":1115,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" ratio of the AUC of simvastatin plus nelfinavir to that of ","suffix":" alone) versus the nelfinavir AUC in the individual subjects","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1225,"endOffset":1236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"l subjects also demonstrated a high correlation between the ","suffix":" AUC ratio and the nelfinavir AUC with an R2 value of 0.81. ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1323,"endOffset":1334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ir AUC with an R2 value of 0.81. Other factors, such as the ","suffix":" AUC in the absence of nelfinavir, gender, and race, were no","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1411,"endOffset":1422,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ce of nelfinavir, gender, and race, were not related to the ","suffix":" AUC ratio. These results suggested that the nelfinavir leve","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":1525,"endOffset":1536,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"e nelfinavir level was a major determinant of the change in ","suffix":" levels. In contrast, the geometric mean AUCτ and Cmax of at","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":2517,"endOffset":2528,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":". The difference in the inhibitory effects of nelfinavir on ","suffix":" and atorvastatin was not unexpected. Simvastatin appears to","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":2566,"endOffset":2577,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"finavir on simvastatin and atorvastatin was not unexpected. ","suffix":" appears to be very sensitive to CYP3A4 inhibitors. Itracona","exact":"Simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":2708,"endOffset":2719,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ssical CYP3A4 inhibitor, also increased the AUC and Cmax of ","suffix":" equivalents markedly, whereas itraconazole had only a moder","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":409,"endOffset":420,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":", which would have a major effect on the bioavailability of ","suffix":" and atorvastatin, and/or at the liver, which would have an ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":534,"endOffset":545,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ve an effect on the bioavailability and elimination rate of ","suffix":" and atorvastatin. In addition, a number of in vitro (4, 10,","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":692,"endOffset":703,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":") studies have suggested that nelfinavir, atorvastatin, and ","suffix":" may also be substrates/inhibitors of the efflux pump P-glyc","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":869,"endOffset":880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"inavir may increase the oral absorption of atorvastatin and ","suffix":" and contribute to the observed clinical interaction. Howeve","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":357,"endOffset":368,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"increase in the systemic concentrations of atorvastatin and ","suffix":" caused by the coadministration of nelfinavir may not reflec","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":565,"endOffset":576,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ve similar cholesterol-lowering effects of atorvastatin and ","suffix":" in the presence and absence of nelfinavir (Table ​(Table2)2","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":714,"endOffset":725,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"icant increase in the systemic exposure of atorvastatin and ","suffix":". These results may suggest different effects of nelfinavir ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" extrapolate to chronic coadministration of atorvastatin or ","suffix":" with nelfinavir in HIV-positive patients. The greater-than-","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":370,"endOffset":381,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"IV-positive patients. The greater-than-500% increase in the ","suffix":" concentration in the presence of nelfinavir was quite exten","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":533,"endOffset":544,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f skeletal muscle damage. Therefore, it is recommended that ","suffix":" not be coadministered with nelfinavir. Nelfinavir had a mor","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":506,"endOffset":517,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"s with healthy volunteers, suggesting that atorvastatin and ","suffix":" did not alter the pharmacokinetics of nelfinavir and its ac","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":649,"endOffset":660,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ite. These results were not unexpected, as atorvastatin and ","suffix":" are weak CYP3A4 inhibitors and their concentrations were mu","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":148,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"of nelfinavir (1,250 mg BID) increased systemic exposure to ","suffix":" approximately 500% and is not recommended for long-term coa","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":238,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":" and is not recommended for long-term coadministration with ","suffix":". Nelfinavir also increased systemic exposure to atorvastati","exact":"simvastatin"},{"setid":"PMC90851","drugname":"sustiva","startOffset":759,"endOffset":766,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"lin. Aspect Treatment HIV Infect., 1997; package insert for ","suffix":" [efavirenz]), and lipodystrophy (13, 21) have been observed","exact":"Sustiva"},{"setid":"PMC90851","drugname":"efavirenz","startOffset":768,"endOffset":777,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ct Treatment HIV Infect., 1997; package insert for Sustiva [","suffix":"]), and lipodystrophy (13, 21) have been observed in HIV-pos","exact":"efavirenz"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":237,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"uctase inhibitors with CYP3A4 inhibitors/substrates such as ","suffix":" (16, 17) and cyclosporine (1, 11) significantly increases t","exact":"itraconazole"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":460,"endOffset":472,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"e especially sensitive to P450 3A4 inhibition. For example, ","suffix":" increases the mean peak concentration and area under the co","exact":"itraconazole"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":747,"endOffset":759,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ated concentrations of simvastatin and lovastatin caused by ","suffix":" or other CYP3A4 inhibitors may increase the risk of rhabdom","exact":"itraconazole"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":2629,"endOffset":2641,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"vastatin appears to be very sensitive to CYP3A4 inhibitors. ","suffix":", a classical CYP3A4 inhibitor, also increased the AUC and C","exact":"Itraconazole"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":2750,"endOffset":2762,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"e AUC and Cmax of simvastatin equivalents markedly, whereas ","suffix":" had only a moderate effect on atorvastatin equivalents (16,","exact":"itraconazole"},{"setid":"PMC90851","drugname":"cyclosporine","startOffset":263,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"3A4 inhibitors/substrates such as itraconazole (16, 17) and ","suffix":" (1, 11) significantly increases the levels of HMG-CoA reduc","exact":"cyclosporine"},{"setid":"PMC90851","drugname":"lovastatin","startOffset":378,"endOffset":388,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" of HMG-CoA reductase inhibitors in plasma. Simvastatin and ","suffix":" appear to be especially sensitive to P450 3A4 inhibition. F","exact":"lovastatin"},{"setid":"PMC90851","drugname":"lovastatin","startOffset":580,"endOffset":590,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"under the concentration-time curve (AUC) of simvastatin and ","suffix":" approximately fivefold but increased the AUC of atorvastati","exact":"lovastatin"},{"setid":"PMC90851","drugname":"lovastatin","startOffset":726,"endOffset":736,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"17). The greatly elevated concentrations of simvastatin and ","suffix":" caused by itraconazole or other CYP3A4 inhibitors may incre","exact":"lovastatin"},{"setid":"PMC90851","drugname":"saquinavir","startOffset":223,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"itors of CYP3A4. The dual protease inhibitor combination of ","suffix":" plus ritonavir has been shown to increase the concentration","exact":"saquinavir"},{"setid":"PMC90851","drugname":"ritonavir","startOffset":239,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" The dual protease inhibitor combination of saquinavir plus ","suffix":" has been shown to increase the concentration of simvastatin","exact":"ritonavir"},{"setid":"PMC90851","drugname":"ritonavir","startOffset":571,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" CYP3A4, although it is not as strong a CYP3A4 inhibitor as ","suffix":". Nelfinavir is a widely prescribed protease inhibitor. It i","exact":"ritonavir"},{"setid":"PMC90851","drugname":"retrovir","startOffset":393,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"htenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7th Conf. ","suffix":". Opportunistic Infect., abstr LB 6, 2000). Nelfinavir, like","exact":"Retrovir"},{"setid":"PMC90851","drugname":"acetonitrile","startOffset":611,"endOffset":623,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"ide (pH 10.5) and then extracted by 2.0 ml of ethyl acetate/","suffix":" (9:1 ratio) mixture. The mixture was centrifuged for 5 min ","exact":"acetonitrile"},{"setid":"PMC90851","drugname":"acetonitrile","startOffset":910,"endOffset":922,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":" of mobile phase (25 mM sodium phosphate, monobasic pH 3.4, ","suffix":"-methanol; 60:32.5:7.5 by volume) and subjected to high-perf","exact":"acetonitrile"},{"setid":"PMC90851","drugname":"acetonitrile","startOffset":553,"endOffset":565,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":" from 0.25 ml of human plasma by protein precipitation with ","suffix":"/acetone (95:5, vol/vol). The atorvastatin or simvastatin eq","exact":"acetonitrile"},{"setid":"PMC90851","drugname":"sodium phosphate, monobasic","startOffset":874,"endOffset":901,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"sidue was reconstituted with 0.15 ml of mobile phase (25 mM ","suffix":" pH 3.4, acetonitrile-methanol; 60:32.5:7.5 by volume) and s","exact":"sodium phosphate, monobasic"},{"setid":"PMC90851","drugname":"acetone","startOffset":566,"endOffset":573,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":" of human plasma by protein precipitation with acetonitrile/","suffix":" (95:5, vol/vol). The atorvastatin or simvastatin equivalent","exact":"acetone"},{"setid":"PMC90851","drugname":"insulin","startOffset":276,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"ol, low-density lipoproteins (LDL), triglycerides, glucose, ","suffix":", and C-peptide, were determined after an overnight fast on ","exact":"insulin"},{"setid":"PMC90851","drugname":"insulin","startOffset":405,"endOffset":412,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" confidence. Other metabolic parameters, including glucose, ","suffix":", and C-peptide, were generally within the normal range and ","exact":"insulin"},{"setid":"PMC90851","drugname":"at 10","startOffset":238,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"Fig. ​Fig.1.1. Following the 14 days of atorvastatin dosing ","suffix":" mg QD, the geometric mean AUCτ and Cmax for atorvastatin eq","exact":"at 10"},{"setid":"PMC90851","drugname":"benadryl","startOffset":666,"endOffset":674,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":" 23 and withdrew from the study. Subject 3 was treated with ","suffix":" and prednisone orally plus Kenalog intramuscularly. The ras","exact":"Benadryl"},{"setid":"PMC90851","drugname":"prednisone","startOffset":679,"endOffset":689,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"rew from the study. Subject 3 was treated with Benadryl and ","suffix":" orally plus Kenalog intramuscularly. The rash resolved afte","exact":"prednisone"},{"setid":"PMC90851","drugname":"kenalog","startOffset":702,"endOffset":709,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ject 3 was treated with Benadryl and prednisone orally plus ","suffix":" intramuscularly. The rash resolved after 13 days. Subject 1","exact":"Kenalog"},{"setid":"PMC90851","drugname":"tylenol","startOffset":834,"endOffset":841,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"erienced a severe migraine headache, which was treated with ","suffix":" and resolved after 2 days. Seven subjects received medicati","exact":"Tylenol"}],[{"setid":"PMC2686068","drugname":"simvastatin","startOffset":200,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"udy in 12 healthy subjects was performed. Subjects received ","suffix":" 40 mg alone or anacetrapib 150 mg co-administered with simv","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":267,"endOffset":278,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin 40 mg alone or anacetrapib 150 mg co-administered with ","suffix":" 40 mg, once daily. Both treatments were administered follow","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"sh-out period of at least 14 days. Safety and tolerability, ","suffix":" and simvastatin acid concentrations, and lipoproteins, were","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":126,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oth treatments were well tolerated. The pharmacokinetics of ","suffix":" and simvastatin acid were similar with and without anacetra","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":304,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"tio [90% confidence interval (CI)] for simvastatin acid and ","suffix":" were 1.36 [1.17, 1.57] and 1.30 [1.14, 1.47], respectively}","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":455,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"cified comparability bounds of (0.50, 2.00). Treatment with ","suffix":" alone led to a mean (95% CI) % reduction from baseline in l","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":208,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"inetic parameters of simvastatin. When co-administered with ","suffix":", anacetrapib appeared to exhibit incremental LDL-C-lowering","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":181,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" quantify any potential pharmacokinetic interaction between ","suffix":" and anacetrapib, following multiple oral doses of each, whe","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ment A, subjects received a once daily oral dose of a 40-mg ","suffix":" tablet (ZOCOR™) for 14 days in the morning. In Treatment B,","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":460,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"les, co-administered with a once-daily oral dose of a 40-mg ","suffix":" tablet for 14 days in the morning. All doses were administe","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":550,"endOffset":561,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"thesis was that the AUC0-24 h geometric mean ratio (GMR) of ","suffix":" and simvastatin acid following multiple oral doses of 40 mg","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":566,"endOffset":577,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"the AUC0-24 h geometric mean ratio (GMR) of simvastatin and ","suffix":" acid following multiple oral doses of 40 mg simvastatin (vs","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":622,"endOffset":633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"and simvastatin acid following multiple oral doses of 40 mg ","suffix":" (vs. anacetrapib alone) is contained within the interval (0","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":273,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" parameter, AUC0-24 h GMR (90% CI) for simvastatin acid and ","suffix":" were 1.36 (1.17, 1.57) and 1.30 (1.14, 1.47), respectively.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":403,"endOffset":414,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":". Similarly, the Cmax GMR (90% CI) for simvastatin acid and ","suffix":" were 1.26 (1.03, 1.55) and 1.24 (1.01, 1.52), respectively.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":595,"endOffset":606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"2 between the two treatments for either simvastatin acid or ","suffix":". While calculated, the half-life values should be interpret","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":231,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the effect of anacetrapib on simvastatin pharmacokinetics. ","suffix":" is a lactone that is readily hydrolysed in vivo to the corr","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":494,"endOffset":505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" system responsible for the metabolism of simvastatin [10]. ","suffix":" is well absorbed (about 60-80%) after oral administration, ","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1643,"endOffset":1654,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" variable in this state than with a high-fat breakfast [3]. ","suffix":"'s absorption is not affected by food, hence not impacted by","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1500,"endOffset":1511,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"lycerides, and hence was not measured in the present study. ","suffix":" is a highly effective marketed drug for the reduction of LD","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1739,"endOffset":1750,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"es the rate-limiting step in cholesterol biosynthesis [10]. ","suffix":", at a dose of 80 mg per day, effectively reduced LDL-C by 4","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":185,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"at baseline and on day 14 at 24 h post dose. Treatment with ","suffix":" alone led to a mean (95% CI) % reduction from baseline in L","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":362,"endOffset":373,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ion of −54% (−44, −63) for anacetrapib co-administered with ","suffix":". The estimated difference (90% CI) (anacetrapib + simvastat","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":424,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"mvastatin. The estimated difference (90% CI) (anacetrapib + ","suffix":" vs. simvastatin alone) in LDL-C mean % change from baseline","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":440,"endOffset":451,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"stimated difference (90% CI) (anacetrapib + simvastatin vs. ","suffix":" alone) in LDL-C mean % change from baseline was therefore −","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":587,"endOffset":598,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"imilarly, the estimated differences (90% CI) (anacetrapib + ","suffix":" vs. simvastatin alone) in other lipoprotein parameters were","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":603,"endOffset":614,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"timated differences (90% CI) (anacetrapib + simvastatin vs. ","suffix":" alone) in other lipoprotein parameters were as follows: HDL","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":603,"endOffset":614,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"timated differences (90% CI) (anacetrapib + simvastatin vs. ","suffix":" alone) in other lipoprotein parameters were as follows: HDL","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":126,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" explored primarily the pharmacokinetic interaction between ","suffix":" and anacetrapib, as it relates to the effect of anacetrapib","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":201,"endOffset":212,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" anacetrapib, as it relates to the effect of anacetrapib on ","suffix":" pharmacokinetics. Simvastatin is a lactone that is readily ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":231,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the effect of anacetrapib on simvastatin pharmacokinetics. ","suffix":" is a lactone that is readily hydrolysed in vivo to the corr","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":476,"endOffset":487,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"s the major enzyme system responsible for the metabolism of ","suffix":" [10]. Simvastatin is well absorbed (about 60-80%) after ora","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":494,"endOffset":505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" system responsible for the metabolism of simvastatin [10]. ","suffix":" is well absorbed (about 60-80%) after oral administration, ","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":718,"endOffset":729,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ailability of active HMG-CoA reductase inhibitors following ","suffix":" tablets is <5% of the oral dose. Therefore, simvastatin was","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":774,"endOffset":785,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ing simvastatin tablets is <5% of the oral dose. Therefore, ","suffix":" was selected as the statin for this drug interaction study.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":873,"endOffset":884,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"for this drug interaction study. Although the 80-mg dose of ","suffix":" is the highest currently approved dose, the recommended usu","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1094,"endOffset":1105,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ent [10]. Therefore, the study investigated a 40-mg dose of ","suffix":" with and without anacetrapib. This simvastatin dose was cho","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1141,"endOffset":1152,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"0-mg dose of simvastatin with and without anacetrapib. This ","suffix":" dose was chosen to increase the sensitivity of the potentia","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1268,"endOffset":1279,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ntial for a pharmacokinetic interaction of anacetrapib with ","suffix":". The anacetrapib dose of 150 mg once daily with a low-fat b","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1643,"endOffset":1654,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" variable in this state than with a high-fat breakfast [3]. ","suffix":"'s absorption is not affected by food, hence not impacted by","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1802,"endOffset":1813,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"his study [10]. A multiple-dose study design was used where ","suffix":" and anacetrapib were dosed orally to steady state and the e","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1918,"endOffset":1929,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"state and the effect of anacetrapib on the plasma levels of ","suffix":" was studied. A duration of 14 days as multiple oral daily d","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":176,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"meaningful effect of anacetrapib on the pharmacokinetics of ","suffix":" (simvastatin acid or simvastatin). This is not unexpected, ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":209,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"on the pharmacokinetics of simvastatin (simvastatin acid or ","suffix":"). This is not unexpected, given data in the literature show","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":307,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"given data in the literature showing drug interactions with ","suffix":" were metabolic in nature, as a result of inhibition or indu","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":507,"endOffset":518,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ingful interaction with a sensitive CYP3A substrate such as ","suffix":" is consistent with the finding that anacetrapib does not in","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":183,"endOffset":194,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"icularly the lipid-altering biomarkers, interaction between ","suffix":" and anacetrapib. Anacetrapib is an investigational CETP inh","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1500,"endOffset":1511,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"lycerides, and hence was not measured in the present study. ","suffix":" is a highly effective marketed drug for the reduction of LD","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1739,"endOffset":1750,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"es the rate-limiting step in cholesterol biosynthesis [10]. ","suffix":", at a dose of 80 mg per day, effectively reduced LDL-C by 4","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1995,"endOffset":2006,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"udy [10]. In the Multicenter Combined Hyperlipidemia Study, ","suffix":", when administered either at 40 or 80 mg per day, elicited ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":1147,"endOffset":1158,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"explain this lack of an additive effect for anacetrapib and ","suffix":". Recently, it was reported that whereas subjects treated wi","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":162,"endOffset":173,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"n additive lipid-altering effects with atorvastatin [7] and ","suffix":" (present study), the lipid-altering effects were anacetrapi","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":151,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"meaningful effect of anacetrapib on the pharmacokinetics of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":190,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":" pharmacokinetics of simvastatin. When co-administered with ","suffix":", anacetrapib appeared to exhibit incremental LDL-C-and Apo ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":339,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","prefix":"ssistance of Rita Chiou and Jin Zhang in outsourcing of the ","suffix":" assay, and the assistance of Josee Cote at the conclusion o","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"cholesterol","startOffset":549,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"5% CI) % reduction from baseline in low-density lipoprotein-","suffix":" (LDL-C) of −36% (−27, −46) compared with a reduction of −54","exact":"cholesterol"},{"setid":"PMC2686068","drugname":"cholesterol","startOffset":391,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"re collected for the measurement of low-density lipoprotein-","suffix":" (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and ","exact":"cholesterol"},{"setid":"PMC2686068","drugname":"cholesterol","startOffset":437,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"y lipoprotein-cholesterol (LDL-C), high-density lipoprotein-","suffix":" (HDL-C), and the apolipoproteins (Apo) B and A1 predose on ","exact":"cholesterol"},{"setid":"PMC2686068","drugname":"cholesterol","startOffset":1421,"endOffset":1432,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ia [7]. Anacetrapib does not meaningfully alter serum total ","suffix":" or triglycerides, and hence was not measured in the present","exact":"cholesterol"},{"setid":"PMC2686068","drugname":"cholesterol","startOffset":1708,"endOffset":1719,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"uctase, the enzyme that catalyses the rate-limiting step in ","suffix":" biosynthesis [10]. Simvastatin, at a dose of 80 mg per day,","exact":"cholesterol"},{"setid":"PMC2686068","drugname":"torcetrapib","startOffset":1428,"endOffset":1439,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":", less than strict additive effects have been observed with ","suffix":", another CETP inhibitor alone and in combination with atorv","exact":"torcetrapib"},{"setid":"PMC2686068","drugname":"torcetrapib","startOffset":1221,"endOffset":1232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ecently, it was reported that whereas subjects treated with ","suffix":" alone demonstrated an enhanced rate of LDL apoB100 cataboli","exact":"torcetrapib"},{"setid":"PMC2686068","drugname":"torcetrapib","startOffset":1815,"endOffset":1826,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"not known whether anacetrapib would behave differently from ","suffix":" with regard to lipoprotein metabolism, and this is currentl","exact":"torcetrapib"},{"setid":"PMC2686068","drugname":"torcetrapib","startOffset":1954,"endOffset":1965,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"investigated. These results appear to suggest, at least for ","suffix":", that there may be a pharmacologically shared mechanism of ","exact":"torcetrapib"},{"setid":"PMC2686068","drugname":"creatinine","startOffset":289,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"s (serum sodium, potassium, chloride, bicarbonate, calcium, ","suffix":", blood urea nitrogen, fasting serum glucose, bilirubin, asp","exact":"creatinine"},{"setid":"PMC2686068","drugname":"urea","startOffset":307,"endOffset":311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"otassium, chloride, bicarbonate, calcium, creatinine, blood ","suffix":" nitrogen, fasting serum glucose, bilirubin, aspartate amino","exact":"urea"},{"setid":"PMC2686068","drugname":"alanine","startOffset":384,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sting serum glucose, bilirubin, aspartate aminotransferase, ","suffix":" aminotransferase, alkaline phosphatase, albumin; haemoglobi","exact":"alanine"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":429,"endOffset":441,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ith dyslipidaemia, both alone as well as in the presence of ","suffix":" [4,5,7]. Thus, the findings of this 14-day study on the lip","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":625,"endOffset":637,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"data on anacetrapib, as monotherapy and in combination with ","suffix":". Anacetrapib has been associated with maximal pharmacodynam","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":1009,"endOffset":1021,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"al reductions in LDL-C and Apo B were similar to those with ","suffix":" 20 mg [7]. Moreover, incremental reductions in LDL-C and Ap","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":1141,"endOffset":1153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"o B were observed when anacetrapib was co-administered with ","suffix":" 20 mg. The net result of treatment with anacetrapib and ato","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":1210,"endOffset":1222,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"tin 20 mg. The net result of treatment with anacetrapib and ","suffix":" was approximately 70% lowering of LDL-C, approximately 50% ","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":864,"endOffset":876,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"with the findings observed with anacetrapib (10-300 mg) and ","suffix":" 20 mg in the Phase 2b study, wherein atorvastatin 20 mg red","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":914,"endOffset":926,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"0 mg) and atorvastatin 20 mg in the Phase 2b study, wherein ","suffix":" 20 mg reduced LDL-C by approximately 42% and when atorvasta","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":977,"endOffset":989,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"rvastatin 20 mg reduced LDL-C by approximately 42% and when ","suffix":" 20 mg was given with anacetrapib 150 mg, LDL-C was reduced ","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":1324,"endOffset":1336,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"rate of LDL apoB100 catabolism, in subjects pretreated with ","suffix":", in which LDL apoB100 catabolism was already enhanced as a ","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":1406,"endOffset":1418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":" LDL apoB100 catabolism was already enhanced as a result of ","suffix":" treatment, there was a reduced LDL apoB100 production rate ","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ears to have less than additive lipid-altering effects with ","suffix":" [7] and simvastatin (present study), the lipid-altering eff","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"gemcabene","startOffset":553,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"pharmacologically dependent effects have been observed with ","suffix":" [16], a discontinued lipid-altering drug. It should be note","exact":"gemcabene"},{"setid":"PMC2686068","drugname":"gemcabene","startOffset":786,"endOffset":795,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"compared with statins, whereas the exact mechanism by which ","suffix":" lowers LDL-C and, more importantly, whether there is a comm","exact":"gemcabene"}],[{"setid":"PMC3187007","drugname":"telaprevir","startOffset":348,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atitis C. This study was conducted to examine the effect of ","suffix":" on atorvastatin and amlodipine pharmacokinetics (PK). This ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"mlodipine and 20 mg atorvastatin was administered on day 1. ","suffix":" was taken with food as a 750-mg dose every 8 h from day 11 ","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":844,"endOffset":854,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lasma samples were collected for determination of the PK of ","suffix":", amlodipine, atorvastatin, ortho-hydroxy atorvastatin, and ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":966,"endOffset":976,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"in, and para-hydroxy atorvastatin. When administration with ","suffix":" was compared with administration without telaprevir, the le","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1018,"endOffset":1028,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"on with telaprevir was compared with administration without ","suffix":", the least-square mean ratios (90% confidence limits) for a","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1370,"endOffset":1380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"4, 12.9) for the Cmax and 7.88 (6.84, 9.07) for the AUC0-∞. ","suffix":" significantly increased exposure to amlodipine and atorvast","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":271,"endOffset":281,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"of patients with chronic hepatitis C (CHC), the addition of ","suffix":" as part of a combination regimen with pegylated interferon ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":434,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ased the rates of sustained virologic response (8, 17, 23). ","suffix":" was recently approved in the United States of America for t","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":131,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" phase 1, open-label, single-center, nonrandomized study of ","suffix":" in combination with Caduet tablets containing 5 mg of amlod","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":392,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"-atorvastatin alone on day 1, followed by a washout period, ","suffix":" at a dose of 750 mg every 8 h (q8h) on days 11 through 26, ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":503,"endOffset":513,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"volunteer logs. All volunteers were ≥90% compliant with the ","suffix":" dosing regimen, and all volunteers received their scheduled","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":565,"endOffset":575,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"amlodipine nor atorvastatin is an inhibitor of CYP3A, while ","suffix":" is a potent inhibitor of CYP3A. Thus, an effect of amlodipi","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":658,"endOffset":668,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"of CYP3A. Thus, an effect of amlodipine and atorvastatin on ","suffix":" pharmacokinetics (PK) was not anticipated. Therefore, telap","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":723,"endOffset":733,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"revir pharmacokinetics (PK) was not anticipated. Therefore, ","suffix":" PK were evaluated only on day 17 and compared to those foun","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":816,"endOffset":826,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" on day 17 and compared to those found historically. Plasma ","suffix":" concentrations were determined at steady state predose and ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":452,"endOffset":462,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"tin-phenyl-d5, para-hydroxy atorvastatin-phenyl-d5, and d11-","suffix":") were extracted from human plasma by liquid-liquid extracti","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1125,"endOffset":1135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"orvastatin (LLOQ, 0.250 ng/ml), and 2.00 to 1,000 ng/ml for ","suffix":" (LLOQ, 2.00 ng/ml).\n                                       ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":322,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":" single dose of amlodipine-atorvastatin coadministered with ","suffix":" were compared to those measured following a single dose of ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":474,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":"n alone. In the analysis, treatment effect (with or without ","suffix":") was considered a fixed effect and subject was a random eff","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":393,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"dministered alone and when administered in combination with ","suffix":". Clinical chemistry and hematology were assessed predose an","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":585,"endOffset":595,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and ","suffix":". Day 17 plasma samples from 2 volunteers were not available","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":425,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"old and 2.79-fold, respectively, by the coadministration of ","suffix":" (Table 1). The mean t1/2 of amlodipine increased from 41.3 ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":437,"endOffset":447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"old and 7.88-fold, respectively, by the coadministration of ","suffix":" (Table 1). The mean apparent clearance (CL/F) decreased fro","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":610,"endOffset":620,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"SD) t1/2 decreased from 9.44 (2.64) h to 6.75 (1.55) h with ","suffix":" coadministration; the difference in t1/2 was not statistica","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":324,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"a-hydroxy atorvastatin in these 2 volunteers increased with ","suffix":" coadministration from 0.30 and 0.54 (mean of 0.42) ng/ml (d","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":130,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"steady-state pharmacokinetic parameters were calculated for ","suffix":" on day 17 after coadministration with a single dose of amlo","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":243,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ngle dose of amlodipine-atorvastatin. The mean (SD) Cmax of ","suffix":" was 3,167 (778) ng/ml, and the mean (SD) AUC0-last of telap","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":308,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"revir was 3,167 (778) ng/ml, and the mean (SD) AUC0-last of ","suffix":" was 20,471 (5,317) h · ng/ml. These values are similar to t","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":208,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"he study due to an adverse event (herpes zoster) during the ","suffix":"-alone period. This was considered possibly related to treat","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"atorvastatin-alone period, in 2 volunteers [10%] during the ","suffix":"-alone period, and in 1 volunteer [5%] during the telaprevir","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":668,"endOffset":678,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"telaprevir-alone period, and in 1 volunteer [5%] during the ","suffix":"-amlodipine-atorvastatin combination period); dizziness (occ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":777,"endOffset":787,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"riod); dizziness (occurred in 2 volunteers [10%] during the ","suffix":"-alone period, and in 3 volunteers [15%] during the telaprev","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":839,"endOffset":849,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"laprevir-alone period, and in 3 volunteers [15%] during the ","suffix":"-amlodipine-atorvastatin combination period); diarrhea (occu","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1013,"endOffset":1023,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"3 periods); nausea (occurred in 1 volunteer [5%] during the ","suffix":"-alone period and in 2 volunteers [11%] during the telaprevi","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1074,"endOffset":1084,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"elaprevir-alone period and in 2 volunteers [11%] during the ","suffix":"-amlodipine-atorvastatin combination period). Rash has been ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1169,"endOffset":1179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"combination period). Rash has been previously reported with ","suffix":" administration (3). A mild papular rash was reported in a s","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1341,"endOffset":1351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"e period of coadministration of amlodipine-atorvastatin and ","suffix":"; the rash resolved without treatment or a change in study d","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":253,"endOffset":263,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" PK of these drugs with and without the coadministration of ","suffix":". A formulation containing a combination of amlodipine and a","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":136,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"g interaction study of telaprevir and midazolam showed that ","suffix":" increased the AUC of oral midazolam almost 9-fold (4), indi","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":218,"endOffset":228,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"he AUC of oral midazolam almost 9-fold (4), indicating that ","suffix":" is a potent inhibitor of CYP3A4. Amlodipine is a dihydropyr","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":538,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"lbumin (∼98%) (15). When amlodipine was coadministered with ","suffix":", its AUC0-∞ increased 2.79-fold and its Cmax increased 1.27","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":878,"endOffset":888,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"h the clearance decrease signifies the inhibitory effect of ","suffix":" on the metabolism of amlodipine. An effect of a similar mag","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":284,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"10.6-fold. These results suggest that the primary effect of ","suffix":" on atorvastatin is to increase its bioavailability (F) by d","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":512,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"glycoprotein-mediated efflux back to the gut. The effect of ","suffix":" on the hepatic metabolism of atorvastatin does not appear t","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":385,"endOffset":395,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"9.44 (2.64) h to 6.75 (1.55) h with the coadministration of ","suffix":", although this difference was not statistically significant","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":141,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"o-hydroxy atorvastatin decreased by approximately 70% after ","suffix":" coadministration; however, most concentrations of para-hydr","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":443,"endOffset":453,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"e before (day 1) and after (day 17) the coadministration of ","suffix":", the concentrations of this metabolite increased about 6-fo","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":913,"endOffset":923,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"mic exposure of atorvastatin during the coadministration of ","suffix":", it is plausible that more para-hydroxy atorvastatin is for","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":303,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"obtained in other studies (21). This suggests that adequate ","suffix":" exposure was achieved in this study and a clinically signif","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":548,"endOffset":558,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ported in other clinical trials after the administration of ","suffix":" alone (8, 17, 23). The low frequency and/or lack of adverse","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":237,"endOffset":247,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"tatin (Cmax and AUC0-∞). Atorvastatin coadministration with ","suffix":" is contraindicated. When amlodipine is coadministered with ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":307,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":" is contraindicated. When amlodipine is coadministered with ","suffix":", caution should be used and an amlodipine dose reduction sh","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"incivek","startOffset":450,"endOffset":457,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"dered. Clinical monitoring is recommended. Please check the ","suffix":" package insert for full information and/or updates (3).\n   ","exact":"INCIVEK"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":166,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"hibitor that is both a substrate and an inhibitor of CYP3A. ","suffix":" and atorvastatin are both substrates of CYP3A and are among","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":379,"endOffset":389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ted to examine the effect of telaprevir on atorvastatin and ","suffix":" pharmacokinetics (PK). This was an open-label, single seque","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":547,"endOffset":557,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"healthy male and female volunteers. A coformulation of 5 mg ","suffix":" and 20 mg atorvastatin was administered on day 1. Telaprevi","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":717,"endOffset":727,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"very 8 h from day 11 until day 26, and a single dose of the ","suffix":"-atorvastatin combination was readministered on day 17. Plas","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":856,"endOffset":866,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were collected for determination of the PK of telaprevir, ","suffix":", atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":1087,"endOffset":1097,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"r, the least-square mean ratios (90% confidence limits) for ","suffix":" were 1.27 (1.21, 1.33) for the maximum drug concentration i","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":1417,"endOffset":1427,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" the AUC0-∞. Telaprevir significantly increased exposure to ","suffix":" and atorvastatin, consistent with the inhibitory effect of ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":498,"endOffset":508,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"lly available as a coformulation (Caduet; Pfizer) (1). Both ","suffix":" and atorvastatin are metabolized primarily by CYP3A (1). CY","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":1100,"endOffset":1110,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"in and organic anion transporter protein (OATP1B1/1B3) (1). ","suffix":" is extensively metabolized, primarily involving oxidation t","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":196,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"revir in combination with Caduet tablets containing 5 mg of ","suffix":" and 20 mg of atorvastatin (amlodipine-atorvastatin). Volunt","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":234,"endOffset":244,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ts containing 5 mg of amlodipine and 20 mg of atorvastatin (","suffix":"-atorvastatin). Volunteers received the following treatment:","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":322,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"lunteers received the following treatment: a single dose of ","suffix":"-atorvastatin alone on day 1, followed by a washout period, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":484,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"very 8 h (q8h) on days 11 through 26, with a single dose of ","suffix":"-atorvastatin on day 17. Outpatient visits occurred at the s","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":139,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"tatin (25-mg fixed dose combination tablets containing 5 mg ","suffix":" and 20 mg atorvastatin; Pfizer Incorporated, New York, NY) ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":125,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"macokinetic evaluations were based on the concentrations of ","suffix":", atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy ato","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":301,"endOffset":311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" 12, 24, 48, 72, 120, 168, and 240 h after a single dose of ","suffix":"-atorvastatin on day 1 and predose and at 0.25, 0.5, 0.75, 1","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":462,"endOffset":472,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"4, 48, 72, 120, 168, and 240 h after another single dose of ","suffix":"-atorvastatin on day 17. Neither amlodipine nor atorvastatin","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":505,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"r single dose of amlodipine-atorvastatin on day 17. Neither ","suffix":" nor atorvastatin is an inhibitor of CYP3A, while telaprevir","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":627,"endOffset":637,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"laprevir is a potent inhibitor of CYP3A. Thus, an effect of ","suffix":" and atorvastatin on telaprevir pharmacokinetics (PK) was no","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":313,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":" (Indianapolis, IN). Analytes and their internal standards (","suffix":"-d4 maleic acid, atorvastatin-d5 sodium salt, ortho-hydroxy ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":836,"endOffset":846,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"sion. The standard curve range was 0.0500 to 25.0 ng/ml for ","suffix":" (lower limit of quantitation [LLOQ], 0.0500 ng/ml), 0.250 t","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":223,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":"e pharmacokinetic parameters (Cmax, AUClast, and AUC0-∞) of ","suffix":" and atorvastatin following a single dose of amlodipine-ator","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":278,"endOffset":288,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":") of amlodipine and atorvastatin following a single dose of ","suffix":"-atorvastatin coadministered with telaprevir were compared t","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":392,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":" were compared to those measured following a single dose of ","suffix":"-atorvastatin alone. In the analysis, treatment effect (with","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":303,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":") were assessed predose and at 8, 10, and 24 h postdose for ","suffix":"-atorvastatin when administered alone and when administered ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":500,"endOffset":510,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"e available following all dosing occasions and analyzed for ","suffix":", atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy ato","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":217,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"c parameter estimates from the noncompartmental analysis of ","suffix":" concentration data are shown in Table 1. Based on the ratio","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":333,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"d on the ratio of the LS means, the mean Cmax and AUC0-∞ of ","suffix":" were increased 1.27-fold and 2.79-fold, respectively, by th","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":464,"endOffset":474,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" coadministration of telaprevir (Table 1). The mean t1/2 of ","suffix":" increased from 41.3 h to 95.1 h, and the mean apparent clea","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":145,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"ation-time profiles of ortho-hydroxy atorvastatin following ","suffix":"-atorvastatin administration on day 1 and day 17 are shown i","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":196,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"evir on day 17 after coadministration with a single dose of ","suffix":"-atorvastatin. The mean (SD) Cmax of telaprevir was 3,167 (7","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":537,"endOffset":547,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"ncluded headache (occurred in 5 volunteers [24%] during the ","suffix":"-atorvastatin-alone period, in 2 volunteers [10%] during the","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":679,"endOffset":689,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"alone period, and in 1 volunteer [5%] during the telaprevir-","suffix":"-atorvastatin combination period); dizziness (occurred in 2 ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":850,"endOffset":860,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"one period, and in 3 volunteers [15%] during the telaprevir-","suffix":"-atorvastatin combination period); diarrhea (occurred in 1 v","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":1085,"endOffset":1095,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"lone period and in 2 volunteers [11%] during the telaprevir-","suffix":"-atorvastatin combination period). Rash has been previously ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":1313,"endOffset":1323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"r (4.8%) on day 24 during the period of coadministration of ","suffix":"-atorvastatin and telaprevir; the rash resolved without trea","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":307,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on of telaprevir. A formulation containing a combination of ","suffix":" and atorvastatin (Caduet) was used in this study for dosing","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":262,"endOffset":272,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"indicating that telaprevir is a potent inhibitor of CYP3A4. ","suffix":" is a dihydropyridine calcium antagonist drug and has been r","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":813,"endOffset":823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"450 (22). Thus, clinically significant changes in the PK of ","suffix":" and atorvastatin, administered as Caduet, were anticipated ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":160,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"t telaprevir significantly inhibited the metabolism of both ","suffix":" and atorvastatin. The bioavailability of amlodipine has bee","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":212,"endOffset":222,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"of both amlodipine and atorvastatin. The bioavailability of ","suffix":" has been reported to be ∼60% (14). It is extensively metabo","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":503,"endOffset":513,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"gh level of binding to the plasma albumin (∼98%) (15). When ","suffix":" was coadministered with telaprevir, its AUC0-∞ increased 2.","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":910,"endOffset":920,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"es the inhibitory effect of telaprevir on the metabolism of ","suffix":". An effect of a similar magnitude on amlodipine has been ob","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":958,"endOffset":968,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"tabolism of amlodipine. An effect of a similar magnitude on ","suffix":" has been observed in other studies with antiviral agents th","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":1130,"endOffset":1140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ined dosing of indinavir and ritonavir increased the median ","suffix":" AUC0-24 by 90% (n = 18) (5).\n                              ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":119,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"on the coadministration of telaprevir with a single dose of ","suffix":"-atorvastatin, the atorvastatin AUC0-∞ increased 7.88-fold a","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":154,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"fter coadministration at steady state with a single dose of ","suffix":"-atorvastatin. The Cmax and AUClast were similar to the stea","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":127,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"nistration of multiple doses of telaprevir with one dose of ","suffix":" and atorvastatin administered in 2 periods was well tolerat","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":651,"endOffset":661,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ency and/or lack of adverse events commonly associated with ","suffix":" and atorvastatin may be attributed to the single-dose regim","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":155,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"suggest that telaprevir significantly increased exposure to ","suffix":" and atorvastatin (Cmax and AUC0-∞). Atorvastatin coadminist","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":273,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"n coadministration with telaprevir is contraindicated. When ","suffix":" is coadministered with telaprevir, caution should be used a","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":349,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"administered with telaprevir, caution should be used and an ","suffix":" dose reduction should be considered. Clinical monitoring is","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":181,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" both a substrate and an inhibitor of CYP3A. Amlodipine and ","suffix":" are both substrates of CYP3A and are among the drugs most f","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":362,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" study was conducted to examine the effect of telaprevir on ","suffix":" and amlodipine pharmacokinetics (PK). This was an open-labe","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"le volunteers. A coformulation of 5 mg amlodipine and 20 mg ","suffix":" was administered on day 1. Telaprevir was taken with food a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":728,"endOffset":740,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"om day 11 until day 26, and a single dose of the amlodipine-","suffix":" combination was readministered on day 17. Plasma samples we","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":868,"endOffset":880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"cted for determination of the PK of telaprevir, amlodipine, ","suffix":", ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin.","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":896,"endOffset":908,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"e PK of telaprevir, amlodipine, atorvastatin, ortho-hydroxy ","suffix":", and para-hydroxy atorvastatin. When administration with te","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":927,"endOffset":939,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy ","suffix":". When administration with telaprevir was compared with admi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1277,"endOffset":1289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"concentration-time curve from 0 h to infinity (AUC0-∞); for ","suffix":", they were 10.6 (8.74, 12.9) for the Cmax and 7.88 (6.84, 9","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1432,"endOffset":1444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"laprevir significantly increased exposure to amlodipine and ","suffix":", consistent with the inhibitory effect of telaprevir on the","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" high blood pressure and angina or coronary artery disease. ","suffix":" is a hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase ","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":513,"endOffset":525,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"s a coformulation (Caduet; Pfizer) (1). Both amlodipine and ","suffix":" are metabolized primarily by CYP3A (1). CYP3A-mediated meta","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":601,"endOffset":613,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" primarily by CYP3A (1). CYP3A-mediated metabolism converts ","suffix":" into two major active metabolites, ortho-hydroxy atorvastat","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":663,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"orvastatin into two major active metabolites, ortho-hydroxy ","suffix":" and para-hydroxy atorvastatin, and three inactive lactone m","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":693,"endOffset":705,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ve metabolites, ortho-hydroxy atorvastatin and para-hydroxy ","suffix":", and three inactive lactone metabolites corresponding to ea","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":941,"endOffset":953,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" ∼70% of the total HMG-CoA reductase inhibitory activity of ","suffix":" (6). Excreted primarily in the bile, atorvastatin is also a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":991,"endOffset":1003,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tivity of atorvastatin (6). Excreted primarily in the bile, ","suffix":" is also a substrate for P-glycoprotein and organic anion tr","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"h Caduet tablets containing 5 mg of amlodipine and 20 mg of ","suffix":" (amlodipine-atorvastatin). Volunteers received the followin","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":245,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ng 5 mg of amlodipine and 20 mg of atorvastatin (amlodipine-","suffix":"). Volunteers received the following treatment: a single dos","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":333,"endOffset":345,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ceived the following treatment: a single dose of amlodipine-","suffix":" alone on day 1, followed by a washout period, telaprevir at","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":495,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"8h) on days 11 through 26, with a single dose of amlodipine-","suffix":" on day 17. Outpatient visits occurred at the screening visi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":160,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"se combination tablets containing 5 mg amlodipine and 20 mg ","suffix":"; Pfizer Incorporated, New York, NY) was administered orally","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"evaluations were based on the concentrations of amlodipine, ","suffix":", ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":139,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy ","suffix":" concentrations were determined predose and at 0.25, 0.5, 0.","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":312,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":", 72, 120, 168, and 240 h after a single dose of amlodipine-","suffix":" on day 1 and predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":473,"endOffset":485,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"120, 168, and 240 h after another single dose of amlodipine-","suffix":" on day 17. Neither amlodipine nor atorvastatin is an inhibi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":520,"endOffset":532,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"f amlodipine-atorvastatin on day 17. Neither amlodipine nor ","suffix":" is an inhibitor of CYP3A, while telaprevir is a potent inhi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":642,"endOffset":654,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"otent inhibitor of CYP3A. Thus, an effect of amlodipine and ","suffix":" on telaprevir pharmacokinetics (PK) was not anticipated. Th","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":340,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"es and their internal standards (amlodipine-d4 maleic acid, ","suffix":"-d5 sodium salt, ortho-hydroxy atorvastatin-phenyl-d5, para-","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":383,"endOffset":395,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"-d4 maleic acid, atorvastatin-d5 sodium salt, ortho-hydroxy ","suffix":"-phenyl-d5, para-hydroxy atorvastatin-phenyl-d5, and d11-tel","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":420,"endOffset":432,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"um salt, ortho-hydroxy atorvastatin-phenyl-d5, para-hydroxy ","suffix":"-phenyl-d5, and d11-telaprevir) were extracted from human pl","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":922,"endOffset":934,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":" quantitation [LLOQ], 0.0500 ng/ml), 0.250 to 100 ng/ml for ","suffix":" (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for para-hydroxy at","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":992,"endOffset":1004,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"in (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for para-hydroxy ","suffix":" (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for ortho-hydroxy a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1063,"endOffset":1075,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"n (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for ortho-hydroxy ","suffix":" (LLOQ, 0.250 ng/ml), and 2.00 to 1,000 ng/ml for telaprevir","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":992,"endOffset":1004,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"in (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for para-hydroxy ","suffix":" (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for ortho-hydroxy a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1063,"endOffset":1075,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"n (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for ortho-hydroxy ","suffix":" (LLOQ, 0.250 ng/ml), and 2.00 to 1,000 ng/ml for telaprevir","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":238,"endOffset":250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":"ic parameters (Cmax, AUClast, and AUC0-∞) of amlodipine and ","suffix":" following a single dose of amlodipine-atorvastatin coadmini","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":289,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":"pine and atorvastatin following a single dose of amlodipine-","suffix":" coadministered with telaprevir were compared to those measu","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":403,"endOffset":415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":"red to those measured following a single dose of amlodipine-","suffix":" alone. In the analysis, treatment effect (with or without t","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":314,"endOffset":326,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"ssed predose and at 8, 10, and 24 h postdose for amlodipine-","suffix":" when administered alone and when administered in combinatio","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":512,"endOffset":524,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"following all dosing occasions and analyzed for amlodipine, ","suffix":", ortho-hydroxy atorvastatin, para-hydroxy atorvastatin, and","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":540,"endOffset":552,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ns and analyzed for amlodipine, atorvastatin, ortho-hydroxy ","suffix":", para-hydroxy atorvastatin, and telaprevir. Day 17 plasma s","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":567,"endOffset":579,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ine, atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy ","suffix":", and telaprevir. Day 17 plasma samples from 2 volunteers we","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":228,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"c parameter estimates from the noncompartmental analysis of ","suffix":" concentration data are shown in Table 1. Based on the ratio","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"he mean plasma concentration-time profiles of ortho-hydroxy ","suffix":" following amlodipine-atorvastatin administration on day 1 a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":156,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"profiles of ortho-hydroxy atorvastatin following amlodipine-","suffix":" administration on day 1 and day 17 are shown in Fig. 3. Bec","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":414,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"17), the concentration-versus-time profile of ortho-hydroxy ","suffix":" is limited to 24 h postdose. As shown in Table 1, the varia","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":226,"endOffset":238,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"volunteers showed detectable concentrations of para-hydroxy ","suffix":" on day 1. The Cmax of para-hydroxy atorvastatin in these 2 ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":274,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"ara-hydroxy atorvastatin on day 1. The Cmax of para-hydroxy ","suffix":" in these 2 volunteers increased with telaprevir coadministr","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":207,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" 17 after coadministration with a single dose of amlodipine-","suffix":". The mean (SD) Cmax of telaprevir was 3,167 (778) ng/ml, an","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":548,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"dache (occurred in 5 volunteers [24%] during the amlodipine-","suffix":"-alone period, in 2 volunteers [10%] during the telaprevir-a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":690,"endOffset":702,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"d, and in 1 volunteer [5%] during the telaprevir-amlodipine-","suffix":" combination period); dizziness (occurred in 2 volunteers [1","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":861,"endOffset":873,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" and in 3 volunteers [15%] during the telaprevir-amlodipine-","suffix":" combination period); diarrhea (occurred in 1 volunteer [5%]","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1096,"endOffset":1108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" and in 2 volunteers [11%] during the telaprevir-amlodipine-","suffix":" combination period). Rash has been previously reported with","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1324,"endOffset":1336,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" day 24 during the period of coadministration of amlodipine-","suffix":" and telaprevir; the rash resolved without treatment or a ch","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"al drug-drug interactions of telaprevir with amlodipine and ","suffix":" were investigated in healthy volunteers by comparing the PK","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":322,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"r. A formulation containing a combination of amlodipine and ","suffix":" (Caduet) was used in this study for dosing convenience. No ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":460,"endOffset":472,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"o liver microsomal incubation and clinical studies (9, 13). ","suffix":", one of the most commonly prescribed HMG-CoA reductase inhi","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":828,"endOffset":840,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" clinically significant changes in the PK of amlodipine and ","suffix":", administered as Caduet, were anticipated with the coadmini","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"gnificantly inhibited the metabolism of both amlodipine and ","suffix":". The bioavailability of amlodipine has been reported to be ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":131,"endOffset":143,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"telaprevir on atorvastatin disposition was more pronounced. ","suffix":" is given in the acid form, and its Cmax is achieved quickly","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":231,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"and its Cmax is achieved quickly (∼1 to 2 h postdose) (10). ","suffix":" acid undergoes extensive first-pass metabolism in the gut a","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":130,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ministration of telaprevir with a single dose of amlodipine-","suffix":", the atorvastatin AUC0-∞ increased 7.88-fold and the atorva","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":130,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ministration of telaprevir with a single dose of amlodipine-","suffix":", the atorvastatin AUC0-∞ increased 7.88-fold and the atorva","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":148,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"laprevir with a single dose of amlodipine-atorvastatin, the ","suffix":" AUC0-∞ increased 7.88-fold and the atorvastatin Cmax increa","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"statin, the atorvastatin AUC0-∞ increased 7.88-fold and the ","suffix":" Cmax increased 10.6-fold. These results suggest that the pr","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":298,"endOffset":310,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"se results suggest that the primary effect of telaprevir on ","suffix":" is to increase its bioavailability (F) by decreasing its fi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":552,"endOffset":564,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" gut. The effect of telaprevir on the hepatic metabolism of ","suffix":" does not appear to be significant in its overall dispositio","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":663,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ts overall disposition. An effect of a similar magnitude on ","suffix":" has been observed in studies using some other CYP3A inhibit","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":773,"endOffset":785,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"me other CYP3A inhibitors. For example, the AUC and Cmax of ","suffix":" were increased about 9-fold when it was coadministered with","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":471,"endOffset":483,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"difference was not statistically significant. Inhibition of ","suffix":" metabolism would be expected to increase the atorvastatin t","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":529,"endOffset":541,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"f atorvastatin metabolism would be expected to increase the ","suffix":" t1/2. This unexpected result may be caused by the inhibitio","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":653,"endOffset":665,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"nhibition of transporters involved in the hepatic uptake of ","suffix":", such as organic anion-transporting polypeptide 1B1 (OATP1B","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":778,"endOffset":790,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"(OATP1B1), which could reduce the volume of distribution of ","suffix":" to an extent similar to or greater than the observed decrea","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1205,"endOffset":1217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"bstrates of OATP1B1, such as cerivastatin, fluvastatin, and ","suffix":", showed unaltered t1/2s, while severalfold AUC and Cmax inc","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":91,"endOffset":103,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"                          The mean AUC0-∞ for ortho-hydroxy ","suffix":" decreased by approximately 70% after telaprevir coadministr","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":215,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"dministration; however, most concentrations of para-hydroxy ","suffix":" were below the LLOQ, making noncompartmental analysis for t","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":357,"endOffset":369,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"lite not feasible. In the 2 volunteers in whom para-hydroxy ","suffix":" was measurable before (day 1) and after (day 17) the coadmi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":614,"endOffset":626,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"er volunteers had measurable concentrations of para-hydroxy ","suffix":". While these results were not anticipated, it has been repo","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":709,"endOffset":721,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"ere not anticipated, it has been reported that para-hydroxy ","suffix":", but not ortho-hydroxy atorvastatin, is also formed by CYP2","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":745,"endOffset":757,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"orted that para-hydroxy atorvastatin, but not ortho-hydroxy ","suffix":", is also formed by CYP2C8 in addition to CYP3A (7). Therefo","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":869,"endOffset":881,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":" Therefore, in the presence of greater systemic exposure of ","suffix":" during the coadministration of telaprevir, it is plausible ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":964,"endOffset":976,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"ation of telaprevir, it is plausible that more para-hydroxy ","suffix":" is formed via CYP2C8 and its concentration in plasma is inc","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":165,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"nistration at steady state with a single dose of amlodipine-","suffix":". The Cmax and AUClast were similar to the steady-state esti","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":142,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ultiple doses of telaprevir with one dose of amlodipine and ","suffix":" administered in 2 periods was well tolerated. There were no","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":666,"endOffset":678,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"k of adverse events commonly associated with amlodipine and ","suffix":" may be attributed to the single-dose regimen of these drugs","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":170,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"laprevir significantly increased exposure to amlodipine and ","suffix":" (Cmax and AUC0-∞). Atorvastatin coadministration with telap","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":202,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":" exposure to amlodipine and atorvastatin (Cmax and AUC0-∞). ","suffix":" coadministration with telaprevir is contraindicated. When a","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"interferon","startOffset":330,"endOffset":340,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" telaprevir as part of a combination regimen with pegylated ","suffix":" and ribavirin significantly increased the rates of sustaine","exact":"interferon"},{"setid":"PMC3187007","drugname":"ribavirin","startOffset":345,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"part of a combination regimen with pegylated interferon and ","suffix":" significantly increased the rates of sustained virologic re","exact":"ribavirin"},{"setid":"PMC3187007","drugname":"cholesterol","startOffset":290,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"coenzyme A (HMG-CoA) reductase inhibitor used to lower high ","suffix":" levels and reduce the risk of heart attack and stroke. Thes","exact":"cholesterol"},{"setid":"PMC3187007","drugname":"caduet","startOffset":472,"endOffset":478,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"with CHC and are commercially available as a coformulation (","suffix":"; Pfizer) (1). Both amlodipine and atorvastatin are metaboli","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":162,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"nter, nonrandomized study of telaprevir in combination with ","suffix":" tablets containing 5 mg of amlodipine and 20 mg of atorvast","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":336,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on containing a combination of amlodipine and atorvastatin (","suffix":") was used in this study for dosing convenience. No signific","exact":"Caduet"},{"setid":"PMC3187007","drugname":"acetaminophen","startOffset":962,"endOffset":975,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"e first administration of the study drug. Occasional use of ","suffix":" or ibuprofen was allowed during the study for the treatment","exact":"acetaminophen"},{"setid":"PMC3187007","drugname":"ibuprofen","startOffset":979,"endOffset":988,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ation of the study drug. Occasional use of acetaminophen or ","suffix":" was allowed during the study for the treatment of pain. Vol","exact":"ibuprofen"},{"setid":"PMC3187007","drugname":"midazolam","startOffset":173,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" midazolam showed that telaprevir increased the AUC of oral ","suffix":" almost 9-fold (4), indicating that telaprevir is a potent i","exact":"midazolam"},{"setid":"PMC3187007","drugname":"indinavir","startOffset":1085,"endOffset":1094,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" that are CYP3A inhibitors. For example, combined dosing of ","suffix":" and ritonavir increased the median amlodipine AUC0-24 by 90","exact":"indinavir"},{"setid":"PMC3187007","drugname":"ritonavir","startOffset":1099,"endOffset":1108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"A inhibitors. For example, combined dosing of indinavir and ","suffix":" increased the median amlodipine AUC0-24 by 90% (n = 18) (5)","exact":"ritonavir"},{"setid":"PMC3187007","drugname":"cyclosporine","startOffset":933,"endOffset":945,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"e. Such a mechanism has been hypothesized for the effect of ","suffix":" (an inhibitor of OATP1B1) on rosuvastatin, a statin which i","exact":"cyclosporine"},{"setid":"PMC3187007","drugname":"cyclosporine","startOffset":1101,"endOffset":1113,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ose t1/2 was decreased by half upon the coadministration of ","suffix":" (19). Other statins that are substrates of OATP1B1, such as","exact":"cyclosporine"},{"setid":"PMC3187007","drugname":"cyclosporine","startOffset":1333,"endOffset":1345,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" increases resulted when the drugs were coadministered with ","suffix":" (18). However, at this time, the effect of telaprevir on OA","exact":"cyclosporine"},{"setid":"PMC3187007","drugname":"rosuvastatin","startOffset":975,"endOffset":987,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"for the effect of cyclosporine (an inhibitor of OATP1B1) on ","suffix":", a statin which is also a substrate of OATP1B1 and whose t1","exact":"rosuvastatin"},{"setid":"PMC3187007","drugname":"cerivastatin","startOffset":1174,"endOffset":1186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"(19). Other statins that are substrates of OATP1B1, such as ","suffix":", fluvastatin, and atorvastatin, showed unaltered t1/2s, whi","exact":"cerivastatin"},{"setid":"PMC3187007","drugname":"fluvastatin","startOffset":1188,"endOffset":1199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"atins that are substrates of OATP1B1, such as cerivastatin, ","suffix":", and atorvastatin, showed unaltered t1/2s, while severalfol","exact":"fluvastatin"}],[{"setid":"PMC3091944","drugname":"warfarin","startOffset":411,"endOffset":419,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"eriod, crossover design, subjects received a 7.5 mg dose of ","suffix":" alone or immediately following a 600 mg intravenous dose of","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":536,"endOffset":544,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" of rifampin. Rifampin did not significantly alter R- or S- ","suffix":" area under the concentration-time curve (AUC) from 0-12 hou","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":778,"endOffset":786,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" rifampin days for both R- (25% reduction; p < 0.001) and S-","suffix":" (15% reduction; p < 0.05). No differences were seen on the ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":226,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"sm, and other thromboembolic events. But, successful use of ","suffix":" has been challenged by its large inter-individual variation","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":307,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"llenged by its large inter-individual variation in required ","suffix":" dose and narrow therapeutic index.(1) Doses can differ >10-","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":483,"endOffset":491,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" anticoagulation. In attempts to explain the variability in ","suffix":" dose, formal pharmacogenetic techniques have been applied t","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":714,"endOffset":722,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"l-recognized that Single Nucleotide Polymorphisms (SNPs) in ","suffix":"'s major metabolizing enzyme (cytochrome P-450 (CYP) 2C9) an","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":878,"endOffset":886,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"n K epoxide reductase; VKORC1) have a significant impact on ","suffix":" dose requirement.(2-5) Multiple investigators have incorpor","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":57,"endOffset":65,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"\n                                                        ","suffix":" is a racemic mixture of S- and R- enatiomers with S-warfari","exact":"Warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":118,"endOffset":126,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"arfarin is a racemic mixture of S- and R- enatiomers with S-","suffix":" being 2-5 times more potent and conferring the majority of ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":308,"endOffset":316,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"re eliminated almost exclusively by CYP metabolism, i.e., S-","suffix":" principally by CYP2C9 metabolism to form the primary metabo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":411,"endOffset":419,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"o form the primary metabolite 7-hydroxywarfarin (14, 15); R-","suffix":" principally by CYP3A4 metabolism to form 10-hydroxywarfarin","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":63,"endOffset":71,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"                                                      Since ","suffix":" is classified as a BDDCS Class 2 drug(10), the potential fo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":288,"endOffset":296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"osition not previously studied. By inhibiting the uptake of ","suffix":" into the liver, warfarin would have decreased access to its","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":313,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"udied. By inhibiting the uptake of warfarin into the liver, ","suffix":" would have decreased access to its major metabolizing CYP e","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":503,"endOffset":511,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"o rat and human hepatocyte data showing decreased uptake of ","suffix":" in the presence of rifampin, a clinical trial in healthy vo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":124,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"the presence of 100 μM rifampin, the uptake of 1 μM racemic ","suffix":" was decreased by 23% in rat hepatocytes (p < 0.05; Figure 1","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":127,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"gure 2 displays the concentration-time profiles of S- and R-","suffix":" after a single oral dose of 7.5 mg warfarin alone or with a","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":171,"endOffset":179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"les of S- and R-warfarin after a single oral dose of 7.5 mg ","suffix":" alone or with a single intravenous dose of rifampin. Data f","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":492,"endOffset":500,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"16). Therefore, in the current study we focused on S- and R-","suffix":" concentration-time data from 0-12 hours (Figure 2 inset) th","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":665,"endOffset":673,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":" OATP inhibition by rifampin and when any uptake effects on ","suffix":" pharmacokinetics, if any, would be seen. Rifampin had no ef","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":759,"endOffset":767,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":" would be seen. Rifampin had no effect on the AUC0-12h of S-","suffix":" or R-warfarin compared to control days when warfarin was gi","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":773,"endOffset":781,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":". Rifampin had no effect on the AUC0-12h of S-warfarin or R-","suffix":" compared to control days when warfarin was given alone (Tab","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":773,"endOffset":781,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":". Rifampin had no effect on the AUC0-12h of S-warfarin or R-","suffix":" compared to control days when warfarin was given alone (Tab","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":812,"endOffset":820,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"h of S-warfarin or R-warfarin compared to control days when ","suffix":" was given alone (Table 1), as well as Cmax (maximum plasma ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":161,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","prefix":"ata showed rifampin significantly decreased the AUC0-∞ of S-","suffix":" by 15% (p < 0.04) and R-warfarin by 25% (p < 0.001) (Figure","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":194,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","prefix":" decreased the AUC0-∞ of S-warfarin by 15% (p < 0.04) and R-","suffix":" by 25% (p < 0.001) (Figure 2; Table 1). The apparent termin","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":287,"endOffset":295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","prefix":"re 2; Table 1). The apparent terminal half-life (t1/2) of S-","suffix":" was not significantly different on rifampin days (p = 0.13)","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":363,"endOffset":371,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","prefix":" significantly different on rifampin days (p = 0.13). For R-","suffix":", a 25% shortening of the terminal t1/2 was seen on rifampin","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":121,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"    The concentration-time profiles of 7-hydroxywarfarin (S-","suffix":" metabolite) and 10-hydroxywarfarin (R-warfarin metabolite) ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":127,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"gure 2 displays the concentration-time profiles of S- and R-","suffix":" after a single oral dose of 7.5 mg warfarin alone or with a","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"ywarfarin (S-warfarin metabolite) and 10-hydroxywarfarin (R-","suffix":" metabolite) after a single oral dose of 7.5 mg warfarin alo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":224,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":" (R-warfarin metabolite) after a single oral dose of 7.5 mg ","suffix":" alone or with a single intravenous dose of rifampin are sho","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1230,"endOffset":1238,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"efore, a significant proportion of AUC0-∞ was extrapolated (","suffix":" alone, 64 +/− 11%; warfarin plus rifampin, 44% +/− 12%,). F","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1258,"endOffset":1266,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"ion of AUC0-∞ was extrapolated (warfarin alone, 64 +/− 11%; ","suffix":" plus rifampin, 44% +/− 12%,). For the same reason, our term","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":108,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[3]/p[1]","prefix":"                 The AUC0-∞ ratio of 7-hydroxywarfarin to S-","suffix":" and 10-hydroxywarfarin to R-warfarin increased 20% and 58% ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":145,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[3]/p[1]","prefix":"7-hydroxywarfarin to S-warfarin and 10-hydroxywarfarin to R-","suffix":" increased 20% and 58% respectively with rifampin treatment ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":224,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"of the widely-used, narrow therapeutic index, anticoagulant ","suffix":". The results of our clinical study demonstrated that co-adm","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":438,"endOffset":446,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" had no effect on the AUC0-12h and Cmax values of S- and R- ","suffix":" or S-warfarin's hydroxyl metabolite. Accordingly, OATP upta","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":452,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" on the AUC0-12h and Cmax values of S- and R- warfarin or S-","suffix":"'s hydroxyl metabolite. Accordingly, OATP uptake transport i","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":452,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" on the AUC0-12h and Cmax values of S- and R- warfarin or S-","suffix":"'s hydroxyl metabolite. Accordingly, OATP uptake transport i","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":579,"endOffset":587,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"is likely not clinically significant for the disposition of ","suffix":" and will provide no further insight into mechanisms of warf","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":643,"endOffset":651,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"arin and will provide no further insight into mechanisms of ","suffix":" drug-drug interactions or genetic variation important in wa","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":156,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ibitor to block the in vivo OATP-mediated hepatic uptake of ","suffix":"(11, 17, 18). Because of rifampin's shorter t1/2 (2.9 ±0.9 h","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":252,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ampin's shorter t1/2 (2.9 ±0.9 h(19)) relative to S- and R- ","suffix":" (39h and 49h respectively, as determined in our clinical st","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":482,"endOffset":490,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ffect, rifampin was only present in plasma for a portion of ","suffix":"'s concentration-time curve.OATP inhibition and any potentia","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":562,"endOffset":570,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"tion-time curve.OATP inhibition and any potential effect on ","suffix":" pharmacokinetics occurred at most during the time of rifamp","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1080,"endOffset":1088,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ters to capture the potential effects of OATP inhibition on ","suffix":" pharmacokinetics were the AUC0-12h and Cmax. No effect on e","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1202,"endOffset":1210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t on either of these pharmacokinetic parameters for S- or R-","suffix":" were seen in the presence of rifampin suggesting OATP trans","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":739,"endOffset":747,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" current study we did not see a change in Vss/F for S- or R-","suffix":" on rifampin days (Table 1), which we would have predicted i","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":122,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"ntrast to our clinical study, our in vitro data showed that ","suffix":" uptake into hepatocytes was inhibited by rifampin in both r","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":284,"endOffset":292,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"ly via OATP uptake transporter inhibition. The magnitude of ","suffix":" uptake inhibition (23% in rat hepatocytes and 34% in human ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1006,"endOffset":1014,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"ld result in additional OATP inhibition and therefore alter ","suffix":" pharmcokinetics, although the clinical relevance would be q","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":244,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":" polymorphisms in the human genome that may be important in ","suffix":" dose selection. In these GWAS studies, no common variants i","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":421,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":"ransporters were found to be significant in determining the ","suffix":" dose requirements of patients.(2-5) Genetic variants of a t","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":788,"endOffset":796,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":"ative predictive value has now been demonstrated nicely for ","suffix":" and OATP uptake transporters through the results of our cli","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":538,"endOffset":546,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"CYP3A4 (25-28), the major metabolizing enzymes for S- and R-","suffix":" respectively, has been described after multiple dose rifamp","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":650,"endOffset":658,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"iple dose rifampin. The effect of multiple dose rifampin on ","suffix":" pharmacokinetics was highlighted in a clinical trial of fou","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":834,"endOffset":842,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":" mg oral rifampin twice per day, a three-fold increase in R-","suffix":" clearance and a two-fold increase in S-warfarin clearance w","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":882,"endOffset":890,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"crease in R-warfarin clearance and a two-fold increase in S-","suffix":" clearance were seen. Interestingly, our clinical study usin","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":999,"endOffset":1007,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":" study using only single dose rifampin immediately prior to ","suffix":" likely demonstrates a mild enzyme inductive effect indicate","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1130,"endOffset":1138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"y the small but significant decrease in AUC0-∞ for S- and R-","suffix":" (15% decrease and 25% decrease respectively) and terminal t","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1208,"endOffset":1216,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"ease and 25% decrease respectively) and terminal t1/2 for R-","suffix":" (25% decrease) with rifampin treatment. The increase in Cma","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1296,"endOffset":1304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":" rifampin treatment. The increase in Cmax and AUC for the R-","suffix":" metabolite 10-hydroxywarfarin and the increase in the AUC r","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1396,"endOffset":1404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"nd the increase in the AUC ratio of 10-hydroxywarfarin to R-","suffix":" further supports induction of R-warfarin metabolism via CYP","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1437,"endOffset":1445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"droxywarfarin to R-warfarin further supports induction of R-","suffix":" metabolism via CYP3A4. The pharmacokinetics of the specific","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1508,"endOffset":1516,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"tabolism via CYP3A4. The pharmacokinetics of the specific S-","suffix":" metabolite 7-hydroxywarfarin did not change with rifampin t","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"eared to be delayed since early in the time course S- and R-","suffix":" concentration-time curves, AUC0-12h, and Cmax were similar ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":892,"endOffset":900,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":" of nifedipine.(30) Nonetheless, the potential induction of ","suffix":" metabolism by single-dose rifampin in our study does not al","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1096,"endOffset":1104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"on was small (especially for the more biologically active S-","suffix":") and it occurred late in the time-course after the primary ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":385,"endOffset":393,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":" volunteer study that also used a single 7.5mg dose of oral ","suffix":".(31) The addition of rifampin had no effect on the warfarin","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":445,"endOffset":453,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"warfarin.(31) The addition of rifampin had no effect on the ","suffix":" pharmacodynamic response as measured by INRmax and AUC0-96h","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":132,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"our single dose clinical study of the effect of rifampin on ","suffix":" pharmacokinetics in healthy volunteers suggeststhat hepatic","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":291,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"in was chosen to maximize OATP inhibition and any effect on ","suffix":" uptake Rifampin is a known inhibitor of the 3 major human O","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":498,"endOffset":506,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":" The uptake study was initiated by addition of 1 μM racemic ","suffix":" (Sigma-Aldrich; St. Louis, MO). After 2 minutes of uptake, ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":498,"endOffset":506,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"ts received on Day 1 of each study period either (A) 7.5 mg ","suffix":" (one 7.5 mg warfarin tab; Bristol-Myers Squibb, Princeton, ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":519,"endOffset":527,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"of each study period either (A) 7.5 mg warfarin (one 7.5 mg ","suffix":" tab; Bristol-Myers Squibb, Princeton, NJ) or (B) 7.5 mg war","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":584,"endOffset":592,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"rin tab; Bristol-Myers Squibb, Princeton, NJ) or (B) 7.5 mg ","suffix":" immediately following a 30-minute intravenous infusion of 6","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":973,"endOffset":981,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"ects fasted starting the night before until 3 hours after a ","suffix":" dose, abstained from caffeinated beverages, alcoholic bever","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1112,"endOffset":1120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"ange juice starting the night before until 24 hours after a ","suffix":" dose. Grapefruit and grapefruit juice were not allowed to b","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":170,"endOffset":178,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","prefix":"surements were collected at the following times relative to ","suffix":" dosing: predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":653,"endOffset":661,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"ct on hepatic OATPs and the anticipated changes in R- and S-","suffix":" pharmacokinetics (i.e. AUC). Given S-warfarin's much longer","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":699,"endOffset":707,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"s in R- and S-warfarin pharmacokinetics (i.e. AUC). Given S-","suffix":"'s much longer half-life(31, 34-41) compared to rifampin(41)","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":835,"endOffset":843,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"in was expected to be present in plasma for only portion of ","suffix":"'s concentration time profile. Data from a previous study by","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":1147,"endOffset":1155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"cordingly, our primary outcome was the AUC0-12h of S- and R-","suffix":", which represents the time a potential inhibitory effect on","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":650,"endOffset":658,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","prefix":"-order absorption rate (ka) constant estimated when fitting ","suffix":" data to a two-compartmental model with first-order absorpti","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":235,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","prefix":"s would provide > 80% power to detect a 30% difference in S-","suffix":" AUC0-∞ between the two treatments. Logarithmic transformati","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":729,"endOffset":737,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","prefix":"f the rifampin treatment values relative to control values (","suffix":" alone) and their 95% confidence intervals were calculated f","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":427,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","prefix":"ltiple reaction monitor was set at 307-161 m/z for R- and S-","suffix":", 323-177 m/z for 7-hydroxy-warfarin, 323-250 m/z for 10-hyd","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":463,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","prefix":"07-161 m/z for R- and S-warfarin, 323-177 m/z for 7-hydroxy-","suffix":", 323-250 m/z for 10-hydroxy-warfarin, 312-166 m/z for d5-wa","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":463,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","prefix":"07-161 m/z for R- and S-warfarin, 323-177 m/z for 7-hydroxy-","suffix":", 323-250 m/z for 10-hydroxy-warfarin, 312-166 m/z for d5-wa","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":500,"endOffset":508,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","prefix":"-177 m/z for 7-hydroxy-warfarin, 323-250 m/z for 10-hydroxy-","suffix":", 312-166 m/z for d5-warfarin (internal standard for S- and ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":529,"endOffset":537,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","prefix":"in, 323-250 m/z for 10-hydroxy-warfarin, 312-166 m/z for d5-","suffix":" (internal standard for S- and R-warfarin) and 312-117 m/z f","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":570,"endOffset":578,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","prefix":"312-166 m/z for d5-warfarin (internal standard for S- and R-","suffix":") and 312-117 m/z for d5-warfarin (internal standard for met","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":254,"endOffset":262,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","prefix":"L plasma with 2.5 mL methyl t-butyl ether containing 1μM d5-","suffix":" as internal standard. After being vortexed for one minute, ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":215,"endOffset":223,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","prefix":"on of 100μL plasma with 500μL of methanol containing 1μM d5-","suffix":" as internal standard. Samples were vortexed for one minute ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":175,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"ere as described by Naidong and colleagues(43). In brief, R-","suffix":" and S-warfarin were separated isocratically on a Cyclobond™","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":190,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"d by Naidong and colleagues(43). In brief, R-warfarin and S-","suffix":" were separated isocratically on a Cyclobond™ I 2000 β-cyclo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":379,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":" 4.6, 5μm guard column (Sigma-Aldrich, St. Louis, MO). R-d5-","suffix":" and S-d5-warfarin (racemic d5-warfarin from Toronto Researc","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":397,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"lumn (Sigma-Aldrich, St. Louis, MO). R-d5-warfarin and S-d5-","suffix":" (racemic d5-warfarin from Toronto Research Chemicals, Inc.,","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":397,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"lumn (Sigma-Aldrich, St. Louis, MO). R-d5-warfarin and S-d5-","suffix":" (racemic d5-warfarin from Toronto Research Chemicals, Inc.,","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":418,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"St. Louis, MO). R-d5-warfarin and S-d5-warfarin (racemic d5-","suffix":" from Toronto Research Chemicals, Inc., Ontario, Canada) ena","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":565,"endOffset":573,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"separated by the β-cyclodextrin column and co-eluted with R-","suffix":" and S-warfarin, respectively. The mobile phase consisted of","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":580,"endOffset":588,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"e β-cyclodextrin column and co-eluted with R-warfarin and S-","suffix":", respectively. The mobile phase consisted of acetonitrile:a","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":580,"endOffset":588,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"e β-cyclodextrin column and co-eluted with R-warfarin and S-","suffix":", respectively. The mobile phase consisted of acetonitrile:a","exact":"warfarin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":249,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"fic organic anion transporting polypeptide (OATP) inhibitor ","suffix":", a clinical study was conducted in 10 healthy volunteers. I","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":480,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"alone or immediately following a 600 mg intravenous dose of ","suffix":". Rifampin did not significantly alter R- or S- warfarin are","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":490,"endOffset":498,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"mmediately following a 600 mg intravenous dose of rifampin. ","suffix":" did not significantly alter R- or S- warfarin area under th","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":645,"endOffset":653,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"(AUC) from 0-12 hours (period of hepatic OATP inhibition by ","suffix":") or Cmax (maximum plasma concentration). AUC0-∞ was decreas","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":719,"endOffset":727,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"max (maximum plasma concentration). AUC0-∞ was decreased on ","suffix":" days for both R- (25% reduction; p < 0.001) and S-warfarin ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":1046,"endOffset":1054,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"Using concomitant administration of single dose intravenous ","suffix":" as a non-specific OATP inhibitor, hepatic uptake inhibition","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":531,"endOffset":539,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"ata showing decreased uptake of warfarin in the presence of ","suffix":", a clinical trial in healthy volunteers was conducted to ex","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":87,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"                                  In the presence of 100 μM ","suffix":", the uptake of 1 μM racemic warfarin was decreased by 23% i","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":223,"endOffset":231,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":" 7.5 mg warfarin alone or with a single intravenous dose of ","suffix":". Data from a previous study by our laboratory and informati","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":361,"endOffset":369,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"d in the package insert, predict relevant concentrations of ","suffix":" for up to 12 hours after a single 600 mg intravenous dose(1","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":625,"endOffset":633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"uld represent the time period of hepatic OATP inhibition by ","suffix":" and when any uptake effects on warfarin pharmacokinetics, i","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":715,"endOffset":723,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[1]","prefix":"ffects on warfarin pharmacokinetics, if any, would be seen. ","suffix":" had no effect on the AUC0-12h of S-warfarin or R-warfarin c","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":331,"endOffset":339,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","prefix":"ife (t1/2) of S-warfarin was not significantly different on ","suffix":" days (p = 0.13). For R-warfarin, a 25% shortening of the te","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":423,"endOffset":431,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","prefix":"warfarin, a 25% shortening of the terminal t1/2 was seen on ","suffix":" days (p < 0.001). The steady-state volume of distribution (","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":276,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":" 7.5 mg warfarin alone or with a single intravenous dose of ","suffix":" are shown in Figure 3. Rifampin had no significant effect o","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":308,"endOffset":316,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":" single intravenous dose of rifampin are shown in Figure 3. ","suffix":" had no significant effect on 7-hydroxywarfarin AUC0-12h or ","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":452,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"armacokinetic parameters (Table 2). For 10-hydroxywarfarin, ","suffix":" also had no effect on the AUC0-12h(Table 2). But, after 12 ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":645,"endOffset":653,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"n treatments began to diverge with higher concentrations on ","suffix":" days (Figure 3b). The Cmax of 10-hydroxywarfarin was increa","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":725,"endOffset":733,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"e 3b). The Cmax of 10-hydroxywarfarin was increased 111% on ","suffix":" days (p < 0.001) but no change in Tmax was seen. Rifampin t","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":783,"endOffset":791,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"n rifampin days (p < 0.001) but no change in Tmax was seen. ","suffix":" treatment also resulted in an 84% increase in the AUC0-120h","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":960,"endOffset":968,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"0.05) of 10-hydroxywarfarin. Terminal t1/2 decreased 50% on ","suffix":" days (p < 0.001). Because of its extremely long terminal t1","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":1272,"endOffset":1280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"was extrapolated (warfarin alone, 64 +/− 11%; warfarin plus ","suffix":", 44% +/− 12%,). For the same reason, our terminal t1/2 esti","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":194,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[3]/p[1]","prefix":"farin to R-warfarin increased 20% and 58% respectively with ","suffix":" treatment (p < 0.01 for both; Table 3).\n                   ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":284,"endOffset":292,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[1]","prefix":"max) vs. baseline INR (INRbaseline; p < 0.01 for both), but ","suffix":" caused no differences in INR measures compared to warfarin ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":333,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"strated that co-administration of the potent OATP inhibitor ","suffix":", given as a single intravenous dose, had no effect on the A","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":189,"endOffset":197,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"mediated hepatic uptake of warfarin(11, 17, 18). Because of ","suffix":"'s shorter t1/2 (2.9 ±0.9 h(19)) relative to S- and R- warfa","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":355,"endOffset":363,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"rmined in our clinical study) and because we could not give ","suffix":" as multiple doses dues to its metabolic enzyme induction ef","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":429,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ltiple doses dues to its metabolic enzyme induction effect, ","suffix":" was only present in plasma for a portion of warfarin's conc","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":624,"endOffset":632,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"rfarin pharmacokinetics occurred at most during the time of ","suffix":" presence, and therefore, outcome measures for our study nee","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":838,"endOffset":846,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"s have shown that after a single 600 mg intravenous dose of ","suffix":" to healthy volunteers, rifampin was present for up to 12-24","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":870,"endOffset":878,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":" 600 mg intravenous dose of rifampin to healthy volunteers, ","suffix":" was present for up to 12-24 hours in plasma. (11, 16) Assum","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":973,"endOffset":981,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"in plasma. (11, 16) Assuming a similar time of exposure for ","suffix":" in our clinical study, the best parameters to capture the p","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":1240,"endOffset":1248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"arameters for S- or R-warfarin were seen in the presence of ","suffix":" suggesting OATP transport of warfarin is not clinically imp","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":266,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" atorvastatin and glyburide with hepatic OATP inhibition by ","suffix":"(11, 12). The AUC of atorvastatin was 680% higher and the AU","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":364,"endOffset":372,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"tin was 680% higher and the AUC of glyburide 130% higher in ","suffix":" vs. control phases. In those clinical studies rifampin also","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":419,"endOffset":427,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"r in rifampin vs. control phases. In those clinical studies ","suffix":" also produced a large decrease in the Vss/F for both drugs ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":751,"endOffset":759,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"dy we did not see a change in Vss/F for S- or R-warfarin on ","suffix":" days (Table 1), which we would have predicted if OATP trans","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":172,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"owed that warfarin uptake into hepatocytes was inhibited by ","suffix":" in both rats and humans (Figure 1) presumably via OATP upta","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":400,"endOffset":408,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"4% in human hepatocytes) was modest at the concentration of ","suffix":" (100 μM) used for the hepatocyte uptake studies. The 100 μM","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":486,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":" the hepatocyte uptake studies. The 100 μM concentration of ","suffix":" used in our hepatocyte uptake studies is significantly high","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":674,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":" in our healthy volunteers after a single IV dose of 600 mg ","suffix":" (17-20μM (11, 16)) and could explain the disagreement betwe","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":934,"endOffset":942,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"le-out the possibility that higher plasma concentrations of ","suffix":" would result in additional OATP inhibition and therefore al","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":87,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"                              Intravenous administration of ","suffix":" conceivably minimized any potential confounding interaction","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":289,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"lack of an interaction cannot be fully confirmed. By giving ","suffix":" as a single dose, we attempted to avoid the well-described ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":600,"endOffset":608,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"rfarin respectively, has been described after multiple dose ","suffix":". The effect of multiple dose rifampin on warfarin pharmacok","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":638,"endOffset":646,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"d after multiple dose rifampin. The effect of multiple dose ","suffix":" on warfarin pharmacokinetics was highlighted in a clinical ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":783,"endOffset":791,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"lthy men.(24) After 3 days of pretreatment with 300 mg oral ","suffix":" twice per day, a three-fold increase in R-warfarin clearanc","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":969,"endOffset":977,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"n. Interestingly, our clinical study using only single dose ","suffix":" immediately prior to warfarin likely demonstrates a mild en","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":1237,"endOffset":1245,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"ively) and terminal t1/2 for R-warfarin (25% decrease) with ","suffix":" treatment. The increase in Cmax and AUC for the R-warfarin ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":1566,"endOffset":1574,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"S-warfarin metabolite 7-hydroxywarfarin did not change with ","suffix":" treatment and therefore is not congruent with induction of ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":252,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"me curves, AUC0-12h, and Cmax were similar with and without ","suffix":". Such a delay is expected based on the mechanism of rifampi","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":313,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"ifampin. Such a delay is expected based on the mechanism of ","suffix":" enzyme induction through activation of the nuclear transcri","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":520,"endOffset":528,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":" the time-course of CYP enzyme induction with multiple-dose ","suffix":" using verapamil as a probe substrate reported a half-life o","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":673,"endOffset":681,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"in CYP enzyme activity.(29) CYP induction after single dose ","suffix":" has previously been shown with a single dose of 1200 mg ora","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":743,"endOffset":751,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"as previously been shown with a single dose of 1200 mg oral ","suffix":" given 12 hours before oral nifedipine, resulting in a 64% d","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":927,"endOffset":935,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"e potential induction of warfarin metabolism by single-dose ","suffix":" in our study does not alter the interpretation of the prima","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":415,"endOffset":423,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"d a single 7.5mg dose of oral warfarin.(31) The addition of ","suffix":" had no effect on the warfarin pharmacodynamic response as m","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":120,"endOffset":128,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"conclusion, our single dose clinical study of the effect of ","suffix":" on warfarin pharmacokinetics in healthy volunteers suggests","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":187,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"a 37°C water bath with either control (0.1% DMSO) or 100 μM ","suffix":". The 100 μM concentration of rifampin was chosen to maximiz","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":225,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"(0.1% DMSO) or 100 μM rifampin. The 100 μM concentration of ","suffix":" was chosen to maximize OATP inhibition and any effect on wa","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":307,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":" maximize OATP inhibition and any effect on warfarin uptake ","suffix":" is a known inhibitor of the 3 major human OATPs, being a mo","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":658,"endOffset":666,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"iately following a 30-minute intravenous infusion of 600 mg ","suffix":" (600 mg rifampin powder for injection reconstituted in 10 m","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":675,"endOffset":683,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"a 30-minute intravenous infusion of 600 mg rifampin (600 mg ","suffix":" powder for injection reconstituted in 10 ml sterile water; ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":567,"endOffset":575,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"plasma concentration-time curve. We were most interested in ","suffix":"'s inhibitory effect on hepatic OATPs and the anticipated ch","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":755,"endOffset":763,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"n S-warfarin's much longer half-life(31, 34-41) compared to ","suffix":"(41), rifampin was expected to be present in plasma for only","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":769,"endOffset":777,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":" much longer half-life(31, 34-41) compared to rifampin(41), ","suffix":" was expected to be present in plasma for only portion of wa","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":769,"endOffset":777,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":" much longer half-life(31, 34-41) compared to rifampin(41), ","suffix":" was expected to be present in plasma for only portion of wa","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":1009,"endOffset":1017,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"e package insert, predict relevant plasma concentrations of ","suffix":" for up to 12 hours after a single 600 mg intravenous dose.(","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":675,"endOffset":683,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","prefix":"rd deviation. In addition, the geometric mean ratios of the ","suffix":" treatment values relative to control values (warfarin alone","exact":"rifampin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":950,"endOffset":962,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ides (OATPs) in the disposition of two BDDCS Class 2 drugs: ","suffix":"(11) and glyburide.(12) Using concomitant administration of ","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":207,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"demonstrated significant changes in the pharmacokinetics of ","suffix":" and glyburide with hepatic OATP inhibition by rifampin(11, ","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":295,"endOffset":307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ith hepatic OATP inhibition by rifampin(11, 12). The AUC of ","suffix":" was 680% higher and the AUC of glyburide 130% higher in rif","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":488,"endOffset":500,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"also produced a large decrease in the Vss/F for both drugs (","suffix":", 93% decrease; glyburide, 60% decrease). This decrease in V","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":396,"endOffset":408,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"mportance of OATP hepatic uptake in healthy voluneteers for ","suffix":"(11) and glyburide(12). Subjects received on Day 1 of each s","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":971,"endOffset":980,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"isposition of two BDDCS Class 2 drugs: atorvastatin(11) and ","suffix":".(12) Using concomitant administration of single dose intrav","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":1158,"endOffset":1167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ptake inhibition resulted in a 1.3 and 6.8 fold increase in ","suffix":" and atorvastin exposure, respectively, as measured by the t","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":224,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ificant changes in the pharmacokinetics of atorvastatin and ","suffix":" with hepatic OATP inhibition by rifampin(11, 12). The AUC o","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":339,"endOffset":348,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"12). The AUC of atorvastatin was 680% higher and the AUC of ","suffix":" 130% higher in rifampin vs. control phases. In those clinic","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":516,"endOffset":525,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"se in the Vss/F for both drugs (atorvastatin, 93% decrease; ","suffix":", 60% decrease). This decrease in Vss/F likely demonstrated ","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":851,"endOffset":860,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"itro effects were similar to what we observed in vitro with ","suffix":". We cannot rule-out the possibility that higher plasma conc","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":417,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"atic uptake in healthy voluneteers for atorvastatin(11) and ","suffix":"(12). Subjects received on Day 1 of each study period either","exact":"glyburide"},{"setid":"PMC3091944","drugname":"verapamil","startOffset":535,"endOffset":544,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"e of CYP enzyme induction with multiple-dose rifampin using ","suffix":" as a probe substrate reported a half-life of 1 day for the ","exact":"verapamil"},{"setid":"PMC3091944","drugname":"nifedipine","startOffset":779,"endOffset":789,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"le dose of 1200 mg oral rifampin given 12 hours before oral ","suffix":", resulting in a 64% decrease in the AUC0-∞ of nifedipine.(3","exact":"nifedipine"},{"setid":"PMC3091944","drugname":"nifedipine","startOffset":836,"endOffset":846,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"al nifedipine, resulting in a 64% decrease in the AUC0-∞ of ","suffix":".(30) Nonetheless, the potential induction of warfarin metab","exact":"nifedipine"},{"setid":"PMC3091944","drugname":"dmso","startOffset":171,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"for 5 minute in a 37°C water bath with either control (0.1% ","suffix":") or 100 μM rifampin. The 100 μM concentration of rifampin w","exact":"DMSO"},{"setid":"PMC3091944","drugname":"mineral oil","startOffset":639,"endOffset":650,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"uot was transferred to a tube containing 700 μL of silicone:","suffix":" mixture (83.3:16.7 v/v). The tube was then centrifuged for ","exact":"mineral oil"},{"setid":"PMC3091944","drugname":"acetonitrile","startOffset":634,"endOffset":646,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"and S-warfarin, respectively. The mobile phase consisted of ","suffix":":acetic acid:triethylamine (1000:3:2.5 v:v:v) and the flow r","exact":"acetonitrile"},{"setid":"PMC3091944","drugname":"triethylamine","startOffset":659,"endOffset":672,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"ely. The mobile phase consisted of acetonitrile:acetic acid:","suffix":" (1000:3:2.5 v:v:v) and the flow rate was 1mL/min. The injec","exact":"triethylamine"}],[{"setid":"PMC3612775","drugname":"cholesterol","startOffset":187,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"pproach to lowering blood levels of low-density lipoprotein ","suffix":" (LDL-C) and the risk of vascular events.1 Standard statin r","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":290,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" eligible for inclusion if they had non-fasting blood total ","suffix":" concentrations of at least 3.5 mmol/L (135 mg/dL) and eithe","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":178,"endOffset":189,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ndard spectrophotometric enzymatic methods to measure total ","suffix":" and lipid fractions (including LDL-C directly) and immunotu","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":532,"endOffset":543,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[3]/p[1]","prefix":"particles, but statin therapy does not reduce the number or ","suffix":" content of Lp(a) particles.33 LPA variant carriers have hig","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":813,"endOffset":824,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[3]/p[1]","prefix":"tudies with direct measures of Lp(a) molar levels and Lp(a)-","suffix":" content are needed to clarify the impact of LPA genotype on","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":144,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" of the LDL-C and apolipoprotein B (ApoB) response to 40 mg ","suffix":" daily was performed in 3895 participants in the Heart Prote","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":240,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d there were similar large reductions in vascular risk with ","suffix":" irrespective of genotypes associated with the lipid respons","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":316,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"spective of genotypes associated with the lipid response to ","suffix":". Consequently, their value for informing clinical decisions","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":268,"endOffset":279,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"sociation analyses of the LDL-C and ApoB responses to 40 mg ","suffix":" daily in 3895 participants in the Heart Protection Study an","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":776,"endOffset":787,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"involving 4 weeks of placebo followed by 4-6 weeks of 40 mg ","suffix":" daily, after which fully compliant individuals were randoml","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":868,"endOffset":879,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ully compliant individuals were randomly allocated to 40 mg ","suffix":" daily or matching placebo for ∼5 years. A non-fasting blood","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":1058,"endOffset":1069,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"atin therapy) and at the end of run-in (i.e. while on 40 mg ","suffix":" daily). The pre-specified primary outcome for assessing the","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":825,"endOffset":836,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[1]","prefix":" associations with either the LDL-C or the ApoB response to ","suffix":" therapy, or if P < 5 × 10−5 for both the LDL-C and ApoB res","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":280,"endOffset":291,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"n') to the randomization visit following 4-6 weeks on 40 mg ","suffix":" daily ('on-statin') in compliant individuals. Linear regres","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":1563,"endOffset":1574,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"e effects of genotypes on the proportional risk response to ","suffix":" during the randomized phase of the Heart Protection Study. ","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":259,"endOffset":270,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":", respectively (Table 1). On average, compliance with 40 mg ","suffix":" daily for 4-6 weeks resulted in a 42.4% reduction in LDL-C ","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":228,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"l/L reduction in LDL-C between participants allocated 40 mg ","suffix":" daily vs. placebo.25 In the genotyped participants, random ","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":319,"endOffset":330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"5 In the genotyped participants, random allocation to 40 mg ","suffix":" daily reduced the proportional 5-year risk of major vascula","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":126,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"nt study identified associations with the lipid response to ","suffix":" for SNPs in three genes-LPA, CELSR2/PSRC1/SORT1, and ABCC2-","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":950,"endOffset":961,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"th the proportional or absolute risk reductions produced by ","suffix":" therapy, suggesting that the clinical relevance of these va","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":1928,"endOffset":1939,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"ute LDL-C reduction associated with some of these variants, ","suffix":" therapy produced large and significant reductions in vascul","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":586,"endOffset":597,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[4]/p[1]","prefix":"ease in myopathy risk seen with this variant in patients on ","suffix":" makes knowledge of this genotype of potential value in guid","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":1188,"endOffset":1199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[5]/p[1]","prefix":"vascular events among genotyped patients randomized between ","suffix":" vs. placebo for 5 years, this is the largest single study o","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":206,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/p[1]","prefix":"cil, British Heart Foundation, Merck & Co (manufacturers of ","suffix":"), and Roche Vitamins Ltd (manufacturers of vitamins). Genot","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"quad","startOffset":224,"endOffset":228,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[1]","prefix":"re selected, and genotypes measured using the Illumina 610K ","suffix":" panel. Genome-wide data were available for 3895 individuals","exact":"Quad"}],[{"setid":"PMC1156914","drugname":"olanzapine","startOffset":413,"endOffset":423,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" polypharmacy, and 13.9 days without antipsychotic therapy. ","suffix":"-initiated patients were significantly more likely to be on ","exact":"Olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":685,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"he number of monotherapy days was significantly greater for ","suffix":" than quetiapine (p < .001), but not for olanzapine versus r","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":736,"endOffset":746,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ater for olanzapine than quetiapine (p < .001), but not for ","suffix":" versus risperidone, or for risperidone versus quetiapine-in","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":342,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"reported higher monotherapy or lower polypharmacy rates for ","suffix":" compared to risperidone [18,19,28,29], and compared to quet","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":456,"endOffset":466,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"compared to quetiapine-treated patients [25,27,30], whereas ","suffix":" and risperidone-treated patients were not found to signific","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":448,"endOffset":458,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"tients initiated on commonly used atypical antipsychotics - ","suffix":", quetiapine, or risperidone - and compared their rates and ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":192,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"ted on one of three commonly used atypical antipsychotics - ","suffix":", quetiapine, or risperidone, in regular oral formulation. P","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":183,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"utcome measures for initiating treatment group comparisons (","suffix":", quetiapine, or risperidone): (a) the percentage of patient","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":254,"endOffset":264,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"6) included patients who were initiated during the study on ","suffix":" (N = 405), quetiapine (N = 115), or risperidone (N = 276). ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":807,"endOffset":817,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ntipsychotics and mood stabilizers; a greater percentage of ","suffix":"-treated patients were treated with typical antipsychotics i","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":229,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"he 1-year period compared to risperidone and to quetiapine. ","suffix":"-treated patients were 2.08 times more likely to be on monot","exact":"Olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":142,"endOffset":152,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"ber of monotherapy days on the initiating antipsychotic for ","suffix":", quetiapine, and risperidone are presented in Table ​Table3","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":354,"endOffset":364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"cy. For monotherapy or polypharmacy initiators, patients on ","suffix":" had a greater number of days of monotherapy on the initiati","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":606,"endOffset":616,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"ns found a significantly longer duration on monotherapy for ","suffix":" compared to quetiapine (p < .001) and a trend toward longer","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":191,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"the time of initiation on the studied atypical medications (","suffix":", quetiapine, and risperidone). These monotherapy-initiated ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":230,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d atypical antipsychotic medications. Patients initiated on ","suffix":" were significantly more likely to be on monotherapy compare","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":505,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"gs appear consistent with several previous studies in which ","suffix":"-treated patients were found to have significantly higher ra","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":974,"endOffset":984,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"which the proportion of schizophrenia patients treated with ","suffix":" monotherapy remained relatively steady over the first 3 mon","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":278,"endOffset":288,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"or of the sponsor's antipsychotic medication (in this case, ","suffix":"). Although we cannot completely rule out this possibility, ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":308,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). The percentage of pati","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":276,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). While similar in many ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":601,"endOffset":611,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"-year post initiation compared to risperidone (p = .043) or ","suffix":" (p = .002). The number of monotherapy days was significantl","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":701,"endOffset":711,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"otherapy days was significantly greater for olanzapine than ","suffix":" (p < .001), but not for olanzapine versus risperidone, or f","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":198,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"gents is sparse [8,26-30]. It is unclear if risperidone and ","suffix":"-treated patients differ on monotherapy parameters. Most pre","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":408,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"pine compared to risperidone [18,19,28,29], and compared to ","suffix":"-treated patients [25,27,30], whereas olanzapine and risperi","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":460,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"ated on commonly used atypical antipsychotics - olanzapine, ","suffix":", or risperidone - and compared their rates and duration of ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":204,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"f three commonly used atypical antipsychotics - olanzapine, ","suffix":", or risperidone, in regular oral formulation. Participants ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":195,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"res for initiating treatment group comparisons (olanzapine, ","suffix":", or risperidone): (a) the percentage of patients on antipsy","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":308,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). The percentage of pati","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":276,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). While similar in many ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":523,"endOffset":533,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ychotic polypharmacy at initiation, which was highest among ","suffix":"-treated patients and lowest for the risperidone treatment g","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":691,"endOffset":701,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"tiation on the index antipsychotic, a greater percentage of ","suffix":"-treated patients were treated with atypical antipsychotics ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":989,"endOffset":999,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ents had fewer antipsychotic monotherapy days. Further, the ","suffix":" treatment group had least males, the lowest illness duratio","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":217,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"apy during the 1-year period compared to risperidone and to ","suffix":". Olanzapine-treated patients were 2.08 times more likely to","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":311,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ients were 2.08 times more likely to be on monotherapy than ","suffix":" (Odds Ratio (OR) = 2.08, 95% Confidence Interval (CI), 1.30","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":541,"endOffset":551,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":", 1.01-1.84, p = .043). Differences between risperidone and ","suffix":" initiators showed a trend toward significance (OR = 1.53, 9","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":154,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"herapy days on the initiating antipsychotic for olanzapine, ","suffix":", and risperidone are presented in Table ​Table33 for patien","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":444,"endOffset":454,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"r of days of monotherapy on the initiating medication while ","suffix":" initiators had the fewest. Using a propensity score bootstr","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":629,"endOffset":639,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"y longer duration on monotherapy for olanzapine compared to ","suffix":" (p < .001) and a trend toward longer duration for risperido","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":728,"endOffset":738,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"d longer duration for risperidone initiators as compared to ","suffix":" (p = .052). The difference between olanzapine and risperido","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":203,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"initiation on the studied atypical medications (olanzapine, ","suffix":", and risperidone). These monotherapy-initiated patients con","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":305,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" significantly more likely to be on monotherapy compared to ","suffix":" (rate and duration) or risperidone-initiated patients (rate","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":648,"endOffset":658,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"rapy compared to risperidone [18,19,28,29], and compared to ","suffix":"-treated patients [25,27,30], with the quetiapine treatment ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":697,"endOffset":707,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ompared to quetiapine-treated patients [25,27,30], with the ","suffix":" treatment group being the least likely to be treated monoth","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":481,"endOffset":491,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"is also important because some antipsychotics, particularly ","suffix":" in low doses, may have been used to treat insomnia rather t","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":638,"endOffset":648,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"phrenia. Although some have speculated that higher doses of ","suffix":" produce better outcome, the available data [35] do not supp","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":773,"endOffset":783,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"his. Davis and Chen [35] observed, however, \"the sponsor of ","suffix":" has 2 studies of dose response, one nearing completion, and","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":828,"endOffset":838,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"the sponsors of risperidone [35], comparing risperidone and ","suffix":" on the rate of antipsychotic polypharmacy. That short term ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":929,"endOffset":939,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"olypharmacy. That short term trial found the relative risk (","suffix":" vs. risperidone) of using antipsychotic polypharmacy to be ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":1010,"endOffset":1020,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"idone) of using antipsychotic polypharmacy to be higher for ","suffix":" compared to risperidone (odds ratio 1.90, 95% CI, 1.29-2.80","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":1206,"endOffset":1216,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":", in which the odds ratio for antipsychotic polypharmacy of ","suffix":" vs. risperidone was 1.53 (95% CI 0.94-2.47, p = 0.085).\n   ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":333,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). The percentage of patients with monotherapy on t","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":301,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). While similar in many aspects, the treatment gro","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":575,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"antipsychotic during the 1-year post initiation compared to ","suffix":" (p = .043) or quetiapine (p = .002). The number of monother","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":182,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"among atypical agents is sparse [8,26-30]. It is unclear if ","suffix":" and quetiapine-treated patients differ on monotherapy param","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":365,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"rapy or lower polypharmacy rates for olanzapine compared to ","suffix":" [18,19,28,29], and compared to quetiapine-treated patients ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":471,"endOffset":482,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"tiapine-treated patients [25,27,30], whereas olanzapine and ","suffix":"-treated patients were not found to significantly differ on ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":475,"endOffset":486,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"y used atypical antipsychotics - olanzapine, quetiapine, or ","suffix":" - and compared their rates and duration of monotherapy duri","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":219,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics - olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":219,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics - olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"ing treatment group comparisons (olanzapine, quetiapine, or ","suffix":"): (a) the percentage of patients on antipsychotic monothera","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":333,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). The percentage of patients with monotherapy on t","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":301,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). While similar in many aspects, the treatment gro","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":570,"endOffset":581,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ighest among quetiapine-treated patients and lowest for the ","suffix":" treatment group. During the 2 months prior to initiation on","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":913,"endOffset":924,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"typical antipsychotics in both oral and depot formulations; ","suffix":" patients had fewer antipsychotic monotherapy days. Further,","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":198,"endOffset":209,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ipsychotic monotherapy during the 1-year period compared to ","suffix":" and to quetiapine. Olanzapine-treated patients were 2.08 ti","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":".002), and 1.36 times more likely to be on monotherapy than ","suffix":" (OR = 1.36, 95%CI, 1.01-1.84, p = .043). Differences betwee","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":525,"endOffset":536,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"OR = 1.36, 95%CI, 1.01-1.84, p = .043). Differences between ","suffix":" and quetiapine initiators showed a trend toward significanc","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":170,"endOffset":181,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"he initiating antipsychotic for olanzapine, quetiapine, and ","suffix":" are presented in Table ​Table33 for patients initiating on ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":690,"endOffset":701,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"uetiapine (p < .001) and a trend toward longer duration for ","suffix":" initiators as compared to quetiapine (p = .052). The differ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":219,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"e studied atypical medications (olanzapine, quetiapine, and ","suffix":"). These monotherapy-initiated patients continued on monothe","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":339,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"n monotherapy compared to quetiapine (rate and duration) or ","suffix":"-initiated patients (rate only) during the 1-year post treat","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":605,"endOffset":616,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"o have significantly higher rate of monotherapy compared to ","suffix":" [18,19,28,29], and compared to quetiapine-treated patients ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":784,"endOffset":795,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":" double-blind randomized study conducted by the sponsors of ","suffix":" [35], comparing risperidone and quetiapine on the rate of a","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":812,"endOffset":823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"dy conducted by the sponsors of risperidone [35], comparing ","suffix":" and quetiapine on the rate of antipsychotic polypharmacy. T","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":944,"endOffset":955,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"at short term trial found the relative risk (quetiapine vs. ","suffix":") of using antipsychotic polypharmacy to be higher for queti","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":1033,"endOffset":1044,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"chotic polypharmacy to be higher for quetiapine compared to ","suffix":" (odds ratio 1.90, 95% CI, 1.29-2.80, p = 0.001), a finding ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":1221,"endOffset":1232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"odds ratio for antipsychotic polypharmacy of quetiapine vs. ","suffix":" was 1.53 (95% CI 0.94-2.47, p = 0.085).\n                   ","exact":"risperidone"}],[{"setid":"PMC3056523","drugname":"itraconazole","startOffset":378,"endOffset":390,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"inhibitory metabolites include three potent CYP inhibitors: ","suffix":" (ITZ),3 fluoxetine,4 and bupropion.5 Norfluoxetine, the pri","exact":"itraconazole"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":321,"endOffset":330,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" p450 (CYP) 3A4 inhibition. The pharmacokinetics of ITZ and ","suffix":" (MDZ) were determined in six healthy volunteers in four ses","exact":"midazolam"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":282,"endOffset":291,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"nal female subject was enrolled, but she withdrew after the ","suffix":" (MDZ) control session because of nausea and vomiting. No ot","exact":"midazolam"},{"setid":"PMC3056523","drugname":"fluoxetine","startOffset":399,"endOffset":409,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"s include three potent CYP inhibitors: itraconazole (ITZ),3 ","suffix":",4 and bupropion.5 Norfluoxetine, the primary circulating me","exact":"fluoxetine"},{"setid":"PMC3056523","drugname":"fluoxetine","startOffset":481,"endOffset":491,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"pion.5 Norfluoxetine, the primary circulating metabolite of ","suffix":", has been shown to be responsible for the persistent CYP2D6","exact":"fluoxetine"},{"setid":"PMC3056523","drugname":"fluoxetine","startOffset":587,"endOffset":597,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"or the persistent CYP2D6 inhibition after administration of ","suffix":",6 although no quantitative prediction of CYP2D6 inhibition ","exact":"fluoxetine"},{"setid":"PMC3056523","drugname":"fluoxetine","startOffset":691,"endOffset":701,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"tion of CYP2D6 inhibition by norfluoxetine as compared with ","suffix":" was shown. Using atomoxetine as an example, quantitative pr","exact":"fluoxetine"},{"setid":"PMC3056523","drugname":"bupropion","startOffset":416,"endOffset":425,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"otent CYP inhibitors: itraconazole (ITZ),3 fluoxetine,4 and ","suffix":".5 Norfluoxetine, the primary circulating metabolite of fluo","exact":"bupropion"},{"setid":"PMC3056523","drugname":"norfluoxetine","startOffset":428,"endOffset":441,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"hibitors: itraconazole (ITZ),3 fluoxetine,4 and bupropion.5 ","suffix":", the primary circulating metabolite of fluoxetine, has been","exact":"Norfluoxetine"},{"setid":"PMC3056523","drugname":"norfluoxetine","startOffset":660,"endOffset":673,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"although no quantitative prediction of CYP2D6 inhibition by ","suffix":" as compared with fluoxetine was shown. Using atomoxetine as","exact":"norfluoxetine"},{"setid":"PMC3056523","drugname":"atomoxetine","startOffset":719,"endOffset":730,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" norfluoxetine as compared with fluoxetine was shown. Using ","suffix":" as an example, quantitative predictions of the contribution","exact":"atomoxetine"},{"setid":"PMC3056523","drugname":"atomoxetine","startOffset":911,"endOffset":922,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"the overall weak in vivo inhibition of CYP3A4 and CYP2D6 by ","suffix":", the metabolites were predicted to be mainly responsible fo","exact":"atomoxetine"},{"setid":"PMC3056523","drugname":"triazolam","startOffset":831,"endOffset":840,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" ingestion time interval on the interaction between ITZ and ","suffix":", a larger magnitude of inhibition was observed when ITZ and","exact":"triazolam"},{"setid":"PMC3056523","drugname":"triazolam","startOffset":901,"endOffset":910,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" a larger magnitude of inhibition was observed when ITZ and ","suffix":" doses were separated by 3 or 12 h as compared with administ","exact":"triazolam"},{"setid":"PMC3056523","drugname":"triazolam","startOffset":393,"endOffset":402,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"with increasing ITZ doses has previously been observed with ","suffix":" when triazolam was administered 3 h after a 200- or 400-mg ","exact":"triazolam"},{"setid":"PMC3056523","drugname":"triazolam","startOffset":408,"endOffset":417,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":" ITZ doses has previously been observed with triazolam when ","suffix":" was administered 3 h after a 200- or 400-mg oral dose of IT","exact":"triazolam"},{"setid":"PMC3056523","drugname":"caffeine","startOffset":382,"endOffset":390,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"ucts for the duration of the study and to avoid alcohol and ","suffix":" from 1 day before through the end of each urine-collection ","exact":"caffeine"},{"setid":"PMC3056523","drugname":"edta","startOffset":1056,"endOffset":1060,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"les were collected through indwelling venous catheters into ","suffix":"-containing tubes (BD Vacutainer; BD Biosciences, Franklin L","exact":"EDTA"}]]}